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Javier Ávila-Román, Researcher, graduated in Biology in 2008 and received his PhD in Pharmacy
in 2014 from Universidad de Sevilla, Spain. He worked as Assistant Professor in the Faculty of
Biology and as Researcher in Faculty of Pharmacy from 2010 to 2017. During this period, he studied
the role of natural products isolated from microalgae, mainly oxylipins (OXL), in Inflammatory Bowel
Diseases (IBD) and associated colon cancer. He moved in 2018 to the Universitat Rovira i Virgili in
Tarragona, Spain and works since then in the Nutrigenomic Group in the Department of Biochemistry
and Biotechnology in the Faculty of Chemistry. His current research interests focus on natural and
nutritional products, and more specifically on the bioactivity of these bioactive products in Metabolic
Syndrome (arterial pressure, insulin resistance, obesity, inflammation) and the deciphering of their
role in circadian and circannual rhythms and their molecular mechanisms.
vii

Preface to ”Marine Anti-inflammatory Agents”
Acute inflammation is a highly regulated process, and its dysregulation can lead to the
development of a chronic inflammatory state which is believed to play a main role in the pathogenesis
of many diseases, including cancer. In recent years, the need to find new anti-inflammatory molecules
has raised the scientific community’s interest for marine natural products. In this regard, the marine
environment represents a source for isolating a wealth of bioactive compounds. In this Special
Issue, the reported products have been obtained from microalgae, sea cucumber, octopus, squid, red
alga-derived fungus, cnidarians, hard-shelled mussel, and sponges.
This Special Issue of Marine Drugs covers both the in vitro and in vivo studies of marine agents
with anti-inflammatory activities, as well as clinical trials conducted in humans. Among the bioactive
molecules reported in the papers are lipid compounds, such as glycolipids, which, for the first time,
demonstrated their preventive effects in an inflammatory model of skin hyperplasia. In addition,
beneficial effects of the carotenoid fucoxanthin were shown in the same model of skin hyperplasia,
in UVB-induced damage and in a model of inflammatory pain. Moreover, frondanol, a lipid extract
from Cucumaria frondosa, attenuated inflammation in an acute colitis model. Another paper evaluated
the fatty acid compositions of lipid extracts from some common seafood organisms, reporting the
highest level of omega 3 polyunsaturated fatty acids and the highest anti-inflammatory activity in
the extracts from octopus and squid byproducts.
Additionally, the anti-inflammatory effects of other marine compounds have been reported,
including hirsutanol A, a sesquiterpene from the red alga-derived marine fungus Chondrostereum sp.
NTOU4196, two zoanthamine alkaloids from the zoantharian Zoanthus cf. pulchellus,
an α-D-glucan from the hard-shelled mussel of Mytilus coruscus, and the polyphenol
pyrogallol-phloroglucinol-6,6-bieckol from an edible marine brown alga.
Finally, this Special Issue is supplemented by three reviews focused on the occurrence of
prostaglandins in the marine environment and their anti-inflammatory role; fish lipid emulsions
used to improve patient outcomes in an inflammatory environment, such as postoperative; and the
chemically induced production of compounds with anti-inflammatory activity from microalgae.
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Abstract: Chronic inflammatory skin diseases such as psoriasis have a significant impact on society.
Currently, the major topical treatments have many side effects, making their continued use in patients
difficult. Microalgae have emerged as a source of bio-active molecules such as glycolipids with
potent anti-inflammatory properties. We aimed to investigate the effects of a glycolipid (MGMG-A)
and a glycolipid fraction (MGDG) obtained from the microalga Isochrysis galbana on a TPA-induced
epidermal hyperplasia murine model. In a first set of experiments, we examined the preventive
effects of MGMG-A and MGDG dissolved in acetone on TPA-induced hyperplasia model in mice.
In a second step, we performed an in vivo permeability study by using rhodamine-containing cream,
ointment, or gel to determinate the formulation that preserves the skin architecture and reaches deeper.
The selected formulation was assayed to ensure the stability and enhanced permeation properties
of the samples in an ex vivo experiment. Finally, MGDG-containing cream was assessed in the
hyperplasia murine model. The results showed that pre-treatment with acetone-dissolved glycolipids
reduced skin edema, epidermal thickness, and pro-inflammatory cytokine production (TNF-α, IL-1β,
IL-6, IL-17) in epidermal tissue. The in vivo and ex vivo permeation studies showed that the
cream formulation had the best permeability profile. In the same way, MGDG-cream formulation
showed better permeation than acetone-dissolved preparation. MGDG-cream application attenuated
TPA-induced skin edema, improved histopathological features, and showed a reduction of the
inflammatory cell infiltrate. In addition, this formulation inhibited epidermal expression of COX-2
in a similar way to dexamethasone. Our results suggest that an MGDG-containing cream could be
an emerging therapeutic strategy for the treatment of inflammatory skin pathologies such as psoriasis.
Keywords: glycolipids; MGDG; skin; inflammation; epidermal hyperplasia; microalgae;
Isochrysis galbana
1. Introduction
Inflammatory skin diseases have a significant impact on the quality of life of patients; one of them
is psoriasis, considered a common immune-mediated inflammatory skin disorder. It is estimated that
2–4% of the population suffers from psoriasis [1]. Although the exact mechanism of this pathology is
Mar. Drugs 2018, 16, 2; doi:10.3390/md16010002 www.mdpi.com/journal/marinedrugs1
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not completely understood, it is known that both genetic predisposition and environmental factors
such as stress, infection, trauma, and use of some drugs play an important role in its etiology [2].
This disease is associated with several comorbidities as cardiovascular diseases, metabolic syndrome,
and psychiatric disorders.
Accumulating evidence has demonstrated that exposure of skin to the protein kinase
C activator 12-O-tetradecanoylphorbol-13-acetate (TPA) induces a pleiotropic tissue response and
promotes macroscopic lesions, peeling, and erythema, mimicking an apparent psoriasis phenotype.
Furthermore, an increase in epidermal thickness has been observed due to the hyperproliferation and
aberrant differentiation of keratinocytes as well as the infiltration of inflammatory leukocytes into the
epidermis and dermis [3]. Activated leukocytes cause uncontrolled production of reactive oxygen
species (ROS), leading to peroxidative damage to skin membranes and contributing to the exacerbation
of lesions. Moreover, these immune cells release growth factors, chemokines, and pro-inflammatory
cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β and IL-17, which interact as
a network in the pathogenesis of psoriasis [4]. The inducible enzyme cyclooxygenase-2 (COX-2) has
also been demonstrated to play a pivotal role in skin proliferative disorders through overproduction
of pro-inflammatory prostaglandins such as PGE2 [5]. Currently, the treatment of psoriasis
includes topical agents (corticoids, vitamin D derivatives, retinoids, and calcineurin inhibitors),
photo-chemo-therapy, and systemic treatments (immunosuppressants and biological drugs) [6].
However, many patients, especially those with moderate to severe generalized psoriasis, are not
adequately treated with effective or long-term therapies and most of them have various degrees of
side effects. Thus, the development of well-tolerated immune-modulatory topical agents can offer
an alternative option for the treatment of psoriatic patients.
Microalgae have emerged as a source of bioactive compounds, including lipids, proteins,
polysaccharides, and carotenoids, which have attracted the interest of the pharmaceutical industry
based on their anti-oxidant, anti-inflammatory, or anti-carcinogenic activity in different skin
inflammatory models [7]. Recently, the anti-inflammatory activity of galactosylglycerides isolated from
the marine microalga Isochrysis galbana (I. galbana), including a monogalactosyldiacylglycerol
(MGDG) fraction [8] and the pure compound monogalactosylmonoacylglyceride
(2S)-1-O-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]-3-O-β-D-galactopyranosylglycerol
(MGMG-A) (data not shown), has been reported through the inhibition of TNF-α production
in LPS-stimulated THP-1 human macrophages. However, data on these compounds’ effects on skin
inflammatory pathologies have not yet been collected.
Given the interesting anti-inflammatory properties and their high yield of these products in this
microalga, we evaluated the preventive effects of the galactosylglycerides MGMG-A and MGDG
from I. galbana in a murine model of TPA-induced epidermal hyperplasia by using a topical application
of acetone-dissolved glycolipids. However, acetone application onto the skin has been reported to
exhibit several drawbacks such as the amount of this organic solvent remaining in contact with the skin,
spreading of the formulation and loss of sample, heterogeneity of the dose contacting with the skin,
and difficulty of applying the sample [9]. It is well known that the topical application of bio-compounds
requires their incorporation into a carrier that offers stability, good permeation, and sufficient time
in contact with the skin. Currently, microalgae products are being used as cosmeceuticals through
their incorporation in face and skin care products [10]. Therefore, our next objective was to use
a pharmaceutical carrier to solve the above limitations of glycolipid solutions. The formulation of these
substances involves the selection of appropriate combinations of formula ingredients with the aim of
exerting a desirable local or systemic effect. Among them, topical formulations of different natures are
used, including ointments, creams, and hydrophilic gels, in which the active compound is suspended
or dissolved. In the present study, once a topical formulation was selected, we finally aimed to study
its effect on a TPA-induced hyperplasia model and determinate its benefit to epidermal skin.
2
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2. Results
2.1. Effects of Glycolipids on IL-6 and IL-8 Production in TNF-A-Stimulated HaCaT Human Keratinocytes
Non-cytotoxic concentrations of the monogalactosylmonoacylglyceride (2S)-1-O-[(6Z,9Z,12Z,15Z)
-octadeca-6,9,12,15-tetraenoyl]-3-O-β-D-galactopyranosylglycerol (MGMG-A) and the
monogalactosyldiacylglycerol fraction (MGDG) were selected to evaluate their effects on
pro-inflammatory cytokines IL-6 and IL-8 production in HaCaT cells. The cytotoxic effect of MGMG-A
and MGDG fraction was studied using the SRB method, resulting in 100% viability at the tested
concentrations (Table S1).
TNF-α-stimulated HaCaT cells manifested high IL-6 and IL-8 levels in comparison with
unstimulated control cells (p < 0.001) (Figure 1). Pre-treatment with the reference compound
dexamethasone (Dex) as well as MGMG-A (10, 30, and 50 μM) and MGDG fraction (10, 30,
and 50 μg/mL) significantly inhibited IL-6 and IL-8 production, with no significant differences between
the different tested concentrations.















































Figure 1. Effects of glycolipids from I. galbana on IL-6 and IL-8 production in TNF-α-stimulated
HaCaT human keratinocytes. (a) IL-6 levels and (b) IL-8 levels in TNF-α-stimulated HaCaT human
keratinocytes. Cells were pre-incubated with the glycolipid MGMG-A (10, 30, 50 μM) and the
fraction MGDG (10, 30, 50 μg/mL) for 1 h, and then stimulated with TNF-α (10 ng/mL) for 24 h.
Dexamethasone (Dex) was used as a positive reference compound at 1 μM. After 24 h, the production
of cytokines in the supernatants was measured by ELISA assay. Results are representative of six
independent experiments (n = 6). Values are means with standard errors represented by vertical bars.
Mean value was significantly different compared with the control group (*** p < 0.001; Student t test).
Mean value was significantly different compared with the TNF-α group (+ p < 0.05, ++ p < 0.01,
+++ p < 0.001; one-way ANOVA followed by Bonferroni’s Multiple Comparison test).
2.2. Topical Application of Acetone-Dissolved Glycolipids Inhibits Skin Inflammation and Hyperplasia in the
Murine TPA-Induced Model
We studied the effect of MGMG-A and MGDG on the murine TPA-induced epidermal
hyperplasia model, which reproduces certain biochemical and histopathological parameters typical of
human psoriasis [11]. TPA administration to mouse skin resulted in the development of macroscopic
lesions (Figure 2a) and skin edema, confirmed by a higher weight of the 1 cm2 punch biopsies compared
3
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with the sham group (p < 0.001) (Figure 2b). Topical treatment with Dex (200 μM), MGMG-A and
MGDG (200 μM or 200 μg/mL, respectively) 30 min prior to TPA application inhibited macroscopic
damage and the skin punch weight (p < 0.001 and p < 0.05, respectively), suggesting an inhibition of
skin edema (Figure 2b). We next examined hematoxylin- and eosin-stained sections of mouse skin
(Figure 2c). Consistent with macroscopic changes, TPA-treated animals exhibited a clear evidence
of edema, epidermal hyperplasia, and massive neutrophilic infiltration compared with the sham
(Figure 2c). Moreover, a marked increase in epidermal thickness was evident in the TPA group
(p < 0.001) (Figure 2d). These results correlated with increased MPO activity, an established marker
for inflammatory cell infiltration into the skin (Figure 2e). Treatment with the pure compound and
glycolipid fraction markedly prevented epidermal hyperplasia (p < 0.01 and p < 0.001, respectively)
(Figure 2c,d), which was associated with a reduction in MPO activity, being significant for MGMG-A
(p < 0.01) (Figure 2e).
 
Figure 2. Topical application of acetone-dissolved glycolipids from I. galbana inhibits skin
inflammation and hyperplasia on the murine 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced
model. The glycolipid MGMG-A (200 μM per site) or the fraction MGDG (200 μg/mL per site) were
topically administered 30 min before TPA application (2 nmol per zone) during three consecutive
days. Dex was used as a positive reference compound (200 μg per site). (a) Representative images of
macroscopic appearance of the dorsal skin; (b) skin edema as punch biopsy; weight of edema (mg/cm2)
was employed as marker of inflammatory skin process; (c) histological appearance of mouse dorsal
skin after H&E-staining (n = 4); Bar = 100 μm. Original magnification 100×. (d) Epidermal thickness
assessment in H&E-stained skin slides; (e) yeloperoxidase (MPO) activity in dorsal skin. Values are
means with standard errors represented by vertical bars. Data are means ± SEM (n = 10 mice/group).
Mean value was significantly different compared with the sham group (*** p < 0.001; Student t test).
Mean value was significantly different compared with TPA group (+ p < 0.05, ++ p < 0.01, +++ p < 0.001;
one-way ANOVA followed by Bonferroni’s Multiple Comparison test).
4
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To support the beneficial effects of glycolipids on skin inflammation, we analyzed the
production of several pro-inflammatory cytokines that are highly involved in psoriasis as well
as the anti-inflammatory cytokine IL-10. Immune cell infiltration detected in the histological
examination of the skin from TPA-treated mice correlated with increased levels of the pro-inflammatory
cytokines TNF-α, IL-1β, IL-6 and IL-17, in comparison with the sham group (p < 0.05, p < 0.01,
p < 0.01, and p < 0.001, respectively) (Figure 3). In accordance with the reduction of the skin edema,
the production of TNF-α, IL-6, and IL-17 was significantly reduced in animals treated with the
glycolipid MGMG-A (p < 0.05, p < 0.001, p < 0.05, respectively) (Figure 3a–d). Regarding the fraction
MGDG, its application resulted in a strong significant suppression of TNF-α and IL-6 levels (p < 0.01,
and p < 0.001) comparable to Dex (Figure 3a,c). IL-10 production analysis revealed increased levels in
the TPA group when compared with the sham (p < 0.05). Nevertheless, pre-treatments showed lower
IL-10 levels when compared to the TPA group, reflecting similar values to the sham (Figure 3e).

































































































Figure 3. Effect of the glycolipid MGMG-A and the fraction MGDG from I. galbana on the production
of cytokines in skin homogenates in the murine 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced
hyperplasia model. (a) TNF-α (pg/mg tissue); (b) IL-1β (pg/mg tissue); (c) IL-6 (pg/mg tissue);
(d) IL-17 (pg/mg tissue); and (e) IL-10 (pg/mg tissue). Values are means with standard errors
represented by vertical bars. Data are means ± SEM (n = 10). Mean value was significantly different
compared with the sham group (* p < 0.05, ** p < 0.01, *** p < 0.001; Student t test). Mean value was
significantly different compared with TPA group (+ p < 0.05, ++ p < 0.01, +++ p < 0.001; one-way
ANOVA followed by Bonferroni’s Multiple Comparison test).
2.3. Effect of the Formulation
The development of topical formulations implies the selection of excipients leading to
improvement in the drug skin delivery. In order to evaluate the skin accumulation and penetration
5
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properties of the examined formulations, sections of the mice skin were analyzed by confocal laser
scanning microscopy (CLSM) at the end of permeation experiments. For these studies, rhodamine
6G, a fluorescent hydrophobic probe, was added as a model drug [12]. The penetration depth of the
fluorescent probe and the relative intensity of fluorescence in the skin layers were compared in three
types of semisolid formulations (gel, cream, and ointment described in Section 4.10). Confocal images
revealed that all the examined formulations penetrated deeply into the stratum corneum (SC) and
diffused into the whole skin thickness, except for the ointment (Figure 4a). Cream showed the higher
probe permeation in 24 h, following the control formulation containing only ethanol and incorporated
into Carbopol® gels. However, the rhodamine 6G incorporated into the lipid ointment was observed
to show a low penetration capacity. In addition to the effect of the carrier nature, deeper skin layers
were more easily visualized when ethanol was present in the composition, as occurred in all the
formulations except for the ointment, where the labeling probe was dissolved in propylene glycol.
The quantitative parameters of histogram distribution revealed a higher fluorescent intensity
and accumulation of rhodamine 6G in the presence of ethanol (Figure 4b). Among all the samples,
the cream system offered the higher fluorescence intensity and adequate symmetry of the normal
distribution of histogram.
 
Figure 4. Effect of the vehicle composition and physicochemical properties of the drug on the
permeation characteristics. (a) Confocal micrographs of mice skin cross sections corresponding to
rhodamine-loaded ethanolic control solution, cream, hydrogel, and ointment. Bar = 200 μm. Original
magnification 100×; (b) Numerical data corresponding to the intensity histogram for each sample.
Mean: arithmetical mean value; mean energy: average image energy; RMS: root mean square value;
skewness: skewness of the distribution; (c) Ex vivo permeability percentages of MGDG formulations
in 24 h (ethanolic control solution, cream, and ointment).
2.4. Ex Vivo Permeation Studies
Permeation profiles of MGDG from the ethanol solution and cream through mice skin membranes
were obtained from the equation described in Section 4.11. Dex-loaded cream was used as the control
formulation. Results showed that permeation of MGDG from the cream (100 ± 1.9% of the applied
6
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dose) was twice that observed from the ethanolic control solution (49.3 ± 3.5%). On the other hand,
the permeated amount of Dex from cream was lower (15 ± 3.1%) in comparison with the other
preparations (Figure 4c). This value can be attributed to the lower partition coefficient of this molecule
(logP 1.83) compared to MGDG, whose lipophilicity resembled a reference diacylglycerol in terms of
lipophilic acyl groups (logP 3.85) [13]. It is well known that the partition coefficient has been widely
used as a measurement for defining the lipophilicity of a drug and the diffusion efficiency across the
membranes [14].
2.5. Topical Pre-Treatment with MGDG-Cream Decreases Skin Inflammation and Hyperplasia in the Murine
TPA-Induced Model
We evaluated the effect of the MGDG-cream formulation on the murine TPA-induced epidermal
hyperplasia model. This cream formulation enabled lipid preservation and high permeation in
comparison with the acetone vehicle. After treatment with TPA for three consecutive days, mice
exhibited the expected psoriasis phenotype, including peeling, erythema, and thickening of the back
skin, accompanied by a marked increase in dorsal skin thickness, weight, and substantial inflammatory
cell infiltration in the dermis (p < 0.001) (Figure 5). Pre-treatment with MGDG-cream (100 mg per
site containing 200 μg of MGDG) attenuated the macroscopic lesions formation (Figure 5a) and
significantly reduced skin edema (p < 0.001) when compared with the cream-TPA group (Figure 5b).
These results were accompanied by a clear inhibition of MPO activity following MGDG-cream
administration (p < 0.001); interestingly, the glycolipid formulation was as effective as the reference
topical treatment with Dex-cream, reaching similar levels to those in the healthy group (Figure 4e).
Histological analysis of H&E-stained skin lesions confirmed an improvement in the microscopic
features of hyperplasia in mice treated with MGDG-cream, evidenced by a reduction of epidermal
thickness (p < 0.05) in relation to the cream-TPA group (Figure 5c,d). It is known that COX-2 plays
an important role in skin pathologies. Immunohistochemical analysis of this enzyme showed that
stimulation with TPA significantly increased COX-2-positive cell numbers (p < 0.001), predominantly
localized in the epidermal layer (Figure 6a), when compared with the sham group. As shown in
Figure 6b, skin from MGDG-cream-treated mice revealed a significant downregulation in the number
of epidermal COX-2-positive stained cells in comparison with the cream-TPA group (p < 0.001).
Figure 5. Cont.
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Figure 5. Topical pre-treatment with cream containing the glycolipid fraction MGDG from I. galbana
decreases skin inflammation and hyperplasia on the murine 12-O-tetradecanoylphorbol-13-acetate
(TPA)-induced model. Glycolipid cream formulation (100 mg per site containing 200 μg of MGDG),
dexamethasone (Dex) (100 mg per site, equivalent at 200 μg of compound), or vehicle (cream with
a comparable volume of ethanol) was topically administered from two days before hyperplasia
induction and 30 min after each TPA application (2 nmol per zone for three consecutive days). Dex was
used as the positive reference compound. (a) Representative images of macroscopic appearance of the
dorsal skin; (b) determination of skin edema as punch biopsy weight; (c) histological appearance of
mouse dorsal skin after H&E-staining (n = 4); Bar = 100 μm. Original magnification 100×. (d) Epidermal
thickness assessment in H&E-stained skin slides; (e) myeloperoxidase (MPO) activity. Values are means
with standard errors represented by vertical bars. Data are means ± SEM (n = 10 mice/group).
Mean value was significantly different compared with the sham group (*** p < 0.001; Student t test).
Mean value was significantly different compared with cream-TPA group (+ p < 0.05, +++ p < 0.001;
one-way ANOVA followed by Bonferroni’s Multiple Comparison test).
Figure 6. Cont.
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Figure 6. Topical pre-treatment with cream containing the glycolipid fraction MGDG from I. galbana
attenuates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced COX-2 expression in mouse skin.
(a) Representative photographs of epidermal COX-2 distribution by immunohistochemical detection;
Bar = 200 μm. Original magnification 200×. (b) Positive COX-2 epidermal layer was assessed by
counting the COX-2 positive cells versus total cells in different immunostained dorsal skin sections
per animal. Representative photomicrographs showing positive epidermal COX-2 staining yielded
a brown product. Values are means with standard errors represented by vertical bars. Data are means
± SEM (n = 4). Mean value was significantly different compared with the sham group (*** p < 0.001;
Student’s t test). Mean value was significantly different to the cream-TPA group (+++ p < 0.001;
one-way ANOVA followed by Bonferroni’s Multiple Comparison test).
3. Discussion
Inflammatory skin diseases have a significant impact on society, with atopic dermatitis, acne,
sunburn, and psoriasis being the most common manifestations. Psoriasis is a chronic, autoimmune,
and multisystem inflammatory disease that affects 2–4% of the population [15]. Currently, conventional
treatments for this disease are based on the degree of severity and range from topical therapy and
systemic agents through to phototherapy or combinations of those. However, many of these therapies
are not recommended for the vast majority of patients afflicted with mild forms of psoriasis due to
their potential risk [16]. Therefore, other treatment approaches for mild psoriasis that require topical
therapy only are still needed. In this regard, natural products provide some options for increasing
the safety and efficacy in the management of this pathology [17]. Microalgae species are a promising
source of a variety of bioactive molecules, including polar lipids such as glycolipids. Lipid-enriched
extracts or pure glycolipids have previously demonstrated their in vitro anti-inflammatory [18,19] and
antitumor properties [20], which make them suitable candidates for further investigation. However,
the use of galactosylglycerides to prevent skin pathologies such as psoriasis has not been previously
evidenced. In this sense, we have recently observed that this kind of metabolite protects human
HaCaT keratinocytes against UVB radiation through inhibition of ROS generation and a decrease in
the production of the pro-inflammatory cytokine IL-6 (data not shown). These findings suggest that this
type of molecule could play a main role not only in protecting the skin from UVB exposure but also in
preventing the skin inflammatory process. In this context, we aimed to evaluate the anti-inflammatory
effects of the glycolipid MGMG-A and MGDG fraction in an experimental TPA-induced hyperplasia
model in mice. Moreover, we used different semisolid formulations in which the glycolipid was loaded
in order to facilitate its topical application and to enhance the permeation mechanism compared to
conventional liquid preparations.
Firstly, we tried to demonstrate the anti-inflammatory potential of the compounds under study in
the in vitro model of TNF-α-stimulated HaCaT keratinocytes. This cytokine plays a crucial role in the
pathogenesis of skin inflammatory diseases such as psoriasis [21]. We observed that pre-treatment
with the compound MGMG-A or the fraction MGDG significantly reduced the production of the
pro-inflammatory cytokines IL-6 and IL-8 in stimulated HaCaT keratinocytes. These results encouraged
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us to evaluate the preventive effects of these products on TPA-induced hyperplasia in murine skin
using two experimental approaches. In the first model, glycolipids dissolved in acetone were
topically administered to dorsal skin 30 min before TPA administration. Our data showed that
TPA clearly caused peeling, erythema, and a strong inflammatory reaction produced by a marked
influx of mononuclear and polymorphonuclear leukocytes in epidermis and dermis. Treatment of
mice with the compound MGMG-A or the fraction MGDG from I. galbana reduced the hyperplasia
manifestations and the inflammation grade, presumably due to an inhibition of inflammatory cells
infiltration, as revealed by an MPO study. These findings are interesting since the cellular infiltrate
has a pathogenic role in psoriasis and its control is extremely important for the attenuation of this
disease [22]. Microscopic analysis of the dorsal skin was in accordance with a macroscopic study
reflecting the attenuation of keratinocytes hyperproliferation in the epidermis after treatment with
acetone-dissolved glycolipids. Our results are in line with a previous report that showed that topical
pre-treatment with the glycoglycerolipids MGDG, DGDG, or SQDG, obtained from a blue-green
alga, reduced inflammation in croton-oil-induced ear edema and in carrageenan-induced paw edema
models [23].
The role of TNF-α, IL-17 and IL-1β in psoriasis pathogenesis has been well documented [24],
being a particularly effective strategy to block their production [25]. In the present study, dorsal skin
samples from TPA group showed increased levels of the pro-inflammatory cytokines TNF-α, IL-1β,
IL-6, and IL-17, which were decreased in mice treated with MGMG-A or MGDG fraction. On the
other hand, IL-10 is considered an anti-inflammatory cytokine since it inhibits T cells and macrophages’
pro-inflammatory cytokine production [26]. In this sense, IL-10 is a rapid-response cytokine that
ameliorates the acute immune response that occurs in recurrent diseases such as psoriasis or IBD [27,28].
In this acute experimental epidermal hyperplasia model, dorsal skin reacted to TPA by increasing
IL-10 production versus a sham, but treatments interestingly prevented this production. These results
are in line with a previous study of murine recurrent colitis in which it is proposed that pre-treatment
with an oxylipin-containing lyophilized biomass from microalgae kept levels of pro-inflammatory
cytokines low, thus the production of IL-10 was not required, supporting a less hyperactive immune
response in the recurrent colitis model [29].
After examining the preventive effects of the compound MGMG-A and fraction MGDG obtained
from I. galbana, we aimed to optimize the permeation behavior of these substances with respect to
previously acetone-dissolved preparations. In skin diseases such as psoriasis, local topical delivery
can be improved by following two main approaches. Firstly, the suitable choice of formulation can
optimize the local targeting. Secondly, the physicochemical parameters of the drug itself, such as
lipophilicity, can also affect the degree of delivery.
Concerning the choice of carrier composition, different formulations, including hydrophilic gel,
cream, and ointment, were prepared and analyzed. For these studies, a fluorescent hydrophobic marker
such as rhodamine 6G, with an oil/water partition coefficient of 2.62, was added as a model drug [30].
The in vivo CLSM study defined the cream as the best vehicle to dig deeper into the skin, preserving
the entity of different tissue layers. This may be due to the fact that the surfactant-like properties of this
heterogeneous disperse system could enhance the amount of permeated rhodamine 6G. On the other
hand, a control solution using ethanol as solvent and hydroalcoholic Carbopol® gels also exhibited
high drug permeation. This could also be attributed to the presence of ethanol in the formulation,
which was used as a solubilizer and permeation enhancer. On the contrary, the deposition of the
fluorophore from lipid ointment onto the skin was very low. This would be ascribed to the hydrophobic
nature of the vehicle, which, being insoluble, did not penetrate through the skin but remained on
the surface, as visualized in Figure 4. Usually, the permeation pathway across the SC resides in the
intercellular lipid domains. Conversely, at the viable epidermis level, the fluorophore is not only
restricted to the cell membranes but also accumulates in the cytosol. In this study, a relationship
between the lipophilicity of the applied formulation on the accumulation of the fluorophore in SC and
viable epidermis was observed. Although the fluorescent label was applied to the SC of mice, only low
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relative accumulation in the deeper layers of the skin was observed for the most lipophilic vehicle,
the ointment. This can be explained since the lipid lamellae constitute only a small region of the SC
compared to the corneocytes. However, the adjacent viable epidermis is much more brightly stained
than SC in samples from the rhodamine-loaded cream and hydrogel formulations, because in this layer
the label can distribute throughout the entire epidermis, which results in a brighter appearance [31].
Once we selected the cream for further studies, an ex vivo permeation process was planned for
comparison of MGDG-loaded cream with MGDG reference solution and Dex-cream. In this assay,
the permeation through mice excised skin was determined using a Franz diffusion apparatus and
degassed absolute ethanol. Since the goal of this study was to find the experimental conditions that
allowed a fast and accurate method to evaluate the permeability properties of different formulations
across the skin, we decided to use ethanol as the solvent forming the receiving compartment because
the assayed molecules (MGDG and Dex) are freely soluble in this medium. This solvent has been
used for analyzing the skin diffusion kinetic of other molecules, such as α-tocopherol acetate [32].
However, the use of this solvent has the potential to extract lipids from the SC and to artificially
increase skin permeability. Since all the formulations tested in these experiments had ethanol as the
penetration enhancer interacting with skin constituents to increase drug flux, this would not affect the
relative results.
The formulations were detected in the receiver medium in a time-dependent manner and
cumulative amount permeated curves were plotted. Concerning MGDG cream with respect to
the MGDG ethanolic solution, the difference in the permeability percentage may be attributed to the
surfactant-like properties of emulsion components and their affinity for the phospholipids of the skin
membrane [33]. A common mechanism of action of surfactants as penetration enhancers involves
firstly a “push” effect to increase the drug solubility and hence to create a high concentration gradient.
Secondly, a “pull” effect is related to the flux of the permeation enhancer through the skin, which can
induce skin structural transformations [34]. In addition, findings from our study indicate that the
cream exerted the best effect in increasing the skin permeation of MGDG compared to Dex, in which
the permeated amount was lower (15 ± 3.1%). In accordance with other studies [35], this behavior can
be attributed to the lower partition coefficient of this molecule (logP 1.83) with respect to MGDG [13].
The interaction of the drug between the water and oil phase can determine the extent of lowering of
the thermodynamic activity in external phase, which is in contact with the skin. Partitioning of the
drug into internal oily phase (higher logP) is due to the hydrophobic characteristic of the drug. As both
molecules are highly lipophilic substances, the extremely slow permeation of Dex from the emulsion
through the mice skin can be explained by the fact that the diffusion of drug through the oily phase is
the limiting step for drug permeation [36].
An important consideration in psoriasis is the skin’s condition. Topical formulations may be
applied either to opened lesions that have lost SC barrier properties or to thickened lesions that
represent an additional barrier to absorption [37]. Thus, our findings suggest that a hydrophilic vehicle
(cream) could be an interesting alternative to improved topical delivery of MGDG in both conditions.
Based on the results above, we carried out a second TPA-induced hyperplasia model in mice
using MGDG-cream. In this experimental model, TPA was applied 1 h before the administration
of MGDG-containing cream to ensure the correct absorption of the product as well as increase its
permeation and protect the lipid integrity. Our data showed that dorsal application of TPA caused
similar manifestations to those detected in the previous model. Consistent with the anti-inflammatory
activity of glycolipids, pre-treatment with MGDG-cream ameliorated macroscopic cutaneous lesions,
skin edema, and MPO activity induced by repetitive application of TPA, which was correlated with
the histological study. Interestingly, the reduction of skin edema and MPO activity was higher with
MGDG-cream than that detected in the MGDG dissolved in acetone, reaching similar levels to those
of the reference corticosteroid Dex-cream.
It has been shown that topical application of TPA activates intracellular transduction signals,
enhancing aberrant expression of COX-2 in mouse skin [38,39]. To further elucidate the mechanisms
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for the anti-inflammatory role of MGDG-cream in damaged skin, we detected this protein expression
by immunohistochemistry. The results evidenced that pre-treatment with MGDG-cream markedly
attenuated COX-2 expression in TPA-stimulated mouse skin, reaching similar levels to Dex-cream.
Furthermore, this effect was confirmed in TNF-α-stimulated HaCaT human keratinocytes pre-treated
with different concentrations of MGDG, showing that this glycolipid fraction reduced COX-2 levels
at 50 μg/mL (data not shown). These findings at least partly suggest that suppression of COX-2
expression may be involved in the preventive effect of this glycolipid fraction on TPA-induced
epidermal hyperplasia.
4. Materials and Methods
4.1. Glycolipids
The extraction of dried biomass of I. galbana with acetone/methanol and the separation
of the extract to obtain the fraction glycolipids has been previously described [8]. The pure
compound MGMG-A was isolated during the microalgae products separation by C18 SPE
cartridges (Supelco, Bellefonte, PA, USA), the elution with MeOH/H2O (90:10, v/v) and
the separation by reverse-phase HPLC (Merck, Darmstadt, Germany) using MeOH/H2O
(98:2, v/v). The spectroscopic data obtained for this compound, which matched those
described in the literature, led to its identification as monogalactosylmonoacylglyceride
(2S)-1-O-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]-3-O-β-D-galactopyranosylglycerol
(MGMG-A) [40]. On the other hand, the separation of the extract of I. galbana previously
described led to obtaining a fraction of monogalactosyldiacylglycerides (MGDG). In the





HaCaT human keratinocytes were obtained from the American Type Culture Collection and
maintained in high glucose Dulbecco’s modified Eagle’s medium (DMEM, GIBCO, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and
100 mg/mL streptomycin in an atmosphere of 5% CO2 at 37 ◦C.
4.3. Cell Viability Assay
Viability of HaCaT cells upon exposure to glycolipid compounds was determined by
the sulforhodamine B (SRB) assay [41]. Briefly, the cells were seeded into 96-well plates at
1 × 104 cells/well. After 24 h, cells were incubated with compounds at the final concentrations
range of 10–100 μM or 10–100 μg/mL (100 μL/well) that were prepared by dilution of stock solutions
(10 mM) in DMSO in fresh medium. After 24, 48, and 72 h, cells were fixed with 50 μL of trichloroacetic
acid (TCA 50% v/v) at 4 ◦C for 1 h and processed as described in the literature.
4.4. Determination of IL-6 and IL-8 Production
HaCaT cells were seeded in six-well plates (2 mL/well) at 5 × 105 cells/well. After 24 h, the cells
were treated with different concentrations of MGMG-A (10, 30 and 50 μM) and MGDG (10, 30 and
50 μg/mL) and dexamethasone (Dex) (1 μM) for 1 h, and then stimulated with TNF-α (10 ng/mL) for
24 h. Then, supernatant fluids were collected and stored at −80 ◦C until IL-6 and IL-8 measurements.
Controls contained a medium with equivalent amounts of solvent compared to treatments, and
were incubated with and without TNF-α. Commercial enzyme-linked immunosorbent assay (ELISA)
kits (Diaclone GEN-PROBE, Besançon, France) were used to quantify cytokines according to the
manufacturer’s protocol. The absorbance at 450 nm was read by a microplate reader.
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4.5. Animals
For the present study, eight-week-old female Swiss CD-1 mice (25–30 g) were supplied by
Janvier-Labs (Le Genest St. Isle, France). Mice were maintained in our animal laboratory under
standard conditions (temperature of 24–25 ◦C, humidity of 70–75% and 12 h light–12 h dark
cycle). Mice were allowed free access to a standard diet (Panlab, Barcelona, Spain) and water ad
libitum. Dorsal hair of the mice was removed using electric clippers and depilatory skin cream
(Deliplus, Barcelona, Spain) in order to maintain a hair-free skin area to carry out the topical treatments.
All studies were performed in accordance with the recommendations of the European Union regarding
animal experimentation (Directive of the European Council 2010/63/EU). The experiments followed
a protocol approved by the Animal Ethics Committee of the University of Seville.
4.6. TPA-Induced Epidermal Hyperplasia Model and Glycolipid Treatments
We evaluated the effect of glycolipids from I. galbana on TPA-induced hyperplasia in murine skin.
Briefly, dorsal skin of female Swiss mice was shaved and 24 h later, animals that displayed no evidence
of hair regrowth or injury were assigned to the different groups.
In a first set of experiments (n = 10 per group), MGMG-A and MGDG dissolved in acetone
(10 μg/μL, 200 μg per site) or the reference agent Dex dissolved in acetone (10 μg/μL, 200 μg per site)
were topically administered to the shaved dorsal skin of animals in an area of 1 cm2 by using
a micropipette (total volume, 20 μL). Vehicle (acetone) was administered in a comparable volume
to sham and TPA group. After 30 min, TPA (2 nmol per site, dissolved in acetone) was topically
applied to the same areas, except the sham, which received a comparable volume of acetone (day 0).
This procedure was repeated for two consecutive days [2]. Mice were sacrificed on day 3 by cervical
dislocation and punch biopsies from the treated dorsal skin were weighed to evaluate edema before
further processing for histology and biochemical parameters.
4.7. MPO Activity
Myeloperoxidase (MPO) activity was assayed as a marker of neutrophil infiltration according to
the method of Grisham et al. [42]. The tissue was thawed, weighed, and homogenized in 10 volumes of
50 mM-PBS (pH 7.4). The homogenate was centrifuged at 20,000× g for 20 min at 4 ◦C. The pellet was
again homogenized in 10 volumes of 50 mM-PBS (pH 6) containing hexadecyl trimethylammonium
bromide (0.5%) and 10 mM-EDTA. This homogenate was subjected to one cycle of freezing/thawing
and a brief period of sonication. A sample of the homogenate (50 μL) was added to a 96-well microplate
and incubated at 37 ◦C for 3 min with a mixture containing o-dianisidine dihydrochloride (0.067%),
hexadecyl trimethyl-ammonium bromide (0.5%) and 0.3 mM-H2O2. Changes in absorbance at 450 nm
were measured with a microplate reader (Labysystem Multiskan EX, Thermo Scientific, New York,
NY, USA). One unit of MPO activity was defined as the amount of enzyme present that produced
a change in absorbance of 1.0 unit/min at 37 ◦C in the final reaction volume containing the acetate.
Results are expressed as units/mg tissue.
4.8. Histological Study
Tissue samples from the dorsal skin of four animals were fixed in 4% buffered paraformaldehyde,
dehydrated by increasing concentrations of ethanol and embedded in paraffin. Tissue sections cut
to 7 μm on a rotary microtome (Leica Microsystems, Wetzlar, Germany) were mounted on slides,
deparaffinized with xylene, rehydrated through graded alcohols, and stained with hematoxylin and
eosin (H&E) according to standard protocols. The tissues were analyzed by a blinded observer under
an Olympus BH-2 microscope (GMI Inc., Ramsey, MN, USA) for determination of histopathological
changes. Epidermal thickness was measured using Scientific Imaging Systems (Biophotonics ImageJ
Analysis Software; National Institutes of Health, Rockville, MD, USA).
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4.9. Measurement of Cytokines in Skin Homogenates
Frozen skin biopsies were homogenized in three volumes of ice-cold tissue lysis buffer containing
PBS (pH 7.2) with 0.1 M of EDTA, 1 mg/mL of leupeptin, 1 mg/mL of pepstatin, 1 mg/mL of aprotinin,
and 1 mM phenylmethylsulfonyl fluoride. Homogenates were centrifuged at 12,000× g for 10 min
at 4 ◦C. Supernatant fluids were stored at −80 ◦C until measurements. Levels of TNF-α, IL-1β, IL-6,
IL-17 and IL-10 were measured by quantitative Enzyme-Linked ImmunoSorbent Assay kits (ELISA)
(Peprotech, Hamburg, Germany), according to the manufacturer’s instructions. Data are reported as
pg/mg tissue.
4.10. Skin Topical Formulations
Hydrophilic gel. Carbopol® 934P (Lubrizol, Cleveland, OH, USA) was selected as a gelling agent
at 1% (w/v) due to its widespread use in pharmaceutical formulations and fast dispersion in water.
Rhodamine 6G solution in ethanol absolute (10 μg/μL) was gradually added to the polymer dispersion
under magnetic stirring. The dispersion was neutralized with triethanolamine to obtain an adequate
consistency suitable for topical application.
Cream. This O/W emulsion was prepared by gradually adding rhodamine (10 μg/μL),
MGDG (10 μg/μL) or Dex (10 μg/μL) solution in ethanol absolute to a cold mix excipient composed
of Caprylic/Capric Triglycerides, Glycol Stearate, PEG-3 Glyceryl Cocoate and Steareth-7 previously
heated to improve the drug interposition. The final formulations contained 0.2% (w/w) MGDG.
Lipophilic ointment. This formulation was obtained using melt emulsification combined with
stirring. Briefly, Brij® 72 (5% w/w) and white soft paraffin (77.3% w/w) were blended under gentle
stirring in a water bath at 70 ◦C to form the lipid phase. Successively, liquid paraffin (5% w/w)
and α-tocopherol (0.002% w/w) were added into the lipid phase until complete interposition at
60 ◦C. Then, rhodamine dissolved in propylene glycol (10 μg/μL) was added to the mixture.
Meanwhile, two solutions of EDTA (0.0065% w/w) and disodium phosphate dihydrate (0.026% w/w)
were prepared with distilled water at 60 ◦C and added dropwise to the lipid phase, with moderate
magnetic stirring at 150 rpm for 20 min. Finally, the rhodamine-loaded ointment was maintained at
room temperature for further use.
4.11. Permeation Studies
In vivo skin depth permeation by confocal laser scanning microscopy (CLSM). Confocal studies
were performed in order to investigate the penetration ability of several formulations through the
different skin layers [43]. Towards this aim, Carbopol® hydrogel, cream, and ointment were prepared
by adding a hydrophobic fluorescent probe, i.e., rhodamine 6G (100 mg per site, equivalent at 200 μg
of compound dissolved in ethanol), in the lipid or in the water-ethanol phase, according to the
composition of formulations. Rhodamine 6G was selected as an equivalent marker for MGDG or
Dex due to their comparable lipophilic properties. Appropriate samples of these formulations were
taken and placed on SC of mice and maintained in contact with the skin for 24 h. At the end of the
experiment, the remaining preparation was carefully washed with purified water from the skin surface.
Then, dorsal skin was excised and rinsed with pH 7.4 phosphate buffer solution, rapidly frozen in liquid
nitrogen and then stored at −80 ◦C. Sections of skin (50 μm thickness) were then perpendicularly
cut with a cryomicrotome and examined to investigate the fluorescent marker distribution in the
different skin layers. Analysis was carried out using a Leica TCS SP II CLSM (Leica, Heidelberg,
Germany) equipped with a Kr-Ar-He-Ne ion laser and a Leica DM IRE 2 microscope endowed with
HCPL Fluotar Leica 10× and 20× dry objectives and HCXPLAN APO Leica X40 multi-immersion
objective (numeric aperture 0.85). For excitation of the fluorescent label the 488 nm wavelength was
used and the fluorescence emission was detected at 520 nm.
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From the confocal images, a mathematical treatment was carried out in order to evaluate the
intensity of fluorescence in the samples, as appeared in the histogram curve provided from Leica
software. Statistical calculations were as follows:
Arithmetical mean value : μ(I) =
1
Npixel
× ∑ Ii, (1)





















where I is the energy intensity, Ii is the energy intensity of each pixel, Imean is the mean value of
energy intensity, Npixel is the number of pixels of the image, μ(I) is the arithmetical mean of the energy
intensity and VAR is the variance.
Ex vivo permeation studies. Diffusion studies were carried out using a Franz diffusion cell
apparatus (SES-Gmgh Analyses system, Bechenheim, Germany) with an effective diffusional area of
3.14 cm2. Excised mice skin was used as a membrane. Animals were sacrificed and full thickness
dorsal skin was excised. A specific portion of the skin was cut and used for the permeation study
after washing it with distilled water. The study was carried out following the methodology previously
reported [44]. Animal skin was inserted between the donor and receiving compartments and adjusted
by means of a pinch clamp. The receiving chamber was filled with 14.5 mL of degassed ethanol
absolute and thermostated by means of a water bath circulator and a jacket surrounding the cell,
maintaining 32 ◦C in the skin surface. The receiving medium was continuously stirred to avoid the
diffusion layer effect.
Once we selected the cream carrier from the previous study, MGDG-cream (0.2% w/w),
MGDG control solution (0.2% w/w), and Dex-cream (0.2% w/w) were accurately measured and
placed on SC in the donor compartment and sealed with parafilm. Aliquots of 0.5 mL were withdrawn
from the receiving medium at predetermined time intervals (0, 0.5, 1, 2, 3, 4, 5, 6 and 24 h) according
to international guidelines and the same volume was replaced with fresh ethanol absolute at the
same temperature. These samples were quantified by HPLC (Hitachi Elite LaChrom, Barcelona,
Spain) for MGDG quantification and spectrophotometry UV-visible (Agilent 8453, Barcelona, Spain)
was used for Dex quantification. HPLC system is equipped with an L-2130 isocratic pump, a diode
array detector L-2455 and L-2200 autosampler. The chromatographic separation was performed on
a reverse-phase LichroCART® C18 column (5 μm, 4.6 mm ID × 150 mm, Agilent, Santa Clara, CA,
USA) using as mobile phase acetonitrile (ACN, solution A): formic acid solution ((0.1% v/v), solution
B) adjusted to pH 2.67 in the following gradient (v/v): 0–6 min, 90% A, 10% B, flux 1 mL/min; 6–15
min, 100% A. The injection volume was 30 μL. The cumulative amount of drug in receptor chamber for
the three formulations (MGDG-cream, MGDG control solution and Dex control solution) was plotted
as a function of time (t, h). The cumulative amount (%) of drug permeated through the skin (P%) was
determined as per the following equation [45]:
P% =
Cn × V + ∑n−1i=1 Ci × Vi
M
× 100, (5)
where Cn is the drug concentration of the nth sampling point (mg/mL), Ci is the drug concentration of
the ith sample point (mg/mL), V is the total volume (14.5 mL) of liquid in receiving pool, Vi is the
volume (0.5 mL) of the ith sampling points and M is the mass of drug (MGDG or Dex).
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4.12. TPA-Induced Epidermal Hyperplasia Model and MGDG-Cream Treatment
Given acetone is considered moderately toxic and irritant and we aim to elaborate an optimal
glycolipid-containing pharmacological formulation, we evaluated the effect of MGDG-cream on
TPA-induced hyperplasia in murine skin. The dorsal skin of female Swiss mice was shaved as
described above.
In this second experimental model (n = 10 per group), a pre-treatment was carried out two days
(day −2 and day −1) before the first TPA challenge (day 0). MGDG-cream formulation (100 mg
per site, containing 200 μg of MGDG dissolved in ethanol at 10 μg/μL), Dex-cream (100 mg per
site, equivalent at 200 μg of compound dissolved in ethanol at 10 μg/μL) or vehicle (cream with
a comparable volume of ethanol) were applied to the shaved dorsal skin of the animals in an area of
1 cm2 using a syringe. On day 0, TPA (2 nmol per site, dissolved in ethanol) was topically applied
to the same areas using a micropipette (total volume of 20 μL). After 1 h, MGDG-cream, Dex-cream,
or vehicle was topically administered. Mice were anesthetized with ketamine (100 mg/kg of animal)
and diazepam (5 mg/kg of animal) during treatments and TPA challenge. This protocol was repeated
for two consecutive days. Mice were sacrificed on day 3 by cervical dislocation and punch biopsies
from the treated dorsal skin were weighed to evaluate edema, before further processing for MPO
activity and histology.
4.13. Immunohistochemical Analysis
Staining of COX-2 was performed using a streptavidin-biotin-peroxidase method [46].
Paraffin-embedded dorsal skin sections (7 μm) were mounted on slides, deparaffinized with xylene,
and rehydrated through graded alcohols. These sections were boiled (10 mM citrate buffer, pH 6.0 for 3
min) for antigen retrieval, followed by cooling at room temperature for 20 min. Endogenous peroxidase
was quenched with 0.3% (v/v) hydrogen peroxide for 20 min. Sections were rinsed with PBS for 10 min.
Nonspecific adsorption was minimized by incubating sections in normal horse serum (Vectastain Kit;
Vector Laboratories, Burlingame, CA, USA) for 20 min. Subsequently, slides were incubated with
rabbit polyclonal anti-COX-2 antibody (Cayman Chemical, Ann Arbor, MI, USA) (1:300) overnight
at 4 ◦C. Then, slides were treated with anti-mouse IgG antibody for 30 min and incubated with the
streptavidin–peroxidase complex for 30 min at room temperature (Vectastain Kit; Vector Laboratories,
CA, USA). The enzymatic activities were developed with 3,3′-diaminobenzidine (DAB), and the
sections were counterstained with hematoxylin. Negative control sections were treated in the same
way, omitting the primary antibody [47]. COX-2 immunoreactivity was examined on all sections
using a microscope Olympus BX61 (Olympus Optical Co. Ltd., Tokyo, Japan). The quantification of
immunohistochemical data was done by counting the number of immunostained brown cells as the
percent of total epidermal cells from 10 microscopic fields of immunostained tissues per animal.
4.14. Statistical Analysis
All values in the figures and text are expressed as arithmetic means ± SEM. Data were evaluated
with GraphPad Prism version 5.00 software (GraphPad Software, Inc., San Diego, CA, USA). In all
cases, the Shapiro–Wilk test was used to verify the normality of the data. The Mann–Whitney U-test
was chosen for non-parametric values. The parametric values groups were analyzed by one-way
analysis of variance (ANOVA) followed by Bonferroni’s Multiple Comparison Test. p values < 0.05 were
considered statistically significant. In the histological experiment, results shown are representative of
at least four independent experiments performed on different days.
5. Conclusions
In conclusion, our study demonstrates for the first time the preventive effects of topical
administration of the glycolipid MGMG-A or a fraction MGDG from I. galbana, in the inflammatory
model of TPA-induced skin hyperplasia. These actions may be associated with a reduction of
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edema, leukocyte infiltration, pro-inflammatory cytokines production and COX-2 expression in skin
mouse. Topical application of MGDG-cream enhanced the sample permeability and consequently,
increased the preventive effects of this product. Future studies are needed to expand the vision of the
mechanisms by which these lipid products improve skin inflammation and will support their potential
use in the development of effective therapeutic strategies for skin pathologies as psoriasis.
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/16/1/2/s1, Table S1:
Viability of HaCaT human keratinocytes treated with different concentrations of MGMG-A and MGDG fraction
isolated from the microalgae Isochrysis galbana.
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Abstract: Microalgae represent a source of bio-active compounds such as carotenoids with potent
anti-inflammatory and antioxidant properties. We aimed to investigate the effects of fucoxanthin
(FX) in both in vitro and in vivo skin models. Firstly, its anti-inflammatory activity was evaluated in
LPS-stimulated THP-1 macrophages and TNF-α-stimulated HaCaT keratinocytes, and its antioxidant
activity in UVB-irradiated HaCaT cells. Next, in vitro and ex vivo permeation studies were developed
to determine the most suitable formulation for in vivo FX topical application. Then, we evaluated
the effects of a FX-containing cream on TPA-induced epidermal hyperplasia in mice, as well as on
UVB-induced acute erythema in hairless mice. Our results confirmed the in vitro reduction of TNF-α,
IL-6, ROS and LDH production. Since the permeation results showed that cream was the most
favourable vehicle, FX-cream was elaborated. This formulation effectively ameliorated TPA-induced
hyperplasia, by reducing skin edema, epidermal thickness, MPO activity and COX-2 expression.
Moreover, FX-cream reduced UVB-induced erythema through down-regulation of COX-2 and iNOS
as well as up-regulation of HO-1 protein via Nrf-2 pathway. In conclusion, FX, administered in a
topical formulation, could be a novel natural adjuvant for preventing exacerbations associated with
skin inflammatory pathologies as well as protecting skin against UV radiation.
Keywords: fucoxanthin; inflammation; epidermal hyperplasia; UVB; photoprotection
1. Introduction
Skin is the organ that acts as main defence against external environment factors, protecting
the organism from harmful substances, mechanical damage, pathological invasion and radiations.
Nonetheless, the normal structure and functionality could be altered by external factors such as toxic
compounds or ultraviolet (UV) radiation, or by internal factors including genetic predisposition,
immune and hormone disorders, or stress. The result of these skin perturbations could trigger an
inflammatory process, an oxidative stress status, an unbalanced epidermal homeostasis, or a limited
immune response, among others [1].
In this respect, inflammatory skin diseases such as psoriasis, atopic dermatitis or rosacea have
harsh clinical implications because of their chronic curse and lead to develop comorbidities that make
difficult their treatment and have a remarkable impact on the quality-of-life of patients [2]. Nowadays,
UV skin exposure to treat these inflammatory conditions is recommended due to its beneficial
effects. In this line, UV radiation achieves long remission periods in psoriasis through activation
of immunosuppressive pathways and keratinocyte apoptosis [3]. On the other hand, detrimental
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effects of UVB radiation exposure (280–315 nm) have been extensively reported: it promotes a strong
acute inflammatory response characterized by activation and recruitment of innate immune cells
such as neutrophils and macrophages to the epidermis and dermis. In addition, UVB radiation is the
main source of reactive oxygen species (ROS) production, which increases the inflammatory response,
causing DNA oxidative damage in keratinocytes [4]. For this reason, new approaches to modulate
the skin inflammation and protect against UV radiation are necessary to supplement the existing skin
anti-inflammatory therapies.
Currently, marine resources are recognized for their variety of biologically active substances [5],
which are becoming important ingredients in skin care products due to their potent anti-inflammatory
and antioxidant actions as well as the safety and low risk in their administration [6]. In this sense,
carotenoids have shown antioxidant, anti-inflammatory or anti-carcinogenic properties in different
skin inflammatory models [7]. Fucoxanthin (FX) is an orange carotenoid present in brown seaweeds,
diatoms and microalgae [8], whose antioxidant activity has been well demonstrated in previous
studies [9,10]. Particularly, FX has shown to enhance AKT/ nuclear factor (erythroid-derived 2)-like 2
(Nrf2)/glutathione (GSH)-dependent antioxidant response in keratinocytes [11]. Moreover, this
carotenoid reduces wrinkle formation and epidermal hypertrophy in mice [12] and suppresses
melanogenesis and prostaglandin synthesis [13]. In addition, FX has been proposed as a photoprotective
compound by stimulating restoration of the skin barrier in UVA-induced sunburn [14]. However,
the protective effect of a FX-containing topical formulation has not been described yet on a skin
inflammatory model. The possibility to administer FX topically has been subjected to several
drawbacks because of its molecular weight and lipophilicity. As it is known, the compound must
diffuse across stratum corneum and tight junctions to achieve effective permeation. In this sense, topical
dosage forms such as creams, ointments, lotions and gels are commonly used for enhancing the
cutaneous penetration. Thus, their composition will affect the drug permeation [15]. Concerning
FX, several preparations have been studied with this aim [16,17]; in all of them, the evaluation of
cutaneous penetration is a useful approach to predict the safety and efficacy of formulations [18].
To date, previous papers have developed topical experiments in mice applying acetone-dissolved
compounds on skin [12,19]. With the aim of solving the irritant effect of acetone for its use in humans,
a previous study from our group recently evaluated a glycolipid fraction-containing cream formulation
on the murine 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced epidermal hyperplasia model.
Our findings reported an anti-inflammatory effect of this formulation with no signs of toxicity [20].
In the present study, we evaluated the anti-inflammatory and antioxidant properties of
FX-containing cream in both in vitro and in vivo models in order to justify its use as adjuvant in
inflammatory skin pathologies in which sun exposition is recommended. Firstly, we carried out two
in vitro models to elucidate its anti-inflammatory and antioxidant activity. Then, FX was dissolved
in absolute ethanol to further be incorporated into several common topical formulations (ointment,
cream or hydrophilic gel). Once a topical formulation was selected, we finally aimed to study its effect
on the TPA-induced hyperplasia model in mice, which mimics psoriatic parameters in dorsal murine
skin, and on the UVB-induced erythema model in hairless mice, which reproduces the consequences
expected in humans receiving acute UVB radiation.
2. Results
2.1. Effect of FX on Cell Viability
The effect of FX on THP-1 macrophages and HaCaT cells viability was measured by using
the sulforhodamine B (SRB) assay. Results from cytotoxicity study showed that none of the tested
concentrations affected cell viability. The inhibitory concentration 50 (IC50) (half maximal inhibitory
concentration) was above 100 μM at 24 h after treatment (Table S1).
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2.2. Effects of FX on TNF-α Production in LPS-Stimulated THP-1 Macrophages and IL-6 and IL-8 Production
in TNF-α-Stimulated HaCaT Human Keratinocytes
Non-cytotoxic concentrations of FX were used to determinate its effect on pro-inflammatory
cytokines in both THP-1 macrophages and human keratinocytes. As shown in Figure 1, all concentrations
tested significantly reduced the production of inflammatory cytokines in both cell models. Interestingly,
the pre-treatment with the carotenoid at 50 μM showed a significant reduction of tumor necrosis factor
alpha (TNF-α) production in lipopolysaccharide (LPS)-stimulated THP-1 macrophages, reaching
similar values to dexamethasone (Dex) (p < 0.001) (Figure 1A). In relation to interleukin (IL)-6 and IL-8
production in HaCaT keratinocytes, similar results were exhibited in cells pretreated with the highest
dose of FX (p < 0.001) (Figure 1B,C).
Figure 1. Effects of fucoxanthin (FX) on pro-inflammatory cytokines production in THP-1
macrophages and HaCaT keratinocytes. (A) Tumor necrosis factor alpha (TNF-α) in lipopolysaccharide
(LPS)-stimulated THP-1 macrophages. (B) Interleukin (IL)-6 and (C) IL-8 in TNF-α-stimulated HaCaT
keratinocytes. Cells were treated with FX (10, 30 and 50 μM) for 1 h, and then stimulated with LPS
(1 μg/mL) in THP-1 macrophages or TNF-α (10 ng/mL) in HaCaT cells for 24 h. Dexamethasone
(Dex) was used as positive reference compound at 1 μM. Production of cytokines in supernatant was
measured by ELISA assay. Results are representative of six independent experiments. Values are means
with standard errors represented by vertical bars. The mean value was significantly different compared
with the control group (*** p < 0.001; Student t test). Mean value was significantly different compared
with the LPS or TNF-α group (+ p < 0.05, ++ p < 0.01, +++ p < 0.001; one-way ANOVA followed by
Bonferroni’s Multiple Comparison test).
2.3. In Vitro Permeation Studies of BC from Different Topical Formulations
The objective of this study was to evaluate the in vitro permeation through artificial membranes of
β-carotene (BC) from different topical formulations. BC was selected because of its structural similarity
with FX. The formulations tested were: ethanolic solution as control, hydrogel, cream and ointment.
BC was detected in the receiver medium in a time-dependent manner and profiles of cumulative
amount of drug permeated have been obtained (Figure 2).
The permeation profiles showed the cream as the most favourable vehicle as penetration enhancer.
When compared with the ethanolic control solution, a high percentage of BC permeated was obtained
at a flux very similar to the control solution, as reported in Table 1. However, the ointment and hydrogel
preparations made it difficult the pass through the membrane, probably due to their lipophilic and
hydrophilic nature, respectively. This was visualized in terms of lower permeation percentages and flux
rates. Hydrophilic cream provided the highest release of BC in comparison with lipophilic ointment or
hydrogels, as previously reported for flavonoids [21]. Therefore, the hydrophilic cream (oil-in-water
(OW) emulsion base) was chosen for incorporating FX and Dex for further studies. As these emulsions
have hydrophilic external phase, they are miscible with water and skin secretions, thus they are not
occlusive and are easily removed from skin.
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Figure 2. Permeation profiles. (A) In vitro permeation profile of β-Carotene (BC) from different topical
formulations: cream, ointment and gel. BC dissolved in absolute ethanol was used as control solution.
Artificial membranes impregnated with N-dodecanol mimicked the skin barrier. Absolute ethanol was
used as release medium. (B) In vitro permeation profiles of fucoxanthin (FX) and dexamethasone (Dex)
from cream formulation. FX dissolved in absolute ethanol was used as control solution. Dex-loaded
cream was used as positive control. The experimental procedure was similar to that for BC. The
percentages of drug release were obtained from the amount of drug that reached the receiver medium
with time. These values are expressed in percentage, where 100% corresponds to the theoretical amount
of drug added to the formulation. Data are represented as the mean ± standard error (n = 3).
Table 1. Total percentage permeated across artificial lipophilic membrane of β-carotene (BC) from
different topical formulations, and flux rate (Jss) (μg/cm2·min) calculated from the slope of amount
permeated per area versus time.
Formulation % Permeation (180 min) Flux (Jss) (μg/cm2·min) r2
Cream 68.38 0.1159 0.9795
Ointment 47.31 0.0548 0.9704
Hydrogel 25 0.0383 0.9403
Control 100 0.1350 0.9862
2.4. Ex Vivo Permeation Studies of FX-Containing Cream
Once the cream was selected as the vehicle for drug formulation, FX-loaded cream was prepared
following the same methodology that for BC. In addition, Dex-loaded cream was formulated as
positive control for the in vivo assay. The permeation profiles of FX contained in the hydrophilic cream
were evaluated with the aim of analyzing the permeation behavior in the mice skin compared to an
ethanolic control solution and Dex-cream.
Results showed a clear improvement of FX permeation with time (Figure 2). As evidenced from
the area under the drug permeation curve (AUC) calculated (48,610, 19,914 and 8671%/h for FX-cream,
FX control and Dex-cream, respectively), the cream vehicle offered a higher amount of FX permeated
with time, whereas the control solution of this molecule showed a lower percentage. Although the
ethanol acts as permeation enhancer, the cream composition, rich in surfactants, made the formulation
improve the amount of FX to cross the membrane. Surprisingly, the permeation profile of Dex-cream
showed 15%, approximately, of drug permeation. This lack of diffusion across the membrane could be
attributed to a lower partition coefficient than FX (1.83 vs. 14.76). Dex has a lower molecular weight
than FX, but the lipophilic nature of the carotenoid makes it a better candidate to interact with the
surfactant components of the cream, which aids the solubilized molecule to reach the receiver medium.
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2.5. Topical Application of FX-Containing Cream Decreases Skin Inflammation and Hyperplasia on the Murine
TPA-Induced Model
To analyze whether topical pre-treatment with FX could reduce the in vivo inflammation, we
studied this carotenoid on the murine TPA-induced epidermal hyperplasia model. Topical pre-treatment
with FX-cream (100 mg per site containing 200 μg of FX) and Dex (100 mg per site containing 200 μg of
Dex) was administered from 2 days before TPA-induced hyperplasia and 1 h after each TPA application
(2 nmol per zone for three consecutive days). Then, 24 h after the last application of TPA, mice were
sacrificed and skin biopsies were removed and weighted. Mice treated with TPA or TPA-cream resulted
in the development of macroscopic lesions as peeling (Figure 3A), confirmed by an increase of weight of
the 1 cm2 punch biopsies of dorsal skin, in comparison with sham group (p < 0.001), with no significant
differences between both groups (Figure 3B). This comparison led us to confirm that cream did not
interfere in TPA action in our experiment. As expected, pre-treatment with the reference compound
Dex significantly reduced the skin punch weight (p < 0.001). Similarly, mice treated with FX-cream
showed a significant attenuation of skin edema when compared with TPA-cream group (p < 0.001)
(Figure 3B). We next analyzed the skin homogenates to evaluate myeloperoxidase (MPO) activity as a
neutrophil infiltration parameter with important relevance in hyperplasia model (Figure 3E). Our results
confirm that this marker significantly increased after TPA application in comparison with sham group
(p < 0.01). Dex application markedly diminished MPO activity in relation to TPA-cream group (p < 0.01).
In a similar way, this parameter was reduced by FX-cream (p < 0.05) (Figure 3E). These results were
confirmed with histological analysis of hematoxylin and eosin (H&E)-stained skin lesions in mice
(Figure 3C), which showed that TPA administration produced a massive neutrophilic infiltration and an
epidermal hyperplasia, because of uncontrolled and abnormal keratinocyte production. This effect was
evidenced by a marked increase of epidermal thickness in this group (p < 0.001). Animals pre-treated
with Dex and FX-cream evidenced a significant improvement in epidermal hyperplasia in relation to
TPA-cream group (p < 0.001, and p < 0.01, respectively) (Figure 3C,D).
Figure 3. Cont.
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Figure 3. Fucoxanthin (FX) ameliorates skin hyperplasia and inflammation induced by
12-O-tetradecanoylphorbol-13-acetate (TPA) in mice (n = 10 mice/group). FX-cream formulation
(100 mg per site at 200 μg), dexamethasone (Dex, 100 mg per site at 200 μg) or vehicle (cream with 0.2%
ethanol) were topically administered as described in Material and methods. (A) Macroscopic mice back
appearance at the end of experiment. (B) Skin edema as punch biopsy. (C) Histological appearance of
mouse dorsal skin after hematoxylin/eosin (H&E)-staining; Bar = 10 mm. Original magnification 100×
(D) Epidermal thickness assessment in H&E-stained skin slides. (E) Myeloperoxidase (MPO) activity.
Values are means with standard errors represented by vertical bars. The mean value was significantly
different compared with the sham group (** p < 0.01, *** p < 0.001; Student t test). The mean value was
significantly different compared with TPA-cream group (+ p < 0.05, ++ p < 0.01, +++ p < 0.001; one-way
ANOVA followed by Bonferroni’s Multiple Comparison test).
To support the beneficial effects of FX on skin inflammation and explore its possible mechanism
of action, we measured cyclooxygenase-2 (COX-2) expression in skin samples (Figure 4). This enzyme
has been shown to have an important role in pathogenesis of skin diseases. Immunohistochemical
analysis of this enzyme exhibited that TPA-induced hyperplasia significantly enhanced COX-2-positive
cell numbers (p < 0.001), principally located in epidermal layer, in comparison with sham (Figure 4B).
Figure 4 shows that the results of mice pre-treated with Dex confirmed the anti-inflammatory effect of
this corticoid (p < 0.001). Interestingly, pre-treatment with FX-cream resulted in a marked decrease
in the number of epidermal COX-2-positive stained cells related with TPA-cream group, reaching
expression levels lower than those in Dex group (p < 0.001).
Figure 4. Cont.
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Figure 4. Topical application of fucoxanthin (FX) reduced 12-O-tetradecanoylphorbol-13-acetate
(TPA)-induced epidermal cyclooxygenase-2 (COX-2) expression in mice. (A) Representative
photographs of epidermal COX-2 distribution by immunohistochemical detection; Bar = 12.7 mm.
Original magnification 200×. (B) Percentage of COX-2 positivity in epidermal layer was assessed by
counting the number of COX-2 positive cells vs. total cells from 10 equal sections of immunostained
dorsal skin per animal (n = 3). Values are means with standard errors represented by vertical bars.
The mean value was significantly different compared with the sham group (*** p < 0.001; Student t test).
The mean value was significantly different compared with TPA-cream group (+++ p < 0.001; one-way
ANOVA followed by Bonferroni’s Multiple Comparison test).
2.6. FX Protects Human HaCaT Keratinocytes against UVB-Caused Damage
To examine the protective effect of FX in irradiated HaCaT cells, we evaluated cell viability by
lactate dehydrogenase (LDH) enzyme activity, ROS levels and IL-6 production after UVB exposure.
As expected, UVB irradiation significantly increased LDH activity, ROS content and IL-6 production in
HaCaT keratinocytes compared to unirradiated control (p < 0.001) (Figure 5A–C). Pre-treatment of
cells with FX 1 h prior to UVB exposure significantly decreased UVB-induced mortality, preserving
cell membrane integrity in a dose-dependent manner at all concentrations used (10, 30 and 50 μM,
p < 0.05, p < 0.01, p < 0.001, respectively) (Figure 5A). We next evaluated intracellular ROS levels
in UVB-irradiated cells based on the dichlorofluorescein diacetate (DCF-DA) assay (Figure 5B).
FX markedly reduced ROS levels by 23, 31 and 32% at the concentration of 10, 30 and 50 μM,
respectively (p < 0.01, p < 0.001, p < 0.001) (Figure 5B).
Figure 5. Protective effect of fucoxanthin (FX) on UVB-induced damage in HaCaT cells. Keratinocytes
were preincubated with FX (10, 30 and 50 μM) for 1 h prior to UVB (50 mJ/cm2) exposure. (A) After
24 h, cell viability was assessed by using lactate dehydrogenase (LDH) assay. (B) Intracellular reactive
oxygen species (ROS) generation was measured 30 min after UVB irradiation by relative fluorescence
intensity using dichlorofluorescin-diacetate (DCF-DA) assay. (C) Interleukin (IL)-6 production was
evaluated by ELISA assay, 24 after UVB exposure. Cell viability and ROS production are expressed
as percentage respect to UVB-irradiated cells and IL-6 levels as pg/mL. Results are representative of
four independent experiments. Values are means with standard errors represented by vertical bars.
The mean value was significantly different compared with the control group (*** p < 0.001; Student
t test). The mean value was significantly different compared with UVB group (+ p < 0.05, ++ p < 0.01,
+++ p < 0.001; one-way ANOVA followed by Bonferroni’s Multiple Comparison test).
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It is known that UVB exposure induces abnormally augmented cytokine production from
keratinocytes, leading to inflammatory skin disorders. To evaluate the effect of FX on IL-6 production,
HaCaT cells were pre-treated for 1 h with this carotenoid, and then were exposed to UVB. Pre-treatment
with FX at the concentrations tested of 10, 30 and 50 μM substantially inhibited this cytokine levels by
23, 31 and 59%, respectively (p < 0.001) (Figure 5C).
2.7. Topical Application of FX-Containing Cream Protects against UVB-Induced Skin Erythema in SKH-1
Hairless Mice
The possible photoprotective effect of the topical pre-treatment with FX-cream in hairless mice
was assayed using an acute proinflammatory UVB dose (360 mJ/cm2) [22]. BC-cream was employed as
reference compound due to its antioxidant and photoprotective activity [23]. Animals were examined
with a dermatoscope for five days, evaluating UVB-induced skin alterations. As shown in Figure 6A,
a single acute UVB exposure accelerated skin damage, showing typical symptoms such as peeling,
loss of moisture, reduction of elasticity and increase of melanin production in comparison with sham
controls (Figure 6A–D). The progressive evaluation of mice showed that pre-treatment with FX-cream
increased the skin moisture (Figure 6B) and elasticity (Figure 6C) and decreased the production of
melanin (Figure 6D), with similar values to BC-cream. In order to confirm the protective profile of FX,
48 h after UVB irradiation, the mice were sacrificed and dorsal skin was examined. Our data reflected
significant increases of skin edema and MPO activity in UVB-irradiated group when compared with
sham (p < 0.001). The reference group, BC-cream, showed pronounced lower levels of these parameters
when compared to UVB-irradiated group (p < 0.001, p < 0.05, respectively) (Figure 6E,F). Similar
results were found after pre-treatment with FX-cream (Figure 6E,F). These findings were confirmed
by histological study by using H&E staining. Histologically, a significant increase in superficial skin
layer thickness due to unregulated keratinocytes proliferation was detected in UVB-irradiated animals
in comparison to sham (p < 0.001) (Figure 6G,H). FX-cream treatment was as effective as topical
application of BC-cream; our data revealed a decrease in keratinocytes proliferation when compared
to UVB-irradiated group, evidenced by a significant reduction of epidermal thickness (p < 0.001)
(Figure 6G,H).
To further explore the possible mechanisms of action of FX, we examined the expression levels
of different inflammatory and antioxidant proteins in dorsal skin samples. Exposure of skin to
UVB induced a significant increase in the pro-inflammatory enzymes iNOS (p < 0.001) and COX-2
(p < 0.001) expression (Figure 7B,C). Neither of these proteins changed significantly in animals
treated with the reference compound BC-cream. However, pre-treatment with FX-cream resulted in a
significant downregulation of COX-2 expression levels in irradiated mice (p < 0.05) in comparison with
UVB-irradiated animals. As regards the iNOS protein, although its expression tended to decrease in
FX-cream-treated animals, no significant differences were observed in relation to UVB-treated mice.
UVB exposure significantly down-regulated the expression of Nrf-2 protein (p < 0.05). BC-cream
application induced a marked increase in Nrf2 levels (p < 0.001) accompanied with a rise of its target
gene heme oxygenase-1 (HO-1) (p < 0.05). In a similar way, FX-cream significantly increased the
expression of these antioxidant proteins in UVB-exposed skin (p < 0.01 and p < 0.05, respectively)
(Figure 7D,E).
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Figure 6. Fucoxanthin (FX) has photoprotective effects in UVB-induced erythema model in hairless mice
(n = 8 mice/group). Mice received a single UVB radiation dose of 360 mJ/cm2. FX-cream formulation
(FX-cream, 100 mg per site at 200 μg), β-carotene-cream (BC-cream, 100 mg per site at 200 μg) or
vehicle (cream with 0.2% ethanol) were topically administered as described in Material and methods.
(A) Macroscopic mice back appearance at the end of experiment. (B) Skin moisture, (C) skin elasticity
and (D) melanin index were evaluated during all experiment. (a.u), arbitrary units. (E) Determination
of skin edema as punch biopsy weight. (F) Myeloperoxidase (MPO) activity. (G) Measurement of the
epidermal thickness in hematoxylin/eosin (H&E)-stained skin slides. (H) Photomicrographs of mouse
dorsal skin after H&E-staining; Bar = 10 mm. Original magnification 100×. Values are means with
standard errors represented by vertical bars. The mean value was significantly different compared with
the sham group (*** p < 0.001; Student t test). The mean value was significantly different compared with
UVB-exposed group (+ p < 0.05, +++ p < 0.001; one-way ANOVA followed by Bonferroni’s Multiple
Comparison test).
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Figure 7. Anti-inflammatory and antioxidant effects of fucoxanthin (FX) in UVB-induced erythema
model in hairless mice (n = 8 mice/group). Mice received a single UVB radiation dose of 360 mJ/cm2.
FX-cream formulation (100 mg per site at 200 μg), β-carotene-cream (BC-cream, 100 mg per site at
200 μg) or vehicle (cream with 0.2% ethanol) were topically administered as described in Material
and methods. (A) Representative Western blot images of different skin proteins. Densitometric
analysis of (B) inducible nitric oxide synthase (iNOS), (C) cyclooxygenase-2 (COX-2), (D) nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) and (E) heme oxygenase-1 (HO-1) proteins. Data were studied
following normalization to the control (housekeeping gene, β-actin). Values are means with standard
errors represented by vertical bars. The mean value was significantly different compared with the sham
group (* p < 0.05, *** p < 0.001; Student t test). The mean value was significantly different compared with
UVB-exposed group (+ p < 0.05, ++ p < 0.01, +++ p < 0.001 one-way ANOVA followed by Bonferroni’s
Multiple Comparison test).
3. Discussion
FX has formerly demonstrated in vitro and in vivo anti-inflammatory and antioxidant
activities [11,14,24]. Nevertheless, the use of topical formulations such as cream/emulsion containing
this carotenoid to prevent exacerbations related with skin inflammatory pathologies and provide
a photoprotective effect has not been previously evidenced. Treatment of the skin with these
topical formulations is a rational approach since avoids gastrointestinal degradation and preserves
bioavailability [25].
Firstly, in the present study, we confirmed the in vitro anti-inflammatory activity of FX through
decrease in TNF-α production in LPS-stimulated macrophages and reduction of IL-6 and IL-8 levels
in TNF-α-stimulated HaCaT keratinocytes. These results led us to evaluate the possible preventive
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effects of this carotenoid on two in vivo acute skin inflammatory models: a hyperplasia model induced
by multiple applications of TPA and an erythema model induced by a single UVB challenge.
Drug delivery across the skin remains as an important challenge in the development of drug
delivery systems. This is mainly attributed to the highly organized intercellular lipids and poor
permeability of stratum corneum [26]. It is also well-known that lipophilic molecules move across the
barrier by a transcellular mechanism whereas hydrophilic agents are likely to follow a paracellular
pathway to cross the skin. FX is lipophilic with a high partition coefficient (log P 6.83–7.54). To date,
some studies with FX have been carried out by dissolving FX in ethanol for applying the drug
dissolved onto the skin [12]. However, this solvent is known to produce dryness effect in the skin.
To improve FX topical application, various hydrophilic and lipid-based formulations have been
developed, firstly using BC as model drug because of its structural similarity to FX [27]. In this
sense, new approaches are desirable in order to avoid the use of uncomfortable formulations such
as paraffin [13]. In order to have a prediction of the in vivo permeation behaviour of the drug
and to avoid the expensive cost of the use of animals or human skin, alternative artificial skin
diffusion apparatus was used for conducting in vitro permeation studies. As regards the formulations
tested (cream, ointment and hydrogel), it was found that lipid-based formulations improved most
efficiently the diffusion of BC through the permeation membrane in a Franz diffusion cell. In contrast,
water-based formulations, such as Carbopol gel, exhibited poor penetration. The composition of cream,
which was highly charged in surfactants, makes it to act as a permeation enhancer that changes the
atmosphere of the lipids to encourage the diffusion of lipid molecules (BC or FX) and/or influence
their solubility [28]. The blend of agents with polar and non-polar properties, which probably mimic
the complex lipid/polar nature of the stratum corneum, makes the cream thermodynamically similar
to the stratum corneum, enabling the permeation of BC through the skin. Other authors incorporated
surfactant-like molecules (D-α-tocopheryl polyethylene glycol 1000 succinate) into the formulations
for synergistically acting with ethanol as solubilizing agents of griseofulvin [29]. This is the reason
why formulations too occlusive and lipophilic (ointment) make difficult the permeation process of
poorly water-soluble compounds. On the contrary, concerning the highly hydrophilic formulations
(gel), it is known that water can generate a resistant boundary at the donor-skin interface (impregnated
in our artificial membranes with dodecanol) and may prolong or delay the permeation of poorly
water-soluble molecules such as BC.
Once we selected the cream as a vehicle for our studies, we proceeded to elucidate the FX
behaviour in terms of permeation kinetics through a comparative study with control solution and
Dex-cream. This carotenoid has been previously formulated in O/W formulations by other authors [16].
Our results showed that, under the experimental conditions used, FX-cream has a higher permeability
though artificial membrane than the other formulations (control solution FX and Dex-cream). Other
authors reported that the differences in penetration might be associated with the variation in the
lipophilicity of the tested compounds [30], as obtained in this case. Although Dex has a lower molecular
weight than FX, which might favour the diffusion across the membrane, its low lipophilicity (log P 1.83)
compared to FX, makes more difficult this passage, showing permeation profiles more reduced [26].
The efficacy of FX-loaded O/W emulsions has been demonstrated as anti-obesity formulations
being prepared by using medium chain triglyceride as an oil phase and l-α-phosphatidylcholine
as an emulsifier [17,31]. This heterogeneous disperse system has been also used for incorporating
other antioxidant molecules such as green tea polyphenols with the aim of preventing UVB-induced
oxidation of lipids in mouse skin [21]. Thus, hydrophilic cream may serve as an optimal delivery
system for FX use in animal models.
TPA is an activator of protein kinase C isoenzymes and a well-known inducer of inflammatory
response in murine skin rising expression of the inflammation mediators [32]. TPA-induced hyperplasia
model in dorsal murine skin reproduces typical manifestations of inflammatory skin pathologies as
psoriasis. In this regards, TPA administration causes macroscopic lesions such as erythema or peeling,
as well as increment of epidermis thickness by hyperproliferation and aberrant differentiation of
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keratinocytes or leukocytes infiltration into the dermis and consequent cytokines and chemokines
production [33]. The pre-treatment with FX-cream ameliorated skin hyperplasia reducing MPO
activity, as indicatory of leucocyte infiltration, and skin edema. These results were related with the
improvement of histological damage by reducing epidermal thickness and neutrophil infiltration,
getting similar levels to those of the reference corticosteroid Dex. The relation between epidermal
differentiation and COX-2 expression has been strongly reported, as well as their connection with
the pathogenesis of psoriasis [34]. In this sense, repeated applications of TPA in dorsal murine skin
induce inflammation symptoms that are accompanied by COX-2 epidermal overexpression in relation
with healthy group [35]. Our data evidenced a reduced COX-2 expression in mice treated with FX,
presenting lower levels than those in Dex group. These findings, at least partly, suggest that suppression
of COX-2 expression may be involved in the preventive effect of this carotenoid on TPA-induced
epidermal hyperplasia. Our results are in agreement with previous in vitro studies that showed the
capacity of FX to modulate inflammatory response through inhibition of COX-2 and iNOS expression
and the consequent decrease of NO and prostaglandin E2 levels [24,36]. The molecular mechanisms
underlying the anti-inflammatory properties of FX may be associated with the suppression of nuclear
factor-kappaB and mitogen-activated protein kinase pathways, similar to those previously reported
for Dex in skin inflammatory pathologies [37]. More recently, FX has shown to downregulate COX-2
levels in a murine model of high-fat-diet-induced obesity [38]. It is well known that inflammatory
pathologies as psoriasis require long-term topical corticosteroids therapy, which is associated with
both topical and systemic adverse effects. Moreover, the chronic use of these compounds may increase
tendency to “steroid addiction syndrome”, which forces to change the corticoid and select one more
potent [39]. For these reasons, the use of a well-tolerated immune-modulatory topical formulation
containing FX could offer a safer alternative to continued use of corticoids for the treatment of skin
inflammatory disorders.
Additionally, it is worth highlighting that since these pathologies benefit from therapeutic sun
exposition, it is very important to assure the photoprotection of exposed skin. Sunscreens are used
to prevent the deleterious effects of UVB due to this radiation remains as an important risk factor
to develop skin lesions [40]. In this sense, further therapeutic strategies targeting UVB-induced
inflammation and oxidative stress are necessary. Thus, our next objective was to examine the
photoprotective effects of FX in an UVB-induced cell damage model in HaCaT keratinocytes, as well
as on an UVB-induced erythema model in hairless mice in order to complete the functional activity
study of this compound as adjuvant treatment in skin inflammatory disorders. It is well known that
UVB irradiation induces cell cytotoxicity through loss of cellular membrane integrity, which leads
to liberation of LDH enzyme from cytosol to the culture medium [41]. Moreover, UVB radiation
causes increased ROS production and DNA damage, as well as a strong inflammatory response,
characterized by the production of inflammatory cytokines, such as IL-6, which leads to premature
skin aging and carcinomas [42]. Recently, it has been demonstrated that the antioxidative role of
FX in HaCaT keratinocytes is related to DNA protection against oxidative stress and the prevention
of apoptosis [43,44]. According with these results, we have shown that pre-treatment of HaCaT
keratinocytes with FX significantly attenuated UVB-induced damage by increasing cell viability and
inhibiting ROS and IL-6 levels.
In relation to in vivo alterations, acute UVB radiation promotes erythema, edema and loss of skin
moisture and elasticity, as well as increases melanin production, which is involved in melanogenesis.
Recently, several studies have revealed the photoprotective effects of FX in UVB-irradiated mice by
reducing melanogenesis parameters [13] and in UVA-induced sunburn by promotion of skin barrier
formation [14]. In addition, this carotenoid prevented skin photoaging in hairless mice through its
antiangiogenic and antioxidant effects [12]. Herein, we report that the topical pre-treatment with
FX-cream formulation ameliorated erythema induced by UVB as well as edema and MPO activity,
which are important inflammation and neutrophil recruitment parameters. Overexpression of COX-2
is highly related to some carcinomas including skin cancer [45]. In this regard, and in accordance to
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the above results from TPA model, we also reported the reduction of COX-2 expression by FX-cream
pre-treatment on UVB-exposed skin, effect not observed upon BC administration.
It has been reported that excessive ROS generation results in oxidative stress in skin cells and
plays a vital role in the initiation, promotion and progression of skin aging, carcinogenesis and many
inflammatory disorders [46]. In this respect, Nrf2 is a transcription factor that perceives variation
in cellular oxidative stress and promotes the transcription of antioxidant genes and detoxification
enzymes such as HO-1 to protect against UVB-induced oxidative damage [47,48]. An in vitro study
has elicited the antioxidant activity of FX by enhancing the Akt/Nrf2/GSH pathways in human
keratinocytes [11]. Moreover, FX has been recently shown to be able to activate Nrf2 signalling
pathway by inducing demethylation of CpG sites in Nrf2 [49]. In accordance with these results,
our data reported that FX and BC offer a similar protection against oxidative stress caused by UVB
exposure via increase of Nrf2 expression and its downstream target HO-1. However, in a previous
paper FX was confirmed to have higher antioxidative effects than BC, due to its more polar nature and
consequent placement in the cell membrane [50]. In the present study, although the two carotenoids
have shown to have similar antioxidant properties, FX provides additional benefits, exhibiting an
anti-inflammatory activity by downregulating COX-2 expression after UVB irradiation. These findings
propose this carotenoid as a natural approach for protecting skin against UV radiation and modulating
the inflammatory response associated.
4. Materials and Methods
4.1. Cell Culture
The THP-1 human monocytic leukemia cell line and HaCaT human keratinocytes were obtained
from the American Type Culture Collection (ATCC, Manassas, VA, USA). THP-1 cells were cultured in
RPMI 1640 medium (GIBCO, Grand Island, New York, NY, USA) containing 10% heat-inactivated fetal
bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin. HaCaT human keratinocytes
were maintained in high glucose Dulbecco’s modified Eagle’s medium (DMEM, GIBCO, Grand Island,
New York, NY, USA). Both cell lines were grown in a humidified atmosphere containing 5% CO2 at
37 ◦C [20].
4.2. Cell Viability Assay
SRB assay was used for determining the viability of THP-1 macrophages and HaCaT cells
upon exposure to FX (Sigma-Aldrich, St. Louis, MO, USA) [51]. Firstly, for differentiation into
macrophages, THP-1 cells were seeded into 96-well plates at 104 cells/well in presence of phorbol
12-myristate 13-acetate (PMA, Sigma-Aldrich, St. Louis, MO, USA) for a final concentration of 0.2 μM
for 72 h in 96-well plates and HaCaT cells were seeded into 96-well plates in the growth medium at
104 cells/well for 24 h to ensure the adherence. Both cellular types were incubated in a humidified
atmosphere of 5% CO2 at 37 ◦C. After that, cells were treated with FX at final concentrations range of
10–100 μM in DMSO 0.1% (v/v) and the cytotoxicity was measured after 24, 48 and 72 h of incubation.
The absorbance was determined at 492 nm in a microplate spectrophotometer (Sinergy HT, Biotek®,
Bad Friedrichshall, Germany).
4.3. Determination of TNF-α Production
THP-1 monocytes were differentiated into macrophages in 96-well plates (104 cells/well). Then,
cells were incubated for 1 h with FX (10, 30 and 50 μM). The positive reference compound used was
Dex (1 μM) (Sigma-Aldrich, St. Louis, MO, USA). Inflammatory response was induced by addition of
LPS (1 μg/mL) except for control group [52]. After 24 h, commercial enzyme-linked immunosorbent
assay (ELISA) kit (Diaclone GEN-PROBE, Besançon, France) was used to quantify TNF-α according to
the manufacturer’s protocol.
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4.4. Determination of IL-6 and IL-8 Production
HaCaT cells were seeded in 6-well plates (5 × 105 cells/well). After 24 h, cells were washed twice
(PBS, 4 ◦C) and medium containing FX (10, 30 and 50 μM) or Dex (1 μM) was added for 1 h, and then
cells were stimulated with TNF-α (10 ng/mL) except for control group. After 24 h, supernatant
fluids were collected and stored −80 ◦C until measurements [20]. Commercial enzyme-linked
immunosorbent assay (ELISA) kit (Diaclone GEN-PROBE, Besançon, France) was used to quantify
IL-6 and IL-8 according to the manufacturer’s protocol.
4.5. Preparation of Topical Formulations
Based on previous studies, topical formulations were performed following the methodology
detailed in Rodríguez-Luna et al. [20]. Thus, three different preparations were developed: hydrogel,
cream and ointment. Concerning the hydrogel, BC (Sigma-Aldrich, St. Louis, MO, USA) solution
in ethanol absolute (10 mg/mL) was gradually added to the polymer dispersion (1% w/v) under
magnetic stirring. The ointment was prepared using both the melt emulsification and stirring steps.
BC dissolved in ethanol (10 mg/mL) was added to the lipid mixture. Regarding cream, three different
preparations were made containing 2 mg/g of drug (BC, FX or Dex). In all of them, the drug was
dissolved in absolute ethanol (10 mg/mL) and added to the excipient cold mixture.
4.6. In Vitro Permeation Studies from Topical Formulations
In vitro drug permeation studies from the topical formulations were performed using a Franz
diffusion cell apparatus (SES-Gmgh Analyses system, Bechenheim, Germany), with 14.5 mL receptor
volume and 3.14 cm2 diffusion area. An appropriately conditioned cellulose nitrate membrane
(Tuffryn®; Pall Corporation, Port Washington, New York, NY, USA), impregnated with lauryl alcohol
(membrane weight increase 90–110%), was employed as artificial lipophilic membrane simulating
the epidermal barrier [53,54]. The membrane was placed in the diffusion cell sandwiching the donor
and receptor compartments. The receiver solution contained absolute ethanol and the donor chamber
was filled with 1 g of formulation at 2 mg/g of BC (cream, ointment or hydrogel). In this study,
BC was employed as reference compound because of its structural similarity with FX. The whole
diffusion cell was thermostated maintaining the temperature at 32 ◦C. Aliquots of 0.5 mL were
withdrawn from the receptor chamber after 0.5, 1, 1.5, 2 and 3 h and replaced with fresh ethanol.
The concentrations of BC were spectrometrically assayed at 454 nm (UV/vis 1601 Shimadzu, Duisburg,
Germany). The cumulative amounts of permeated drug per unit area in the receiver chamber (μg/cm2)
were plotted as a function of time (h). The slope of the linear portion of the plot was presented as
steady state flux (Jss, μg/cm2/h). From the permeation profiles, the AUC was calculated using the
trapezoidal rule as a quantitative parameter for studying the permeation magnitude [55].
4.7. Animals
Female Swiss CD-1 mice (25–30 g) were purchased from Janvier-Labs (Le Genest St Isle,
France) and female SKH-1 hairless mice (18–20 g) from Charles River Laboratories (Écully, France).
Mice were maintained under standard conditions (temperature of 24–25 ◦C, humidity of 70–75%
and 12 h light-12 h dark cycle) and were allowed free access to a standard diet (Panlab) and
water ad libitum. All studies were performed in accordance with the recommendations of the
European Union regarding animal experimentation (Directive of the European Council 2010/63/EU).
The experiments followed protocols approved by the Animal Ethics Committee of the University of
Seville (Protocol 06/04/2018/042).
4.8. Ex Vivo Permeation Studies from Creams
Once the cream carrier was chosen from the previous study, ex vivo diffusion studies were
performed using excised mice skin as a membrane for evaluating the permeation behaviour of
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FX-loaded cream. Moreover, Dex-cream was included because it was used as positive control in
the in vivo hyperplasia study. Swiss CD-1 mice were sacrificed by cervical dislocation and full dorsal
skin was excised. A specific portion of the skin was washed with distilled water and cut for the
permeation assay. The study was carried out following the methodology previously reported [56].
Animal skin was inserted between the donor and receiving compartments and adjusted by means of a
pinch clamp. The receiving chamber was filled with 14.5 mL of degassed ethanol absolute and was
thermostated by means of a water bath circulator and a jacket surrounding the cell, maintaining 32 ◦C
in the skin surface. The receiving medium was continuously stirred to avoid diffusion layer effect.
FX-cream (0.2% w/w), FX control solution in ethanol (0.2% w/w) and Dex-cream (0.2% w/w)
were accurately measured and placed on stratum corneum in the donor compartment and sealed with
parafilm. The same procedure as previously described was followed [56]. Absolute ethanol was used
as solvent in the receiver compartment. The concentrations of Dex were spectrometrically assayed
at 254 nm (UV/vis 1601 Shimadzu). The FX content in the ethanol solutions was analyzed by using
HPLC method. The analysis was performed on a Hitachi Elite Lachron HPLC system equipped with a
L-2130 isocratic pump, a diode array detector L-2455 and a L-2200 autosampler. Separation was carried
out within a chromatographic C18 column (Merck, RP-18 LichroCART® 150 mm × 4 mm, 5 μm).
For drug analysis, the injection volume was 10 μL, and the flow rate and column temperature were
set at 1.0 mL/min and 25 ◦C, respectively. The mobile phase consisted of A (formic acid 0.1%) and B
(acetonitrile). The elution program was: 6 min isocratic at 90% B, followed by a gradient to 100% B at
10 min. Afterwards, the column was re-equilibrated during 5 min at 90% B. The cumulative amount of
drug in receptor chamber for the three formulations (FX-cream, FX control solution and Dex-cream)
was measured as a function of time (t, h). The cumulative amount (%) of drug permeated through the
skin (P%) was determined as per the following equation [57]:
P% =
Cn · V + ∑n−1i=1 Ci · Vi
M
· 100 (1)
where Cn is the drug concentration of the nth sampling point (mg/mL), Ci is the drug concentration
of the ith sample point (mg/mL), V is the total volume (14.5 mL) of liquid in receiving pool, Vi is the
volume (0.5 mL) of the ith sampling points and M is the mass of drug (FX or Dex) [20].
4.9. TPA-Induced Epidermal Hyperplasia Model and Treatments
Female Swiss CD-1 mice (n = 10 per group) were used to study the effect of FX on TPA-induced
hyperplasia in mice dorsal skin. Briefly, the dorsal hair of animals was removed with an electric clipper
and treated with depilatory cream (Deliplus, Barcelona, Spain) [35]. After 24 h, the animals were
assigned to the different groups: Sham (vehicle: 100 mg of cream with 0.2% of ethanol); TPA control
group; TPA-Cream (vehicle: 100 mg of cream with 0.2% of ethanol); Dex-cream (100 mg of cream per
site, containing 200 μg of Dex dissolved in ethanol at 10 μg/mL); FX-cream formulation (100 mg of
cream per site, containing 200 μg of FX dissolved in ethanol at 10 μg/mL). The creams were applied to
the dorsal skin in an area of 1 cm2 using a syringe, during 2 days before the hyperplasia induction.
Mice were anesthetized with ketamine (100 mg/kg of animal) and diazepam (5 mg/kg of animal)
during treatments and TPA challenge. On day 4, TPA (2 nmol of TPA, dissolved in 20 μL of ethanol)
was topically applied to the same areas on all groups except in sham group. After 1 h, FX-cream,
the Dex-cream or vehicle were administered following the mentioned protocol. This procedure was
replicated during two consecutive days. After 24 h of the last TPA dorsal application (day 7), mice
were sacrificed by cervical dislocation and punch biopsies from the treated dorsal skin were weighed
to evaluate edema, before further processing for histology and biochemical parameters.
4.10. MPO Activity
The measurement of MPO activity was used as a marker of neutrophil infiltration [58]. The tissue
was thawed, weighed and homogenized in 10 volumes of 50 mM-PBS (pH 7.4). Then, the homogenate
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was centrifuged at 20,000× g for 20 min at 4 ◦C and the pellet was again homogenized in 10 volumes
of 50 mM-PBS (pH 6) containing hexadecyl trimethylammonium bromide (0.5%) and 10 mM-EDTA.
This homogenate was subjected to one cycle of freezing/thawing and sonicated. The homogenate
samples (50 μL) were added to 96-well microplate and incubated at 37 ◦C for 3 min with a measurement
mix (o-dianisidine dihydrochloride (0.067%), hexadecyl trimethyl-ammonium bromide (0.5%) and
0.3 mM-H2O2). The changes in absorbance were monitorized at 450 nm with a microplate reader
(Labysystem Multiskan EX, Thermo Scientific, New York, NY, USA). MPO activity unit was defined as
the amount of enzyme present that produced a change in absorbance of 1.0 unit/min at 37 ◦C in the
final reaction volume containing acetate. Results are expressed as units/mg tissue [20].
4.11. Histological Study
The samples were fixed in paraformaldehyde, dehydrated by increasing concentrations of ethanol
and embedded in paraffin. For H&E stains, tissue sections were cut to 7 μm on a rotary microtome
(Leica Microsystems, Wetzlar, Germany), mounted on slides, deparaffinized with xylene, rehydrated
through graded alcohols and stained according to standard protocols. All tissue sections were
examined under an Olympus BH-2 microscope (GMI Inc., Ramsey, MN, USA) for determination
of histopathological changes. Epidermal thickness was measured by using Scientific Imaging Systems
(Biophotonics ImageJ Analysis Software; National Institutes of Health, Rockville, MD, USA).
4.12. Immunohistochemical Analysis
COX-2 expression was measured by immunohistochemical analysis by using a streptavidin-
biotin-peroxidase method [59]. Paraffin-embedded dorsal skin sections (7 μm) were mounted on
slides, deparaffinized with xylene and rehydrated through graded alcohols. These sections were
boiled (10 mM citrate buffer (pH 6.0) for 3 min) for antigen retrieval, followed by cooling at room
temperature for 20 min. Endogenous peroxidase was quenched with 0.3% (v/v) hydrogen peroxide
for 20 min and the sections were washed (PBS, 10 min). To minimize the non-specific adsorption
the sections were incubated in normal horse serum (Vectastain Kit; Vector Laboratories, Burlingame,
CA, USA) for 20 min. Afterwards, slides were incubated with rabbit polyclonal anti-COX-2 antibody
(Cayman Chemical, Ann Arbor, MI, USA) (1:300) overnight at 4 ◦C. Then, the samples were treated
with anti-mouse IgG antibody. After 30 min, the cells were incubated with the streptavidin–peroxidase
complex for 30 min, at room temperature (Vectastain Kit; Vector Laboratories, Burlingame, CA, USA).
The enzymatic activities were developed with 3,3′-diaminobenzidine (DAB), and the sections were
counterstained with hematoxylin. Negative control sections were treated in the same way, omitting
the primary antibody. To examine COX-2 immunoreactivity, the microscope Olympus BX61 was used
(Olympus Optical Co. Ltd., Tokyo, Japan). The quantification of immunohistochemical data was done
by counting the number of immunostained cells as percent of total epidermal cells from 10 microscopic
fields of immunostained tissues per animal.
4.13. UVB Irradiation of HaCaT Keratinocytes
Human keratinocytes were exposed to UVB radiation as previously described [60]. Briefly, the
cells were grown to confluence and were treated with different concentrations of FX (10, 30 and 50 μM)
for 1 h. Then, the medium was removed and a thin layer of PBS was added. Cells were exposed to a
single dose of UVB radiation (50 mJ/cm2) for 1 min. The UVB source was a CL-1000M UV Crosslinker
(UVP, Upland, CA, USA), which was used to deliver an energy spectrum of UVB light (280–315 nm;
peak intensity, 302 nm). After UVB irradiation, the cells were supplied with fresh complete medium
and incubated for 24 h.
4.14. Analysis of Intracellular LDH Activity
The measure of cytosolic enzyme LDH is one of the commonly used methods for assessing loss of
cellular membrane integrity. The assay is based on the conversion of lactate to pyruvate in the presence
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of LDH with the consequence oxidation of NADH as previously described [61]. HaCaT cells were
seeded in 6-well plates (5 × 105 cells/well). After 24 h, cells were treated with FX (10, 30 and 50 μM)
for 1 h and then, were irradiated with UVB. After 24 h, cell-free supernatants and cell lysates were
mixed in a 96-well plate and the absorbance was read by using a microplate reader system (Sinergy HT,
Biotek®, Bad Friedrichshall, Germany). LDH leakage was estimated calculating the LDH activity in
the cell-free medium and LDH activity in lysates ratio. Results were represented as the percentage (%)
of change in activity compared with the control cells.
4.15. Intracellular ROS Scavenging Activity
For quantification of ROS in HaCaT cells, the DCF-DA assay was employed [62]. HaCaT cells
were seeded in nin96-well plates (104 cells/well). Non-irradiated cells were used as negative control.
After 24 h, cells were treated with FX (10, 30 and 50 μM) for 1 h and then, were exposed to UVB. Post
irradiation, cells were incubated with 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) solution
(5 mg/mL) in PBS for 30 min [63]. The fluorescence of the 2′,7′-dichlorofluorescein (DCF) product was
determined using a fluorescence plate reader (Sinergy HT, Biotek®, Bad Friedrichshall, Germany) at
485 nm for excitation and 535 nm for emission.
4.16. Determination of IL-6 Production in UVB-Exposed HaCaT Keratinocytes
HaCaT cells (5 × 105 cells/well) were seeded in 6-well plates. After 24 h, cells were treated with
FX (10, 20 and 50 μM) for 1 h and then, were exposed to UVB. After 24 h, supernatant fluids were
collected and ELISA kit (Diaclone GEN-PROBE, Besançon, France) was employed to quantify IL-6
according to the manufacturer’s protocol. The absorbance at 450 nm was read by a microplate reader
(Labysystem Multiskan EX, Thermo Scientific, New York, NY, USA).
4.17. UVB-Induced Erythema in Hairless Mice
Female SKH-1 hairless mice (n = 8 per group) were used to study the effect of FX on UVB-induced
erythema. Animals were distributed to the different groups: Sham (vehicle: 100 mg of cream with
0.2% of ethanol); UVB (100 mg of cream with 0.2% of ethanol); BC-cream (100 mg of cream per site,
containing 200 μg of BC dissolved in ethanol at 10 μg/μL) as reference control; FX-cream (100 mg
per site, containing 200 μg of FX dissolved in ethanol at 10 μg/μL). The formulations were applied
on the dorsal skin (1 cm2/area) by using a syringe, and starting 2 days before irradiation. On day
3, 30 min after application of the substances, all groups except the sham control were exposed to an
acute UVB dose (360 mJ/cm2) as previously described [22]. Then, 48 h after UVB exposure, mice
were macroscopically evaluated and sacrificed. At this end-point time, a pronounced UVB-induced
cutaneous inflammation was shown [4].
4.18. Dermatoscope Measurements
Dorsal skin was macroscopically examined every day by using a multi-dermatoscope
(Dermatoscope MDS 800, Microcaya, Bilbao, Spain). Corneometer® was used to determinate the
hydration in the stratum corneum through electrical capacitance of the skin surface [64]. A Cutometer®
probe was used as suction method to analyse the real elasticity of skin [65]. In the last step, Mexameter®
was employed to analyse the redness skin by melanin index [66]. Every day, dorsal skin of mice was
assessed twice and finally the results were expressed in arbitrary units (a. u.) or by a melanin index
scale (1-36).
4.19. Western Blot Assay
Frozen dorsal skin tissues from UVB-induced erythema model were randomly selected (6 per
group), weighed and homogenized in ice-cold buffer (50 mM Tris-HCl, pH 7.5, 8 mM MgCl2, 5 mM
ethylene glycol bis (2-aminoethyl ether)-N,N,N′,N′-tetra acetic acid, 0.5 mM EDTA, 0.01 mg/mL
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leupeptin, 0.01 mg/mL pepstatin, 0.01 mg/mL aprotinin, 1 mM phenylmethylsulfonyl fluoride, and
250 mM NaCl). The homogenates were centrifuged (12,000× g, 15 min, 4 ◦C), and the supernatants
were collected and stored at −80 ◦C. To determinate the protein concentration of the homogenates
was used the Bradford colorimetric method [67]. Samples of the supernatants with equal amounts of
protein (25 μg) were separated on 10% acrylamide gel by sodium dodecyl sulfate polyacrylamide gel
electrophoresis. Then, the proteins were electrophoretically transferred onto a nitrocellulose membrane
and incubated with specific primary antibodies: rabbit anti-inducible nitric oxide synthase (iNOS)
(1:1000; Stressgen-Enzo Life Sciences, Farmingdale, NY, USA); rabbit anti-COX-2 (1:3000; Cayman
Chemical®, Ann Arbor, MI, USA); rabbit anti-Nrf2, rabbit anti-HO-1 (1:1000; Cell Signaling, Danvers,
MA, USA) overnight at 4 ◦C. After rinsing, the membranes were incubated with the horseradish
peroxidase-linked (HRP) secondary antibody anti-rabbit (1:1000; Cayman Chemical®, Ann Arbor,
MI, USA) or anti-mouse (1:1000; Dako®, Atlanta, GA, USA) containing blocking solution for 1 h at
room temperature. To prove equal loading, the blots were analyzed for β-actin expression using an
anti-β-actin antibody (1:1000; Sigma Aldrich®, St. Louis, MO, USA). Immunodetection was performed
using an enhanced chemiluminescence light-detecting kit (SuperSignal West Pico Chemiluminescent
Substrate, Pierce, IL, USA). Then, the immunosignals were monitorized by using LAS-3000 Imaging
System (Fujifilm Image Reader, Valhalla, NY, USA) and densitometric data were studied after
normalization to the control (housekeeping gene). The signals were analyzed and quantified with
a Scientific Imaging Systems (Biophotonics ImageJ Analysis Software, National Institute of Mental
Health, Bethesda, MD, USA) and expressed as percentage respect to sham control group [68].
4.20. Statistical Analysis
All values in the figures and text are expressed as arithmetic means ± SEM. Data were evaluated
with GraphPad Prism version 5.00 software (GraphPad Software, Inc., San Diego, CA, USA). In all
cases, the Shapiro-Wilk test was used to verify the normality of the data. The Mann-Whitney U-test
was chosen for non-parametric values. The parametric values groups were analyzed by one-way
analysis of variance (ANOVA) followed by Bonferroni’s Multiple Comparison Test. p values < 0.05
were considered statistically significant.
5. Conclusions
In conclusion, the in vitro anti-inflammatory, antioxidant and protective activity of FX has
been confirmed in human keratinocytes. Furthermore, we have demonstrated for the first time
the anti-inflammatory activity of a topical formulation containing FX in hyperplasic skin, reducing cell
infiltrate and epidermal COX-2 expression, which has a main role in the progression of hyperplasia and
the consequent skin damage. In addition, this carotenoid protects mice against superficial skin damage
induced by UVB through inhibition of inflammatory mediators and promotion of antioxidant responses
through Nrf2 pathway. For these reasons, FX, administered in a well-tolerated topical formulation
and that improves its permeation, could be a novel natural adjuvant for preventing exacerbations
associated with skin inflammatory pathologies as well as protecting skin against UV radiation.
Supplementary Materials: The following is available online at http://www.mdpi.com/1660-3397/16/10/378/s1,
Table S1: Viability of THP-1 human macrophages and HaCaT human keratinocytes cells treated with different
concentrations of fucoxanthin (FX). Values are mean ± ES (%) of three independent experiments (n = 3).
Author Contributions: The authors’ contributions are follows: E.T., V.M. and J.Á.-R. designed the study protocol;
A.R.-L., J.Á.-R. and E.T., conducted the in vivo and histological experiments and analysed the data; A.R.-L., M.J.C.,
A.M.R. and M.L.G.-R. executed technologic experiments; A.R.-L., E.T., J.Á.-R., V.M. and M.L.G.-R. wrote the draft
of the manuscript. All the authors critically reviewed and approved the final version of the manuscript. None of
the authors has any conflicts of interest to declare.
Funding: This study was supported by grants from Consejería de Innovación, Ciencia y Empresa-Junta de
Andalucía POLFANAT-P12-AGR-430. The authors thank “Centro de Investigación, Tecnología e Innovación” of
the University of Seville for providing technical assistance.
37
Mar. Drugs 2018, 16, 378















Nrf2 nuclear factor E2-related factor 2
ROS reactive oxygen species
SRB sulforhodamine B




1. Fernández-García, E. Function Skin protection against UV light by dietary antioxidants. Food Funct. 2014,
5, 1994–2003. [CrossRef] [PubMed]
2. Nijsten, T. Atopic dermatitis and comorbidities: Added value of comprehensive dermatoepidemiology.
J. Investig. Dermatol. 2017, 137, 1009–1011. [CrossRef] [PubMed]
3. Hart, P.H.; Norval, M.; Byrne, S.N.; Rhodes, L.E. Exposure to ultraviolet radiation in the modulation of
human diseases. Annu. Rev. Pathol. Mech. Dis. 2018, 14, 421058260. [CrossRef] [PubMed]
4. Duncan, F.; Martin, J.; Wulff, B.; Stoner, G.; Tober, K.; Oberyszyn, T.; Kusewitt, D.; Van Buskirk, A. Topical
treatment with black raspberry extract reduces cutaneous UVB-induced carcinogenesis and inflammation.
Cancer Prev. Res. 2009, 2, 54–56. [CrossRef] [PubMed]
5. Berthon, J.-Y.; Nachat-Kappes, R.; Bey, M.; Cadoret, J.-P.; Renimel, I.; Filaire, E. Marine algae as attractive
source to skin care. Free Radic. Res. 2017, 51, 555–567. [CrossRef] [PubMed]
6. Brunt, E.G.; Burgess, J.G. The promise of marine molecules as cosmetic active ingredients. Int. J. Cosmet. Sci.
2018, 40, 1–15. [CrossRef] [PubMed]
7. Milani, A.; Basirnejad, M.; Shahbazi, S.; Bolhassani, A. Carotenoids: Biochemistry, pharmacology and
treatment. Br. J. Pharmacol. 2017, 174, 1290–1324. [CrossRef] [PubMed]
8. Zhang, H.; Tang, Y.; Zhang, Y.; Zhang, S.; Qu, J.; Wang, X.; Kong, R.; Han, C.; Liu, Z. Fucoxanthin: A promising
medicinal and nutritional ingredient. Evid. Based. Complement. Alternat. Med. 2015, 2015, 723515. [CrossRef]
[PubMed]
9. D’Orazio, N.; Gemello, E.; Gammone, M.A.; de Girolamo, M.; Ficoneri, C.; Riccioni, G. Fucoxantin: A treasure
from the sea. Mar. Drugs 2012, 10, 604–616. [CrossRef] [PubMed]
10. Jang, E.J.; Kim, S.C.; Lee, J.-H.; Lee, J.R.; Kim, I.K.; Baek, S.Y.; Kim, Y.W. Fucoxanthin, the constituent of
Laminaria japonica, triggers AMPK-mediated cytoprotection and autophagy in hepatocytes under oxidative
stress. BMC Complement. Altern. Med. 2018, 18, 97. [CrossRef] [PubMed]
11. Zheng, J.; Piao, M.J.; Kim, K.C.; Yao, C.W.; Cha, J.W.; Hyun, J.W. Fucoxanthin enhances the level of reduced
glutathione via the Nrf2-mediated pathway in human keratinocytes. Mar. Drugs 2014, 12, 4214–4230.
[CrossRef] [PubMed]
12. Urikura, I.; Sugawara, T.; Hirata, T. Protective effect of fucoxanthin against UVB-induced skin photoaging in
hairless mice. Biosci. Biotechnol. Biochem. 2011, 75, 757–760. [CrossRef] [PubMed]
38
Mar. Drugs 2018, 16, 378
13. Shimoda, H.; Tanaka, J.; Shan, S.-J.; Maoka, T. Anti-pigmentary activity of fucoxanthin and its influence
on skin mRNA expression of melanogenic molecules. J. Pharm. Pharmacol. 2010, 62, 1137–1145. [CrossRef]
[PubMed]
14. Matsui, M.; Tanaka, K.; Higashiguchi, N.; Okawa, H.; Yamada, Y.; Tanaka, K.; Taira, S.; Aoyama, T.;
Takanishi, M. Protective and therapeutic effects of fucoxanthin against sunburn caused by UV irradiation.
J. Pharmacol. Sci. 2016, 132, 55–64. [CrossRef] [PubMed]
15. Marwah, H.; Garg, T.; Goyal, A.K.; Rath, G. Permeation enhancer strategies in transdermal drug delivery.
Drug Deliv. 2016, 23, 564–578. [CrossRef] [PubMed]
16. Dai, J.; Kim, J.-C. Chemical stability and skin permeation of fucoxanthin-loaded microemulsions. J. Drug
Deliv. Sci. Technol. 2013, 23, 597–601. [CrossRef]
17. Dai, J.; Kim, J.-C. In vivo anti-obesity efficacy of fucoxanthin-loaded emulsions stabilized with phospholipid.
J. Pharm. Investig. 2016, 46, 669–675. [CrossRef]
18. Freitas, J.V.; Praça, F.S.G.; Bentley, M.V.L.B.; Gaspar, L.R. Trans-resveratrol and beta-carotene from sunscreens
penetrate viable skin layers and reduce cutaneous penetration of UV-filters. Int. J. Pharm. 2015, 484, 131–137.
[CrossRef] [PubMed]
19. Arasa, J.; Martos, P.; Terencio, M.C.; Valcuende-Cavero, F.; Montesinos, M.C. Topical application of
the adenosine A2A receptor agonist CGS-21680 prevents phorbol-induced epidermal hyperplasia and
inflammation in mice. Exp. Dermatol. 2014, 23, 555–560. [CrossRef] [PubMed]
20. Rodríguez-Luna, A.; Talero, E.; Terencio, M.C.; González-Rodríguez, M.L.; Rabasco, A.M.; de los Reyes, C.;
Motilva, V.; Ávila-Román, J. Topical Application of Glycolipids from isochrysis galbana prevents epidermal
hyperplasia in mice. Mar. Drugs 2017, 16, 2. [CrossRef] [PubMed]
21. Bernatoniene, J.; Masteikova, R.; Davalgiene, J.; Peciura, R.; Gauryliene, R.; Bernatoniene, R.; Majiene, D.;
Lazauskas, R.; Civinskiene, G.; Velziene, S.; et al. Topical application of calendula officinalis (L.): Formulation
and evaluation of hydrophilic cream with antioxidant activity. J. Med. Plants Res. 2011, 5, 868–877.
22. Sirerol, J.A.; Feddi, F.; Mena, S.; Rodriguez, M.L.; Sirera, P.; Aupí, M.; Pérez, S.; Asensi, M.; Ortega, A.;
Estrela, J.M. Topical treatment with pterostilbene, a natural phytoalexin, effectively protects hairless mice
against UVB radiation-induced skin damage and carcinogenesis. Free Radic. Biol. Med. 2015, 85, 1–11.
[CrossRef] [PubMed]
23. Stahl, W.; Sies, H. β-Carotene and other carotenoids in protection from sunlight 1–3. Am. J. Clin. Nutr. 2012,
96, 1179–1184. [CrossRef] [PubMed]
24. Kim, K.-N.; Heo, S.-J.; Yoon, W.-J.; Kang, S.-M.; Ahn, G.; Yi, T.-H.; Jeon, Y.-J. Fucoxanthin inhibits the
inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced
RAW 264.7 macrophages. Eur. J. Pharmacol. 2010, 649, 369–375. [CrossRef] [PubMed]
25. Martinez, R.M.; Pinho-Ribeiro, F.A.; Vale, D.L.; Steffen, V.S.; Vicentini, F.T.M.C.; Vignoli, J.A.; Baracat, M.M.;
Georgetti, S.R.; Verri, W.A.; Casagrande, R. Trans-chalcone added in topical formulation inhibits skin
inflammation and oxidative stress in a model of ultraviolet B radiation skin damage in hairless mice.
J. Photochem. Photobiol. B Biol. 2017, 171, 139–146. [CrossRef] [PubMed]
26. Xie, F.; Chai, J.-K.; Hu, Q.; Yu, Y.-H.; Ma, L.; Liu, L.-Y.; Zhang, X.-L.; Li, B.-L.; Zhang, D.-H. Transdermal
permeation of drugs with differing lipophilicity: Effect of penetration enhancer camphor. Int. J. Pharm. 2016,
507, 90–101. [CrossRef] [PubMed]
27. Mahamongkol, H.; Bellantone, R.A.; Stagni, G.; Plakogiannis, F.M. Permeation study of five formulations of
alpha-tocopherol acetate through human cadaver skin. J. Cosmet. Sci. 2005, 56, 91–103. [PubMed]
28. Williams, A.C.; Barry, B.W. Penetration enhancers. Adv. Drug Deliv. Rev. 2012, 64, 128–137. [CrossRef]
29. Aggarwal, N.; Goindi, S.; Mehta, S.D. Preparation and evaluation of dermal delivery system of griseofulvin
containing vitamin E-TPGS as penetration enhancer. AAPS PharmSciTech 2012, 13, 0–7. [CrossRef] [PubMed]
30. Taofiq, O.; González-Paramás, A.; Barreiro, M.; Ferreira, I. Hydroxycinnamic acids and their derivatives:
cosmeceutical significance, challenges and future perspectives, a review. Molecules 2017, 22, 281. [CrossRef]
[PubMed]
31. Maeda, H.; Hosokawa, M.; Sashima, T.; Funayama, K.; Miyashita, K. Effect of medium-chain triacylglycerols
on anti-obesity effect of fucoxanthin. J. Oleo Sci. 2007, 56, 615–621. [CrossRef] [PubMed]
32. Laihia, J.K.; Taimen, P.; Kujari, H.; Leino, L. Topical cis-urocanic acid attenuates oedema and erythema in
acute and subacute skin inflammation in the mouse. Br. J. Dermatol. 2012, 167, 506–513. [CrossRef] [PubMed]
39
Mar. Drugs 2018, 16, 378
33. Perera, G.K.; Di Meglio, P.; Nestle, F.O. Psoriasis. Annu. Rev. Pathol. Mech. Dis. 2012, 7, 385–422. [CrossRef]
[PubMed]
34. Ikai, K. Psoriasis and the arachidonic acid cascade. J. Dermatol. Sci. 1999, 21, 135–146. [CrossRef]
35. Andrés, R.M.; Montesinos, M.C.; Navalón, P.; Payá, M.; Terencio, M.C. NF-κB and STAT3 inhibition as a
therapeutic strategy in psoriasis: In vitro and in vivo effects of BTH. J. Investig. Dermatol. 2013, 133, 2362–2371.
[CrossRef] [PubMed]
36. Zhao, D.; Kwon, S.H.; Chun, Y.S.; Gu, M.Y.; Yang, H.O. Anti-neuroinflammatory effects of fucoxanthin
via inhibition of Akt/NF-κB and MAPKs/AP-1 pathways and activation of PKA/CREB pathway in
lipopolysaccharide-activated BV-2 Microglial. Cells Neurochem. Res. 2017, 42, 667–677. [CrossRef] [PubMed]
37. Fan, H.J.; Xie, Z.P.; Lu, Z.W.; Tan, Z.B.; Bi, Y.M.; Xie, L.P.; Wu, Y.T.; Zhang, W.T.; Liu-Kot, K.; Liu, B.; et al.
Anti-inflammatory and immune response regulation of Si-Ni-San in 2,4-dinitrochlorobenzene-induced atopic
dermatitis-like skin dysfunction. J. Ethnopharmacol. 2018, 222, 1–10. [CrossRef] [PubMed]
38. Tan, C.P.; Hou, Y.H. First evidence for the anti-inflammatory activity of fucoxanthin in high-fat-diet-induced
obesity in mice and the antioxidant functions in PC12 cells. Inflammation 2014, 37, 443–450. [CrossRef]
[PubMed]
39. Hajar, T.; Leshem, Y.A.; Hanifin, J.M.; Nedorost, S.T.; Lio, P.A.; Paller, A.S.; Block, J.; Simpson, E.L.
(the National Eczema Association Task Force) A systematic review of topical corticosteroid withdrawal
(“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J. Am. Acad. Dermatol. 2015,
72, 541–549. [CrossRef] [PubMed]
40. Saewan, N.; Jimtaisong, A. Natural products as photoprotection. J. Cosmet. Dermatol. 2015, 14, 47–63.
[CrossRef] [PubMed]
41. Lakatos, P.; Szabó, É.; Hegedus, C.; Haskó, G.; Gergely, P.; Bai, P.; Virág, L. 3-Aminobenzamide protects
primary human keratinocytes from UV-induced cell death by a poly(ADP-ribosyl)ation independent
mechanism. Biochim. Biophys. Acta Mol. Cell Res. 2013, 1833, 743–751. [CrossRef] [PubMed]
42. Leerach, N.; Yakaew, S.; Phimnuan, P.; Soimee, W.; Nakyai, W.; Luangbudnark, W.; Viyoch, J. Effect of Thai
banana (Musa AA group) in reducing accumulation of oxidation end products in UVB-irradiated mouse
skin. J. Photochem. Photobiol. B Biol. 2017, 168, 50–58. [CrossRef] [PubMed]
43. Heo, S.-J.; Jeon, Y.-J. Protective effect of fucoxanthin isolated from Sargassum siliquastrum on UV-B induced
cell damage. J. Photochem. Photobiol. B. 2009, 95, 101–107. [CrossRef] [PubMed]
44. Zheng, J.; Piao, M.J.; Keum, Y.S.; Kim, H.S.; Hyun, J.W. Fucoxanthin protects cultured human keratinocytes
against oxidative stress by blocking free radicals and inhibiting apoptosis. Biomol. Ther. 2013, 21, 270–276.
[CrossRef] [PubMed]
45. Kanekura, T.; Higashi, Y.; Kanzaki, T. Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate
on cyclooxygenase (COX)-2 expression and cell growth in human skin squamous carcinoma cells. Cancer Lett.
2000, 161, 177–183. [CrossRef]
46. Fehér, P.; Ujhelyi, Z.; Váradi, J.; Fenyvesi, F.; Róka, E.; Juhász, B.; Varga, B.; Bombicz, M.; Priksz, D.; Bácskay, I.;
et al. Efficacy of pre- and post-treatment by topical formulations containing dissolved and suspended
silybum marianum against UVB-induced oxidative stress in guinea pig and on HaCaT keratinocytes.
Molecules 2016, 21, 1269. [CrossRef] [PubMed]
47. Zhong, J.; Li, L. Skin-derived precursors against UVB-induced apoptosis via Bcl-2 and Nrf2 upregulation.
Biomed. Res. Int. 2016, 2016, 6894743. [CrossRef] [PubMed]
48. Furue, M.; Uchi, H.; Mitoma, C.; Hashimoto-Hachiya, A.; Chiba, T.; Ito, T.; Nakahara, T.; Tsuji, G.
Antioxidants for healthy skin: The emerging role of aryl hydrocarbon receptors and nuclear factor-erythroid
2-related factor-2. Nutrients 2017, 9, 223. [CrossRef] [PubMed]
49. Yang, Y.; Yang, I.; Cao, M.; Su, Z.-Y.; Wu, R.; Guo, Y.; Fang, M.; Kong, A.-N. Fucoxanthin elicits epigenetic
modifications, Nrf2 activation and blocking transformation in mouse skin JB6 P+ cells. AAPS J. 2018, 20, 32.
[CrossRef] [PubMed]
50. Sangeetha, R.K.; Bhaskar, N.; Baskaran, V. Comparative effects of beta-carotene and fucoxanthin on retinol
deficiency induced oxidative stress in rats. Mol. Cell. Biochem. 2009, 331, 59–67. [CrossRef] [PubMed]
51. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.;
Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990,
82, 1107–1112. [CrossRef] [PubMed]
40
Mar. Drugs 2018, 16, 378
52. De los Reyes, C.; Ortega, M.J.; Rodríguez-Luna, A.; Talero, E.; Motilva, V.; Zubía, E. Molecular
characterization and anti-inflammatory activity of galactosylglycerides and galactosylceramides from the
microalga isochrysis galbana. J. Agric. Food Chem. 2016, 64, 8783–8794. [CrossRef] [PubMed]
53. Mura, P.; Celesti, L.; Murratzu, C.; Corsi, S.; Furlanetto, S.; Corti, P. In vitro studies of simulated percutaneous
absorption: influence of artificial membrane impregnation agent. Acta Technol. Leg. Med. 1993, 4, 121–136.
54. Maestrelli, F.; González-Rodríguez, M.L.; Rabasco, A.M.; Mura, P. Preparation and characterisation of
liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery. Int. J. Pharm.
2005, 298, 55–67. [CrossRef] [PubMed]
55. Cirri, M.; Maestrelli, F.; Mennini, N.; Mura, P. Combined use of bile acids and aminoacids to improve
permeation properties of acyclovir. Int. J. Pharm. 2015, 490, 351–359. [CrossRef] [PubMed]
56. López-Pinto, J.M.; González-Rodríguez, M.L.; Rabasco, A.M. Effect of cholesterol and ethanol on dermal
delivery from DPPC liposomes. Int. J. Pharm. 2005, 298, 1–12. [CrossRef] [PubMed]
57. Li, Z.; Liu, M.; Wang, H.D.S. Increased cutaneous wound healing effect of biodegradable liposomes
containing madecassoside: preparation optimization, in vitro dermal permeation, and in vivo bioevaluation.
Int. J. Nanomed. 2016, 11, 2995–3007. [CrossRef] [PubMed]
58. Grisham, M.B.; Benoit, J.N.; Granger, D.N. Assessment of leukocyte involvement during ischemia and
reperfusion of intestine. Methods Enzymol. 1990, 186, 729–742. [PubMed]
59. Talero, E.; Alvarez de Sotomayor, M.; Sánchez-Fidalgo, S.; Motilva, V. Vascular contribution of adrenomedullin
to microcirculatory improvement in experimental colitis. Eur. J. Pharmacol. 2011, 670, 601–607. [CrossRef]
[PubMed]
60. Huang, J.-H.; Huang, C.-C.; Fang, J.-Y.; Yang, C.; Chan, C.-M.; Wu, N.-L.; Kang, S.-W.; Hung, C.-F. Protective
effects of myricetin against ultraviolet-B-induced damage in human keratinocytes. Toxicol. In Vitro 2010,
24, 21–28. [CrossRef] [PubMed]
61. Verhulst, C.; Coiffard, C.; Coiffard, L.J.M.; Rivalland, P.; De Roeck-Holtzhauer, Y. In vitro correlation between
two colorimetric assays and the pyruvic acid consumption by fibroblasts cultured to determine the sodium
laurylsulfate cytotoxicity. J. Pharmacol. Toxicol. Methods 1998, 39, 143–146. [CrossRef]
62. Wang, H.; Joseph, J.A. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate
reader. Free Radic. Biol. Med. 1999, 27, 612–616. [CrossRef]
63. Hyun, Y.J.; Piao, M.J.; Zhang, R.; Choi, Y.H.; Chae, S.; Hyun, J.W. Photo-protection by 3-bromo-4,
5-dihydroxybenzaldehyde against ultraviolet B-induced oxidative stress in human keratinocytes.
Ecotoxicol. Environ. Saf. 2012, 83, 71–78. [CrossRef] [PubMed]
64. Haruta-Ono, Y.; Ueno, H.; Ueda, N.; Kato, K.; Yoshioka, T. Investigation into the dosage of dietary
sphingomyelin concentrate in relation to the improvement of epidermal function in hairless mice. Anim. Sci. J.
2012, 83, 178–183. [CrossRef] [PubMed]
65. Nishimori, Y.; Edwards, C.; Pearse, A.; Matsumoto, K.; Kawai, M.; Marks, R. Degenerative alterations
of dermal collagen fiber bundles in photodamaged human skin and UVB-irradiated hairless mouse skin:
Possible effect on decreasing skin mechanical properties and appearance of wrinkles. Soc. Investig. Dermatol.
2001, 117, 1458–1463.
66. Wang, Y.Y.; Hong, C.T.; Chiu, W.T.; Fang, J.Y. In vitro and in vivo evaluations of topically applied capsaicin
and nonivamide from hydrogels. Int. J. Pharm. 2001, 224, 89–104. [CrossRef]
67. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248–254. [CrossRef]
68. Talero, E.; Bolivar, S.; Ávila-Román, J.; Alcaide, A.; Fiorucci, S.; Motilva, V. Inhibition of chronic ulcerative
colitis-associated adenocarcinoma development in mice by VSL#3. Inflamm. Bowel Dis. 2015, 21, 1027–1037.
[PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Protective Effects of Fucoxanthin on Ultraviolet
B-Induced Corneal Denervation and Inflammatory
Pain in a Rat Model
Shiu-Jau Chen 1,2,†, Ching-Ju Lee 3,4,†, Tzer-Bin Lin 5, Hsien-Yu Peng 2, Hsiang-Jui Liu 6,
Yu-Shan Chen 4 and Kuang-Wen Tseng 2,7,*
1 Department of Neurosurgery, Mackay Memorial Hospital, Taipei 10449, Taiwan; chenshiujau@gmail.com
2 Department of Medicine, Mackay Medical College, New Taipei 25245, Taiwan; hypeng@mmc.edu.tw
3 Internal Medicine, Taipei Hospital, Ministry of Health and Welfare, New Taipei 24213, Taiwan;
lululee66@yahoo.com.tw
4 Department of Business Administration, National Taipei University, New Taipei 24741, Taiwan;
yushan@gm.ntpu.edu.tw
5 Department of Physiology, School of Medicine, College of Medicine, Taipei Medical University,
Taipei 11049, Taiwan; tblin2@tmu.edu.tw
6 Department of Optometry, Mackay Junior College of Medicine, Nursing and Management,
New Taipei 11260, Taiwan; s458@eip.mkc.edu.tw
7 School of Life Science, National Taiwan Normal University, Taipei 10610, Taiwan
* Correspondence: tseng@mmc.edu.tw; Tel.: +886-2-2636-0303 (ext. 1227)
† These authors contributed equally to this work.
Received: 15 February 2019; Accepted: 28 February 2019; Published: 5 March 2019
Abstract: Fucoxanthin is a carotenoid with many pharmaceutical properties that is found in brown
seaweed. However, the effects of fucoxanthin on corneal innervation and intense eye pain have not
been extensively examined. To clarify the protective roles and underlying mechanisms of fucoxanthin
on ocular lesions, we investigated the beneficial effects and mechanisms by which fucoxanthin
ameliorates ultraviolet B (UVB)-induced corneal denervation and trigeminal pain. Treatment with
fucoxanthin enhanced the expression of nuclear factor erythroid 2-related factor 2 in the cornea.
Inhibition of typical denervation and epithelial exfoliation in the cornea were observed in rats treated
with fucoxanthin following UVB-induced nerve disorders. Moreover, the active phosphorylated
form of p38 MAP kinase (pp38) and the number of glial fibrillary acidic protein (GFAP)-positive
neural cells were significantly reduced. Decreased expression of neuron-selective transient receptor
potential vanilloid type 1 (TRPV1) in the trigeminal ganglia neurons was also demonstrated in rats
treated with fucoxanthin after UVB-induced keratitis. Symptoms of inflammatory pain, including
difficulty in opening the eyes and eye wipe behaviour, were also reduced in fucoxanthin-treated
groups. Pre-treatment with fucoxanthin may protect the eyes from denervation and inhibit trigeminal
pain in UVB-induced photokeratitis models.
Keywords: fucoxanthin; ultraviolet B; denervation
1. Introduction
Photokeratitis, a condition caused by exposure of the eyes to UV radiation, causes opacifications
of the cornea, decreases visual acuity and induces inflammatory pain. UV-induced ocular damage
has been demonstrated in previous human and animal studies [1,2]. The cornea absorbs about 90%
of UVB radiation and is most sensitive to UVB impairment [3]. UVB rays irritate the superficial
corneal epithelium, causing inhibition of mitosis, production of nuclear fragmentation and loosening
of the epithelial layer, inducing an inflammatory response, such as stromal swelling and leukocyte
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infiltration [4]. UVB-induced corneal disorders could be caused by oxidative stress, as well as by the
production of reactive oxygen species and inflammatory cytokines [5]. Oxidative stress may cause
significant damage to cell structures and functions by increasing DNA mutations or inducing DNA
damage and genome instability [6]. In addition, inflammatory cytokines have also been found to play
an important role in promoting fibrosis, scarring and inflammatory pain in the cornea [7].
The transparent tissue of the cornea, which has about 2500 nerve endings per mm2, is one of
the most densely innervated avascular tissues in mammals [8]. Its dense innervation contributes to a
wide range of corneal sensations and to the maintenance of corneal epithelial integrity; touching the
cornea causes an involuntary reflex that closes the eyelid. The ophthalmic branch of the trigeminal
ganglion afferent nerve fibres enters the corneal stroma through the limbus and innervates the corneal
epithelium [9]. Corneal nerves penetrate the corneal periphery in a radial distribution to form the
sub basal nerve plexus and influence signal transduction cascades involved in epithelial function,
organization and homeostasis [10,11]. It is therefore essential to conserve the cooperative interplay
between the corneal innervation and epithelial microenvironments.
The trigeminal ganglia comprise neuronal cells and two types of glial cells: satellite cells and
Schwann cells. The cell bodies of the primary afferent neurons are surrounded completely by several
satellite glial cells that form distinct functional units. Sensitization of nociceptor fibres alters the
sensitivity and pain observed during eye surface inflammation [12]. Neuron-selective transient
receptor potential vanilloid type 1 (TRPV1), the capsaicin receptor primarily expressed by nociceptive
sensory ganglion neurons, is directly activated and sensitized by chemical mediators released during
tissue injury [13]. Previous studies have shown that the active phosphorylated form of p38 MAP kinase
(pp38) is involved in cellular responses to external signals such as pain, growth factors, stress and
inflammatory mediators [14,15]. Activated satellite glial cells release several inflammatory and immune
mediators in response to inflammation and nerve damage and influence other sensory neurons within
the ganglion [16]. The immunoreactivity against glial fibrillary acidic protein (GFAP), an intermediate
filament protein, is not readily detectable in satellite glial cells in the resting state or under normal
physiological conditions. However, following nerve injury, inflammation or viral infection, GFAP
is detectable in the satellite glial cells of the peripheral nervous system that are activated by these
pathologies. Interestingly, neuron–glia interactions have been shown to be involved in all stages of
inflammation and pain associated with several diseases [17,18].
Nuclear factor erythroid 2-related factor 2 (Nrf2), a basic leucine zipper transcription factor,
mediates much of the protective anti-oxidant response, regulates a coordinated transcriptional program
that maintains cellular redox homeostasis and protects the cell from oxidative injury [19]. Nrf2 regulates
numbers of that play important roles in the anti-oxidant enzyme response, including “direct” and
“indirect” enzymes [20]. The “direct” response enzymes include catalase or superoxide dismutase and
the “indirect” enzymes include heme oxygenase-1, glutathione and thioredoxin generating enzymes.
Nrf2 is an important mechanistic link between managing the anti-oxidant gene expression stress
response and cell survival.
Fucoxanthin is an orange pigment present in brown seaweeds, such as Hizikia fusiformis,
Laminaria japonica and Sargassum fulvellum and is responsible for their high anti-oxidant content [21].
It is metabolized to fucoxanthinol and amarouciaxanthin in vivo [22] and has therapeutic properties,
such as anti-oxidant [23], anti-cancer [24], anti-inflammatory [25], anti-obese [26], anti-diabetic [27]
and anti-angiogenic activities [28] and has a protective effect on the liver, blood vessels of the brain,
bones and skin. We have previously demonstrated that pre-treatment with fucoxanthin inhibited the
ultraviolet B-induced expression of pro-inflammatory cytokines in the cornea [29]. However, the effects
of fucoxanthin on epithelial denervation and inflammatory pain in the avascular cornea have not been
extensively examined. Studies examining the reduction of corneal irregularity and inflammatory pain
during corneal wound healing are of great clinical value.
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2. Results
2.1. Effect of Fucoxanthin on Nrf2 Expression
To investigate the effect of fucoxanthin on Nrf2 translocation in the cornea, experimental animals
were first pre-treated with fucoxanthin ranging from 0.1 to 10 mg/kg for 6 days via oral administration.
The Nrf2 protein levels were measured using western blotting analysis (Figure 1). Compared
with the control group (no pre-treatment with fucoxanthin), the groups pre-treated with 0.1, 1 and
10 mg/kg fucoxanthin showed higher levels of Nrf2 protein. Moreover, Nrf2 expression increased
with fucoxanthin pre-treatment.
Figure 1. Fucoxanthin treatment enhanced the expression of Nrf2. Protein extraction was prepared
and separated using SDS-PAGE, followed by western blot analysis with antibodies against Nrf2
and GAPDH. Increases in Nrf2 were observed following fucoxanthin treatment. Protein levels were
measured using western blotting and band intensity was quantified using ImageJ software. The data
are expressed as means ± standard deviation (SD) (n = 5 rats per group). + p < 0.05, ++ p < 0.01;
one-way ANOVA followed by Dunnett’s multiple comparison test.
2.2. Effect of Fucoxanthin on UVB-Induced Corneal Denervation
In an attempt to define the relationship between increased Nrf2 in the ocular tissues and
degenerating corneal nerve endings in the groups treated with fucoxanthin, the general neuronal
marker protein gene product (PGP) 9.5 was targeted for corneal tissue staining. In the control group,
abundant epithelial nerves were found in the corneas and the nerve plexus had been arranged in a
crisscrossed, dense and continuous pattern of immunoreactivity toward PGP 9.5 (Figure 2A). However,
fewer, discontinuous and punctate-like degenerating nerves were observed in the epithelial layer
of the cornea after UVB exposure (Figure 2B). In the 10 mg/kg fucoxanthin treatment group, the
experimental animals showed a significant decrease in corneal denervation and an increase in nerve
density (Figure 2E) compared with those treated with 0.1 or 1 mg/kg fucoxanthin groups after UVB
irradiation (Figure 2C,D).
After statistical analysis of the corneal innervation, the reduction in corneal nerve density was
statistically significant in the UVB group (25.3 ± 4.8%, p < 0.05) compared with the control. In contrast,
the 10 mg/kg fucoxanthin treatment group displayed reduced denervation in the cornea (78.6 ± 5.5%,
p < 0.05) compared with the UVB group. These findings suggest that the UVB-induced denervation in
the cornea was effectively inhibited by treatment with 10 mg/kg fucoxanthin (Figure 3).
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Figure 2. Protective effects of fucoxanthin on nerve innervation after UVB-induced denervation in
corneal tissues. Nerve innervation was evaluated via immunohistochemistry using a general neural
marker PGP 9.5. Nerve innervation was compared between the following groups: blank control
(A), UVB (B), UVB/0.1 mg/kg fucoxanthin (C), UVB/1 mg/kg fucoxanthin (D) and UVB/10 mg/kg
fucoxanthin (E) groups. A significant reduction in the epithelial nerve innervation of the corneal
tissues is evident after UVB-induced nerve injury (B) compared with the blank control group (A).
Nerve innervation was significantly protected by 10 mg/kg fucoxanthin treatment and the corneal
denervation was significantly decreased.
Figure 3. Effects of fucoxanthin on nerve innervation after UVB irradiation in the corneal tissues. Nerve
innervation was compared with blank control, UVB, UVB/0.1 mg/kg fucoxanthin, UVB/1 mg/kg
fucoxanthin and UVB/10 mg/kg fucoxanthin groups. A significant reduction in the nerve innervation
of the corneal tissues and UVB-induced nerve injury is evident in the UVB-treated group compared with
the blank control group. Nerve innervation was increased by treatment with fucoxanthin. The results
are presented as means ±SD (n = 5 rats per group). The mean value was significantly different compared
with the UVB/vehicle group (* p < 0.05; Student t test). The mean value was significantly different
as UVB/0.1 and 1 mg/kg fucoxanthin groups compared with UVB/10 mg/kg fucoxanthin group
(# p <0.05; Student t test). The mean value was significantly different compared with UVB-exposed
group (+ p < 0.05; one-way ANOVA followed by Bonferroni’s multiple comparison test).
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2.3. Effect of Fucoxanthin on UVB-Induced Corneal Epithelial Disorganization
Because of the protective effects of fucoxanthin treatment against UVB-induced corneal
denervation, the relationship between corneal denervation and pathological examinations was applied
to superficial corneal inspection. Analyses of corneal smoothness and corneal lissamine green staining
were conducted. The corneas of the blank control rats were transparent, regular and neat and
their reflecting ocular surface was intact (Figure 4A). UVB exposure caused severe damage to the
corneal epithelial surface, including distortion and deformation (Figure 4C). In contrast, corneas
treated with fucoxanthin showed mild corneal epithelial disorganizations following UVB irradiation.
Moreover, significant enhancement of corneal epithelial organization was observed in the groups
treated with 1 and 10 mg/kg fucoxanthin (Figure 4G,I) compared with the corneal damage detected in
the UVB-treated experimental animals.
Figure 4. Effects of fucoxanthin on UVB-induced corneal disorders. Analyses of corneal smoothness
and corneal lissamine green staining were conducted. The extent of corneal integrity and transparency
was compared between the following groups: blank control (A,B), UVB (C,D), UVB/0.1 mg/kg
fucoxanthin (E,F), UVB/1 mg/kg fucoxanthin (G,H) and UVB/10 mg/kg fucoxanthin. The cornea,
which is normally transparent, becomes cloudy when damaged. UVB irradiation caused serious
damage to the corneal tissue (C,D), including severe exfoliation, deteriorated smoothness, corneal
opacity and intense staining with lissamine green, as compared with the blank controls (A,B). Corneal
smoothness and surface staining analysis showed that fucoxanthin treatment preserved corneal
integrity and transparency (E–J).
The epithelial cells lining the corneal surface were stained with lissamine green to evaluate
the ocular surface damage. Corneas of the blank control group remained largely unstained by
lissamine green (Figure 4B), whereas signs of corneal surface disorders, including a strikingly
irregular ocular surface and intense staining with lissamine green, were present after UVB radiation
(Figure 4D). Treatment with 1 and 10 mg/kg fucoxanthin led to decreased lissamine green staining
(Figure 4H,J). Compared with the corneal injuries detected in the UVB-treated groups, significantly
fewer punctate-stained areas were observed on the ocular surfaces of the group treated with 10 mg/kg
fucoxanthin (Figure 4J).
Semi-quantitative analyses of corneal smoothness and lissamine green staining were scored
(Figure 5) and significant differences were observed between all scores of the UVB-treated groups and
those of the blank control. The corneas of the fucoxanthin-treated groups showed decreased corneal
damage scores. Moreover, the analysis also revealed significantly decreased scores in the group treated
with 10 mg/kg fucoxanthin as compared with the groups treated with 0.1 and 1 mg/kg fucoxanthin.
Thus, the protective effects of fucoxanthin treatment against UVB-induced damage to the corneal
innervation and epithelium were observed.
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Figure 5. Semi-quantitative analyses of the effects of fucoxanthin on ocular surface irregularity (A) and
lissamine green staining scores (B) following UVB-induced corneal damage. Data are shown as mean ±
SD) (n = 5 rats per group). The mean value was significantly different compared with the UVB/vehicle
group (* p < 0.05; Student t test). The mean value was significantly different as UVB/0.1 and 1 mg/kg
fucoxanthin groups compared with UVB/10 mg/kg fucoxanthin group (# p <0.05; Student t test).
The mean value was significantly different compared with UVB-exposed group (+ p < 0.05; one-way
ANOVA followed by Bonferroni’s multiple comparison test).
2.4. Effect of Fucoxanthin on UVB-Induced pp38, GFAP and TRPV1 Expression in the Trigeminal Ganglia
Neural activation results in increased levels of active pp38 MAP kinase, a key regulatory protein
involved in signal transduction in response to inflammatory stimuli that result in changes in gene
expression. To determine the relationship between UVB-induced corneal disorders and increased
pp38 levels in vivo, the active levels of pp38 were monitored using immunohistochemistry. After
UVB-induced photokeratitis, elevated levels of p38 were readily detected in both neurons and
neighbouring satellite glial cells (Figure 6A). Moreover, the number of GFAP-immunopositive activated
glial cells typically surrounding the neurons and TRPV1-positive neuronal cells were significantly
increased in the trigeminal ganglion of the UVB/vehicle group (Figure 6B,C). In contrast, the number
of pp38-positive neural cells, GFAP-positive activated glial cells and TRPV1-positive neuronal cells was
limited in the UVB/10 mg/kg fucoxanthin group (Figure 6D–F) compared with the other UVB-treated
group. These results imply that activation of satellite glial and neuronal cells was partially suppressed
by fucoxanthin treatment.
2.5. Effect of Fucoxanthin on UVB-Induced Corneal Injury-Evoked Eye Wipe Behavior
To assess the impact of fucoxanthin-suppressed activation of satellite glial and neuronal cells, we
evaluated the symptoms of inflammatory pain and eye wipe behaviour (Figure 7). Difficulty opening
the eyes, the symptom of inflammatory pain, was observed in the UVB-irradiated group (Figure 7D).
Moreover, a single drop of 5 M NaCl to the ocular surface evoked consistent increases in eye wiping
after UVB irradiation compared with the blank control group during a 5-min test period on day 6.
The frequency of the eye wipes evoked by UVB-induced photokeratitis was high. In contrast, the
animals showed reduced eye wipe frequency in the UVB/10 mg/kg fucoxanthin group compared
with the UVB/vehicle group. These results indicated that UVB-induced eye wipe behaviour was
suppressed in the fucoxanthin-treated group (Figure 7G).
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Figure 6. Characterization of pp38-, GFAP- and TRPV1-positive cells in the trigeminal ganglia of
UVB/vehicle and UVB/10 mg/kg fucoxanthin groups. Sections were stained with haematoxylin and
antibodies against pp38, GFAP and TRPV1. Expression of pp38 was increased in neuronal (arrowheads,
A) and glial cells (arrows, A) in the trigeminal ganglion after UVB-induced photokeratitis. Note that
the number of GFAP-immunopositive activated glial cells typically surrounding neurons (double
arrows, B) and TRPV1-positive neuronal cells (double arrowheads, C) were significantly increased in
the UVB/vehicle group. In contrast, the number of pp38-positive neural cells, GFAP-positive activated
glial cells and TRPV1-positive neuronal cells were limited in the UVB/fucoxanthin group (D–F).
Figure 7. Effects of fucoxanthin on eye wipe behaviour after UVB-induced corneal damage. The cornea
is composed of highly innervated tissue and pain caused by corneal damage is very intense.
Photokeratitis caused inflammatory pain symptoms, including difficulty opening the eyes and eye
wipe behaviour. Symptoms of inflammatory pain were compared between the following groups: blank
control (A,B), UVB/vehicle (C,D) and UVB/10 mg/kg fucoxanthin treatment (E,F). Difficulty opening
the eyes, the symptom of inflammatory pain, was reduced with fucoxanthin treatment (E,F). Eye wipe
behaviour analysis showed a high frequency of eye wiping evoked by UVB-induced photokeratitis. In
contrast, the animals showed reduced eye wiping in the UVB/10 mg/kg fucoxanthin group compared
with the UVB group. The data are expressed as means ± SD (n = 5 rats per group). The mean value
was significantly different compared with the UVB/vehicle group. (* p < 0.05; Student t test, G).
3. Discussions
UVB-induced corneal disorders could be caused by oxidative stress, as well as by the production
of reactive oxygen species and inflammatory cytokines [5]. The main characteristic of an antioxidant
is its ability to induce enzymes that snare free radicals. In this respect, Nrf2 and its interaction
with anti-oxidant response element increase the transcription that play important roles in the
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anti-oxidant enzyme response, such as quinone oxidoreductase 1, heme oxygenase-1 and superoxide
dismutase [20]. Fucoxanthin has been shown to be able to augment cellular antioxidant defence by
inducing Nrf2-driven expression in in skin cells in vivo and in vitro [30,31]. In the present study, Nrf2
expression increased with fucoxanthin treatment in corneal tissues. It is possible that Nrf2 at higher
expression interact with other mechanisms to increase the activity of antioxidant in corneal tissues.
Eye signs are often associated with corneal denervation and endocrinal disorders [32,33]. Nerve
innervation anomalies affect epithelium metabolism, proliferation and wound healing, compromising
the health of the cornea and visual axis [32]. The corneal epithelium preserves the intraepithelial corneal
nerves and the intraepithelial nerve terminals that spread out toward the apical surface [34]. The
corneal nerves typically release neuronal factors that promote corneal epithelial homeostasis and effect
signal transduction cascades involved in epithelial function, organization and homeostasis [10,11]. In
the present study, UVB radiation caused a significant reduction in the epithelial nerve innervation of
corneal tissues, resulting in evident UVB-induced nerve injury. We demonstrated that UVB irradiation
impairs the density and morphology of the sensory nerves within the corneal epithelium. In addition,
serious damage to the corneal tissues, including severe exfoliation, deteriorated smoothness and
corneal opacity, was detected more frequently in the UVB-irradiated groups than in the non-irradiated
groups. In the present study, we observed that reduced corneal nerve density was significantly
correlated with the disorganization of the corneal epithelium in UVB-irradiated eyes. In contrast,
treatment with fucoxanthin inhibited UVB-induced corneal denervation and preserved the integrity of
the corneal surface.
UVB radiation is non-invasive, produces localized inflammation and has been applied to
humans in previous studies examining cutaneous pain [35–37]. Ocular itching and oedema are
the most frequent symptoms complained by patients not only with photokeratitis but also with
keratoconjunctivitis, due to the frequent corneal involvement [38]. The inflammatory responses
involved in peripheral nerve damage also include the recruitment of immune cells to the site of injury.
Immune cells, including neutrophils and macrophages, are involved in the release of various kinds
of pro-inflammatory mediators that contribute to pain [39,40]. The corneal epithelium, the primary
protector of the optic axis and the most densely innervated tissue in the body, changes after UVB
exposure and corneal inflammation is a common clinical problem that causes ocular pain. Many
studies on the mechanisms of neuropathic pain have used animal models of injury to the peripheral
nerve, which involves multiple complex mechanisms. TRPV1 is an essential component of the cellular
signalling mechanisms through which tissue damage or infection produces thermal hyperalgesia
and pain hypersensitivity is primarily expressed on small, unmyelinated sensory neurons in the
trigeminal ganglia [41,42]. Recent evidence suggests that activity of the satellite glial cells connected
with gap junctions and reduces the pain threshold in the trigeminal ganglion. Furthermore, inhibition
of satellite glial cell activation causes a significant reduction in neuronal excitability and nocifensive
reflexes [43,44]. Otherwise, the proximity of satellite glial cells and neuronal cell bodies favours
interactions through paracrine signalling and contributes to the sensitization of afferent neurons.
Glia and neurons form an integrated network that modulates the excitability of pain pathways.
Pp38 involves both the neuronal and glial activation during inflammatory for the trigeminal ganglia
activation model [15]. In the present study, aside from sensory neurons, GFAP-positive activated glial
cells that typically surround neurons in the trigeminal ganglia were limited and eye wipe behaviour
evoked by UVB damage was suppressed in the UVB/10 mg/kg fucoxanthin-treated group. Thus,
suppressive effects of fucoxanthin on pp38, TRPV-1 and GFAP may be important in avoid inflammatory
pain following photokeratitis in the trigeminal ganglia.
Previous studies have reported that neuropathic pain involves the modulation of motor activity.
Neuropathic orofacial pain leads to difficulties in mandibular movements of the orofacial region,
including mastication, swallowing, speaking and toothbrushing [45,46]. Following injury to the
sensory branch of trigeminal nerve, not only are the number of activated satellite glial cells in the
trigeminal ganglia and microglia cells in the trigeminal sensory increased but the activity of the
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glial cells in the trigeminal motor nuclei is also evoked [47–49]. It remains unclear how hyperactive
glial cells interact with motor neurons. It is possible that pro-inflammatory mediators released from
activated glial cells affect the excitability of motor neurons. The blink reflex is mediated by sensory
fibres of the trigeminal nerve (cranial nerve V 1) and the efferent limb via the motor fibres of the facial
nerve (cranial nerve VII). Anatomically, the afferent corneal V1 fibres may synapse within the main
sensory nucleus and facial motor neurons in turn provide input to close the eyelids. Various ganglia
and sensory and motor nuclei are involved in the feedback loops between the cornea surface and
orbicularis oculi muscles. UVB-induced disorders of the cornea cause inflammatory pain and may
alter the wink function. In the present study, we observed that the eyelids appeared closer together in
the UVB irradiation groups than in the blank control group and that fucoxanthin treatment restored
the distance between the eyelids.
Nrf2 is a transcription factor with potent antioxidant effects against cellular damage and may
serve an essential role in the protection against various inflammatory diseases [50]. Otherwise, pp38
signalling pathways are associated in the regulation of the Nrf2-mediated cytoprotective effect [51].
In the present study, we demonstrated that oral pre-treatment with fucoxanthin promoted the
expression of Nrf2. Exposure of the ocular surface to UVB-induced changes in corneal innervation,
epithelial organization and neural activity in the trigeminal ganglia matched well with increases in
the frequency of eye wipe behaviour. By contrast, significant suppression of corneal denervation
and epithelial disorganization was observed in the groups treated with fucoxanthin compared with
the corneal damage detected in the UVB-treated experimental animals. Activated neural cells in the
trigeminal ganglia and eye wipe behaviour were also reduced and UVB-induced inflammatory pain
was suppressed in fucoxanthin-treated groups. These results demonstrated that fucoxanthin treatment
upregulated the expression of Nrf2, inhibited the denervation of corneal tissue and activated neural
cells of the trigeminal ganglia. These findings suggested that fucoxanthin has a protective effect against
UVB-induced corneal denervation and inflammatory pain and the mechanism may be associated with
regulation by Nrf2 pathway in rats.
4. Materials and Methods
4.1. Experimental Animals
Fifty male SD rats (6–8 weeks old) were obtained from the Animal Department of BioLASCO
Taiwan Co (Taipei, Taiwan, ROC). Experimental rats were quarantined and allowed to acclimate
for 1 week before beginning experimentation. Experimental rats were housed 3–4 per cage under
standard laboratory conditions with a 12-h light/dark cycle. Care and treatment of animals were
conducted in accordance with standard laboratory animal protocols (IACUC-A1050023) approved
by the Animal Care Committee (Mackay Medical College). Food and water were available ad libitum.
The experimental protocols for the present study were approved by the Institutional Animal Care and
Use Committee and the animals were cared for in accordance with the institutional ethical guidelines.
4.2. UVB-Induced Photokeratitis and Fucoxanthin Treatment
Rats were randomly divided into five groups: Group I, blank control (no UVB exposure or
fucoxanthin treatment); Group II, UVB (exposure to UVB irradiation without treatment); Group
III, UVB/0.1 mg/kg fucoxanthin (exposure to UVB irradiation and pre-treatment with fucoxanthin
(Sigma-Aldrich, St. Louis, MO, USA) oral administration at 0.1 mg/kg body weight); Group IV,
UVB/1 mg/kg fucoxanthin (exposure to UVB irradiation and pre-treatment with fucoxanthin oral
administration at 1 mg/kg body weight); and Group V, UVB/10 mg/kg fucoxanthin (exposure to UVB
irradiation and pre-treatment fucoxanthin oral administration at 10 mg/kg body weight). To induce
corneal damage in vivo, the eyes of the rats in Groups II, III, IV and V were exposed to UVB irradiation
using the procedures reported in our previous study [29]. The wavelength of the UVB source peaked at
308 nm (range, 280–315 nm). After anaesthesia with intraperitoneal injection of sodium pentobarbital
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(60 mg/kg bodyweight), the oculus was exposed to 550 μW/cm2 of UVB light (UVGL-58; UVP Inc.,
San Gabriel, CA) for 4 min in a darkroom. Group II (UVB) was exposed to UVB irradiation daily for a
period of 5 days (Day 2 to Day 6). Groups III, IV and V (UVB/fucoxanthin at various concentrations
per kg body weight) were exposed to UVB irradiation daily for a period of 5 days and treated daily
with their respective concentrations of fucoxanthin (1 day before UVB exposure) for a period of 6 days
(Day 1 to Day 6).
4.3. Tissue Fractionation and Western Blot
Rats were sacrificed by cervical dislocation after deeply anaesthesia with chloral hydrate
(400 mg/kg of body weight, intraperitoneally). Corneas were rinsed once with ice-cold phosphate
buffered saline (PBS) and then lysed with PBS containing 1% Triton X-100, 0.1% SDS, 0.5% sodium
deoxycholate, 1 μg/mL leupeptin, 10 μg/mL aprotinin and 1 mM phenylmethylsulphonyl fluoride
on ice for 15 min. After sonication for 30 s using microprobe sonicator, crude extracts were subjected
to centrifugation at 4 ◦C. All protein concentrations were measured by a protein assay (Bio-Rad
laboratories, Richmond, CA, USA). Equal amounts (50 μg) of protein extracts were separated
electrophoresed on 8% SDS-polyacrylamide gel and then transblotted onto the ImmobilonTM-P
membrane. After being blocked with 10% non-fat milk in Tween-20/PBS, blots were incubated with
rabbit anti-Nrf2 antibody (SAB4501984; Sigma-Aldrich, St. Louis, MO, USA) and then incubated with
horseradish peroxidase-conjugated secondary antibodies. The signal of specific proteins was detected
using enhanced chemiluminescence kit (ECL; PerkinElmer Life Sciences, Inc. Boston, MA, USA).
4.4. Immunohistochemistry for Nerve Innervations in Corneal Tissues
Experimental rats were deeply anesthetized using chloral hydrate and intracardially perfused
with a fixative containing 4% paraformaldehyde. A 2-mm circular corneal epithelial defect was made
in each rat using a scalpel blade. For immunocytochemistry, whole-mount tissues or 50-μm cryostat
sections were collected. The floating sections were rinsed in PBS, incubated in 1.5% hydrogen peroxide
for 45 min to eliminate endogenous peroxidase activity and finally blocked for 1 h in PBS containing
5% goat serum and 0.5% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA). Nerve innervation was
evaluated via immunohistochemistry using antibodies against general neural marker protein PGP
9.5 (AB1761, Chemicon, Temecula, CA, USA). The reaction products of nerve profiles in the cornea
were evaluated using a Vector ABC kit and the 3,3-diaminobenzadine (DAB) reaction (Vector Labs,
Burlingame, CA, USA). PGP 9.5-immnopositive nerve fibres in the epithelium of each cornea were
counted at a magnification of 400× with a light microscope. Nerves were traced and the total length
calculated with commercial software (Adobe Illustrator; Adobe Systems, San Jose, CA, USA) using an
object-length function was reported in a previous protocol [52], with slight modifications. The density
of the nerves was then charted as a percentage of the control.
4.5. Determination of Corneal Injuries
Rat corneal damage was appraised as in our previous study [29]. A circular illumination source
was attached to a stereoscopic microscope (Stemi DV4 Stereo Microscope, Carl Zeiss, Oberkochen,
Germany), which was then used to evaluate the corneas. Ocular surface irregularity was graded on
a scale of 0–4 as follows: grade 0, absent; grade 1, mild; grade 2, moderate; grade 3, severe with a
twisted circle shape; and grade 4, severe with an undistinguished shape. After corneal smoothness
was scored, the ocular surface was stained with 1% lissamine green (Sigma-Aldrich, St. Louis, MO,
USA) and washed three times with PBS. Images of the corneal surface after lissamine green staining
were taken and scored according to the grading system based on the proportion of staining noted in
the damaged cornea. The severity of corneal damage was graded on a scale from 0 to 4. Briefly, the
total area without dot staining was designated as grade 0; grade 1, less than 25% of the corneal surface
was stained with dotted punctuate staining; grade 2, 25–50% of the corneal surface was stained with
diffuse punctuate staining; grade 3, 50–75% of the corneal surface was stained with punctuate staining
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and apparent corneal defects; and grade 4, more than 75% of the corneal surface was stained with
profuse punctuate staining and more serious corneal defects. Corneal scoring was performed by three
observers who had no prior knowledge of photokeratitis.
4.6. Immunohistochemistry of pp38, TRPV1 and GFAP in Trigeminal Ganglia
Whole trigeminal ganglia were fixed in 4% paraformaldehyde for 45 min, embedded in
media (Miles, Elkhart, IN, USA), maintained at the optimal cutting temperature and frozen in
isopentane supercooled with liquid nitrogen. Using a cryostat (Leica Microsystems, Heidelberg,
Germany), 8-μm cryosections were cut and collected on silanized slides (DAKO, Tokyo, Japan).
For immunohistochemical staining of the trigeminal ganglion, serial sections were reacted with
rabbit anti-activated pp38 MAP kinase anti-serum (ab47363; Abcam, Cambridge, MA, USA), rabbit
anti-GFAP (ab7260; Abcam, Cambridge, MA, USA) or rabbit anti-TRPV1 anti-serum (ab6166; Abcam,
Cambridge, MA, USA) after dilution in PBS containing 4% normal goat serum and 0.3% Triton
X-100 (Sigma-Aldrich, St. Louis, MO, USA). Sections were then reacted with biotinylated goat
anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA), avidin and biotin-peroxidase complex
(Vector Laboratories) and visualized with 0.1% DAB.
4.7. Eye Wipe Behavior Test
The eye wipe test was performed using hypertonic saline as the inducing stimulus following a
previous protocol [53], with modifications. This is a sensitive test for acute ocular irritation-related
behaviour in conscious rats that is non-invasive and non-inflammatory. A single drop of NaCl (5 M,
20 μL) was placed on the ocular surface with a micropipette and the number of eye wipes with the
ipsilateral forelimb that occurred in 30 s was counted on day 6. Means and standard deviations were
calculated for all parameters determined in this study. Comparison analyses between any two groups
were performed using Student’s t-test. A p-value < 0.05 was considered statistically significant.
4.8. Statistical Analysis
Statistics were analysed using the SPSS program (SPSS, Inc., Chicago, IL, USA). Means and
standard deviations were calculated for all parameters determined in this study. In all samples,
Kolmogorov-Smirnov test was used to verify the normality of the data. The non-parametric values were
analysed by Mann–Whitney test. The parametric values groups were analysed by one-way analysis
of variance (ANOVA) followed by Dunnett’s or Bonferroni’s multiple comparison test. Statistically
significant differences between groups were defined as p < 0.05.
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Abstract: Excessive exposure to ultraviolet (UV) radiation is the main risk factor to develop skin
pathologies or cancer because it encourages oxidative condition and skin inflammation. In this sense,
strategies for its prevention are currently being evaluated. Natural products such as carotenoids or
polyphenols, which are abundant in the marine environment, have been used in the prevention of
oxidative stress due to their demonstrated antioxidant activities. Nevertheless, the anti-inflammatory
activity and its implication in photo-prevention have not been extensively studied. Thus, we aimed
to evaluate the combination of fucoxanthin (FX) and rosmarinic acid (RA) on cell viability, apoptosis
induction, inflammasome regulation, and anti-oxidative response activation in UVB-irradiated HaCaT
keratinocytes. We demonstrated for the first time that the combination of FX and RA (5 μM RA plus
5 μM FX, designated as M2) improved antioxidant and anti-inflammatory profiles in comparison
to compounds assayed individually, by reducing UVB-induced apoptosis and the consequent ROS
production. Furthermore, the M2 combination modulated the inflammatory response through
down-regulation of inflammasome components such as NLRP3, ASC, and Caspase-1, and the
interleukin (IL)-1β production. In addition, Nrf2 and HO-1 antioxidant genes expression increased in
UVB-exposed HaCaT cells pre-treated with M2. These results suggest that this combination of natural
products exerts photo-protective effects by down-regulating NRLP3-inflammasome and increasing
Nrf2 signalling pathway.
Keywords: fucoxanthin; rosmarinic acid; NRLP3; inflammasome; anti-oxidative; anti-inflammatory;
photo-protection; UVB
1. Introduction
Skin is considered as the outmost protective barrier in the body, protecting from detrimental
substances, mechanical damage, pathological invasion and radiation that could cause perturbations to
the skin structure. In this sense, skin is a well-known essential piece of the immune system. Several
factors can contribute to the initiation and development of cutaneous alterations. In this line, the
excessive exposure to UV radiation remains the main risk factor for the skin cancer [1]. Solar UV
radiation consists of three broad ranges of wavelength: UVC (100–280 nm), UVB (280–315 nm) and
UVA (315–400 nm). UVB causes dermal changes, affects epidermal function and is the main factor
responsible for the development of melanoma and non-melanoma skin cancer [2]. In this regard, a high
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dose of UVB exposure promotes cutaneous inflammation, which is traduced in sunburn, photo-aging,
DNA damage, immunosuppression and induction of skin cancer [3].
It has been extensively studied that UVB-induced ROS production leads to activation of
mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB), among others, which
further promote inflammation and apoptosis in cells and increase skin aging [4]. Furthermore, this
type of inflammation results in the production of cytokines as tumour necrosis factor alpha (TNF-α),
IL-6 and IL-1β, which are released by keratinocytes after UVB irradiation [5]. In this sense, it
has been reported the relation between IL-1β secretion and activation of protein complexes called
inflammasome [6]. Inflammasome is a wide cytosolic multiprotein complex that acts as mediator of the
innate immune system, which is activated by multiple types of tissue damages. The nucleotide-binding
domain, leucine-rich-repeat-containing family, pyrin domain-containing 3 (NLRP3) is the most studied
inflammasome. NLRP3 gen induction results in activation of caspase-1, which by cleavage catalyses
the processing of pro-IL-1β in cytosol to mature form, leading to IL-1β production in the extracellular
medium [7]. In the last years, some authors have demonstrated the implication of NLRP3 inflammasome
in tumorigenesis and cancer development, specifically in basal cell carcinomas [8,9].
Nowadays, non-melanoma skin cancer (NMSC) remains the most frequently diagnosed cancer in
Caucasian people worldwide and strategies for its prevention are being developed [10]. At this regards,
photo-chemoprevention by natural products is one of the most studied alternatives for skin protection,
due to their anti-oxidative actions [1]. Although the anti-inflammatory properties of natural compounds
have not been extensively investigated yet, in recent years, different studies have evaluated the beneficial
effects of these compounds in photoprotection through their anti-inflammatory activity [1].
In last years, microalgae have been employed as a vast source of bioactive molecules with
potential activity in inflammation and cancer [11]. Specifically, carotenoids have shown antioxidant,
anti-inflammatory or anti-carcinogenic properties in several skin inflammatory models [12,13].
The orange carotenoid fucoxanthin (FX) is not exclusive from marine environmental [14] but it is
an extensive compound produced by microalgae and brown seaweeds, as previously published [15]
and it is known for its potent antioxidant properties. Nevertheless, its effect on NRLP3-inflammasome
regulation has been little explored.
Polyphenols are the most popular antioxidant molecules in our diet, and exhibit other properties
as anti-inflammatory or anti-neoplastic agents. For this reason, these compounds are also proposed as
an important key for the management of skin protection [16]. In this regard, rosmarinic acid (RA) is a
phenolic ester that has been traditionally isolated from some terrestrial plants as Rosmarinus officinalis
L. or Melissa officinalis L. [17]. Moreover, this polyphenol has been abundantly found in Zostera marina
seagrass beds [18,19]. This aspect is very interesting since Zostera has a rapid generation time and
similar requirements to microalgae; thus it could be a great source to obtain a traditional phenolic
compound like this. RA has been widely studied due to its remarkable biological and pharmacological
activities, including anti-microbial, antioxidant and anti-inflammatory properties [20]. Until now, only
a limited number of studies have dealt with the effect of RA on NLRP3-inflammasome [21–23], and
none of them on human immortalized HaCaT keratinocytes.
These antecedents led us to evaluate the effects of a combination of FX and RA on ROS production,
apoptosis prevention, cell cycle alterations, inflammasome regulation and Nrf2 pathway activation, in
UVB-exposed human keratinocytes.
2. Results
2.1. Effects of RA and FX on Cell Viability
The UVB intensity was selected in a preliminary study in which three different intensities
(100, 150 and 225 mJ/cm2) were tested. To study the cell viability was used MTT assay
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). As expected, a UVB dose-dependent
effect on cell death and morphology was observed. The intensity of 100 mJ/cm2 was chosen for further
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assays since it allowed over 50% of cell survival and showed a significant difference in comparison
with non-irradiated control group (Figure 1A). In addition, MTT results showed that the treatment with
RA or FX at 5 μM, M1 (2.5 μM RA + 5 μM FX) and M2 (5 μM RA + 5 μM FX) significantly increased




Figure 1. Selection of UVB dose and effect of rosmarinic acid (RA), fucoxanthin (FX) and combinations
on cell viability and ROS production in UVB-irradiated HaCaT cells. (A) Effect of different UVB doses
on cell viability determined by MTT assay. Results are expressed as percentage respect to untreated
control cells and bars represents mean ± SEM of four independent experiments (n = 4) in duplicate.
(*** p < 0.001 vs. untreated cells; Student t test) (B) Effect of RA, FX and their combinations on cell
viability in human HaCaT keratinocytes was measured by MTT assay after 24 h of UVB exposition.
(C) Intracellular ROS generation was evaluated 30 min after UVB irradiation by relative fluorescence
intensity using 2’,7’-dichlorodihydrofluorescein diacetate (DCF-DA) assay. For experiments B and
C, cells were pre-treated with RA (2.5 and 5 μM), FX (5 μM) and two combinations M1 (2.5 RA plus
5 μM FX) and M2 (5 μM RA plus 5 μM FX), for 1 h. Then, cells were irradiated with selected UVB
dose (100 mJ/cm2) and incubated for the required times. Results are expressed as percentage respect
to untreated control cells (B) or UVB-exposed control cells (C), and bars represents mean ± SEM
of at least six independent experiments (n = 6) in duplicate. The mean was significantly different
compared to control cells (*** p < 0.001; Student t test). The mean was significantly different compared
to UVB-irradiated cells (+ p < 0.05, ++ p < 0.01 and +++ p < 0.001; one-way ANOVA followed by
Bonferroni’s multiple comparison test).
2.2. Effect of RA and FX on UVB-induced ROS Production.
It is well known that intracellular ROS levels can be increased by UVB exposure [24]. In this sense,
HaCaT cells were treated with the compounds for 1 h and then were irradiated with UVB (100 mJ/cm2).
Cells exposed to UVB showed a significant increase in ROS production in comparison with non-exposed
control cells (p < 0.001). The pre-treatment with either RA at the concentration of 2.5 or 5 μM or
FX at 5 μM notably reduced intracellular ROS levels by 12%, 12% and 10%, respectively (p < 0.01).
Nevertheless, concomitant administration of RA and FX (M1 or M2) showed a more marked decrease in
ROS production, by 21% and 22%, respectively (p < 0.001) than the single treatments (Figure 1C).
2.3. Effect of RA and FX on Apoptosis
It is well reported that apoptosis is the most important type of programmed cell death in response
to cell damage induced by UVB exposure [25]. In this sense, Annexin V (annexin family of intracellular
protein)-FITC assay allows to differentiate cell subpopulations in different stages as necrotic (R1),
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viable (R2), early apoptosis (R3) or late apoptosis (R4). For this assay, only the adherent cells were
considered, which means that the dead cells in suspension after UVB irradiation were not analysed and
thus significant changes were not observed in this phase [26]. Our results showed that UVB exposure,
in comparison with non-irradiated cells, significantly decreased the percentage of viable cells from 88%
to 20%, increased the number of cells in early apoptosis from 1% to 5% and strongly augmented the
percentage of cells in late apoptosis from 8% to 72% (Figure 2A). Regarding to pre-treatments, neither
RA nor FX exhibited percentages changes in the different subpopulations, respect to UVB-exposed
cells. Nevertheless, the treatment with M1 or M2 allowed a significant reduction of the percentage of





Figure 2. Effect of rosmarinic acid (RA), fucoxanthin (FX) and combinations on apoptosis and cell cycle
arrest by using flow cytometry. (A) Results of Annexin V-FITC assay as percentage of cells in different
apoptotic phases; R1: necrotic cells (Annexin V-FITC negative, PI positive), R2: viable cells (Annexin
V-FITC negative, PI negative), R3: early apoptotic cells (Annexin V-FITC positive, PI negative), R4:
late apoptotic cells (Annexin V-FITC positive, PI positive). Cells were pre-treated with RA (2.5 and
5 μM), FX (5 μM) and two combinations M1 (2.5 RA plus 5 μM FX) and M2 (5 μM RA plus 5 μM FX),
then were irradiated with selected UVB dose (100 mJ/cm2) and incubated for 24 h. (B) Cell cycle phase
distribution of UVB-exposed HaCaT cells. Cells were incubated with treatments for 48 h. Data are
expressed as percentage and bars represents mean ± SEM of four independent experiments (n = 4) in
duplicate. Results are expressed as percentage and bars represents mean ± SEM of four independent
experiments (n = 4) in duplicate. The mean value was significantly different compared with control
group (*** p < 0.001, ** p < 0.01, * p < 0.05 vs. untreated cells; Mann–Whitney U-test). The mean value
was significantly different compared with UVB-irradiated cells + p < 0.05, ++ p < 0.01 vs. UVB-irradiated
cells; Kruskal–Wallis test followed by Dunn’s multiple comparison test).
2.4. Effect of RA and FX on Cell Cycle
It is well known that UV light exposure promotes skin photo-damage such as cell death and
DNA damage and, consequently, cell cycle arrest [27]. Our results indicated that UVB-exposure highly
affects the percentage of cells at G0/G1 phase, showing a reduction in this percentage from 68% to 50%,
accompanied by an increase in apoptotic sub-G1 subpopulations from 3% to 14%, compared with
non-exposed cells (Figure 2B). Moreover, UVB-exposed control group showed a significant increase in
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the percentage of cells in S phase, from 16% to 24%, and a marked decrease of cells in G2/M phase from
13% to 3% in comparison with non-irradiated control group. Pre-treatment with RA or FX at 5 μM, as
well as concomitant administration of RA and FX at 5 μM (M2) significantly augmented the number of
cells at G0/G1 phase in comparison with UVB-exposed cells. However, the percentage of cells in S
phase was only reduced by M2, reaching similar values that those in control group (Figure 2B).
2.5. Effect of RA and FX on Inflammasome Regulation
It has been well documented that inflammasome can be activated by several factors, among them
UVB exposure [8]. In the present study, we demonstrated that UVB irradiation led to up-regulation
of NLRP3, ASC and caspase-1 expression and, consequently, promoted a significant increase in IL-1β
production in comparison with non-exposed cells (Figure 3A–D). Pre-treatment with either RA or FX at
5 μM did not significantly modify the expression levels of inflammasome-related proteins. Nevertheless,
combination of RA and FX at 5 μM (M2) significantly down-regulated NLRP3 and ASC expression levels
(p < 0.01) as well as caspase-1 levels (p < 0.05) in comparison with UVB-exposed cells. Furthermore,
pre-treatment with M2 reduced IL-1β production in a significant manner (p < 0.01) (Figure 3D).
Figure 3. Effect of rosmarinic acid (RA), fucoxanthin (FX) and concomitant administration of RA and FX
(M2) on inflammasome components expression and IL-1β levels in UVB-exposed HaCaT keratinocytes.
Cells were pre-treated with RA (5 μM), FX (5 μM) and M2 (5 μM RA plus 5 μM FX) for 1h, then were
UVB-irradiated (100 mJ/cm2) and incubated for 24 h. Densitometry analysis of (A) nucleotide-binding
domain, leucine-rich-repeat-containing family, pyrin domain- containing 3 (NLRP3), (B) inflammasome
adaptor protein (ASC) and (C) caspase-1 positivity were performed following normalization to the
control (β-actin housekeeping gene). (D) IL-1β production was evaluated by ELISA assay. Results are
expressed as percentage respect to UVB-irradiated control and bars represents mean ± SEM of four
independent experiments (n = 4). The mean value was significantly different compared with control
group (* p < 0.05, ** p < 0.01 and *** p < 0.001; Mann–Whitney U-test). The mean value was significantly
different compared with UVB-irradiated cells (+ p < 0.05 and ++ p < 0.01; Kruskal–Wallis test followed
by Dunn’s multiple comparison test).
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2.6. Effect of RA and FX on Nrf-2 Antioxidant Signaling Pathway
To further elucidate the photo-protective mechanism of the combination of RA and FX, we
evaluated the capacity to activate antioxidant pathways as Nrf2, which promotes the transcription of
antioxidant genes and detoxification of enzymes such as heme-oxygenase 1 (HO-1) to protect against
an oxidative damage as UVB exposure [28]. Our results showed that UVB irradiation prevented the
increase of Nrf2 and HO-1 expression (Figure 4A–B). Non-irradiated control cells (sham) did not exhibit
the highest expression levels of these antioxidant proteins because these cells were not exposed to any
stress. Nevertheless, UVB-exposed HaCaT cells and pre-treated with FX at 5 μM or the combination
of RA and FX at 5 μM (M2) significantly up-regulated Nrf2 expression levels (p < 0.05 and p < 0.01,
respectively), reaching higher values that those in control cells. Regarding HO-1 expression, only M2
was able to significantly enhance this protein levels (p < 0.05).
Figure 4. Effect of rosmarinic acid (RA), fucoxanthin (FX) and concomitant administration of RA and
FX (M2) on Nrf2 and HO-1 expression in UVB-exposed HaCaT keratinocytes. Cells were pre-treated
with RA (5 μM), FX (5 μM) and M2 (5 μM RA plus 5 μM FX) for 1 h, then were UVB-irradiated (100
mJ/cm2) and incubated for 24 h. Densitometry analysis of (A) Nrf2 and (B) HO-1 were performed
following normalization to the control (β-actin housekeeping gene). Data shown are expressed as
percentage respect to UVB-irradiated control and bars represents mean ± SEM of four independent
experiments (n = 4). The mean value was significantly different compared with control group (* p < 0.05;
Mann–Whitney U-test). The mean value was significantly different compared with UVB-irradiated
cells (+ p < 0.05 and ++ p < 0.01; Kruskal–Wallis test followed by Dunn’s multiple comparison test.
3. Discussion
Skin represents the first barrier that protects us from the deleterious effects of solar UV radiation,
which is the main cause for skin cancer. Nevertheless, human skin is normally exposed to UV irradiation
in a non-controlled way. Whereas a short-term UV exposure might suppress immune function or
trigger an inflammatory response, chronic UV exposition conduces to photo-aging, DNA damage,
or carcinoma [29]. Skin has an antioxidant system, composed by enzymatic and non-enzymatic
antioxidants, to prevent against toxic exogenous/endogenous ROS levels. Nowadays, it is well known
the importance of natural substances that support the endogenous antioxidant systems of the skin via
diet or dermatological preparations [30]. To develop new skin photo-protective agents it is necessary
to understand the molecular mechanism of UV-induced cellular responses and determine how these
products may act in the skin cells. In this sense, many treatments with a unique compound have
demonstrated successful results against photo-damage, but a more hopeful impact was obtained when
a combination of several compounds was used [31]. The efficacy of combinations could be due to the
synergistic effect of their components. In this regard, natural products may be good candidates for
skin photo-protection due to their low toxicity and high antioxidant capacity [32]. Thus, the present
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study aimed to evaluate the preventive effect of a combination of RA and FX in UVB-exposed human
HaCaT keratinocytes.
It is well reported that UVB radiation increases ROS production and DNA damage as well as
promotes a strong inflammatory response characterized by pro-inflammatory mediator production [33].
In this condition, apoptosis activation can eliminate the irreversibly damaged cells that could harbour
oncogenic mutation [25]. In this line, FX has demonstrated antioxidant activity offering protection
against DNA damage and preventing cellular apoptosis in HaCaT human keratinocytes [34,35]. In a
similar way, several studies have reported that RA reduces ROS production, protects against DNA
damage and regulates apoptotic markers in vitro [31,36]. According to these findings, our results
showed that the pre-treatment with FX or RA at 5 μM significantly attenuated UVB-induced damage
by increasing cell viability and inhibiting ROS production in human HaCaT keratinocytes, but did not
modify the number of apoptotic cells after UVB exposure. Nevertheless, the selected combination of
RA and FX at 5 μM at equal dose (M2) not only improved cell viability and ROS levels in comparison
with FX and RA administered separately, but also enhanced the cellular protection, reducing the
number of cells in apoptosis after UVB irradiation. In addition to cellular responses previously detailed,
UVB exposure also affected cell cycle dynamics. Previous studies have reported that UV exposure
activates cell cycle arrest in both G1 and G2 phases [37]. At this respect, our results reported that
UVB irradiation significantly reduced cells at G0/G1 phase when compared with non-exposed cells.
Furthermore, a S-phase delay was observed in UVB-exposed cells although it did not show to be highly
affected by the treatments. The pre-treatment with FX, RA and concomitant administration of RA and
FX (M2) significantly increased the percentage of cells at G0/G1 and reduced the percentage of cells
at sub-G1. In this sense, our observations are in accordance with the results obtained in apoptosis
assay. M2 prevented cell damage, reducing the percentage of cells under apoptosis 24 h after UVB
exposure. In consequence, this combination promoted a higher percentage of viable cells at 48 h in
UVB-exposed cells.
In terms of inflammation, it has been reported that pro-IL-1β is cleaved and IL-1β is released
from cells as a pro-inflammatory cytokine after NLRP3 inflammasome activation [38]. Thus, it could
be concluded that IL-1β production in keratinocytes is inflammasome-dependent [6]. Moreover,
NLRP3 inflammasome activation by UVB increases not only IL-1β but also other pro-inflammatory
cytokines such as IL-1α, IL-6, TNF-α or the mediator PGE2 [7]. In this line, NLRP3 inflammasome
plays an important role in UVB-induced skin inflammatory responses and has a critical function in
skin pathologies initiation such as cancer [8]. In addition, the inflammasome adaptor protein ASC
has shown anti-tumour activity by activation of tumour suppressor protein p53 in UVB-irradiated
keratinocytes [39]. Due to the high connection between inflammasome, inflammation and cancer, the
therapeutic strategies targeting inflammasome-related products are currently in development and
suppose a pivotal tool for skin pathologies and cancer prevention [40]. In previous studies, FX has
shown anti-inflammatory activity through NF-κB and MAPKs signalling pathways regulation [41],
and consequently the down-regulation of IL-1β, TNF-α, inducible nitric oxide synthase, and
cyclooxygenase-2 expression [42–44]. On the other hand, the polyphenol RA has been previously
reported to inhibit pro-inflammatory cytokines production, including IL-1β, and to down-regulate
NF-κB signalling pathway in skin cells [45]. In addition, this polyphenol has shown to modulate
inflammasome activation, through down-regulation of caspase-1, NLRP3 and ASC expression in
a poly(I:C)-induced inflammation in an infectious model by using epidermal keratinocytes [21].
Moreover, due to its anti-inflammatory properties, RA has been proposed to ameliorate allergic
reactions in allergic rhinitis and rhinoconjunctivitis [46]. Furthermore, this compound has shown to
prevent cisplatin-induced apoptosis in chemotherapy by down-regulating the caspase-1 expression [47].
However, the role of FX or RA on NLRP3 inflammasome regulation in human keratinocytes has
not been studied yet. In this line, our findings reported for the first time that the combination of
RA and FX notably reduced inflammasome-related proteins such as NLRP3, ASC and caspase-1 in
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UVB-irradiated HaCaT keratinocytes. Interestingly, this effect was not detected when both compounds
were administered separately, suggesting the beneficial effect of concomitant treatment with RA and FX.
The antioxidant role of FX and RA has been well-described. FX has shown to promote
AKT/Nrf2/GSH-dependent antioxidant response in keratinocytes [48,49], as well as reduce wrinkles
formation and epidermal hypertrophy in mice [50] and supress melanogenesis and prostaglandin
synthesis [51]. In this line, due to its antioxidant activity, this carotenoid has been proposed as a
photo-protective compound by stimulating skin barrier restoration in UVA-induced sunburn [52].
Furthermore, a previous study by our group evidenced that FX increased Nrf2 and HO-1 expression in
UVB-induced acute erythema in SKH-1 hairless mice [44]. These results are in line with other authors
that suggest that this compound could be an interesting strategy to counteract UVB-induced oxidative
damage in skin [53]. At this regard, similar properties have been demonstrated with RA applications,
confirming the antioxidant activity of this polyphenol via activation of Nrf2-antioxidant system [54,55].
In accordance with these findings, the combination between FX and RA (M2) used in this study showed
an up-regulation of Nrf2 transcriptional factor and its main target gene HO-1. These data indicate that
the protective activity of M2 may be due to the reduction of oxidative stress through modulation of
Nrf2 signalling pathway.
4. Materials and Methods
4.1. Compounds
RA and FX were obtained from Sigma-Aldrich (St. Louis, MO, USA). RA and FX stocks were
prepared in DMSO at 10 mM and diluted to the desired concentration with culture medium. Controls
were incubated with the corresponding quantity of DMSO, which was always below 1% and did not
affect cell viability
4.2. Cell Line
Human immortalized keratinocytes HaCaT were obtained from the American Type Culture
Collection (ATCC) and maintained in high glucose Dulbecco’s modified Eagle’s medium (DMEM,
GIBCO, Grand Island, NY, USA) containing 2 mM l-glutamine. The culture media was supplemented
with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin and 100 mg/mL streptomycin (PAA
Laboratories, Pasching, Austria). Cultures were incubated in an atmosphere of 5% CO2 at 37 ◦C.
4.3. UVB-Irradiation
The CL-1000M UV Crosslinker system (UVP, Upland, CA, USA), formed by 5 UVB tubes (8 W),
was used to submit an energy spectrum of UVB radiation (peak intensity 302 nm, inside of the spectrum
of UVB light 280–315 nm). To prevent UVB light absorption by the cell culture medium the medium
was replaced by a thin layer of phosphate buffer solution (PBS) to cover the cells during irradiation.
Three UVB intensities were evaluated (100, 150 and 225 mJ/cm2) to determine the most suitable to
evaluate cell cycle alterations and apoptosis [22]. In this sense, 100 mJ/cm2 was selected for the study.
4.4. Cell Proliferation Assay
Cell viability was evaluated by the colorimetric 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl
tetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, MO, USA) assay, which determines the
formation of purple formazan in viable cells and allows estimate cellular viability [56]. MTT assay was
performed according to protocol described with slight modifications. Briefly, HaCaT cells were seeded
at a density of 104 cells/well in a 96-well plate for 24 h. Cells were pre-treated with different doses either
RA (2.5, 5, 7.5 and 10 μM) or FX (5, 10, 15 and 20 μM) and the sixteen possible combinations between
RA and FX, for 1 h. Then, the culture medium was replaced with a thin layer of PBS and exposed to
a single dose of UVB radiation at 100 mJ/cm2. Cells were supplied with fresh culture medium and
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incubated for 24 h. Absorbance was measured at 570 nm using a Synergy HT Multi-mode Microplate
Reader (BioTek Instruments, Winooski, VT, USA).
4.5. Intracellular ROS Scavenging Activity
The 2’,7’-dichlorodihydrofluorescein diacetate (DCF-DA) assay was used to detect intracellular
ROS levels in HaCaT keratinocytes [57]. Briefly, keratinocytes were seeded at 104 cells/well in 96-well
plates and were treated with RA (2.5 and 5 μM), FX (5 μM) and the combinations M1 (2.5 RA plus 5 μM
FX) and M2 (5 μM RA plus 5 μM FX) for 1 h. After UVB exposure (100 mJ/cm2), cells were incubated
with 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA) solution (5 mg/mL) in PBS for 30 min at
37 ◦C. Then, the medium was discarded and the cells were washed with PBS. The fluorescence of the
2’,7’-dichlorofluorescein (DCF) product was determined by using a fluorescence plate reader (Sinergy
HT, Biotek®, Bad Friedrichshall, Germany) at 485 nm for excitation and 535 nm for emission.
4.6. Apoptosis Determination
Apoptosis was evaluated by flow cytometry using Annexin V-FITC Apoptosis detection kit from
BD Pharmingen (Franklin Lakes, NJ, USA), as previously reported [26]. Briefly, HaCaT cells were
seeded at 5 × 105 cells/well in 6-well plates and incubated for complete adhesion. The day after seeding,
cells were treated with RA (2.5 and 5 μM), FX (5 μM) and mixtures M1 (2.5 RA plus 5 μM FX) and
M2 (5 μM RA plus 5 μM FX) for 1 h. After that, treatments were removed and cells were irradiated
at 100 mJ/cm2, and then incubated with fresh medium for 24 h. Cells were harvested and suspended
in binding buffer at 105 cells/mL. Then, annexin V-FITC and propidium iodide (PI) were added as
indicated in the manufacture’s protocol. Subsequently, samples were kept in darkness for 15 min and
400 μL of binding buffed were added. Fluorescence intensity of PI and FITC-Annexin-V-stained cells
was determined on a Coulter Epics XL Flow Cytometer (Beckman Coulter, Hialeah, FL, USA). Data
were obtained using the SYSTEM II (v.2.5.) software examining 104 events. The cytogram of FITC
fluorescence in log scale versus PI fluorescence in log scales allows the identification of viable cells
(Annexin V-FITC negative, PI negative), early apoptotic cells (Annexin V-FITC positive, PI negative),
late apoptotic cells (Annexin V-FITC positive, PI positive) and necrotic cells (Annexin V-FITC negative,
PI positive). Flow cytometry data were analysed by FlowJo software (Tree Star Inc., Ashland, OR, USA).
4.7. Cell Cycle Determination
For cell cycle determination, a similar procedure to apoptosis evaluation was carried out, with the
difference of that after irradiation, cells were incubated with fresh medium for 48 h. After incubation,
keratinocytes were harvested by trypsinization as previously detailed [26], fixed in 85% cold ethanol
(5 × 105 cells/mL) and kept at −20 ◦C until further analysis. Ethanol was eliminated, cells were
resuspended in PBS, and the cell suspension was filtered through a 35 μm nylon mesh to separate
aggregated cells. Then, 50 μL RNase (1 mg/mL) and 50 μL PI (1 mg/mL) were added to each sample,
which was then incubated for 20 min in darkness at room temperature until analysis. DNA content
was determined on a Coulter Epics XL Flow Cytometer (Beckman Coulter, Hialeah, FL, USA). Data
were acquired using the SYSTEM II (v. 2.5.) software examining 104 events. Percentages of cells in
apoptotic-sub G1, G0/G1, S and G2/M were calculated using CXP software.
4.8. Determination of IL-1β Production
HaCaT cells were seeded at 5 × 105 cells/well in 6-well plates, incubated for 24 h and treated with
either RA (5 μM), FX (5 μM) or M2 (5 μM RA plus 5 μM FX), for 1 h. Then, the cells were irradiated at
100 mJ/cm2, and incubated with fresh medium for 24 h. Supernatant fluids were collected and stored at
−80 ◦C until use. Commercial enzyme-linked immunosorbent assay (ELISA) kits (Diaclone GEN-PROBE,
Besançon cedex, France) was used to quantify IL-1β production according to the manufacturer’s protocol.
The absorbance at 450 nm was read by a microplate reader (Sinergy HT, Biotek®, Bad Friedrichshall,
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Germany). To calculate the concentration of IL-1β (pg/mL), a standard curve was constructed using
serial dilutions of cytokine standards provided with the kit.
4.9. Western Blot Analysis
The cell culture and treatments were similar to those carried out for cytokine production.
Then, HaCaT cells were harvested by trypsinization, centrifuged and resuspended in lysis buffer
(50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton-X-100, 1 mM
phenylmethylsulphonyl fluoride, protease inhibitor cocktail tablet, 0.5 mM sodium orthovanadate,
20 mM sodium pyrophosphate). The homogenates were centrifuged (12,000 g, 15 min, 4 ◦C), and
the supernatants were collected and stored at −80 ◦C. Bradford colorimetric method was utilized
to determine the protein concentration of the homogenates [58]. Samples of the supernatants with
equal amounts of protein (20 μg) were separated on 10% acrylamide gel by sodium dodecyl sulphate
polyacrylamide gel electrophoresis. Next, the proteins were electrophoretically transferred onto a
nitrocellulose membrane and incubated with specific primary antibodies: rabbit anti-ASC (Bio-Rad,
Hercules, CA, USA) (1:1000), rabbit anti-NLRP3 (1:1000), rabbit anti-Nrf2 (1:1000), rabbit anti-HO-1
(1:1000), rabbit anti-caspase-1 (1:1000) (Cell Signaling, Danvers, MA, USA) overnight at 4 ◦C. After
rising, the membranes were incubated with the horseradish peroxidase-linked (HRP) secondary
antibody anti-rabbit (Cayman Chemical®, Ann Arbor, MI, USA) (1:1000) or anti-mouse (Dako®,
Atlanta, GA, USA) (1:1000) containing blocking solution for 1 h at room temperature. To prove equal
loading, the blots were analysed for β-actin expression using an anti-β-actin antibody (Sigma Aldrich®,
St. Louis, MO, USA). Immunodetection was performed employing an enhanced chemiluminescence
light-detecting kit (SuperSignal West Pico Chemiluminescent Substrate, Pierce, IL, USA). Then, the
immunosignals were monitored by using an Amersham Imaging 600 (GE Healthcare Life Sciences,
Barcelona, Spain) and densitometric data were analysed after normalization to the control (housekeeping
gene). The signals were analysed and quantified with a Scientific Imaging Systems (Biophotonics
ImageJ Analysis Software, National Institute of Mental Health, Bethesda, MD, USA) and expressed as
total percentage respect to UVB-exposed control group.
4.10. Statistical Analysis
All values in the figures and text are expressed as arithmetic means ± standard error of the mean
(S.E.M.). Data were evaluated with GraphPad Prism® Version 5.00 software (San Diego, CA, USA).
In all cases, the Shapiro–Wilk test was used to verify the normality of the data. The Mann–Whitney
U-test was chosen for non-parametric values. The parametric values groups were analysed by one-way
analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test. p values < 0.05 were
considered statistically significant.
5. Conclusions
In conclusion, we have demonstrated for the first time that the combination of RA and FX shows
additional benefits in comparison with the compounds administered separately on UVB-irradiated
keratinocytes. The studied combination (M2) increased cell viability by reducing UVB-induced
apoptosis and decreased intracellular ROS production. Moreover, the concomitant administration of
RA and FX showed anti-inflammatory activity through NLRP3 inflammasome modulation, as well as
antioxidant properties via up-regulation of Nrf2/HO-1 antioxidant system. Overall, we propose the
combination of RA and FX as a natural promising tool in prevention of UVB-induced skin alterations
as photo-aging, skin inflammation and its derivation to pre-cancerous lesions and skin carcinomas.
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Abbreviations
ASC apoptosis-attached-speck-like protein containing a CARD
DCFH-DA 2’,7’-dichlorodihydrofluorescein diacetate
FX Fucoxanthin
HO-1 heme oxygenase 1
IL Interleukin
NMSC non-melanoma skin cancer
NLRP3 nucleotide-binding domain, leucine-rich-repeat-containing family, pyrin domain- containing 3
Nrf2 nuclear factor E2-related factor 2
ROS reactive oxygen species
SRB sulforhodamine B
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Abstract: Frondanol is a nutraceutical lipid extract of the intestine of the edible Atlantic sea cucumber,
Cucumaria frondosa, with potent anti-inflammatory effects. In the current study, we investigated
Frondanol as a putative anti-inflammatory compound in an experimental model of colonic
inflammation. C57BL/6J male black mice (C57BL/6J) were given 3% dextran sodium sulfate (DSS) in
drinking water for 7 days to induce colitis. The colitis group received oral Frondanol (100 mg/kg
body weight/per day by gavage) and were compared with a control group and the DSS group.
Disease activity index (DAI) and colon histology were scored for macroscopic and microscopic
changes. Colonic tissue length, myeloperoxidase (MPO) concentration, neutrophil and macrophage
marker mRNA, pro-inflammatory cytokine proteins, and their respective mRNAs were measured
using ELISA and real-time RT-PCR. The tissue content of leukotriene B4 (LTB4) was also measured
using ELISA. Frondanol significantly decreased the DAI and reduced the inflammation-associated
changes in colon length as well as macroscopic and microscopic architecture of the colon. Changes
in tissue MPO concentrations, neutrophil and macrophage mRNA expression (F4/80 and MIP-2),
and pro-inflammatory cytokine content (IL-1β, IL-6 and TNF-α) both at the protein and mRNA
level were significantly reduced by Frondanol. The increase in content of the pro-inflammatory
mediator leukotriene B4 (LTB4) induced by DSS was also significantly inhibited by Frondanol.
It was thus found that Frondanol supplementation attenuates colon inflammation through its potent
anti-inflammatory activity.
Keywords: Frondanol; Cucumaria frondosa; DSS colitis; colon inflammation
1. Introduction
Inflammatory bowel disease (IBD) refers to Crohn’s disease (CD) or ulcerative colitis (UC),
which involve both small and large intestines. IBD is characterized by chronic inflammation with
mucosal ulceration in the intestinal tract [1]. The prevalence of IBD is increasing (150–250/100,000) in
developed nations [2], and greatly diminishes quality of life because of the morbidity associated with
it such as pain, vomiting, and diarrhea. IBD also increases the risk of colorectal cancer [2]. The current
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mainstream therapies for IBD are sulfasalazine, corticosteroids, immunosuppressive agents such as
azatriopine, and anti-tumor necrosis factor-α antibodies, either as single agents or in combination,
to inhibit aberrant immune response and inflammation. However, the adverse effects associated with
these treatments over prolonged periods as well as the concomitant high relapse rate of the disease
limits their use [3]. With the lack of effective treatment, in addition to the associated side effects and
costs, many IBD patients turn to complementary and alternate therapy [4].
The marine environment has been of great interest for drug discovery in the last several decades,
as researchers acknowledge its promising potential for new drug leads. To date, only a few drugs
from marine sources have been isolated, developed, and approved to treat diseases such as cancer,
but the search continues [5]. Sea cucumbers have been used for hundreds of years as food and folk
medicine in the communities of Asia and the Middle East [6]. Sea cucumbers are also referred to
as ‘marine ginseng’, and they contain numerous useful specific compounds that could have broad
applications in agricultural, nutraceutical, pharmaceutical, and cosmeceutical products [7]. Frondanol
is a US-patented nutraceutical lipid extract of the intestines of the edible Atlantic sea cucumber
Cucumaria frondosa. Frondanol has potent anti-inflammatory activity. It has been purported to
suppress inflammation in the adjuvant arthritis rat model and ear edema mice model when it is
administered either orally or applied topically [8]. Frondanol exhibits potent inhibitory activity on
both 5-lipoxygenase (5-LOX) and 12-lipoxygenase (12-LOX) pathways, suppressing the production of
12-hydroxyeicosatetraenoic acid (12-HETE), 5-hydroxyeicosatetraenoic acid (5-HETE), and leukotriene
B4 (LTB4) in human polymorphonuclear cells [8]. There is considerable evidence for the involvement
of the 5-LOX pathway in colitis. The products of 5-LOX, 5-HETE, and LTB4 are markedly increased
in the dextran sodium sulfate (DSS) model [9–11]. When DSS-treated animals are given a 5-LOX
inhibitor or an LTB4 antagonist, colonic shortening as well as histological and inflammatory scores
were improved in the mouse model of colonic inflammation [9,11–13]. Therefore, we hypothesized
that Frondanol may attenuate the inflammatory responses seen in IBD. Various experimental animal
models of IBD have been developed to mimic the pathophysiological processes that characterize
UC [14,15]. Perhaps the most accepted model of colon inflammation is the murine model of colitis
that utilizes oral administration of DSS, a murine chemical colitogen to induce UC [16]. In the present
study, we investigated the efficacy of Frondanol in attenuating the colonic inflammation induced by
DSS in mice.
2. Results
2.1. Effect of Frondanol on Disease Activity Index (DAI) and Colon Length
In C57BL/6J mice, 3% DSS in drinking water induced distinct features of ulcerative colitis.
There was a marked and significant increase in the DAI score in the DSS-treated group (p < 0.001).
Frondanol administration significantly prevented the increase in the DAI score in DSS-treated animals
(p < 0.05, Figure 1). However, Frondanol alone had no significant effect on the DAI score compared
with the control. DSS treatment significantly reduced colon length (cm) when compared to the control
(p < 0.001). Frondanol treatment in of the DSS group significantly prevented the shortening of colon
length (p < 0.05, Figure 2a,b). However, Frondanol alone did not affect colon length compared to
the control.
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Figure 1. Effect of Frondanol on disease activity index (DAI) and colon length. Dextran sodium sulfate
(DSS) treatment significantly increased the DAI score. Frondanol treatment significantly decreased
the DAI score compared to the DSS-treated group. Data were obtained from n = 8 animals in each
group and are expressed as means ± SEM (control vs. DSS, *** p < 0.001 and DSS vs. Frondanol + DSS.
* p < 0.05, was obtained by one-way ANOVA followed by Tukey’s multiple comparison test).
 
Figure 2. Effect of Frondanol on colon length. The average colon length (cm) (a,b) was significantly
decreased in the DSS-treated group. Frondanol treatment significantly prevented the shortening of
colon length compared to the DSS-treated group. Data were obtained from n = 8 animals in each group
and are expressed as means ± SEM (control vs. DSS *** p < 0.001, DSS vs. DSS + Frondanol, and control
vs. DSS + Frondanol * p < 0.05. NS indicate not significant was obtained by one-way ANOVA followed
by Tukey’s multiple comparison test).
2.2. Effect of Frondanol on Microscopic Architecture
The healthy normal control colon section depicted typical architecture of a colon with normal
thickness of the submucosa and muscle layer, as well as regular crypt structure in the mucosa. In the
DSS-treated control group, colonic inflammation reached up into the submucosa with focal loss of
crypts and surface epithelium. In contrast, the Frondanol-treated DSS group had intact epithelium
with minimal loss of crypt and inflammation compared the normal control group (Figure 3a).
The most reproducible histological abnormality in the DSS-treated control group was excessive
crypt damage with edema, collapse, or complete destruction (Figure 3a). Crypt damage score was
significantly worse in DSS-mice compared with untreated controls and Frondanol-treated DSS animals
(p < 0.0001 and p < 0.001, respectively, Figure 3a,b). However, the crypt damage score was still
significantly higher in the Frondanol-treated DSS group compared with healthy controls (p < 0.001).
Frondanol alone had no effect on the crypt damage score. The colonic inflammation score was markedly
and significantly increased in the DSS-treated mice compared to untreated control animals (p < 0.0001,
Figure 3c). Frondanol treatment in the DSS-treated group significantly prevented the increase in
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colonic inflammation score compared to DSS treatment alone (p < 0.001, Figure 3c). The inflammation
score was still significantly elevated in the Frondanol-treated DSS group compared to healthy controls,
indicating only partial, but significant protection of both colonic crypt damage and inflammation by
Frondanol (p < 0.001, Figure 3c). Frondanol alone (without DSS) had no significant effect on the colon
inflammation score compared to controls. These results confirm that Frondanol has a protective effect
on the colonic micro architecture, damaged by DSS treatment.
 
Figure 3. Effect of Frondanol on colon histology. (a) Hematoxylin and Eosin (H&E) staining was carried
out to provide material for microscopic scoring (Scale Bars: 100 μm). Microscopic analysis shows
typical architecture of the colon with normal thickness of the submucosa, muscle layer, and regular
crypt structure in the mucosa in the control. The DSS-treated colon section shows focal loss of crypts
and surface epithelium with inflammation reaching up to the submucosa. Frondanol protected the
microscopic architectures in the DSS-treated group. Crypt distortion score and colon inflammation score
(b,c) were significantly higher in the DSS-treated group. Frondanol treatment significantly lowered both
crypt distortion and colon inflammation scores. All of the histology pictures are represented at 20×
magnification. Data were obtained from n = 8 animals in each group and are expressed as means ± SEM.
(control vs. DSS +++ p < 0.0001, DSS vs. DSS + Frondanol, and control vs. DSS + Frondanol *** p < 001,
obtained by one-way ANOVA followed by Tukey’s multiple comparison test).
2.3. Effect of Frondanol on the Expression of Myeloperoxidase (MPO) Protein, F4/80 Macrophage Marker
mRNA, and Macrophage Inflammatory Protein-2 (MIP-2) mRNA Concentrations
Myeloperoxidase (MPO) is an enzyme secreted from activated neutrophils and is commonly used
a marker to assess the level of neutrophil infiltration at a site of inflammation. MPO concentrations
were measured in colon homogenates using an ELISA assay. MPO concentrations were markedly and
significantly increased in the DSS group compared to the control (p < 0.001, Figure 4a). Frondanol
73
Mar. Drugs 2018, 16, 148
administration significantly prevented the DSS-induced increase in MPO concentrations (p < 0.01),
indicating the role of Frondanol in mitigating inflammatory response induced by DSS. Frondanol alone
did not significantly affect MPO concentrations (Figure 4a). In DSS-induced colitis, both neutrophil and
macrophage infiltration was significantly increased. We measured mRNA expression of F4/80 protein
as a marker of macrophage infiltration. F4/80 mRNA was significantly increased in the DSS-treated
group compared to the control (p < 0.001). Frondanol treatment in the DSS-treated animals significantly
(p < 0.01) prevented F4/80 mRNA expression (p < 0.001, Figure 4b). However, Frondanol alone had no
effect on F4/80 mRNA expression. MIP-2 mRNA expression massively and significantly increased
in the DSS-treated group compared to the control (p < 0.001, Figure 4c). Frondanol administration
in the DSS-treated group significantly prevented the increase in MIP-2 mRNA expression (p < 0.001,
Figure 4c). However, the group receiving Frondanol treatment following DSS still had an MIP-2 mRNA
level higher than that of the control (p < 0.05, Figure 4c). Frondanol alone had no effect on MIP-2
mRNA expression. These results confirm that Frondanol limits the infiltration of macrophages and
neutrophils due to damage induced by DSS.
Figure 4. Effect of Frondanol on MPO concentration, F4/80 neutrophil markers, and MIP-2 mRNA
expression. DSS treatment significantly enhanced neutrophil infiltration, as marked by an increase in (a)
MPO concentration and (b,c) F4/80 and MPI-2 mRNA expression compared to the control. Frondanol
administration significantly decreased (a) MPO activity, F4/80, and MIP-2 mRNA expression in the
DSS-treated group. Frondanol alone did not affect (a) MPO concentration, (b) F4/80, or (c) MIP-2
mRNA expression. MPO concentrations were quantitated using ELISA. F4/80 and MIP-2 mRNA
expression studies were carried out using real-time RT-PCR. Data were obtained from n = 8 animals
for MPO concentration and n = 6 animals for mRNA expression studies in each group, and are
expressed as means ± SEM (control vs. DSS, and DSS vs. DSS + Frondanol, *** p < 0.001; control vs.
DSS + Frondanol, * p < 0.05. NS indicate not significant was obtained by one-way ANOVA followed
by Tukey’s multiple comparison test).
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2.4. Effect of Frondanol on Pro-Inflammatory Cytokine Protein and mRNA Concentrations
DSS treatment caused massive increases in protein concentrations of the pro-inflammatory
cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6) (p < 0.001, Figure 5a,b), and tumor necrosis
factor-α (TNF-α), (p < 0.01, Figure 5c), as well as the relative expression of the mRNAs for these
respective cytokines (IL-6 and IL-1β, p < 0.001; TNF-α, p < 0.01, Figure 5d–f). Frondanol administration
prevented increases in pro-inflammatory cytokines and their respective mRNA expression in response
to DSS treatment (p < 0.001 for IL-6, IL-1β and p < 0.01 for TNF-α cytokines. p < 0.001 for IL-6,
and p < 0.05 Il-1β and TNF-α mRNAs). In control animals, Frondanol alone had no effect on the
expression of the cytokines or their respective mRNAs. These results indicate that Frondanol strongly
inhibits the pro-inflammatory cytokine response induced by DSS.
 
 
Figure 5. Effect of Frondanol on pro-inflammatory cytokine protein and mRNA expression. Frondanol
significantly inhibits pro-inflammatory cytokines both at the protein level (IL-6 (a), IL-1β (b) and
the TNF-α (c)) and mRNA expression level in the DSS-treated group (Il-6 (d), IL-1β (e), TNF-α (f)).
Pro-inflammatory cytokine proteins were measured using ELISA and the expression of their respective
mRNAs were measured in using real-time RT-PCR. Data were obtained from n = 8 animals for ELISA and
n = 6 animals for mRNA expression studies in each group, and are expressed as means ± SEM. (ELISA
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results of IL-6 and IL-1β: control vs. DSS, and DSS vs. DSS + Frondanol, *** p < 0.001; control vs.
DSS + Frondanol, * p < 0.05. ELISA of TNF-α: control vs. DSS, and control vs. DSS + Frondanol,
** p < 0.001. mRNA expression of IL-6: control vs. DSS, and DSS vs. DSS + Frondanol, *** p < 0.001.
IL-1β: control vs. DSS ** p < 0.01; DSS vs. DSS + Frondanol, and control vs. DSS + Frondanol, * p < 0.05.
TNF-α: control vs. DSS *** p < 0.001; DSS vs. DSS + Frondanol, and control vs. DSS + Frondanol,
* p < 0.05. NS indicate not significant was obtained by one-way ANOVA followed by Tukey’s multiple
comparison test).
2.5. Effect of Frondanol on Leukotriene B4 (LTB4)
LTB4 is secreted from neutrophils, and a markedly increased response is seen in inflammatory
conditions. Frondanol is reported to inhibit the function of 5-lipoxygensase, which is upstream
of leukotriene B4 synthase [8]. In our DSS model, LTB4 concentrations were measured using
a commercially available ELISA kit. DSS administration markedly increased LTB4 concentrations
compared with the control (p < 0.01). Frondanol treatment completely prevented this increase
(p < 0.001) in DSS-treated animals, reflecting its inhibitory effect on LTB4 production. As expected,
Frondanol alone had no effect on the LTB4 level in control animals (Figure 6).
Figure 6. Effect of Frondanol on LTB4 concentrations. Frondanol administration significantly reduced
LTB4 level in the DSS-treated group. Data were obtained from n = 8 animals in each group and are
expressed as means ± SEM (control vs. DSS and DSS vs. DSS + Frondanol, ** p < 0.01. NS indicate not
significant was obtained by one-way ANOVA followed by Tukey’s multiple comparison test).
3. Discussion
In the current study, we investigated the effects of Frondanol on DSS-induced experimental
colitis. The DSS-induced colitis model is a widely accepted model of colon inflammation for both
understanding the disease process as well as screening the efficacy of various anti-inflammatory
natural and dietary compounds because of its clinical relevancy to human ulcerative colitis [17].
Frondanol is a US-patented nutraceutical non-polar extract of the intestines of the edible Atlantic
sea cucumber, Cucumaria frondosa, which has potent anti-inflammatory properties. This extract should
not be confused with Frondanol A5, which is a polar extract of skin from the same animal that has
been shown to have potent anti-cancer properties [18]. Frondanol suppresses inflammation in the
adjuvant-induced arthritis model [18], developed in rats as a model for screening compounds that
might prove useful in the treatment of rheumatoid arthritis in humans. In this model, Frondanol
(10 mg/kg by gavage) was reported to be at least as effective as phenylbutazone (10 mg/kg) and
more effective than hydrocortisone (10 mg/kg) [8]. In the mouse ear inflammatory edema model
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using croton oil (containing phorbol esters and arachidonic acid) Frondanol was applied topically and
suppressed the edematous response by 84% [8]. Frondanol was also reported to reduce the proliferation
of peripheral blood mononuclear cells stimulated by the mitogen concanavalin A. Frondanol at 0.1%
suppressed concanavalin A-induced proliferation by 85% in human and 95% in sheep mononuclear
cells [19]. In the mixed lymphocyte reaction (MLR), Frondanol reduced thymidine incorporation by
40–52% at 0.025% and by 82–98% at 0.05%; this was similar to the inhibition caused by the cyclosporin
A control, which reduced the MLR by 37–75% at 100 ng/mL and by 81–90% at 500 ng/mL [8,19].
Cell viability was maintained by these concentrations of Frondanol, indicating the lack of toxicity of
the compound.
With regard to the mechanism of action of the effects of Frondanol, the extract has reported
potent inhibitory activity on 5-LOX, 12-LOX, and cyclooxygenase pathways. Frondanol suppressed the
production of 5-HETE and LTB4 from human polymorphonuclear cells by 53% and 62%, respectively,
at a concentration of 0.01% [8]. Similarly, Frondanol suppressed the production of 12-HETE by
44% at the same concentration [8]. Frondanol also caused a concentration-dependent reduction of
PGE2 production. In separate studies on the effect of Frondanol on 5-LOX activity, dose-responsive
effects were seen. Frondanol at 0.01% inhibited the production of 5-HETE and LTB4 by 84.7 ± 0.8%
and 75.2 ± 7.2%, respectively. At 0.1% Frondanol inhibited the production of 5-HETE and LTB4
by 98.4 ± 0.8% and 91.9 ± 0.6%, respectively (unpublished results). While Frondanol suppresses
the production of pro-inflammatory eicosanoids, it increases the activity of the anti-inflammatory
15-LOX, as evidenced by a concentration-dependent increase in the production of 15-HETE (Personal
Communication, Peiying Yang, MD Anderson Cancer Center, Houston, TX, USA).
The inhibitory effects of Frondanol on 5-LOX and 12-LOX activity could be explained, at least in
part, by some of the known constituent fatty acids in the extract. For example, 12-methyl tetradecanoic
(12-MTA) acid is a major constituent of Frondanol (20–30% by weight) and this branched chain fatty
acid has potent 5-LOX and 12-LOX inhibitory activity [20]. Topical administration of 12-MTA has been
reported to reduce MPO activity by inhibiting neutrophil infiltration at the site of injury when the
cornea was damaged by chemical injury [21]. Another fatty acid constituent of Frondanol is myristoleic
acid, which also potently inhibits 5-LOX activity [22]. Myristoleic acid is found at lower concentrations
in Frondanol, but has potent 5-LOX inhibitory effects. These fatty acids are likely to contribute to
the anti-inflammatory effects of Frondanol. Astaxanthin is a carotenoid present in Frondanol that
has marked anti-inflammatory effects, and has also been shown to suppress inflammation in the DSS
colitis model [23].
In the present study, Frondanol markedly suppressed the inflammation driven by oral DSS
administration. This was evidenced by marked decreases in the disease activity index (DAI), reduction
in colon length, and macroscopic and microscopic architecture changes that reflected the inflammation.
Frondanol also attenuated the increases in MPO concentrations, neutrophil and macrophage mRNA
expression (F4/80 and MIP-2), and pro-inflammatory cytokine production (IL-1β, IL-6 and TNF-α) at
both at the protein and mRNA levels, as well as the increase in the expression of the pro-inflammatory
mediator LTB4.
Prevention of the DSS-induced increase in MPO concentrations indicates that Frondanol prevents
the accumulation of polymorphonuclear granulocytes in DSS-induced colitis tissue, since MPO activity
reflects the increase in neutrophil accumulation in the submucosa due to the severity of colitis [24].
The increased levels of LTB4 in colonic tissue from DSS-treated mice are strongly implicated in
attracting both neutrophils and macrophages to the site of injury, thus amplifying the inflammatory
cascade in IBD [10].
Along with neutrophils, the infiltration of macrophages also increases during the course of
colitis, indicating its involvement in the inflammatory process [25,26]. To determine the level of
macrophage infiltration, we quantitated the F4/80 mRNA expression level. F4/80 is considered
a surrogate biomarker for infiltrating macrophages, suggesting the role of innate immune cells in
DSS-induced colitis [27]. Frondanol significantly decreased F4/80 mRNA expression, thus suggesting
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its role in preventing the further recruitment of macrophages in colitis. MIP-2 is a chemoattractant
secreted by both neutrophils and macrophages, and plays a central role in recruiting an increased
number of neutrophils and macrophages at the site of injury [28]. Furthermore, in the DSS-induced
model of colitis, MIP-2 plays an integral role in the recruitment of neutrophils and macrophages [28].
Additionally, it has also been shown that overexpression of MIP-2 enhances the severity of DSS-induced
colitis, Ohtsuka et al. [29] suggesting its crucial role in the development of DSS-induced colitis.
Thus, we quantitated the expression of MIP-2 mRNA by real time PCR. The MIP-2 mRNA level
was significantly upregulated in DSS-induced mice, and Frondanol beneficially and significantly
decreased the MIP-2 mRNA expression level. These studies suggest that Frondanol prevents the
upregulation of MIP-2, thereby decreasing neutrophil accumulation as reflected by MPO concentration.
These data reflecting macrophage statuses in the treated animals could partially explain Frondanol’s
anti-inflammatory role in protecting against DSS-mediated colitis.
Frondanol significantly suppressed the DSS-induced production of pro-inflammatory cytokines
(IL-6, IL-1β, and TNF-α) both at the protein and mRNA levels. When Frondanol was administered by
oral gavage (10 mg/kg weight) in the adjuvant arthritis model, it was as effective as phenylbutazone
and much more effective than hydrocortisone at a similar dose [8]. In another model of inflammation,
mouse ear edema was induced by croton oil, which contains phorbol esters and arachidonic acid
(potent mediators of inflammation), and was subsequently reduced by 84% when Frondanol was
applied topically [8].
There is considerable evidence for the involvement of the 5-LOX pathway and COX-2 in the
DSS model of colitis [9,11–13,30,31]. A recent study reported the measurement of lipid inflammatory
mediators throughout the different phases of inflammation [9]. In the induction phase, prostaglandin
E2 (PGE2) and thromboxane A2 (TBA2) increased 2-fold [9]. In the acute phase, the production of n-6
fatty acid-derived leukotrienes increased by more than 10-fold, while that of the anti-inflammatory
n-3 fatty acid-derived leukotrienes decreased [9]. In the recovery phase, the production of protectin
D1 increased 3-fold [9]. The 5-LOX inhibitor B-98 reduced the colonic shortening and histological
inflammatory score in DSS-treated mice [11]. In the DSS model, a peroxisome proliferator-activated
receptor gamma (PPARγ) agonist, 5-ASA (that blocks nuclear factor kappa B-induced production of
pro-inflammatory eicosanoids), a LOX inhibitor (AA-861), or an LTB4 receptor antagonist all prevented
erosions in the large bowel [12]. The anti-inflammatory agent 5-ASA and the LTB4 receptor antagonist
also prevented the shortening of the colon [12]. The COX inhibitor indomethacin and the thromboxane
A2 inhibitor OKY-046 were ineffective [12]. This study indicates the importance of lipoxygenase
products in this model [12]. Intracolonic administration of a selective 5-LOX inhibitor, zileuton,
accelerated healing in a rat model of colitis [32]. In a DSS study using a LOX inhibitor (AA-861)
and linolenic acid supplementation, the combination was able to suppress the excessive chloride
secretion that results in diarrhea. Linolenic acid is metabolized to the anti-inflammatory eicosanoids
PGE1 and TBA1 and prevents the formation of leukotrienes, while AA-861 is a selective 5-LOX and
LTB4 inhibitor [13]. In another study, DSS caused a marked inflammatory response in the colon and
a subsequent 5-fold increase in eicosanoid production [31]. This increase was completely prevented
by treatment with olsalazine (a prodrug that delivers 5-ASA directly into the colon) [31]. In a study
investigating the production of eicosanoids in patients with relapsing ulcerative colitis, luminal PGE2
and LTB4 concentrations were positively correlated with disease activity and were reduced to near
normal levels by successful treatment with specific inhibitors of the prostaglandin and leukotriene
pathways [33]. Indeed, as surrogate biomarkers, prostaglandin and leukotriene expressions appear to
be better indicators of treatment outcomes for relapsing ulcerative colitis than the traditional clinical
indices of disease activity [33].
In addition to its inflammatory role, the 5-LOX pathway also appears to be involved in
colitis-associated neoplasia. 5-lipoxygenase is overexpressed in all adenomatous colonic polyps
and in colonic carcinomas, but it is not expressed in normal mucosal cells or hyperplastic polyps [34].
Indeed, 5-LOX has been proposed as a marker for early pancreatic intraepithelial neoplastic lesions [35].
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Lipoxygenase inhibitors block the growth of human colonic cancer cells in culture and induce apoptosis
in these cells [34]. Other proteins in the 5-LOX pathway are also expressed in colonic cancer cells,
including LTB4 receptors [36]. Furthermore, the LTB4 receptor antagonist etalocib blocks cancer cell
growth both in vitro and in vivo and enhances the effect of gemcitabine on colon cancer growth in
a mouse xenograft model [36]. Finally, the reported observation that Fondanol activates 15-LOX is
interesting since, when overexpressed, this enzyme suppresses colitis-associated colon cancer through
inhibition of the IL-6/STAT3 signaling pathway [37,38].
4. Materials and Methods
4.1. Chemicals and Reagents
Dextran Sulfate Sodium (DSS), molecular weight 36,000–50,000 Da, was purchased from
Sigma-Aldrich (St. Louis, MO, USA). Frondanol was supplied by Coastside Bio Resources (Deer Isle,
ME, USA). Enzyme-linked immunosorbent assay (ELISA) kits for the measurement of concentrations of
myeloperoxidase (MPO), interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α),
and leukotriene B4 (LTB4) in colon tissues were obtained from R&D systems (Minneapolis, MN,
USA). RNA extraction was performed using RNeasy kits obtained from Qiagen (Hilden, Germany).
SYBR green and reverse transcription kit to convert mRNA into cDNA was purchased from Applied
Biosystems (Foster City, CA, USA). Primers for the real time (RT-PCR) quantification of mRNA
expression were supplied by Macrogen Inc. (Seoul, Korea).
4.2. Experimental Animals
C57BL/6J male mice (10–12 weeks old) were used for the study. Mice were housed individually in
controlled environmental conditions at a room temperature 23 ± 2 ◦C, with a 12-h light-dark cycle and
ad libitum access to food and water. Animal experiments were performed in accordance with protocols
approved by the UAEU Animal Care and Research Ethical Committee on 6 June 2017 (ERA_2017_5567).
4.3. Experimental Design, Induction of Colitis and Tissue Collection
The mice were randomly assigned to four groups. Group 1: control untreated, Group 2: control
treated with Frondanol, Group 3: DSS-induced colitis untreated, and Group 4: DSS-induced colitis
treated with Frondanol. Fresh 3% DSS solutions were made every morning in autoclaved drinking
water. The two DSS groups of mice were given 3% DSS for 8 days (day 0–day 7) as previously described,
while the control groups received only autoclaved tap water [24]. The two treated groups were given
Frondanol (100 mg/kg body weight/per day) using refined sunflower oil as a vehicle by gavage,
for a total volume of 150 μL. The control groups were administered only 150 μL of refined sunflower oil.
Mice were euthanized on the eighth day by intraperitoneal (IP) injection of pentobarbital (80 mg/kg
body weight). After laparotomy, the colon was excised, and the length of each colon was measured
carefully and photographed to determine colonic shortening induced by DSS treatment. Subsequently,
each colon was flushed thoroughly with ice-cold normal saline (0.9% NaCl) several times to remove
remnant DSS and then the colon was cut into several circular pieces. For histology, a small circular
piece of tissue (5 mm) was taken, measuring 5 cm from distal to caecum, from all animals and fixed
in 4% buffered formalin for histology (hematoxylin and eosin staining). Remaining pieces of tissue
were snap-frozen in liquid nitrogen and then stored at −80 ◦C for subsequent extraction for ELISA
and mRNA expression studies.
4.4. Macroscopic Assessment or Disease Activity Index (DAI)
To establish disease activity index (DAI), body weight, stool consistency, and rectal bleeding were
monitored in each mouse daily to score the severity of colitis using a previously described scoring
system (Table 1) [39]. The sum of the three values constitutes the DAI, resulting in a total clinical score
ranging from a minimum of 0 to a maximum of 12.
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Table 1. Disease activity index score.
Weight Loss Score Stool Consistency Score Rectal Bleeding Score
No loss 0 Normal 0 No Blood 0
1–5% 1 Loose stool 2 Heme occult + ve and visual pellet bleeding 2




Concentrations of MPO and cytokines (IL-6, IL-1β, and TNF-α) and LTB4 were quantified using
ELISA assays, according to the manufacturer’s protocol. Briefly, approximately 100 mg pieces of colon
tissue were weighed and homogenized using a T-25 digital Ultra TURRAX homogenizer (Staufen,
Germany) at 14,000 RPM in 1 ml ice-cold phosphate-buffered saline solution (PBS, pH = 7.2) containing
a proteases cocktail (St. Louis, MO, USA) at 4 ◦C. The homogenate was centrifuged at 12,000× g
for 10 min. The supernatant was used for the measurement of MPO, IL-6, IL-1β, TNF-α, and LTB4.
The results were calculated as pg/mg tissue.
4.6. Colonic Cytokine mRNA Content Determined by Real-Time PCR
Total RNA was extracted from frozen pieces of colon using the RNeasy Mini-Kit. The quality
and the quantity of total RNA were assessed using a NanoDrop 2000 spectrophotometer (Thermo
Fisher Scientific Inc., Waltham, MA, USA). Reverse transcription was carried out using a high capacity
cDNA Reverse Transcription kit. Real-time polymerase chain reaction (PCR) was performed using
the QuantStudio 7 Flex Real-Time PCR System (Applied Biosytems, Culver City, CA, USA) with
SYBR Select Master Mix (Applied Biosystems). The obtained data was normalized using 18s RNA
as a reference gene and the 2−ΔΔCT method was used as a relative quantification method for mRNA
expression [40]. Primer sequences for each mRNA are shown in Table 2 [41,42].









After overnight fixation in 4% buffered formalin, tissues were placed in 100% ethanol overnight.
Tissues were then embedded in paraffin for routine histology. Four transverse sections (2 μm) taken
from each colonic sample were stained with hematoxylin and eosin (H&E) and examined by light
microscopy (Zeiss, Stuttgart, Germany). Colonic crypt distortion and inflammation were evaluated
microscopically. The histological scoring was performed by an experienced pathologist (SAM) in
a blinded fashion. Histological examination of tissues from DSS-treated animals involved a scoring
system that includes the evaluation of the severe disruption of tissue architecture, the severity of
edema, the massive immune cell infiltration indicating inflammation, crypt damage, and any significant
area of complete epithelial denudation. Colonic crypt distortion and inflammation were scored out
of 8. The histology scoring system is indicated in Tables 3 and 4 [39]. All the histology pictures are
represented at 20× magnification.
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Table 3. Crypt score = product of percentage of crypt change and crypt distortion, graded out of
a maximum score of 8.
Crypt Grade
Quantification of the
Percentage of Crypt Change
Crypt Distortion—Graded
Based on the Extent of
Involvement
Grade 0: Intact crypt 1 1–25% 0 No cryptdistortion
Grade 1: Shortening and loss of basal1/3 of crypts 2 26–50% 1 1–25%
Grade 2: Loss of basal 2/3 of crypts 3 51–75% 2 26–50%
Grade 3: Loss of entire crypt with intactsurface epithelium 4 76–100% 3 51–75%
Grade 4: Loss of both entire crypt andsurface epithelium (erosion) 4 76–100%
Table 4. Score of inflammation = grade of inflammation × percentage of involvement, graded out of a




Involvement of Mucosal Surface Area
Hyperplastic Epithelium—Graded
Based on the Extent of Involvement
0 0 No inflammation 0 None
1 1 1–25% 1 1–25%
2 2 26–50% 2 26–50%
3 3 51–75% 3 51–75%
4 4 76–100% 4 76–100%
4.8. Statistics
All statistical analysis was carried out using SPSS Software (Armonk, NY, USA). Comparisons
between groups were performed by one-way analysis of variance (ANOVA), followed by Tukey’s
post-hoc test for multiple comparisons. Data are plotted as means ± SEM in the figures. p values < 0.05
were considered statistically significant.
5. Conclusions
These studies demonstrate that Frondanol, a non-polar extract from the edible Atlantic sea
cucumber Cucumaria frondosa, has marked anti-inflammatory properties in a mouse model of colitis.
These anti-inflammatory effects are most likely attributable to the inhibitory effects of the extract on
5-LOX, 12-LOX, and cyclooxygenase enzymes, with perhaps a contribution from activation of the
15-LOX pathway. This nutraceutical may be of value in the treatment of this condition. Furthermore,
since both the LOX and COX pathways were implicated in the development of precancerous colonic
polyps, the use of such broad-spectrum LOX and COX inhibitors together with the activation of 15-LOX
may be valuable in the chemoprevention of colitis-associated colon cancer.
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Abstract: Marine organisms are a rich source of biologically active lipids with anti-inflammatory
activities. These lipids may be enriched in visceral organs that are waste products from common
seafood. Gas chromatography-mass spectrometry and fatty acid methyl ester (FAME) analyses
were performed to compare the fatty acid compositions of lipid extracts from some common
seafood organisms, including octopus (Octopus tetricus), squid (Sepioteuthis australis), Australian
sardine (Sardinops sagax), salmon (Salmo salar) and school prawns (Penaeus plebejus). The lipid
extracts were tested for anti-inflammatory activity by assessing their inhibition of nitric oxide (NO)
and tumor necrosis factor alpha (TNFα) production in lipopolysaccharide (LPS)-stimulated RAW
264.7 mouse cells. The lipid extract from both the flesh and waste tissue all contained high amounts
of polyunsaturated fatty acids (PUFAs) and significantly inhibited NO and TNFα production. Lipid
extracts from the cephalopod mollusks S. australis and O. tetricus demonstrated the highest total
PUFA content, the highest level of omega 3 (ω-3) PUFAs, and the highest anti-inflammatory activity.
However, multivariate analysis indicates the complex mixture of saturated, monounsaturated, and
polyunsaturated fatty acids may all influence the anti-inflammatory activity of marine lipid extracts.
This study confirms that discarded parts of commonly consumed seafood species provide promising
sources for the development of new potential anti-inflammatory nutraceuticals.
Keywords: seafood waste; polyunsaturated fatty acid; NO inhibition; fish oil; marine nutraceuticals
1. Introduction
Acute and chronic inflammation is the basis of many serious diseases including asthma,
cardiovascular diseases, and rheumatoid arthritis [1]. The stimulation of macrophages during the
inflammatory response gives rise to overproduction of several pro-inflammatory mediators, including
nitric oxide (NO) via inducible nitric oxide synthase (iNOS) [2]. NO overproduction can lead to tissue
damage through cytokine-mediated processes. This molecule can also cause vasodilation, edema,
and cytotoxicity [3,4]. Macrophage stimulation also leads to the overproduction of many cytokines
including TNFα and interleukins (IL). These pro-inflammatory cytokines have many roles, including
the recruitment and activation of more macrophages, effects on the endothelial cells in the blood
vessels, as well as playing a role in the perception of pain generated from inflammation [5]. Cytokines
such as TNFα are powerful pro-inflammatory mediators during infection, trauma, or surgery, which
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can trigger short- and long-term effects on the peripheral and central nervous system, leading to
exacerbated pain processed by directly affecting specific receptors on sensorial neurons [6,7]. Thus,
these pro-inflammatory cytokines and NO are reliable markers for screening new anti-inflammatory
treatments in vitro and in vivo.
The conventional management of inflammation relies mainly on the use of steroidal and
non-steroidal anti-inflammatory drugs (NSAIDs). Both drug families are well-known for their common
and serious side effects [8], especially when associated with long term consumption, such as is often
required for the treatment of chronic inflammatory diseases. Consequently, there is a critical need to
identify new sources of less harmful treatments, particularly for the management of diseases associated
with chronic inflammation. Our increased understanding of the impact of food and diet on health has
driven the search for novel natural medicines [9]. A recent study has shown that patients suffering
from chronic inflammatory diseases are more likely to seek out natural anti-inflammatory agents with
the intention to minimize the side effects associated with long term use of steroid and NSAIDs [8].
Therefore, the development of new safer anti-inflammatory nutraceuticals is of clinical interest and
could have a significant impact on the treatment of inflammatory cases. Functional foods and marine
extracts provide a relatively untapped source of potential anti-inflammatory agents, but claims need to
be evidence-based.
In comparison to saturated fats, dietary polyunsaturated fatty acids (PUFAs) can have a number
of positive impacts on health when incorporated into the diet to meet deficiencies from sub-optimal
dietary intake. The human body relies on food as a source of long chain PUFAs, as it is unable to
synthesize PUFAs larger than 18 carbons [10]. Both omega 3 (ω-3) alpha-linolenic and omega 6 (ω-6)
linoleic PUFAs are considered essential for mammals and can only be obtained from the diet. Seafood
(fish and shellfish) lipids are the main sources of biologically active ω-3 long chain PUFAs [10,11]. These
PUFAs are known to minimize the occurrence and severity of chronic inflammatory conditions [12–15],
cancer [16–18], obesity [19,20], and cardiovascular diseases [10,21,22]. Dietary PUFAs have been
shown to improve the quality of life for people suffering from chronic inflammatory diseases such as
arthritis, asthma, and neuroinflammatory diseases [11]. Long chain ω-3 PUFAs can directly inhibit
inflammation by competing with arachidonic acid or indirectly by affecting the transcription factors or
nuclear receptors responsible for inflammatory gene expression [23].
Docosahexaenoic acid (C22:6 ω-3) (DHA) and eicosapentaenoic acid (C20:5 ω-3) (EPA) are the
most valuable long chain PUFAs and are considered potent anti-inflammatory agents as a result of
the amount and type of the eicosanoids they generate, which interfere with intracellular signaling
pathways, transcription factors, and gene expression mechanisms [24]. DHA has been shown to
reduce the levels of IL-1β and TNFα in LPS-stimulated peripheral blood mononuclear cells (PBMNC)
in vitro [25]. Furthermore, studies have shown that a number of health problems including increased
inflammatory processes [26], poor fetal development, and a higher risk of Alzheimer’s diseases are
associated with diets low in EPA and DHA PUFAs [27].
Omega 3 PUFAs can be commercially sourced from oily fishes including salmon, sardine, and
mackerel [10]. There is some evidence that seafoods from temperate Australian origins contain
higher amounts of DHA compared to seafood from the northern hemisphere [28]. Some of the
PUFA-rich Australian marine organisms include crustaceans, such as school prawn and tiger prawn,
oily fishes such as sardine and salmon, and mollusks, including octopus, squid, shelled gastropods,
and bivalves [28]. In Western countries like Australia, there is a significant level of waste from
underutilization of parts of seafood, as only the choice flesh is consumed by many people. However,
valuable PUFAs might not only occur in the predominantly eaten components of the seafood
organisms, but could also be present in the undervalued presumptive waste tissues of fish and
shellfish. For example, in fish, lipids are not only stored in the subcutaneous tissue, belly flap, and
muscle, but are also high in mesenteric tissue, head, and liver [29]. A number of previous studies
have investigated the quality of fatty acids in seafood waste tissues. For example, high levels of ω-3
rich PUFAs were found in lipid extracts from the head (26%), intestine (24%), and liver (23%) from
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the sardine Sardinella lemuru [30], and similarly in the tuna Euthynnus affinis (head 28.77%; intestine
27.43%; liver 23.98%) [31]. Significant amounts of the valuable ω-3 EPA and DHA were also found
in eye orbital samples of tuna in an Australia-based study [28,32]. Therefore, the byproducts of the
seafood industry could be a source of high-quality anti-inflammatory fatty acids.
To date, investigations on the anti-inflammatory activity of fish oil have been insufficiently
investigated, and consequently, results remain inconclusive [33]. Nevertheless, there is some clinical
evidence to support the benefits of krill oil in the treatment of inflammatory conditions [34,35],
suggesting that the specific PUFA composition may be important for anti-inflammatory activity. Many
molluscan products and derivatives are used in traditional medicines for the treatment of inflammatory
conditions [36], and mollusks are also known to be rich in beneficial PUFAs [37]. Examples of lipid
extracts from mollusk with demonstrated in vivo and in vitro anti-inflammatory activity include the
New Zealand green-lipped mussel Perna canaliculus [38], Filopaludina bengalensis foot [39], Indian
green mussel Perna viridis [40,41], Mytilus unguiculatus (Hard-shelled mussel) [40], and sea hares
Aplysia fasciata and Aplysia punctata [42]. Despite the promising anti-inflammatory activity of lipid
extracts from mollusks, the only natural anti-inflammatory nutraceuticals available over-the-counter
as anti-inflammatory medications are Lyprinol and Biolane sourced from the lipid extract of the
New Zealand green-lipped mussel Perna canaliculus [38], and CadalminTM, the lipid extract from a
closely related species of bivalve Perna viridis in India [41,43]. The anti-inflammatory activities of lipid
extracts from predatory cephalopod mollusks are yet to be tested.
This study aims to investigate the composition of lipid extracts from common Australian seafoods
including oily fish, prawns, and cephalopods, with a comparison of the edible flesh and under-utilized
by-products. The anti-inflammatory activity of these lipid extracts was compared using in vitro assays
for NO and TNFα inhibition and the inhibition concentrations (IC50s) were correlated to the fatty acids
composition to provide further insight into how the fatty acid compositions of marine lipid extracts
influence the anti-inflammatory potential.
2. Results
2.1. Comparison of Fatty Acid Composition from Lipid Extracts of Different Seafood and Waste Products
As expected for oily fish, the highest yield of lipid extract was recovered from the Australian
sardine, followed by salmon (>100 mg/g tissue, Figure 1A). Substantially lower quantities were
recovered from the cephalopods and prawns (5–40 mg/100 g tissue, Figure 1A). Higher quantities of
oil were recovered from the viscera and/or heads of all species in comparison to the flesh. The lipid
extracts from the cephalopod mollusks had the highest proportion of PUFAs comprising over 40% of
the fatty acid composition (Figure 1B, Table 1). Salmon had the lowest percentage of PUFAs (<25%),
but the highest percentage of MUFAs, with over 45% of the total fatty acids (Figure 1B and Table 1).
Permutational analysis of variance (PERMANOVA) revealed a significant difference between species
in the composition of fatty acid classes (Pseudo F = 16.4, p = 0.001). Pair-wise analysis revealed that
the octopus, squid, prawns, and sardines were not significantly different in the relative proportion of
fatty acid classes (p > 0.05); however, salmon was significantly different to octopus (p = 0.0091), squid
(p = 0.0066) and sardines (p = 0.0017). Specifically, there were significantly less saturated fatty acids and
more monounsaturated fatty acids in salmon compared to squid (SFA p = 0.0035, MUFA, p = 0.0054)
and sardines (SFA p = 0.001, MUFA = 0.0031). Salmon had significantly less PUFAs than octopus
(p = 0.0144), squid (p = 0.0144), and sardines (p = 0.0202). The PUFAs were also significantly lower in
prawns compared to octopus (p = 0.0302) and squid (p = 0.0276). The waste products (viscera and
heads), did not have a significantly different profile to the more frequently consumed cephalopod flesh
or fish fillets, but the prawn heads and viscera had less MUFA, relative to SFA and PUFA, compared to
the body flesh (Figure 1B). All extracts had a healthy ω-6/ ω-3 ratio of less than or close to 1 (Table 1B),
with the ratio as low as 0.1 in sardines and the flesh of octopus. The ratio of saturated to unsaturated
fatty acids was also less than 1 for all species.
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Figure 1. Lipid composition of some common Australian seafood flesh and waste streams: (A) The
amount of oil extracted from the flesh (mg/g tissue); (B) the amount of the main fatty acid classes
and other hydrocarbons (dimethyl acetal aldehydes) in the lipid extracts (mg/g oil). The fatty acids
were quantified by GC-FID and identified against reference standards with supplementary GC-MS
analyses. The samples are: Octopus tetricus flesh and viscera, Sepioteuthis australis (squid) flesh and head;
Sardinops sagax (Australian sardine) flesh and viscera, including heads; Salmo salar (Atlantic salmon)
flesh and head (SH); and Penaeus plebejus (Australian school prawn) flesh and head, including viscera.
Multivariate comparison of the overall fatty acid profiles in the oil extracts revealed significant
differences between the species (Pseudo-F = 9.59 p = 0.0007), but not between the different types
of tissue (Pseudo-F = 2.73, p > 0.05), and there was no significant interaction between these factors
(Pseudo-F = 1.6, p > 0.05). Pair-wise tests confirmed that S. salar (salmon) has a different fatty acid
composition to all species except prawns (p < 0.01), which is driven by a higher percentage of oleic,
linoleic, and eicosatrienoic acids in the salmon and prawn heads (Figure 2 and Table 1A). The squid
contained higher proportions of stearic acid, arachidonic (ARA), and docosahexaenoic acid (DHA),
and were significantly different to sardines (p = 0.015), which, along with octopus and prawn bodies,
have a higher percentage of the SFA arachidic and the ω-3 PUFA, EPA (Figure 2).
87
Mar. Drugs 2019, 17, 155
Figure 2. Principal coordinate ordination (PCO) of the fatty acid composition of various Australian
seafood species. Vector overlay based on the Pearson correlation (r > 0.8) identifies the main fatty acids
contributing to the separation between extracts, with higher levels of the specifically labeled fatty acids
occurring in samples in the direction of the vector.
The amounts of EPA, DPA, and DHA per 100g of the seafood tissue were estimated from the yield
of oil in the original tissue (Table 1B). Due to high oil yields, the sardines were the best source of these
ω-3 PUFAs, with a total amount of over 3500mg/100g tissue in the flesh and over 6000 mg/100 g in
the viscera. The viscera of octopus and heads of salmon also had high ω-3 yields with totals of over
1000mg/100g tissue. In all species, the viscera and/or head waste streams produced larger amounts of
EPA, DPA, and DHA (Table 1B).
2.2. Cytotoxicity
At 50 μg/mL, none of the seafood extracts caused any reduction in cell viability for either
3T3-ccl-92 fibroblasts or RAW 264.7 macrophages (Table 2).
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2.3. NO Inhibition
Lipid extracts from all Australian seafood organisms demonstrated significant NO inhibition in
LPS-stimulated RAW 264.7 cells compared to the solvent positive control, except the lipid extract from
school prawn bodies, which only showed weak NO inhibition (Supplementary Figure S1 and Table 2).
Lipid extracts from the octopus showed strong NO inhibition with the lowest IC50s of 65 μg/mL.
The lipid extracts from the waste by-products showed higher NO inhibition (lower IC50s) than the
more commonly consumed flesh for octopus, squid, salmon, and prawns. All of the Australian seafood
lipid extracts were active at much lower concentrations than the reference nutraceutical oils, Lyprinol
and Deep Sea Krill oil, at the maximum concentration (Table 2). In fact, Lyprinol showed no inhibition
of NO in this assay at the maximum solubility.
Multivariate RELATE analysis using a Spearman rank correlation demonstrated a significant
relationship between NO inhibition and fatty acid composition (Rho = 0.302, p = 0.0477,
9999 permutations). BEST analysis revealed that a combination of four fatty acids explained the greatest
amount of variation in NO inhibiting activity, with a correlation coefficient of 0.428. NO inhibition
correlated with lower levels of oleic acid (C18:1) and higher levels of C18:3n-6, C20:2 and C22:2.
Univariate correlations to investigate the relationship between IC50 for NO and the amount of particular
fatty acids in the extracts revealed different trends depending on the fatty acid class (Supplementary
Figure S2). Negative relationships (i.e., lower IC50 at higher concentrations = stronger activity) were
observed for total SFAs (R2 = 0.4) and PUFA (R2 = 0.3), as well as ω-3 PUFAs (R2 = 0.3), EPA (R2 = 0.4),
and to a lesser extent, DHA (R2 = 0.2). Conversely, MUFAs showed a positive relationship (higher
IC50s = weaker activity) (R2 = 0.3), along with ω-9 FAs (R2 = 0.3). Surprisingly NO activity increased
with higher SFA:UFA ratios (R2 = 0.4), driven largely by inactive MUFAs, but decreased with higher
ω-6:ω-3 ratios (R2 = 0.3), as expected. There was no relationship between NO inhibitory activity and
the amount of ω-6 PUFAs, the ω-3 DPA, or unidentified components in the extracts (Supplementary
Figure S2).
2.4. TNF-Alpha Inhibition
Lipid extracts from all the seafood samples demonstrated significant TNFα down-regulatory
effects reducing the levels of TNFα in the RAW 264.7 supernatant (Supplementary Figure S3, Table 2).
Octopus viscera again showed the lowest IC50 (51 μg/mL), whereas the body of prawns had the
highest IC50 at ~200 μg/mL. The extract from seafood by-products showed greater TNFα inhibition
than the edible flesh for all species (Table 2), and this was most noticeable in prawns, with an IC50
nearly three times lower in the heads and viscera that are routinely discarded in Australia. The fish
viscera and heads were approximately twice as active as the fillets.
There was a significant correlation between NO inhibition and TNFα inhibition (R2 = 0.631),
although the Australian sardine fillet had lower TNFα activity than would have been predicted
from the NO inhibition. Multivariate RELATE analysis revealed a marginally significant relationship
between TNFα inhibition and fatty acid composition (Rho = 0.269, p = 0.058, 9999 permutations).
BEST analysis identified only two fatty acids, with a correlation coefficient of 0.334. TNFα inhibition
was weakly correlated with lower levels of linolenic acid (C18:2) and higher levels of stearic acid
(C18:0). Univariate correlations investigating the relationship between IC50 for TNFα and the amount
of particular fatty acids in the extracts (Supplementary Figure S4) revealed similar trends to NO
inhibition (Supplementary Figure S2). Decreasing TNFα IC50 with higher quantities were observed for
total SFAs (R2 = 0.3) and PUFA (R2 = 0.4), as well as ω-3 PUFAs (R2 = 0.4), DHA (R2 = 0.3), and to a
lesser extent, EPA (R2 = 0.2). MUFAs again showed the reverse trend, along with ω-9 FAs (R2 = 0.3).
TNFα IC50 decreased with higher SFA:UFA ratios (R2 = 0.2), but increased with higher ω-6:ω-3 ratios
(R2 = 0.2). There was again no relationship between TNFα IC50 inhibitory activity and the amount of
ω-6 PUFAs, the ω-3 DPA, or unidentified components in the extracts (Supplementary Figure S2).
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3. Discussion
This study demonstrates the quality and anti-inflammatory activity of lipids extracted from
different Australian seafood. Seafood is known to be high in PUFAs, which have been previously
associated with anti-inflammatory activity. All of the extracts tested in this study contain a high
content of PUFAs, with ω-6/ω-3 ratios less than one. Simopoulos [44] found that lower ratios are
desirable for reducing the risk of many chronic diseases, with ratios < 4:1 reducing mortality from
chronic disease, and ratios less than 3:1 suppressing inflammation due to arthritis. We found that
lower ω-6/ω-3 ratios correlated with higher NO and TNFα inhibitory activity across a range of
seafood extracts. Furthermore, Western diets typically contain excessive levels of saturated fats and
omega 6 fatty acids, which promote the pathogenesis of many diseases, including inflammatory
conditions [44]. Our lipid extracts from Australia seafood all had saturated to unsaturated fatty
acid ratios of less than 1, but higher amounts of MUFAs rather than SFAs were related to lower
NO and TNFα inhibitory activity. Overall, the entire fatty acid composition appears to influence
anti-inflammatory activity in vitro. Nevertheless, all of our extracts provided a good source of ω-3 fatty
acids and significantly inhibited LPS stimulated NO and TNFα production by macrophages in vitro.
This indicates the potential to value-add the Australian seafood industry based on high-quality marine
oils with anti-inflammatory activities.
Anti-inflammatory fatty acids were not only found in the flesh that is normally consumed in
Australian seafood, but are also present in high quantities in unprocessed parts like the head and
viscera. In fact, the viscera and heads produced a higher yield of oils and contained higher quantities
of commercially important long-chain ω-3 PUFAs EPA, DPA, and DHA with known healthy attributes
for seafood consumers. The yields of these ω-3 PUFAs in the under-utilized/non-processed parts
were substantially higher than in the edible flesh for most species (e.g., ten times the DHA in octopus
viscera compared to flesh; four times the amount of EPA in prawn heads compared to flesh; and nearly
double the EPA, DPA, and DHA in salmon heads and sardine viscera/heads compared to the flesh).
This data is consistent with previous studies which have demonstrated high-quality fatty acid profiles
in the uneaten tissues of mackerel tuna fish Euthynnus affinis, ray-finned fish Sardinella lemuruand, and
Alaska pink salmon Oncorhynchus gorbuscha [30,31,45]. Overall the yields of EPA and DHA are similar
to the range previously reported for mollusks, fish, and crustaceans (e.g., Reference [46]), although
the Australian sardine is particularly notable for containing over 1000mg/100g tissue of both EPA
and DHA in both the flesh and viscera. Australian seafood waste streams could therefore be used
to generate a sustainable source of high-value marine lipids if they can be rapidly processed in a
centralized facility to prevent oxidation and degradation.
All the lipid extracts from Australian seafood tested in this study showed significant inhibition
of NO and TNFα, except those from the body of school prawns. As a neurotransmitter, NO is a
potent inflammatory mediator, as well as playing a role in wound healing and maintaining blood
pressure [47]. However, there are many diseases associated with the overproduction of NO, including
liver cirrhosis, rheumatoid arthritis, infection, autoimmune diseases, and diabetes [48]. Similarly, TNFα
is an important pro-inflammatory mediator that can lead to damaging effects, including neuropathic
pain, when over-expressed [49]. Inflammation and neuropathic pain are complex problems involving
many mediators and coupled signaling pathways which reduce the effectiveness of single compounds
for drug development [49]. Natural extracts that contain a mixture of potential inhibitors of inducible
NO Synthase (iNOS), TNFα expression, and other inflammatory pathway modulators might be
effective for controlling chronic inflammation. For example, studies on the NZ Green-lipped mussel
extract Lyprinol®, in a rat model for arthritis, have demonstrated that it modulates inflammatory
cytokines (TNFα, IL-6, IL-1α, and IL-γ) and decreases the synthesis of some proteins associated
with inflammation, whilst increasing malate dehydrogenase synthesis, which is related to glucose
metabolism [50]. The effects on regulatory proteins were proposed to reduce energy for MHC-1
activation as a novel mechanism of action with anti-inflammatory efficacy at lower doses than other
fish oil preparations. Lyprinol is a patented combination of 50 mg of PCSO-524® (lipid extract
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from P. canaliculus), 100 mg of a proprietary oleic acid blend, and 0.225 mg of vitamin E, so the
ω-3 fatty acids in this mussel lipid extract may act synergistically with the anti-oxidant Vitamin
E. Similarly, krill oil contains the antioxidant astaxanthin which can prevent lipid peroxidation,
thus preserving of the ω-3 fatty acids EPA and DHA, in addition to acting directly on a number
of biomarkers [51]. Krill oil has been shown to modulate cytokines, lipidogenesis, lipid peroxide,
oxidative enzymes, glucose metabolism, and the endocannabinoid system in a range of animal
studies [52]. It is possible that some of the unidentified components in our extracts have anti-oxidant
activity and/or immunomodulatory activity that complements or enhances the activity of ω-3 fatty
acids. Further in vivo studies investigating a range of anti-inflammatory markers and modulators
will be required to establish the mechanism of action and novel potential of these Australian seafood
lipid extracts.
The anti-inflammatory effects of fish oils and krill oil are typically attributed to long chain ω-3
PUFAs [14,52]. Similarly, we found a correlation between the amount of ω-3 PUFAs in the extracts and
the IC50s for both LPS stimulated NO and TNFα inhibition in RAW264.7 macrophages. In particular,
the concentrations of both EPA and DHA were found to correlate with higher activity, but with EPA
showing a stronger relationship with NO inhibition and DPA explaining more of the variation in
TNFα inhibition. Previous studies on pure DHA and EPA have confirmed that these ω-3 PUFAs
strongly inhibit NO production (IC50 < 25 μM) [53] and inducible NO synthase in LPS stimulated
RAW264 macrophages (DHA at 30μM and EPA at 60 μM) [54]. Both EPA and DHA (100 μM) have
also been shown to reduce TNFα secretion in LPS stimulated RAW264.7 cells after 24 hr exposure to
100 μM [55], and they significantly inhibit the secretion and transcription of TNFα in LPS stimulated
THP-1 macrophages at 25 mM [56]. These studies lend support to the idea that EPA and DHA
are contributing to the in vitro anti-inflammatory activity in our extracts, however, without further
purification and testing against the pure compounds, we cannot conclude that there are no other
factors involved. Indeed, higher concentrations of saturated fatty acids were also found to correlate
with NO and TNFα inhibition, and our multivariate correlations indicate that the overall composition
of fatty acids is important, along with potentially unidentified factors.
In this study, lipid extracts from the two cephalopod mollusks contained the highest proportion
of ω-3 PUFAs and were associated with relatively high NO and TNFα inhibition. This supports the
use of the flesh from octopus (Zhang Yu) and squid (Qiang Wu Zei) in traditional Chinese Medicine for
inflammatory conditions [36]. Our comprehensive review of the anti-inflammatory, wound healing,
and immunomodulatory activity of mollusks [36] found no previous in vitro studies on cephalopod
extracts, and only a handful of in vivo animal models that have tested the ink and melanoprotein of
squid [57,58]. Nevertheless, one previous study found that cuttlefish (Ommastrephes bartrranii) liver
oil significantly reduced formalin and carrageenan-induced paw edema in rats fed 1% cuttlefish liver
oil for 45 days [59]. We found that the cephalopods produce a fairly low yield of oil in comparison
to oily fish, and consequently, they had lower overall amounts of EPA, DPA, and DHA per mg of
tissue. This suggests the cephalopods may not be as good a functional food for dietary intake of ω-3
PUFAs based on the mass obtainable from the wet weight of edible tissue as compared to some other
seafood, such as the Australian sardines, which have very high yields of ω-3 PUFAs in their flesh.
However, the viscera and heads of octopuses and squids produce a significant waste stream that could
be value-added based on their high-quality anti-inflammatory oils. For example, a large proportion
of Southern jig squid fishery is sold as processed tubes in Australia, generating approximately 48%
viscera as waste from ~1000 t annual harvest [60]. This justifies further investigation into cephalopod
lipid extracts for anti-inflammatory applications.
The fatty acid profiles of the cephalopod and sardine lipid extracts are dominated by ω-3
PUFAs, whereas the salmon and prawns contain relatively high MUFA and ω-9 PUFAs. The high
NO activity of sardine and cephalopod extracts reflects their richness in ω-3 fatty acids, especially
DPA, DHA, and EPA, which are arguably the healthiest PUFAs [12,23,61]. The main ingredients of
the well-known anti-inflammatory nutraceutical Lyprinol® and Biolane®, lipid extracts from the New
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Zealand green-lipped mussel (GMLE) Perna canaliculus, are long chain ω-3 PUFA. The percent of the
ω-3 PUFA in GMLE is about 37.1% of the total fatty acids [40]. A similar proportion of ω-3 PUFAs
was found in the cephalopod mollusk extracts in this study. Interestingly, however, the different levels
of ω-3 fatty acids in the various seafood extracts were not found to correlate directly with either NO
or TNFα inhibitory concentrations in this study. Rather, lower levels of the MUFA oleic acid and
higher levels of the ω-6 acids gamma-linolenic (C18:3), eicosadienoic (C20:2) and docosadienoic (C22:2)
correlated with higher NO activity, whereas lower levels of linolenic (C18:2) and higher levels of the
SFA stearic acid (C18:0) explained more of the variation in TNFα inhibitory concentrations. This implies
that the overall composition of fatty acids in seafood oils could influence the anti-inflammatory activity,
with particular fatty acids having either beneficial or antagonistic effects. This may help explain the
variable outcomes from clinical trials on the use of fish oils for some inflammatory conditions [62,63].
The minimal anti-inflammatory activity detected in our prawn flesh extract was similar to that
observed for a commercial krill oil in the same assays. The fatty acid composition of our prawn extracts
was similar to that previously reported for a commercial krill oil (10% ω-3 PUFAs, 14% ω-6 PUFAs
and 35% MUFAs), which was found to significantly modulate inflammation and lipid metabolism in
mice transgenic for TNFα [33]. Antarctic krill oil has also been shown to inhibit LPS-induced iNOS
in a rodent model [64] and to protect against rheumatoid arthritis in mouse models, but without
effects on serum cytokines [35]. Further research on Penaeid extracts is therefore justified despite
the relatively low in vitro activity. In particular, the waste streams from aquacultured prawns can be
sustainably produced in comparison to wild harvested krill, although their fatty acid compositions
could be impacted by an artificial diet [65].
Lyprinol®, the anti-inflammatory nutraceutical composed of lipid extracts from the Green-lipped
mussel Perna canaliculus, was also used as a reference drug but did not show detectable inhibition
of NO and TNFα in our in vitro assays. Green-lipped mussel extracts have been previously found to
suppress iNOS expression and inhibit NO production in LPS-induced RAW264.7 cells by regulating
nuclear factor kappa B [66], as well as inhibiting TNFα in LPS-stimulated human THP-1 monocytes [67].
Therefore, the lack of activity in both the commercial marine oils we tested is likely due to their relative
insolubility in ethanol as a result of product formulation. Furthermore, in vitro assays do not always
provide a good predictor of in vivo activity. Nevertheless, given the wealth of evidence relating to the
beneficial effects of ω-3 PUFAs in clinical trials, the preliminary in vitro anti-inflammatory activity
observed here, along with the beneficial fatty acid composition of Australian seafood extracts, justifies
further research to value-add the industry by developing a sustainable supply of high-quality fish oil.
4. Materials and Methods
4.1. Chemicals and Reagents
Escherichia coli LPS (O128:B12, Sigma-Aldrich, Castle Hill, Australia), sulfanilic acid, N-(1-Naphthyl)
ethylenediamine (NED), 85% orthophosphoric acid sodium nitrite (NaNO2), and HPLC grade solvents
were obtained from Sigma Aldrich (St. Louis, MO, USA). The mouse TNFα ELISA kit was purchased
from BD biosciences (Sparks, MD, USA). Penicillin–streptomycin solution, Dulbecco’s Modified
Eagle’s Medium (DMEM), fetal bovine serum (FBS), sodium pyruvate, and L-glutamine were from Life
Technology Australia (Mulgrave, VIC, Australia). The two cell lines, RAW264.7 mouse macrophages
and 3T3 Swiss albino (ATCC® CCL92™) cell lines, were purchased from the American Type Culture
Collection (ATCC®, Manassas, VA, USA).
4.2. Sample Collection
Fresh seafood used in this study including octopus (Octopus tetricus n = 3), Australian sardine
(Sardinops sagax n = 4), salmon (Salmo salar n = 3), school prawn (Penaeus plebejus, n = 12), and squid
(Sepioteuthis australis n = 3) were purchased fresh from Ballina seafood co-op., Ballina, Australia.
Salmon and squid viscera are processed during harvesting to prevent degradation and fouling of the
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prime edible flesh; however, the heads of these organisms are still available as a waste stream. All other
species were obtained whole and the typically consumed flesh was separated from the waste streams,
including internal organs (viscera) and heads. Lyprinol (BLACKMORES®, Alexandria, Australia) and
Krill oil (Swisse, Collingwood Melbourne, Australia) were purchased from a local pharmacy.
4.3. Lipid Extraction
Extracts from the cephalopods, O. tetricus and S. australis, included the tentacles and mantle tissue
(edible flesh) and body viscera, comprised of the gastrointestinal tract and other internal organs for
O. tetricus and just the heads for S. australis. Extracts from the fish included flesh fillets and viscera,
including heads from S. sagax, and just the head from S. salar. The head with viscera (waste) and body
(edible flesh) were also extracted from the school prawn Penaeus plebejus. Lipids were extracted as
above using a solvent to tissue ratio of 19 mL final volume for every 1 g tissue.
The solvent homogenates were vacuum filtered through Whatman paper (No. 1) into separating
funnels. Saturated NaCl solution (6.2 M) was added to the solvent phase to a final ratio of 8:4:3
(Chloroform: methanol: NaCl solution). The organic phases were collected and the solvent evaporated
on a rotary evaporator (Rotavapor® R-114; BÜCHI Labortechnik AG, Flawil, Switzerland). Extracted
lipids were transferred into glass vials, dried under a stream of nitrogen gas, weighed on an analytical
balance to calculate yield per g tissue, and then covered and stored in minimal hexane at −80 ◦C
until required.
4.4. Fatty Acid Methyl Ester (FAME) Analysis
Subsamples of 200 μL of foot and viscera lipid extracts from all species were placed in 10 mL
pyrex glass vials for derivitization. NaCl in methanol solution (0.5 M, 1.5 mL) was added under
nitrogen gas, capped and shaken for 10 secs. Samples were then heated at 100◦C for 10 min in a dry
block and cooled. Two mL of 14% Boron trifluoride in methanol was added and bubbled with nitrogen
gas for 8 s, then placed in a 100 ◦C dry block for 30 min. After cooling, 1 mL of hexane containing 1 μg
2,6-Di-tert-butyl-4-methylphenol (BHT) was added, and samples were shaken for 30 s. Saturated NaCl
solution (5 mL) was added and the samples were shaken to create an upper lipid layer, which was
collected and stored at −80 ◦C for FAMEs and GC-MS analysis.
FAMEs were analyzed using a GC (Agilent 6890N, Santa Clara, CA, USA) coupled to an
Agilent 6890 flame ionization detector (FID) using a BPX 70 capillary column (70% cyanopropyl
polysilphenylene-siloxane, 50 m length, 0.22 mm internal diameter and 0.25 μm thickness). The FID
was operated at 260 ◦C and the split injector was maintained at 230 ◦C. High-purity helium was used
as the carrier gas and maintained with a linear flux of 1 mL/min. The GC oven was held at 100 ◦C for
5 min and then raised to 240 ◦C at a rate of 5 ◦C/min. 1 μL of each subsample extract was injected
with a split ratio of 200:1 and a column flow of 1 mL/min.
FAMEs were identified by peak retention time and elution order and compared against a reference
FAMEs standard test mix (SUPELCO 37-Component FAME Mix CRM47885, Bellefonte, PA, USA)
and a marine test mix PUFA No.1 (Marine Source, Analytical Standards, Sigma-Aldrich, Castle
Hill, Australia). Some samples were further analyzed using an Agilent gas chromatography-mass
spectrometer (GC-MS) with an Agilent 5973 Mass Selective Detector to confirm the identity of the fatty
acids. The mass spectra were recorded at 70 eV ionization voltage over the mass range of 35–550 amu.
To facilitate the identification of DPA, which was not in the test mix, a soft ionization MS technique at
40 eV ionization voltage was employed to ionize the lipid molecules in the D. orbita samples without
causing extensive fragmentation. The spectrum was compared on MS databases (WILEY 275 online
and NIST98, Gaithersburg, MD, USA), along with retention times and elution order from extensive
literature searches including the American Oil Chemists’ Society. The relative composition of each
identified fatty acid was calculated by peak integration from the GC [68]. The concentration of each
fatty acid was estimated using BHT as an internal standard. In each sample, the area under the curve
for each fatty acid was calibrated against the peak area for BHT and adjusted for molecular weight,
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then scaled for the concentration on 1mg per g extract. For the ω-3 PUFAs EPA, DHA, and DPA, we
also calculated the yield per 100 g of tissue by adjusting for the amount of crude lipid extract obtained
per g of tissue that was extracted.
4.5. Cell Lines and Cell Culture
The Murine RAW264.7 macrophages and 3T3 fibroblast cell lines were obtained from American
Type Cell Culture (ATCC). Both cell lines were maintained in 10% FBS supplemented DMEM, 100 μg/L
streptomycin, and 100 IU/mL penicillin at 37 ◦C and 5% CO2 atmosphere. Cells were passaged every
48–72 h [69].
4.6. Lipid Extract Preparation
Lipid extracts were dried under nitrogen gas flow before being weighed and dissolved in
HPLC-grade 100% ethanol. The stock solutions of the lipid extracts were diluted in color-free DMEM
before being added to the cell culture, and the final concentration of ethanol in all experiments was
around 0.35%. Stock solutions of the lipid extracts were prepared fresh on the day of the experiment
prior to addition to the cell culture. The solubility of all extracts in the cell cultures was confirmed under
an inverted microscope (200 and 400×). Each sample was tested in triplicate and each experiment was
repeated independently at least three times on different days.
4.7. Cytotoxicity Assay
Toxicity of the lipid extracts used in this study was assessed using a crystal violet cytotoxicity
assay as previously described by Feoktistova, et al. [70] using both the RAW 264.7 macrophages and
3T3 ccl-92 fibroblasts cell lines. Briefly, cells were seeded at a density of 2 × 104 cells/well in a 96-well
plate and then incubated for 18–24 h. Lipid extracts were added then and incubated for 24 h before the
media was aspirated and the cells washed twice in a gentle stream of water. Water was removed by
tapping the plate on a pile of paper towel followed by addition of 50 μL of 0.5% crystal violet staining
solution and incubated for 20 min at room temperature. The plate was then washed 4 times with water
and air dried for 2 h. Finally, 200 μL of methanol was added to each well and incubated for 20 min at
room temperature on a rocker. The optical density was then measured at 570 nm using Anthos Zenyth
200rt plate reader (Anthos Labtec Instruments, Heerhugowaard, Netherlands). Chlorambucil in a
gradient concentration was used as a positive control.
4.8. NO Inhibition Assay
The production of NO by LPS stimulated RAW 264.7 macrophages was measured in the cell
culture supernatant using the Greiss reaction method as previously described by Ahmad et al. [64].
In brief, RAW 264.7 macrophages were seeded at a density of 106 cell/mL and incubated overnight.
The following day, cells were incubated with different concentrations of the extracts 50, 25, 12.5, 6.25,
or 3.125 μg/mL 1 h prior to LPS stimulation. Twenty-four h after LPS stimulation, the supernatant
was collected, and an equal volume of supernatant and Greiss’ reagent was mixed in a 96 well plate
and incubated in dark for 10–15 min. Absorbance was read at 550 nm using an Anthos Zenyth 200rt
plate reader (Anthos Labtec Instruments, Heerhugowaard, Netherlands). Sodium nitrite was used
as a standard in this assay, and all assays were repeated in triplicate. The commercially available
marine nutraceuticals Lyprinol (BLACKMORES®, Sydney, Australia) and Deep Sea Krill oil (Swisse,
Collingwood, Australia) were used as reference anti-inflammatory nutraceuticals at the same test
concentrations. Dexamethasone at 2.5 μM concentration was used as a reference drug. All assays were
repeated three times.
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4.9. TNF Alpha Inhibition Assay
The levels of TNFα produced by LPS stimulated RAW 264.7 macrophages in the cell culture
supernatant were measured using a mouse TNFα ELISA kit (R&D Systems, Minneapolis, MN, USA)
and performed as per the manufacturer’s instructions. All extracts were tested in five different
concentrations 50 μg/mL, 25 μg/mL, 12.5 μg/mL, 6.25 μg/mL, and 3.125 μg/mL. Dexamethasone
was used as a reference anti-inflammatory drug, and untreated, stimulated cells (LPS + ethanol)
were used as a positive control. Absorbance was read at 450 nm using an Anthos Zenyth 200rt
plate reader (Anthos Labtec Instruments, Heerhugowaard, Netherlands). The commercially available
marine nutraceuticals Lyprinol® (BLACKMORES®, Alexandria, Australia) and Deep Sea Krill oil
(Swisse, Collingwood Melbourne, Australia) were used as reference anti-inflammatory nutraceuticals.
The assays were repeated in triplicate.
4.10. Statistical Analysis
PRIMER v 7 + PERMANOVA software (version 7, Primer-e, Albany, New Zealand) was used
to explore the multivariate differences in lipid profiles, and univariate analyses were used to test
differences in specific lipid classes and anti-inflammatory activity between the various seafood extracts.
Separate Euclidean distance similarity matrices were created for the fatty acid percent composition,
the composition of fatty acid classes, and the totals for each fatty acid class (SFA, MUFA, PUFA and ω-3,
ω-6, n-9, ω-3:ω-6 and DMAAs), as well as the IC50 for NO inhibition and TNFα inhibition. Principle
Coordinate Ordination plots were generated on the fatty acid composition with vector overlay based
on Pearson’s correlation with a cut-off at r > 0.8 to identify which fatty acids contributed most to the
separation between samples.
To assess the relationship between fatty acid composition and NO inhibition or TNFα
inhibition, relate analyses were undertaken on PRIMER V7 using Spearman rank correlation and
9999 permutations. This was followed by a BIOENV stepwise model on the Euclidean distance
similarity matrix to identify which set of fatty acids explained the most variability for each of the
anti-inflammatory markers.
5. Conclusions
In conclusion, lipid extracts from Australian marine seafood were found to contain a high ratio of
unsaturated: saturated fatty acids and significant anti-inflammatory activity. The inhibition of NO and
TNFα in LPS stimulated macrophages was correlated with higher levels of SFAs and PUFA, and in
particular the ω-3 PUFAs EPA and DHA, as well as with lower levels of MUFAs, thus indicating that
the overall composition of marine lipid extracts can influence the anti-inflammatory activity. High
valued marine oils rich in healthy ω-3 PUFAs were not only demonstrated in the edible parts of seafood,
but the under-utilized components of these organisms showed similar if not higher proportions of
PUFAs and anti-inflammatory activity. In particular, the byproducts from cephalopod mollusks appear
to have good anti-inflammatory activity, with potential for the development of another high-quality
marine oil for nutraceutical applications. Further in vitro and in vivo studies are required to optimize
and develop the seafood waste stream as used for natural anti-inflammatory treatments.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/3/155/s1,
Figure S1: The NO inhibitory activity of lipid extracts from different seafood organisms; (A) Penaeus plebejus
(Australian school prawn), body flesh and head, including viscera; (B) Sardinops sagax (Australian sardine)
flesh and viscera, including heads; (C) Salmo salar (Atlantic salmon) flesh and heads; (D) Sepioteuthis australis;
(E) Octopus tetricus * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus the LPS + Solvent control. Figure S2:
Correlations between NO inhibitory activity (IC50) of lipid extracts and the amount of certain fatty acid classes
or ratios in different seafood organisms. Figure S3: The TNFα inhibitory activity of lipid extracts from different
seafood organisms; (A) Penaeus plebejus (Australian school prawn), body flesh and head, including viscera;
(B) Sardinops sagax (Australian sardine) flesh and viscera, including heads; (C) Salmo salar (Atlantic salmon) flesh
and heads; (D) Sepioteuthis australis; (E) Octopus tetricus * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus
the LPS + Solvent control. Figure S4: Correlations between the TNFα inhibitory activity (IC50) of lipid extracts
and the amount of certain fatty acid classes or ratios in different seafood organisms.
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Abstract: Activated human monocytes/macrophages, which increase the levels of matrix
metalloproteinases (MMPs) and pro-inflammatory cytokines, are the essential mechanisms for
the progression of sepsis. In the present study, we determined the functions and mechanisms of
hirsutanolA (HA), which is isolated from the red alga-derived marine fungus Chondrostereum sp.
NTOU4196, on the production of pro-inflammatory mediators produced from lipopolysaccharide
(LPS)-treated THP-1 cells. Our results showed that HA suppressed LPS-triggered MMP-9-mediated
gelatinolysis and expression of protein and mRNA in a concentration-dependent manner without
effects on TIMP-1 activity. Also, HA significantly attenuated the levels of TNF-α, IL-6, and IL-1β
from LPS-treated THP-1 cells. Moreover, HA significantly inhibited LPS-mediated STAT3 (Tyr705)
phosphorylation, IκBα degradation and ERK1/2 activation in THP-1 cells. In an LPS-induced
endotoxemia mouse model, studies indicated that HA pretreatment improved endotoxemia-induced
acute sickness behavior, including acute motor deficits and anxiety-like behavior. HA also attenuated
LPS-induced phospho-STAT3 and pro-MMP-9 activity in the hippocampus. Notably, HA reduced
pathologic lung injury features, including interstitial tissue edema, infiltration of inflammatory cells
and alveolar collapse. Likewise, HA suppressed the induction of phospho-STAT3 and pro-MMP-9 in
lung tissues. In conclusion, our results provide pharmacological evidence that HA could be a useful
agent for treating inflammatory diseases, including sepsis.
Keywords: signal transducer and activator of transcription 3 (STAT3); matrix metalloproteinases-9
(MMP-9); interleukin (IL); lipopolysaccharide (LPS); acute sickness behavior; acute lung injury (ALI)
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1. Introduction
Sepsis is defined as an abnormal host response to infection, which triggers inflammation throughout
the body and causes life-threatening organ dysfunction [1]. Sepsis and septic shock are significant
public health concerns, affecting millions of people around the world with high mortality and poor
diagnosis [1–3]. Notably, in-hospital mortality of sepsis has declined in the last two decades because of
established evidence-based managements, which improve the outcome of the critically ill patient [2,4,5].
Nevertheless, deterioration of health after sepsis is still common, including physical disability and
cognition impairment [3]. Because of the high mortality rate and serious complications, it is critical to
develop new and novel approaches to the treatment of sepsis.
The innate immune system is the first line of defense against microorganism, but the uncontrolled
inflammatory response can lead to tissue damage [6,7]. Tissue-resident leukocytes recognize the
molecules released from pathogens and dead host cells via a pattern recognition receptor activating
downstream transcription factors, especially NF-κB and AP-1, leading to the production of inflammatory
mediators. These inflammatory mediators then initiate localized transmigration of leukocytes to the
infection site to destroy pathogens [7]. The positive feedback loop between cytokines and immune cells
leads to an auto-amplifying phenomenon and cytokine storm, eventually resulting in injuries to multiple
organs during sepsis [7–9]. The emblematic pro-inflammatory cytokines, including tumor necrosis
factor (TNF)-α, interleukin (IL)-1β and IL-6 are major products generated by monocyte/macrophages
and neutrophils. These pro-inflammatory cytokines play a critical role in pathophysiologic processes of
sepsis associated-organ injuries and -cognition impairment, as described previously [9,10]. Therefore,
pro-inflammatory cytokines are considered as the therapeutic targets for the treatment of sepsis or as
diagnostic biomarkers of sepsis [11,12].
Matrix metalloproteinases (MMPs) are zinc- and calcium-dependent endopeptidases; these
enzymes involve in biological processes including tissue remodeling and angiogenesis via degrading
the extracellular matrix [13]. Also, MMPs can regulate non-matrix substrates in pathological processes.
For example, MMP-9 has been shown to cleave and activate pro-inflammatory cytokines, and degrade
the complement of tight junction protein [14]. Therefore, several reports [13,15–17] have shown that
MMP-9 plays an essential role in the pathogenesis of inflammation diseases, such as multiple sclerosis,
arthritis, ischemic stroke, and sepsis. Leukocytes-mediated MMP-9 production and secretion could
be induced by inflammatory response, in particular endotoxemia, CD11bhigh GR-1high neutrophils
are the main producers of MMP-9 [18,19]. The serum levels of MMP-9 are elevated in patients
with both sepsis and septic animal models [13,20]. The MMP-deficient mice have low lethality
in a lipopolysaccharide (LPS)-induced endotoxemia model [21]. In addition, synthetic inhibitor
Regasepin1-inhibiting neutrophil MMP-9 and MMP-8 protects mice against endotoxin shock [22].
Further, MMP-9 blockade attenuated blood-brain-barrier dysfunction in a cecal ligation and puncture
rat model of sepsis [23]. Thus, MMP-9 inhibition could provide a therapeutic strategy of sepsis.
Hirsutanol A (HA), a hirsutane-type sesquiterpene, which is isolated from marine fungus
Chondrostereum sp. NTOU4196, attenuates NO production in LPS-activated murine BV-2 microglial
cells as described previously [24]. This report [24] supports the notion that HA could be a potential
anti-inflammatory agent. In this study, we determined the inhibitory effect and mechanism of HA
on production of MMP-9 and pro-inflammatory cytokine (TNF-α, IL-1β, and IL-6) from LPS-treated
human monocytic THP-1 cells. In an LPS-induced endotoxemia mouse model, we further evaluated
the protective effect of HA on endotoxemia-induced acute sickness behavior and acute lung injury
(ALI).
2. Results
2.1. HA Inhibited MMP-9-Mediated Gelatinolysis Induced by LPS
To determine whether HA modulated the production of MMP-9, MMP-2, or TIMP-1 from
LPS-activated monocytes, THP-1 cells were pretreated with HA (2, 5, and 10 μM) for 15 min, followed
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by the addition of LPS (50 ng/mL) within 24 h. Zymography showed that LPS (50 ng/mL) significantly
enhanced extracellular MMP-9-mediated gelatinolysis by up to 3.06 ± 0.12-fold, and pretreatment with
HA (2, 5, and 10 μM) strongly inhibited MMP-9-mediated gelatinolysis in a concentration-dependent
manner by 2.88 ± 0.37-, 2.56 ± 0.25-, 1.97 ± 0.49-, and 1.37 ± 0.48-fold compared with that under
the normal condition, respectively (Figure 1A). In addition, the pretreatment of HA (10 μM) had no
effect on monocytic extracellular MMP-9 gelatinolysis in the absence of LPS (Figure S1). Systematic
TIMP-1 protein levels are increased during endotoxemia [18]. Similarly, as shown in Figure 1B, THP-1
cells constitutively releasing TIMP-1 was enhanced by LPS stimulation. The pretreatment of HA
did not upregulate the TIMP-1 production of THP-1. In contrast, HA (10 μM) attenuated TIMP-1
enhanced by LPS challenge. Furthermore, to confirm whether HA suppressed extracellular MMP-9
gelatinolysis by down-regulating MMP-9 expression, intracellular MMP-9 protein expression was
evaluated by immunoblotting. As shown in Figure 1C, compared with the resting condition, THP-1
cells treated with LPS for 24 h strongly induced up-regulation of MMP-9 protein expression by up to
3.71 ± 1.18-fold compared with that under the normal condition. Pretreatment with HA at different
concentrations for 15 min followed by the addition of LPS (50 ng/mL) within 24 h decreased MMP-9
expression to 2.55 ± 0.98-, 1.70 ± 0.67-, and 1.04 ± 0.14-fold, respectively, in a concentration-dependent
manner. Similarly, LPS (50 ng/mL) significantly increased the expression of MMP-9 mRNA in
THP-1 cells by up to 25.42 ± 8.53-fold compared with normal conditions, and pretreated with HA (5
and 10 μM) significantly suppressed LPS-mediated MMP-9 mRNA expression down to 9.26 ± 7.17-
and 8.62 ± 6.84-fold, respectively (Figure 1D). These results suggested that HA down-regulated
MMP-9-mediated gelatinolysis occurred at both transcriptional and protein expression levels.
Figure 1. Cont.
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Figure 1. Effect of HA on MMP-9-mediated gelatinolysis and expression induced by LPS. THP-1 cells
(5 × 105 cells/0.5 mL) were dispensed onto 24-well plates and treated with LPS (50 ng/mL) for 24 h.
Cells were treated with the indicated concentrations of HA (2, 5 and 10 μM) or vehicle for 15 min before
treatment with a stimulant. Cell-free supernatants were then assayed for MMPs and TIMP-1 activity by
gelatin zymography (A) and reverse zymography (B). THP-1 cells (106 cells/mL) were dispensed onto
6-well plates and were treated with LPS (50 ng/mL) for 24 h (C) or 8 h (D) at the indicated concentrations
of HA or vehicle for 15 min before treatment with LPS. Cell lysates were obtained and analyzed for
MMP-9 protein expression by Western blotting or for MMP-9 mRNA expression by RT-PCR. Data
represent means ± S.D. from three independent experiments. # p < 0.05, ## p < 0.01 and ### p < 0.001 as
compared with the resting, * p < 0.05, ** p < 0.01 and *** p < 0.001 as compared with the vehicle.
2.2. HA Attenuated Pro-Inflammatory Cytokines Production Induced by LPS
To determine whether HA down-regulated the level of the pro-inflammatory cytokines TNF-α,
IL-6, and IL-1β production by activated monocytes, THP-1 cells were pretreated with different
concentrations of HA (0.5–10 μM) for 15 min followed by the addition of LPS (50 ng/mL) within 4 h or
24 h. As shown in Figure 2A, compared with the resting condition, THP-1 cells stimulated with LPS for
4 h significantly increased extracellular TNF-α levels by up to 345.8± 73.0 pg/106 cells, and pretreatment
with HA at different concentrations significantly attenuated the extracellular TNF-α production in a
concentration-dependent manner to 249.5 ± 33.5, 198.8 ± 29.1, 94.5 ± 7.1, and 21.0 ± 5.1 pg/106 cells,
respectively. Likewise, LPS significantly increased extracellular IL-6 levels by up to 303.0 ± 182.5 pg/106
cells. Pretreatment with different concentrations of HA significantly suppressed the extracellular
IL-6 levels in a concentration-dependent manner to 101.0 ± 54.2, 8.5 ± 6.8, and 6.2 ± 9.5 pg/106 cells,
respectively (Figure 2B). Also, as shown in Figure 2C, LPS markedly enhancing extracellular IL-1β
production to 32.3± 17.0 pg/106 cells, and pretreatment with HA at different concentrations significantly
decreased the extracellular IL-1β levels in a concentration-dependent manner to 23.8 ± 10.6, 18.6 ± 8.4,
and 9.5 ± 5.5 pg/106 cells, respectively (Figure 2C). In addition, the pretreatment of HA (5 μM) did not
induce pro-inflammatory cytokines production of THP-1 without LPS challenge (Figure S2). Notably,
HA (2, 5, and 10 μM) and the combination of LPS and HA (10 μM) did not have a significant cytotoxic
effect against THP-1 cells based on MTT assay, respectively (Figures 2D and S3).
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Figure 2. Effect of HA on pro-inflammatory cytokines production induced by LPS in THP-1 cells
without cellular toxicity. THP-1 cells (5 × 105 cells/0.5 mL) were dispensed onto 24-well plates and
were treated with the indicated concentrations of HA or vehicle for 15 min followed by treatment with
LPS (50 ng/mL) for 4 h (A) and 24 h (B,C). Cell-free supernatants were then assayed for the level of
TNF-α (A), IL-6 (B) and IL-1β (C) by ELISA. (D) THP-1 cells treated with the indicated concentrations
of HA or vehicle for 24 h. Cell viability was quantified by the ability of mitochondria to reduce the
tetrazolium dye MTT in viable cells. Data represent means ± S.D. from three independent experiments.
## p < 0.01 and ### p < 0.001 as compared with the resting; * p < 0.05, ** p < 0.01 and *** p < 0.001 as
compared with the vehicle.
2.3. HA Suppressed IκB-α Degradation and the Phosphorylation Level of STAT3 and ERK1/2 Induced by LPS
While the JAK2-STAT3 pathway is essential to regulate the immune response, it is considered
to be involved in an “early” inflammatory response during sepsis [25]. To examine the effects of HA
on LPS-mediated STAT3 activation, the phosphorylation levels of STAT3 (Tyr705) were determined
by western blotting. THP-1 cells stimulated with LPS for 24 h significantly induced the level of
phosphorylated-STAT3 (Tyr705) by up to 3.65 ± 0.29-fold, and pretreatment of HA (2, 5, and 10 μM)
significantly attenuated LPS-mediated activation of STAT3 (Tyr705) down to 2.27 ± 0.60-, 1.39 ± 0.48-,
and 1.08 ± 0.16-fold, respectively (Figure 3A). On the other hand, MMP-9 expression was regulated by
various transcription factors, such as NF-κB, AP-1, and SP-1 [26]. Therefore, the effect of HA on the
LPS-induced activation of MAPKs (p38, ERK), degradation of the inhibitor of kappa B alpha (IκBα)
and the phosphorylation level of IκB kinase alpha/beta (IKKα/β) was determined by western blotting.
To examine whether HA regulates the IKKα/IκBα/NF-κB cascade, THP-1 cells were pretreated with HA
(2, 5, and 10 μM) or parthenolide (PTL; 10μM, an inhibitor of the NF-κB pathway) for 15 min followed
by the addition of LPS (50 ng/mL) within 60 min. As shown in Figure 3B, significant degradation of IκBα
was observed in THP-1 stimulated with LPS (50 ng/mL) for 60 min, and the pretreatment with different
concentrations of HA significantly prevented the degradation of IκBα in a concentration-dependent
manner by 0.55 ± 0.13-, 0.74 ± 0.13-, and 0.95 ± 0.10-fold, respectively. Similarly, LPS significantly
enhanced the level of phosphorylated IKKα by up to 4.60 ± 0.72-fold, and pretreatment with HA (5 and
108
Mar. Drugs 2019, 17, 360
10 μM) attenuated the IKKα phosphorylation down to 3.79 ± 0.27-, and 3.14 ± 0.16-foldcompared with
basal levels of the normal condition, respectively (Figure S4). To investigate whether HA regulates the
activation of ERK or p38 MAPK, THP-1 cells were pretreated with HA (2, 5, and 10 μM), PD (PD98059,
a MEK MAPK inhibitor; 20 μM), or SB (SB203580, a p38 MAPK inhibitor; 10 μM) for 15 min followed by
the stimulation of LPS within 30 min. As shown in Figure 3C, the phosphorylation levels of ERK was
strongly induced by LPS to 1.80± 0.46-fold compared with the resting condition, while the pretreatment
with HA at different concentrations significantly inhibited LPS-stimulated ERK phosphorylation in
a concentration-dependent manner by 1.39 ± 0.16-, 1.14 ± 0.03-, and 1.08 ± 0.21-fold, respectively.
Notably, LPS significantly enhanced the phosphorylation levels of p38 by up to 1.68 ± 0.12-fold, and
pretreatment with SB (10 μM) attenuated the p38 phosphorylation down to 0.44 ± 0.13-fold compared
with the resting condition. However, unlike SB, pretreatment with HA at different concentrations
did not affect p38 activation (Figure 3D). On the other hand, the pretreatment of HA (10 μM) did not
induce phosphorylation of STAT3 and degradation of IκBα in THP-1 without LPS challenge (Figure S5).
These results suggested that HA attenuated MMP-9 expression through regulating IKKα/IκBα/NF-κB-
and ERK-associated signaling in THP-1 cells during LPS treatment.
Figure 3. Effect of HA on STAT3, MAPK and NF-κB activation induced by LPS in THP-1 cells. THP-1
cells (106 cells/mL) were dispensed onto 6-well plates and were treated with the indicated concentrations
of HA (2, 5 and 10 μM), parthenolide (PTL, 10 μM), PD98059 (PD, 20 μM), SB203580 (SB, 10 μM) or
vehicle followed by treatment of LPS (50 ng/mL) for 24 h (A), 60 min (B), and 30 min (C,D), respectively.
Cell lysates were obtained and analyzed for IκBα degradation and the level of phosphorylated-STAT3,
ERK and p38 MAPK by Western blotting. Data represent means ± S.D. from three independent
experiments. # p < 0.05, ## p < 0.01 and ### p < 0.001 as compared with the resting; * p < 0.05, ** p < 0.01
and *** p < 0.001 as compared with the vehicle.
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2.4. The Activation of JAK2-STAT3 Cascade Was Associated with LPS-Mediated MMP-9 Production
To determine the effects of JAK2-STAT3 inhibition on MMP-9 production, THP-1 cells were
pretreated with AG490 (a JAK2 inhibitor; 5, 10, 20, and 40 μM) or HA (5, and 10μM) for 15 min
followed by the addition of LPS (50 ng/mL) for 24 h. As described in zymography, compared
with the LPS-stimulating condition, the pretreatment of AG490 (20, 40 μM) significantly lessened
extracellular MMP-9-mediated gelatinolysis down to 1.71 ± 0.41-, and 0.92 ± 0.15-fold, respectively
(Figure 4A). Interestingly, at the same concentration, HA was more potent than AG490 on attenuating
MMP-9-mediated gelatinolysis induced by LPS. The ERK1/2 inhibition suppress LPS-mediated STAT3
(Tyr705) activation and AP-1 expression in THP-1 cells [27]. Also, the inhibition of JAK2-STAT3
cascade lessens NF-κB phosphorylation in LPS-stimulated THP-1 cells [25]. As shown in Figure 3,
HA pretreatment both down-regulated ERK1/2 phosphorylation and prevented IκBα degradation in
LPS-challenged THP-1 cells. To investigate the difference between MEK inhibition and HA pretreatment
on LPS-mediated STA3 (Tyr705) phosphorylation and whether HA regulated STAT3 activation in
LPS-challenged-monocytes, THP-1 cells were pretreated with HA (10 μM) or PD (10 μM) for 15 min
followed by the addition of LPS within 3 h or 5 h. As shown in Figure 4B, THP-1 cells stimulated
with LPS for 5 h significantly induced STAT3 (Tyr 705) phosphorylation by up to 5.03 ± 0.50-fold,
and pretreatment with HA (10 μM) significantly inhibited the phosphorylation levels to 1.44 ± 0.41-fold
(Figure 4B). At the same concentration, HA was more potent than PD to inhibit STAT3 phosphorylation.
To compare the difference between the effect of HA and JAK2-inhibitor on LPS-mediated IκBα/NF-κB
cascade, THP-1 cells were pretreated with HA (10 μM) or AG490 (20 μM) for 15 min followed by
the addition of LPS for 60 min. As indicated in Figure 4C, HA (10 μM) and AG490 (20 μM) caused
similar efficacy on the inhibition of extracellular MMP-9 activity. At the same condition as stated
above, HA was more effective than JAK inhibitor for preventing LPS-induced IκBα degradation
in THP-1 cells. Taken together, these results suggested that HA regulated the functions of various
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Figure 4. Effect of JAK2-STAT3 cascade inhibition on LPS-mediated MMP-9 expression. THP-1 cells
(5 × 105 cells/0.5 mL) were dispensed onto 24-well plates and treated with LPS (50 ng/mL) for 24 h.
Cells were treated with the indicated concentrations of AG490 (5, 10, 20, and 40 μM), HA (5 and 10 μM)
or vehicle for 15 min before treatment with LPS. Cell-free supernatants were then assayed for MMPs
activity by gelatin zymography (A). THP-1 cells (106 cells/mL) were dispensed onto 6-well plates and
were treated with LPS (50 ng/mL) for 3 h, 5h (B) and 60 min (C) at the indicated concentrations of
HA, PD (10 μM), AG490 (10 μM) or vehicle for 15 min before treatment with LPS. Cell lysates were
obtained and analyzed for STAT3 (Tyr705) phosphorylation and IκBα degradation by Western blotting.
Data represent means ± S.D. from three to four independent experiments, respectively. ## p < 0.01 and
### p < 0.001 as compared with the resting; * p < 0.05 and *** p < 0.001 as compared with the vehicle;
ΔΔΔ p < 0.001 as compared with the group pretreated with HA pre-treatment.
2.5. HA Decreased LPS-Mediated Acute Sickness Behavior
Body weight loss, acute motor deficits, and anxiety-like behavior are typical sickness behaviors
that are mediated by systemic immune responses [28]. As indicated in Figure 5A, the 5-min period
of OFT after LPS-injection for 2 h and 24 h, respectively, were presented using heat-maps. The total
distance traveled by LPS-challenged mice was dramatically reduced by 57% compared to control mice
(Saline-2073.0 ± 224.9 vs. LPS-888.9 ± 625.5, p < 0.001). HA (30 mg/kg) pretreatment significantly
prevented LPS-induced acute locomotor deficits compared to the LPS-challenged group at 2 h
(Figure 5C, p < 0.05). As shown in Figure 5D, the LPS-injected mice group spent significantly less
time in the open area than the control group (p < 0.001). HA pretreatment significantly lessened the
LPS-induced reduction in the time spent in the open area (p < 0.001). One day after LPS injection,
HA pretreatment still significantly improved the reduction of the time spent in the open area and the
total distance traveled induced by LPS-injection (p < 0.05, Figure 5E,F). Also, pretreatment reduced
body weight loss and body temperature abnormalities mediated by LPS at 24 h compared with the
LPS-challenged group (Figure S6A,B). As shown in Figure 6 A, the 5-min period of the EZM tests
were tracked as a Heat-map at one day after the LPS injection. As shown in Figure 6B, the percentage
of entries in the open quadrants was significantly lower in the LPS-challenged group than in the
control group (p < 0.01). HA-pretreatment significantly lessened the decline of time spent in the
open quadrants compared to the behaviors observed in the LPS challenge group (p < 0.05). A slight
decrease in the percentage of entries in the open quadrants was observed in the LPS challenge group
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compared to the control group, but no significant differences were observed among the 3 groups
(p > 0.05, Figure 6C). To further determine whether HA pretreatment regulated STAT3 activation and
pro-MMP-9 expression in the hippocampus during endotoxemia-mediated acute sickness behavior
and anxiety-like behavior, the expression levels of phosphorylated STAT3 (Tyr705) and pro-MMP-9
expression were evaluated by immunoblotting and gelatin zymography, respectively. Compared
with the control group, LPS significantly increased the expression levels of STAT3 phosphorylated on
Tyr705 in the hippocampus to 2.55 ± 0.90 fold. The increase in phosphorylated STAT3 protein levels
was reduced by HA pretreatment to 50% as compared with the LPS-challenged group (LPS-2.55 ±
0.90-fold vs. HA-1.29 ± 0.37 fold, p < 0.01) (Figure 6D). Additionally, zymography showed that sample
of hippocampus post-LPS challenged significantly enhanced MMP-9-mediated gelatinolysis by up to
1.44 ± 0.17-fold, and pretreatment with HA significantly attenuated MMP-9-mediated gelatinolysis by
28% as compared with the LPS-challenged group (LPS-1.44 ± 0.17-fold vs. HA 1.03 ± 0.09, p < 0.01)
(Figure 6E). Furthermore, LPS injection significantly increased the number of CD68+ phagocytes in
the CA3 hippocampal region compared with the control group. Compared with the septic group, the
pretreatment of HA reduced the infiltration of CD68+ phagocytes (Figure S7).
Figure 5. Cont.
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Figure 5. Effect of HA on sickness behavior in the open field test following a systemic LPS challenge.
(A) Experimental timeline and design. (B) Heat-map represented the tracks of mice in the different
groups in OFT, red = more time, blue = less time. (C) Total distance traveled 5 min in the different
groups administrated with sterile saline or LPS (0.83 mg/kg, i.p) for 2 h. (D) Percentage of time spent in
5 min in the open area in the different groups for 2 h. (E) Total distance traveled 5 min in the different
groups challenged with sterile saline or LPS (0.83 mg/kg, i.p) for 24 h. (F) Percentage of time spent in
5 min in the central area in the different groups for 24 h. Data represent group means ± S.D., n = 7
mice/group. ## p < 0.01 and ### p < 0.001 as compared with the saline control group (Control); * p < 0.05
and *** p < 0.001 as compared with the co-solvent group (vehicle).
Figure 6. Cont.
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Figure 6. Effect of HA on anxiety-like behavior in the elevated zero maze test, and the expression of
phospho-STAT3 and MMP-9 in the hippocampus following systemic LPS challenge. (A) The structure
diagram of EZM was described as the left panel. Heat-map illustrated the tracks of mice in the different
groups in EZM test, red = more time, blue = less time. (B) Percentage of time spent in 5 min in the
open arms (gray) in the different groups administrated with sterile saline or LPS (0.83 mg/kg, i.p) for
25 h. (C) Percentage of entries into the open arms in 5 min in the different groups for 25 h. Mice were
sacrificed after behavior tests, and then hippocampus was collected immediately. Homogenates of
the hippocampus were obtained and analyzed for the phosphorylation of STAT3 by Western blotting
(D, n = 5), and assayed for MMPs activity by gelatin zymography (E, n = 3). Data represent group
means ± S.D., n = 3 to 7 mice/group. ## p < 0.01 as compared with the saline control group (Control);
* p < 0.05 and ** p < 0.01 as compared with the co-solvent group (vehicle).
2.6. HA Improved Pulmonary Histological Changes during Endotoxemia
Pulmonary edema caused by Gram-negative bacterial infection is the primary manifestation of
organ failure and the most common cause of sepsis-related death [29]. It has been reported [30] that
STAT3 blocker inhibits the LPS-mediated inflammatory response in mice with acute lung injuries
(ALI). One day after intraperitoneal injection of LPS (0.83 mg/kg), histology image analysis was
done to assess the effect of HA pretreatment on endotoxemia-mediated lung injury. As shown in
Figure 7A, LPS induced pathologic lung injury, including interstitial tissue edema, infiltration of
inflammatory cells, and alveolar collapse, which were reduced in the HA-pretreated group compared
to the LPS-challenged group. Furthermore, LPS significantly augmented the expression levels of
phosphorylated STAT3 (Tyr705) in lung tissue compared to the control group, and HA pretreatment
reversed the upregulation of STAT3 phosphorylation induced by LPS (Figure 7B). On the other hand,
one day after LPS was challenged, the protein levels of MMP-9 were significantly increased, and
pretreatment with HA significantly attenuated the MMP-9 expression induced by LPS of the lung
tissues (Figure 7C). Notably, BALF collected from mice injected at one day after LPS treatment also
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showed an increase in the MMP-9-mediated gelatinolysis by 1.65 ± 0.25 fold compared to control mice.
The pretreatment of HA significantly reduced MMP-9 activity in BALF collected from the HA group
compared with the LPS-challenged group (LPS-1.65 ± 0.25-fold vs. HA-1.04 ± 0.36 fold, p < 0.05)
(Figure 7D).
Figure 7. Effect of HA on LPS-mediated histopathological changes and the production of phospho-STAT3
and MMP-9 in lung tissues and BALF. Mice in the different groups administrated with sterile saline
or LPS (0.83 mg/kg, i.p) which were sacrificed after behavior tests, and then BALF and lung tissues
were collected immediately for following experiments. (A) Representative hematoxylin and eosin
(H&E)-stained sections of right lung lobes at 400 × original magnification showed exaggerated acute
inflammatory infiltration, alveoli destruction and interstitial edema in LPS group (scale bar = 100 μm).
Homogenates of the left lung lobes were obtained and analyzed for the expression of phospho-STAT3
(B) and pro-MMP-9 (C, n = 3) by Western blotting, and assayed for MMPs activity in BALF by gelatin
zymography (D, n = 3). Data represent group means ± S.D., n = 3 to 7 mice/group. # p < 0.05, ## p < 0.01
and ### p < 0.001 as compared with the saline control group (Control); * p < 0.05 as compared with the
co-solvent group (vehicle).
3. Discussion
The course of sepsis is often accompanied by many serious complications, such as acute lung
injury or sepsis-associated encephalomyelitis, which causes high mortality and poor prognosis [7–9].
Systemic inflammatory response during sepsis promotes the abnormal activation of immune cells
such as monocyte, which plays a crucial role in organ damage. The infiltration of monocytes causes
organ damage, which are associated with the elevation of MMPs and cytokines. MMPs degrade the
extracellular matrix leading to abnormal leakage of endothelial tight junctions, which is responsible for
the development of edema and organ dysfunction [31–34]. It had been reported that MMP-9 blockade
attenuates the cellular transmigration of monocytes induced by LPS [35]. MMP-2 and MMP-9 blocker
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could reverse the increase of permeability of the blood-brain barrier and improve acute cognitive
alteration associated with sepsis [23]. LPS activates TLR4 downstream signaling including ERK, p38, and
NF-κB pathway to upregulate the production of MMP-9 and pro-inflammatory cytokines [26,36]. In the
present study, HA pretreatment inhibited LPS-induced ERK1/2 phosphorylation and IκB degradation
without cytotoxicity. Notably, HA significantly attenuated LPS-induced MMP-9 mRNA and protein
expression and suppressed LPS-mediated extracellular TNF-α, IL-1β, and IL-6 levels. Taken together,
these results suggested that HA downregulated THP-1 cells expressing MMP-9 and pro-inflammatory
cytokines. These results support our hypothesis that HA improved monocyte-mediated lung injury
and anxiety-like behavior during endotoxemia.
In the present study, we showed that HA pretreatment significantly inhibited STAT3 tyrosine
phosphorylation in THP-1 cells during LPS stimulation for 24 h. Variety of different stimuli including
LPS and pro-inflammatory cytokines activate JAK-STAT3 signaling which exhibits crosstalk between
different pathways and involves in the up-regulation of pro-inflammatory mediators, such as
IL-6 [25,27,37]. JAK2-STAT3 cascade is activated after 30 min of LPS stimulation, whereas JAK2
blockade strongly inhibits LPS-induced STAT3 (tyr705) phosphorylation [25], and JAK2 also modulates
the phosphorylation of the IκBα in neurons [38]. Our study showed that AG490 significantly suppressed
both LPS-mediated IκBα degradation and MMP-9 production, indicating that JAK2 was also involved
in the regulation of MMP-9 expression during LPS stimulation. Interestingly, the effects of HA on
attenuating LPS-induced IκBα degradation and MMP-9 production were more potent than JAK2
inhibitor AG490. Contrary to other studies, we found significant STAT3 tyrosine phosphorylation after
LPS challenged THP-1 cells were given LPS for 3 h. Inhibition of ERK-AP-1 pathway downregulate
LPS-induced phosphorylation of STAT3 [27]. Similarly, in the present study, pretreatment with
MEK inhibitor PD98059 significantly prevented LPS-induced ERK1/2 phosphorylation in THP-1
cells. But, at the same concentration, HA pretreatment was more potent than MEK inhibitors to
suppress LPS-mediated STAT3 phosphorylation. These results suggested that HA might suppress
phosphorylation of STAT3 via regulating upstream signal molecules, such as JAK2 and Myd88.
However, the detailed mechanisms of HA regulating STAT3 activation need further investigation in
future studies.
During central nervous system (CNS) inflammation, infiltrated immune cells released chemokines
and cytokines that recruited and activated more leukocytes into inflamed site resulting complex
long-term immune responses and accumulation of neurotoxic products [39,40]. It has been reported
that circulating IL-6 and TNF-α levels were significantly linked to patients with the severity of anxiety,
depression and cognitive impairment [10,41]. Similarly, elevated systemic pro-inflammatory cytokines
levels were associated with sickness behavior, including locomotor activity deficiency, anxiety- and
depressive-like behavior in systemic LPS-challenged mice [42–46]. LPS-induced acute-sickness behavior,
including anxiety- and depressive-like behavior was prevented by attenuating among TNF-α, IL-1β,
and IL-6 levels of brain and plasma of mice [46,47]. In the present study, intraperitoneal administration
of LPS-induced significant locomotor deficits, body weight loss, and anxiety-like behavior, while
pretreatment with HA was effective in preventing acute sickness behavior caused by LPS. Additionally,
the hippocampus in mice sacrificed after 24 h of behavioral testing showed that pretreatment with
HA reduced the level of MMP-9 induced by LPS. It had been indicated that inhibition of MMP-9 and
MMP-2 levels could effectively reduce the level of inflammatory cytokines in the brain and improve
cognitive impairment caused by sepsis [23]. CCR2+/CD68+ activated microglia/macrophages were
increased following LPS challenge in the hippocampus [48]. Similarly, LPS challenge induced CD68+
inflammatory cell recruitment in the CA3 hippocampal region, and HA pretreatment prevented the
infiltration of CD68+ microglia/macrophages in the hippocampus induced by LPS injection. However,
whether HA could regulate the elevation of pro-inflammatory cytokine levels in the hippocampus and
serum in the acute phase (2 h) remains to be confirmed.
During endotoxemia, high levels of TNF-α and IL-6 could activate JAK2-STAT3 cascade in
CNS [23,37]. STAT3 was associated with the expression of serotonin reuptake transporter (SERT)
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known to affect food intake and body weight [49]. The blockade of STAT3 activation in the
hippocampus and in the hypothalamus attenuated depression-like behavior and anorexia in mice
suffered neuroinflammation, respectively [50,51]. In the present study, intraperitoneal administration of
LPS did significantly induce increase STAT3 phosphorylation in the hippocampus, whereas pretreatment
with HA significantly lessened the level of phosphorylated STAT3 in the hippocampus, which may
help further explain that HA could improve the body weight loss and sickness behavior caused by LPS.
However, whether HA could regulate the performance of SERT or serotonin in the hippocampus still
needs further verification. On the other hand, STAT3 rapidly activates in the lungs during LPS-induced
systemic inflammation, and STAT3 activation occurs before significant lung injury [30,52]. Blockade
of STAT3 activity could attenuate LPS-mediated inflammatory cell infiltration and damage in the
lung [30]. Our results demonstrated that HA obviously attenuated lung injury features accompanied
by suppression of LPS-induced STAT3 activation and MMP-9 production in lung tissues or BALF.
These results provided evidence that HA reduced LPS-mediated upregulation of pro-inflammatory
mediators and increased vascular permeability.
Although hirsutanol A was reported to be effective on anti-tumor growth in vivo [53], we found HA
attenuated the activation of monocyte and microglia [24]. The disruption of blood-brain barrier (BBB)
was induced by LPS-associated leukocyte activation. Inhibition of pro-inflammatory TLR4 activation
represents an impairment of BBB dysfunction and neuroinflammation [54]. The lung inflammation and
injuries are also implicated with monocyte activation [55]. According to these findings, we supposed
HA regulated monocyte- and microglia-mediated injuries in brain and lung during inflammatory
cascade. However, this study still has some potential limitations. CD11bhigh GR-1high neutrophils are
not only the main source of MMP-9, but also the recruitment of neutrophils play important roles in
MMP-9-associated tissue damages during endotoxemia [18]. HA may also block the recruitment of
neutrophils, thereby preventing MMP-9-induced lung injuries. However, it is necessary to further
investigate the effects of HA on neutrophils during endotoxemia. In addition, according to our findings,
HA pre-treatment attenuated STAT-3 phosphorylation induced by LPS challenge. However, we had
not directly assessed HA regulates the expression of MMP-9 in hippocampus and lung tissue through
regulating STAT3. Clinical sepsis treatment is often administered after the onset of the disease; although
HA treatment improves several symptoms induced by endotoxemia in in vivo model, it is still different
from the actual clinical situation. In further study, the detail molecular mechanism of HA interacted
with STAT3 and the suitability for septic preclinical studies should be determined.
4. Materials and Methods
4.1. Materials
Hirsutanol A (HA), was obtained from Professor Tzong-Huei Lee [24]. Anti-mouse
immunoglobulin (Ig) G-conjugated horseradish peroxidase (HRP) complexes (cat. No NA934)
and anti-rabbit IgG-conjugated HRP complexes (cat. No NA931) were purchased from Amersham
Biosciences (Sunnyvale, CA, USA). Anti-rat IgG-conjugated CFTM488A (cat. No #20014) were purchased
from Biotium (Fremont, CA, USA). The rabbit polyclonal antibody (pAb) specific for human native
92-kDa MMP-9 (cat. No AB19016) was purchased from MilliporeSigma (St. Louis, MO, USA). The mouse
mAb specific for α-tubulin (cat. No MS-581-P1) was purchased from LabVision/NeoMarkers (Fremont,
CA, USA). The rabbit mAb specific for STAT3 (cat. No 12640S), phospho-STAT3 (Tyr705; cat. No 9145S),
IκB-α (cat. No 4812S), and p-IKKα/β (Ser176/Ser177) (cat. No 2697S) were purchased from Cell Signaling
(Danvers, MA, USA). The rabbit pAb specific for phospho-ERK (Thr202/Tyr204) (cat. No 9101S) and
phospho-p38 MAPK (Thr180/Tyr182; cat. No 9211S) were purchased from Cell Signaling (Danvers, MA,
USA). The mouse mAb specific for ERK (cat. No 9107S) was purchased from Cell Signaling (Danvers,
MA, USA). The rabbit pAb specific for p38 MAPK (cat. No GTX110720), β-actin (cat. No GTX109239)
and IKKα (cat. No GTX132964) were purchased from GeneTex (Irvine, CA, USA). Thiazolyl blue
tetrazolium bromide (MTT; cat. No M5655-1G), 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid
117
Mar. Drugs 2019, 17, 360
(HEPES; cat. No H4034-1KG), sodium dodecyl sulfate (SDS; cat. No L3771-500G), phenylmethylsulfonyl
fluoride (PMSF; cat. No P-7626), leupeptin (cat. No L2023-5MG), aprotinin (cat. No A1153-5MG),
sodium fluoride, sodium orthovanadate (cat. No S6508-10G), sodium pyrophosphate (cat. NO
S6422-100G), diethyl pyrocarbonate (DEPC; cat. No 159220-5G), lipopolysaccharide (LPS; cat. No
L3880-100mg), parthenolide (PTL; cat. No P0667-5MG), SB203580 (SB; cat. No S8307-1MG), PD98059
(PD; cat. No P215-1MG), AG490 (cat. No 658401-5MGCN) and bovine serum albumin (BSA; cat. No
A7906-100G) were purchased from MilliporeSigma (St. Louis, MO, USA). All other chemicals used in
this study were of reagent grade.
4.2. Cell Cultivation
THP-1 cells (human acute monocytic leukemia line) were obtained from American Type Culture
Collection (Manassas, VA, USA). Cells (passage 6 to passage 30) were maintained in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine serum (FBS). HEPES (18 mM), NaHCO3
(23.57 mM), L-glutamine (3.65 mM), penicillin (90 units/mL) and streptomycin (90 μg/mL) (cat. NO
10378-016, PSQ, GIBCOTM, Thermo Fisher Scientific; Waltham, MA, USA). Cells were sub-cultured
regularly twice a week (1.2 × 106 cells/ml in 75T flask), as previously described [56].
4.3. Gelatin and Reverse Zymography
THP-1 cells (5 × 105 cells/0.5 mL), seeding into 24-well plate in RPMI 1640 medium containing
0.5% FBS were pretreated with or without HA for 15 min and were subsequently stimulated with LPS
(50 ng/mL) for 24 h, followed by the collection of the supernatants. The extracellular MMPs levels were
evaluated by MMP-mediated gelatinolysis via gelatin zymography. TIMP-1 activity was determined
via reverse zymography, as previously described [56,57].
4.4. Cellular Viability Assay
THP-1 cells (5 × 105 cells/0.5 mL) were seeded into 24-well plate in RPMI 1640 medium containing
0.5% FBS, then incubated in 24-well plates with indicated concentrations of HA at 37 ◦C for 24 h.
The cytotoxic effects of HA on the viability of THP-1 cells were determined by the MTT colorimetric
assay, as previously described [56].
4.5. Western Blot Analyses
THP-1 cells (1.0 × 106 cells/mL) were seeded into 6-well plate in RPMI 1640/FBS (0.5%) medium
were pretreated with or without indicated concentrations of HA for 15 min, followed by stimulation of
LPS (50 ng/mL) for the indicated time. Cells were harvested and lysed as previously described [56].
The samples separated by SDS-PAGE and were blotted onto PVDF or nitrocellulose membranes
(cat. NO RPN303F and RPN303D, Hybond™, Amersham™, GE Healthcare, Chicago, IL, USA).
The blots were probed with the indicated antibodies and then were visualized by using the enhanced
chemiluminescence (cat. NO 32106, PierceTM, Thermo Fisher Scientific; Waltham, MA, USA) and
exposure to UVP GelDoc-It2 310 Imaging System (Labrepco; Horsham, PA, USA). The images were
cropped, formatted, and adjusted for brightness in Adobe Illustrator. The respective fold was analyzed
as previously described [56].
4.6. Reverse Transcription Polymerase Chain Reaction (RT-PCR) Analysis
THP-1 cells (1.0 × 106 cells/mL) were seeded into 6-well plate in RPMI 1640/FBS (0.5%) medium
were pretreated with or without indicated concentrations of HA for 15 min, followed by stimulation of
LPS (50 ng/mL) for 8 h. Total RNA was isolated from THP-1 cells using TRIsure™ (cat. NO BIO-38033,
Bioline, Trento, Italy) following the manufacturer’s instructions, and 1 μg of total RNA was reverse
transcribed into cDNA using a commercial kit (cat. NO 10928-042, Super Script On-Step RT-PCR
system, GIBCOTM, Thermo Fisher Scientific; Waltham, MA, USA). The nucleotide sequences of the
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primers used for amplification were as follows: for MMP-9, sense 5′-CGTGG AGAGT CGAAA TCTCT
G-3′ and antisense 5′-CCAAA CTGGA TGACG ATGTC T-3′; for GAPDH, sense 5′-CCACC CATGG
CAAAT TCCAT GGCA-3′ and antisense 5′-TCTAG ACGGC AGGTG CAAAT CACC-3′. PCR was
performed using the following conditions: 28 cycles of a 15 s denaturation step at 94 ◦C, a 30 s annealing
step at 54 ◦C, and a 60 s extension step at 72 ◦C for MMP-9; followed by 25 cycles of a 15 s denaturation
step at 94 ◦C, a 30 s annealing step at 67 ◦C, and a 60 s extension step at 72 ◦C for GAPDH. The
respective amplified PCR products were analyzed as previously described [56].
4.7. Measurement of Cytokine Levels by the Enzyme-Linked Immunosorbent Assay (ELISA)
THP-1 cells (5 × 105 cells/0.5 mL) were seeded into 24-well plate in RPMI 1640 medium (cat.
NO 31800-022, GIBCOTM, Thermo Fisher Scientific; Waltham, MA, USA) containing 0.5% FBS, then
pretreated with or without HA for 15 min and were subsequently stimulated with LPS (50 ng/mL) for
the indicated time, and followed by collection of the supernatants. The extracellular levels of TNF-α,
IL-6, and IL-1β produced by THP-1 cells were determined using the ELISA Ready-SET-Go! kit (cat.
NO #88-7346-88 TNF-α, #88-7066-2 IL-6, and #88-7010-88 IL-1β, eBioscience; San Diego, CA, USA).
The quantitative levels of the cytokines were analyzed as previously described [58].
4.8. LPS-Induced Endotoxemia In Vivo and Drug Treatment
Male C57BL/6 mice (8–10 weeks, 25–28 g) were purchased from bioLASCO, Taiwan Co., Ltd
(Taipei, Taiwan). The Institutional Animal Care and Use Committee (IACUC) of Taipei Medical
University approved the animal experiments in this study (LAC-2015-0195). To develop mouse
endotoxemia models, LPS (E. coli LPS, serotype 0127:B8) was dissolved in pyrogen-free sterile
saline (0.9% w/v NaCl) at a concentration of 0.5 mg/mL and intraperitoneally injected at the dose
of 0.83 mg/kg of body weight [45]. C57BL/6 mice were assigned to receive a volume of 1.66 mL/kg
LPS or an equal amount of normal saline via intraperitoneal injection. For evaluating the effects of
HA on the endotoxemia-mediated sickness behavior, anxiety-like behavior and lung inflammation,
HA was dissolved in co-solvent as cremophor EL (cat. NO C5135-500G, MilliporeSigma, St. Louis,
MO, USA)/ethanol (1:1) and was diluted (1:10) with pyrogen-free sterile saline (0.9% w/v NaCl),
and intraperitoneally administered 30 min before LPS-injection at 30 mg/kg of body weight. Animals
were randomized into three experimental groups (n = 7) for behavioral and biochemical assessment.
The group III (HA group) were intraperitoneally administrated with HA, and the group I (Saline control
group) group II were injected with an equal volume of vehicle (co-solvent) before LPS injection. After
30 min, the group I challenged with Saline, group II and group III challenged with LPS (0.83 mg/kg,
i.p.), respectively. LPS-mediated behavior impairments were assessed by OFT and EPM 2/24 h and
25 h, respectively, post-LPS or saline challenge. Animals were continuously monitored for 26 h. At the
end of the above behavioral test, the mice were sacrificed and the target organs were harvested.
4.9. Behavioral Testing
The Open Field Test (OFT)—The OFT was performed in an opaque white plastic box (46.5 × 50.5
× 50.5 cm) and illuminated from overhead (an average of 30 lux). The central zone was defined as the
23.25 × 25.25 cm interior portion of the box. Mice were gently and individually placed in the center
of the apparatus and allowed to explore for 5 min. The test period was recorded by a video camera
located above the center of the apparatus. Between trials, the box was cleaned with 75% ethanol.
Exploratory locomotor activity (eLMA) was used to reflect acute sickness behavior and was measured
as the total distance traveled by each mouse in the box. The anxiety-like phenotype of an individual
mouse’s behavior was assessed by measuring the percentage of time spent in the central or peripheral
area of the box [45]. All of the variables were analyzed using Ethovision XT 11 tracking software
(Noldus, Leesburg, VA, USA).
The Elevated Zero Maze test (EZM test)—The maze was constructed of opaque white plastic in
a circular track 5 cm wide, 68 cm in diameter, elevated 51 cm from the floor, and illuminated from
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overhead (average 30 lux). The maze was divided into four quadrants of equal length with two
opposing open quadrants and two opposing closed quadrants with white plastic walls 12 cm in height.
Mice were gently placed in the center in the center of a closed quadrant. An overhead video camera
recorded the location of the mice in a 5 min test period. The anxiety-like behavior was assessed by
measuring the percent time and entries in the open quadrants. The maze was cleaned with 75% ethanol
between mice. All of the variables were analyzed using Ethovision XT 11 tracking software (Noldus,
Leesburg, VA, USA).
4.10. Bronchoalveolar Lavage Fluid (BALF) and Lung Tissues Collection
At the end of the above behavioral test, the mice were sacrificed by an excess of anesthetic.
The chest was opened, a 20 Gauge blunt needle was inserted, and 0.8 mL of ice-cold sterile PBS was
dropped into the lungs through a tracheal incision. The recovered BALF was centrifuged at 500× g
for 10 min, the protein levels of the cell-free supernatant were quantified and used to evaluate the
pro-MMP-9 concentration by gelatin zymography [59]. The lung tissues were harvested immediately
after collection of BALF. Right lobes of the lung were fixed in 4% formalin and paraffin embedded
and stained with hematoxylin and eosin (HE). Whole digital images were obtained using virtual
microscopy (Aperio CS2 Leica Microsystems, Wetzlar, Germany). Tagged Image File Format (TIFF)
images extracted using image processing software (ImageScope, ver. 9.1.19.1567, Leica Microsystems).
Left lobes of lung were immediately frozen in liquid nitrogen, and 50 mg samples of frozen lung tissue
were subsequently homogenized with 2 mL Precellys homogenization tube containing three 1.4-mm
and three 2.8-mm ceramic beads (Bertin Technologies, Rockville, Maryland) with 7 volumes (7 mL/g
tissue) of homogenization buffer which containing 1× protease inhibitor (cat. NO 11 873, 580 001, Roche,
Mannheim, Germany). The samples were homogenized (Minilys®; Bertin Technologies, Rockville,
Maryland) twice at 5000 rpm for 30 s and then centrifuged at 5000× g for 5 min at 4 ◦C. The collected
supernatant was incubated at 4 ◦C for 30 min, then centrifuged at 12,000× g for 20 min and then stored
at −80 ◦ C before additional experiments.
4.11. Hippocampus Tissues Collection
The hippocampus tissue was harvested immediately after the lung tissues were preserved.
The hippocampus was quickly removed on an ice-cold metal plate, and was transferred into a 2 mL
Precellys homogenization tube containing three 1.4-mm ceramic beads (Bertin Technologies, Rockville,
MD, USA) with a homogenization buffer (7 mL/g tissue) which containing 1× protease inhibitor (cat.
NO 11 873, 580 001, Roche, Mannheim, Germany). The samples were homogenized (Minilys®; Bertin
Technologies, Rockville, MD, USA) twice at 5000 rpm for 15 s and then centrifuged at 5000× g for 5 min
at 4 ◦C. The collected supernatant was incubated at 4 ◦C for 30 min, then centrifuged at 12,000× g for
20 min and then stored at −80 ◦C before additional experiments.
4.12. Statistical Analyses
The experimental results are represented as the means ± S.D. for the number of observations.
Analysis of experiments was performed using one-way analysis of variance (ANOVA) followed by a
multiple comparison test (Student–Newman–Keuls test) via SigmaStat v3.5 software (SYSTAT Software,
San Jose, CA, USA). p < 0.05 was considered to indicate statistical significance.
5. Conclusions
These results indicated that HA strongly attenuated MMP-9, TNF-α, and IL-6 via regulating
the TLR4 downstream signaling pathways, including ERK-1/2, NF-κB, and STAT3. Our findings
demonstrated that the novel fungal sesquiterpene HA could provide new opportunities for the
development of different strategies on pro-inflammatory cytokines- and MMP-9-associated diseases,
such as endotoxemia.
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Abstract: Two new zoanthamine alkaloids, namely 3-acetoxynorzoanthamine (1) and 3-
acetoxyzoanthamine (2), have been isolated from the zoantharian Zoanthus cf. pulchellus collected off
the coast of the Santa Elena Peninsula, Ecuador, together with three known derivatives: zoanthamine,
norzoanthamine, and 3-hydroxynorzoanthamine. The chemical structures of 1 and 2 were determined
by interpretation of their 1D and 2D NMR data and comparison with literature data. This is the first
report of zoanthamine-type alkaloids from Zoanthus cf. pulchellus collected in the Tropical Eastern
Pacific. The neuroinflammatory activity of all the isolated compounds was evaluated in microglia
BV-2 cells and high inhibitory effects were observed in reactive oxygen species (ROS) and nitric oxide
(NO) generation.
Keywords: zoantharia; Tropical Eastern Pacific; Zoanthus pulchellus; zoanthamine; inflammation
1. Introduction
Zoanthamines are a bioactive family of marine alkaloids featuring a unique chemical architecture
of fused cycles culminating in an unusual azepane ring. They have been isolated essentially
from marine zoantharians, particularly from the genus Zoanthus. The first alkaloid of this group
was isolated in 1984 from an unidentified species of Zoanthus, collected off the coast of India by
Faulkner et al. [1]. Following this first description, several studies on the chemical diversity of
species of the genus Zoanthus have led to the discovery of additional zoanthamine-type alkaloids,
including zoanthenamine, zoanthenamide [2], norzoanthamine, oxyzoanthamine, norzoanthaminone,
cyclozoanthamine, epinorzoanthamine [3], zoanthaminone [4], zoaramine [5], kuroshines [6],
epioxyzoanthamine [7], zoanthenol [8], hydroxylated zoanthamines and norzoanthamines [9], and two
halogenated zoanthamines [10]. This interesting family of alkaloids has been structurally classified
in two different groups based on the presence of a methyl at C-19 (Type I) or its absence (Type II),
also called norzoanthamines [10]. Due to the structural complexity of these natural products, the first
Mar. Drugs 2018, 16, 242; doi:10.3390/md16070242 www.mdpi.com/journal/marinedrugs125
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total synthesis of norzoanthamine was accomplished by Miyashita et al. in 2004 [11], who also
synthesized other analogues [12,13]. Other research groups are now addressing this synthetic challenge
through alternative approaches [14–16]. Up to date, 38 zoanthamine-type alkaloids have been reported
from zoantharian species essentially inhabiting the Central Indo-Pacific and these polycyclic alkaloids
seem to be chemical markers of zoantharians from the genus Zoanthus. In addition, some members of
this family have displayed a wide range of biological activities against P388 murine leukemia cells [3]
as well as anti-osteoporosis, anti-inflammatory, and anti-bacterial activity, and have also been found to
inhibit human platelet aggregation [9,17]. The most promising therapeutic application is associated
with norzoanthamine in the treatment of osteoporosis, as it inhibits interleukin-6, a primary mediator
of bone resorption. Furthermore, an interesting study by Tachibana et al. suggested that the principal
function of norzoanthamine in Zoanthus sp. is collagen strengthening [18].
In our continuous investigation of the bio- and chemodiversity of marine invertebrates present
in the understudied Marine Protected Area El Pelado, Santa Elena, Ecuador, located in the Tropical
Eastern Pacific [19,20], we came across a massive substrate cover of the intertidal region by undescribed
fluorescent green zoantharians. A first taxonomic assessment of these zoantharian species led to the
identification of the main species as being closely related to Zoanthus cf. pulchellus, previously described
in the Caribbean [21]. No chemical study of this species has been reported so far, and our first chemical
screening by UHPLC-HRMS revealed unknown masses related to the zoanthamine family as major
compounds of the extract. In this paper, we describe the isolation and structure elucidation of two new
zoanthamine alkaloids, namely 3-acetoxynorzoanthamine (1) and 3-acetoxyzoanthamine (2) (Figure 1),
along with the known zoanthamine [1], norzoanthamine [3], and 3-hydroxynorzoanthamine [8] from
the Eastern Pacific zoantharian Zoanthus cf. pulchellus, as well as their biological activity in cellular
pathways related to oxidative stress and neuroinflammation.
Figure 1. Structures of 3-acetoxynorzoanthamine (1) and 3-acetoxyzoanthamine (2), isolated from
Zoanthus cf. pulchellus.
2. Results
Colonies of the zoantharian Zoanthus cf. pulchellus were collected by hand in the intertidal coast
of San Pedro, Santa Elena, Ecuador. The sample was freeze-dried and extracted with a mixture
of solvents CH3OH:CH2Cl2 (v/v; 1:1). The extract was then fractionated through reversed-phase
C18 Vacuum Liquid Chromatography (VLC) using a mixture of solvents of decreasing polarity.
The aqueous methanolic fractions were analyzed by UPLC-DAD-ELSD, combined, and then subjected
to semipreparative RP-HPLC using a C18 column to yield two new zoanthamine-type alkaloids:
3-acetoxynorzoanthamine (1) and 3-acetoxyzoanthamine (2), along with the known zoanthamine [1],
norzoanthamine [18], and 3-hydroxynorzoanthamine [8].
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Compound 1 was obtained as a brown amorphous powder and (+)-HRESIMS analyses revealed a
major molecular peak at m/z 540.2956 [M + H]+, consistent with the molecular formula C31H41NO7
for the neutral molecule. A preliminary inspection of the 1H and 13C NMR data revealed characteristic
signals of the zoanthamine family, as already speculated on the basis of the HRMS data: an olefinic
proton at δH 5.90 (H-16) along with four methyl singlets at δH 0.97 (H-28), 0.99 (H-25), 1.15 (H-29),
and 2.00 (H-27), and a methyl doublet at δH 0.87 (H-30) together with two ketone signals at δC 198.5
(C-17) and δC 209.0 (C-20), one ester signal at δC 172.3 (C-24), and two olefinic carbons at δC 125.6
(C-16) and 160.0 (C-15) (Table 1). The absence of a second doublet of a methyl present in zoanthamines
was indicative of a loss of the methyl CH3-26 at C-19; therefore, the compound belonged to the
norzoanthamine-type. Unlike most studies on norzoanthamines, in order to make the NMR table more
homogeneous, we decided to keep the numbering of the zoanthamines especially for the methyls 27,
28, 29, and 30. Comparing with analogues of this type, we observed the presence of an additional
methyl singlet signal at δH 2.11 corresponding to an acetyl moiety (Table 1). The presence of the
acetyl group on an oxygen at C-3 was evidenced by the deshielding of the signal corresponding to the
methine H-3 with δH 4.62 and key H-3/C-1′ and H3-2′/C-1′ HMBC correlations.
Table 1. 1H and 13C NMR data in ppm for compounds 1 and 2 in CDCl3 (500 MHz for 1H NMR and
125 MHz for 13C NMR data).
1 2





45.53.19, d (7.0) 3.20, d (7.0)
2 4.58, br d (6.5) 75.6 4.59, d (7.0) 75.7
3 4.62, br t (3.0) 72.5 4.63, t (3.0) 72.6
4 2.44, br sext (5.5) 26.0 2.43, br sext (6.0) 26.1
5
1.92, dd (12.0, 6.0)
40.3
1.95, dd (12.5, 6.0)
40.41.36, t (12.5) 1.37, t (13.0)
6 - 90.1 - 90.2
7
1.88, dd (12.5, 4.5)
29.8
1.90, dd (12.5, 4.5)
29.91.80, dt (12.5, 3.5) 1.80, dt (12.5, 3.5)
8
1.66, td (13.5, 3.5)
23.7
1.67, td (14.0, 3.5)
23.81.57, dt (13.5, 4.0) 1.57, dt (14.0, 4.0)
9 - 40.0 - 40.5





42.01.94, d (13.0) 1.93, d (13.0)
12 - 39.9 - 39.8





30.72.24, br s 2.22, br s
15 - 160.0 - 160.1
16 5.90, s 125.6 5.92, s 127.0
17 - 198.5 - 197.3
18 2.69, td (12.0, 6.5) 46.4 2.66, dd (12.5, 6.5) 48.2
19
2.62, dd (14.5, 6.5)
42.4 3.02, dq (7.0, 6.5) 45.92.50, dd (14.5, 12.0)
20 - 209.0 - 212.2
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Table 1. Cont.
1 2
No. δH, mult. (J in Hz) δC δH, mult. (J in Hz) δC
21 2.83, s 59.1 3.23, s 53.9





36.12.36, d (20.0) 2.37, d (20.0)
24 - 172.3 - 172.4
25 0.99, s 21.1 0.98, s 20.8
26 - - 1.17, d (7.0) 13.9
27 2.00, s 24.4 2.01, s 24.6
28 0.97, s 18.5 0.99, s 18.5
29 1.15, s 18.4 1.21, s 18.4
30 0.87, d (7.0) 16.3 0.89, d (7.0) 16.4
Ac - 171.2 - 171.4
2.11, s 21.1 2.14, s 21.2
We then addressed the question of the relative configurations of the different chiral centers.
To the best of our knowledge, this is the first occurrence of an acetoxy group at position C-3 for
zoanthamines; however, other analogues oxygenated at this position have already been described.
First, 3-hydroxynorzoanthamine was isolated from an undescribed species of Zoanthus from the Canary
Islands in the Atlantic Ocean [8]. Later, kuroshines C and F as well as 3β-hydroxyzoanthenamide also
possess an hydroxyl group at this position [6]. All these four derivatives were shown to have a hydroxyl
group on the β-side of the polycyclic compound and this position was deduced from nOes between
H-3 and other protons of the azepane ring. In our case, and because both H-3/H-4a and H-3/H-4b
coupling constant values were not fully conclusive, we relied on the key H-3/H-1b nOe correlation to
place H-3 on the opposite side of the bridged oxygen (α-side). Subsequently, the acetoxy group was
located on the β-side like for the other four 3-hydroxylated analogues. The very low coupling constant
values of H-3 with H-2 and H-4 were similar to those observed for all 3-hydroxylated compounds and
in perfect agreement with this relative configuration. Additionally, a previous study by Uemura et al.
assigned the absolute configuration of norzoanthamine as 2R, 4S, 6S, 9S, 10R, 12R, 13R, 18S, 21S,
and 22S and suggest the same absolute configuration for all norzoanthamine-type alkaloids [22].
In our case, the positive specific rotation obtained for 1 was in accordance with that obtained for
3-hydroxyzoanthamine and therefore confirmed the same absolute configuration [8].
Compound 2 was isolated as an amorphous yellowish powder and the molecular formula
C32H43NO7 was deduced from HRESIMS revealing a major peak at m/z 554.3115 [M + H]+;
therefore, 2 is an homologue of 1. A quick inspection of the 1H NMR spectrum evidenced the
presence of the acetoxy group at C-3 as in 1. An additional methyl signal at δH 1.17 (d, J = 7.0 Hz,
H3-26) suggested that 2 is a member of the zoanthamine-type alkaloids. The presence of the methyl at
C-19 was confirmed by the key H-19/C-26 and H3-26/C-18/C-19 HMBC correlations. The β-position
of the methyl 26 was then inferred from the coupling constant value JH-18/H-19 of 6.0 Hz, reminiscent of
an axial/equatorial coupling. Because H-18 is placed in an axial position, H-19 should be placed in
an equatorial position; therefore, the methyl 26 occupies the corresponding axial β-position at C-19.
The β-position of the acetoxy at C-3 was deduced from the same coupling constant values of H-3 as
for 1, and the absolute configuration was supposed to be the same as that of 1, again because of similar
positive specific rotations.
The compounds were tested for biological activity in the BV-2 microglia cell line, a cellular
model often used in neuroinflammation studies. The first step was to determine the effect of
compounds on cell viability. Five concentrations (from 0.001 to 10 μM) were investigated and after
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24 h of incubation no effects on cell viability were observed, which suggested non-toxic compounds.
Microglia-mediated inflammation is known to produce reactive oxygen species (ROS) and release
nitric oxide (NO), and thus induce oxidative damage [23]. Therefore, zoanthamines were checked as
modulators within these processes. BV-2 cells were activated with lipolysaccharide (LPS) to simulate
neuroinflammatory conditions. As shown in Figure 2, when cells were pre-treated with the same
concentrations of compounds for 1 h and then incubated for 24 h with LPS (500 ng/mL), a significant
reduction in ROS production was observed. As expected, the stimulation of BV-2 cells with LPS
significantly increased the ROS production, 50% (p < 0.001), while the compounds alone did not induce
any effect. However, when cells were pre-treated with norzoanthamine and 1, a dose-dependent
inhibitory effect was observed, while 3-hydroxynorzoanthamine, zoanthamine, or 2 were effective
at all concentrations tested, with 2 being the most potent ROS inhibitor. From these results, 0.1 and
1 μM were chosen to investigate the effect on NO release (Figure 3). Zoanthamine alkaloids alone
did not produce any effect on NO production, while LPS treatment increased it by three times. In the
presence of this family of compounds, NO release was significantly inhibited. The anti-inflammatory
effect of zoanthamines was previously investigated in neutrophils [10]. From our results in the
BV-2 cellular model, zoanthamine and derivatives show effective properties as protective drugs in
neuroinflammation processes.
 
Figure 2. Effect of zoanthamines on intracellular reactive oxygen species (ROS) production in microglia
BV-2 cell line. Cells were pre-treated with 3-hydroxynorzoanthamine (A); norzoanthamine (B);
zoanthamine (C); 1 (D); and 2 (E) at different concentrations (0.001, 0.01, 0.1, 1, and 10 μM) 1 h
and then stimulated with lipolysaccharide (LPS) (1 μg/mL) for 24 h. ROS production is presented as a
percentage of cells control, being the result of mean fluorescence intensity ± SEM of three independent
experiments. The values are shown as the difference between cells treated with LPS alone versus cells
treated with zoanthamines in presence of LPS by ANOVA followed by post hoc Dunnett’s test. * p < 0.05
and ** p < 0.01, and LPS-treated cells versus control cells ### p < 0.001.
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Figure 3. Effect of zoanthamines on nitric oxide (NO) production in BV-2 microglia cell line. Cells were
pre-treated with 3-hydroxynorzoanthamine (3-HNZ), norzoanthamine (NZ), zoanthamine (Z), 1, and 2
(0.1 or 1 μM) for 1 h and then stimulated with lipolysaccharide (LPS) (500 ng/mL) for 24 h. The values
are presented in percentage of cells control, being the result of mean ± SEM of a minimum of three
independent experiments. The cells treated only with LPS were compared to cells treated with
compounds in presence of LPS by ANOVA followed by post hoc Dunnett’s test. * p < 0.05 and ** p < 0.01,
and LPS-treated cells versus control cells ### p < 0.001.
3. Discussion
The isolation of two 3-acetoxy derivatives of zoanthamine and norzoanthamine in Zoanthus cf. pulchellus
strengthens the hypothesis that zoanthamines are markers of the genus Zoanthus. However, another species
identified as Zoanthus cf. sociatus was found in the same area and did not present any zoanthamine
derivatives [21]. Nevertheless, even if these compounds should not be considered as taxonomic
markers of the genus Zoanthus, they are clear and characteristic features of some species of Zoanthus
and could facilitate a more precise classification of this group.
Interestingly, we first ran the NMR analyses of 1 in a different solvent, CD3OD, and observed clear
changes for the signals surrounding the nitrogen atom. Especially, the signals corresponding to H-11
disappeared. This observation reinforced the conclusions on zoanthamine analogues reached by the
group of Norte [8]. In a highly polar and protic solvent, the opening of the lactone ring would give rise
to an iminium ion at C-11 in equilibrium with its enamine base that can be trapped by exchangeable
deuterium atoms provided by the protic deuterated solvent. This behavior signals the high reactivity
of this family of compounds at this particular position.
Because these compounds were isolated after a purification step involving acetic acid in the eluent
of the HPLC, we wanted to ascertain the presence of these compounds in the collected specimen.
For this purpose, we inspected the chemical profiles obtained before any contact with acetic acid and
were able to observe the masses corresponding to the new compounds 1 and 2. These analyses rule
out the possibility of a transformation during the purification process.
Finally, the activity observed for all compounds highlights the potential of zoanthamine
derivatives as new ROS and NO modulators in neuronal processes, and we will continue our efforts in
the study of their mode of action in neuroinflammatory related diseases.
4. Materials and Methods
4.1. General Experimental Procedures
Optical rotation measurements were obtained at the sodium D line (589.3 nm) with a 10-cm cell at
20 ◦C on a UniPol L1000 polarimeter (Schmidt + Haensch, Berlin, Germany). The UV measurements were
obtained on a Cary 300 UV-Visible spectrophotometer (Agilent, Santa-Clara, CA, USA). NMR spectra
were recorded on a Inova 500 MHz spectrometer (500 and 125 MHz for 1H and 13C, respectively)
(Varian, Palo Alto, CA, USA), and signals were referenced in ppm to the residual solvent signals
(CDCl3, at δH 7.26 and δC 77.16 ppm). HRESIMS data were obtained with a UHPLC-qTOF 6540 mass
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spectrometer (Agilent, Santa Clara, CA, USA). Purification was carried out on a HPLC equipped with
a PU4087 pump (JASCO, Tokyo, Japan) and a UV4070 UV/Vis detector (JASCO, UV, Tokyo, Japan).
4.2. Biological Material
Specimens of Zoanthus cf. pulchellus were collected by hand on rocks of the shoreline of San Pedro
located in the Santa Elena Peninsula, Ecuador. A sample with a voucher 161125SP-01 is stored at
CENAIM-ESPOL (San Pedro, Santa Elena, Ecuador). This species has been previously identified using
morphological and molecular data [21].
4.3. Extraction and Isolation
The freeze-dried sample of Z. cf. pulchellus (200 g) was extracted with a mixture of solvents
DCM/MeOH (1:1) three times (500 mL) at room temperature. The collected extract was concentrated
under reduced pressure to obtain the extract (10 g). The extract was subjected to C18 reversed-phase
VLC (LiChroprep® (Merck KGaA, Darmstadt, Germany) RP-18, 40–63 μm, 1:25 ratio for the weight
of C18 used, funnel of 10 cm × 10 cm) using a mixture of solvents of decreasing polarity (1) H2O;
(2) H2O/MeOH (1:1); (3) H2O/MeOH (1:3); (4) MeOH; (5) MeOH/DCM (3:1); (6) MeOH/DCM (1:1);
and (7) DCM using 500 mL of each solvent. The aqueous-methanolic fraction F3 was purified by
reversed-phase HPLC (Ultra AQ C18, 10 × 250 mm, 5 μm) using an isocratic method CH3CN:H2O:Acetic
acid (30:70:0.1) as a mobile phase with a flow rate of 3 mL/min with detection at λ 254 nm for
20 min yielding compound 1 (52.7 mg) and the known compounds norzoanthamine (6.3 mg) [3]
and zoanthamine (6.6 mg) [1]. The methanolic fraction F4 was purified by reversed-phase HPLC
(Ultra AQ C18, 10 × 250 mm, 5 μm) using the following mobile phases: (A) CH3CN/Acetic acid 0.1%;
(B) H2O/Acetic acid 0.1%; starting with an isocratic 0–25 min with A 22, B 78; linear gradient for
25–30 min until A 100; then isocratic for 30–60 min at a flow rate of 3 mL/min with UV detection at
λ 254 nm to yield compounds 2 (12.3 mg) and the known 3-hydroxynorzoanthamine (2.7 mg) [8].
4.4. 3-Acetoxynorzoanthamine (1)
Amorphous yellow powder; [α]20D +10 (c 0.45, CH3OH); UV (CH3OH) λmax (log ε) 237 (4.1) nm;
1H NMR and 13C NMR data see Table 1; HRESIMS (+) m/z [M + H]+ 540.2956 (calc. for C31H42NO7
540.2956Δ + 0.0 ppm) (Spectra in the Supplementary Materials).
4.5. 3-Acetoxyzoanthamine (2)
Amorphous yellowish powder; [α]20D + 6.7 (c 0.12, CH3OH); UV (CH3OH) λmax (log ε) 238 (4.0) nm;
1H NMR and 13C NMR data see Table 1; HRESIMS (+) m/z [M + H]+ 554.3115 (calc. for C32H44NO7
554.3112Δ + 0.5 ppm) (Spectra in the Supplementary Materials).
4.6. Biological Assays
4.6.1. Cell Culture
The microglia BV-2 cell line was obtained from InterLab Cell Line Collection (ICLC) (Genova,
Italy), number ATL03001. Cells were maintained in Roswell Park Memorial Institute Medium (RPMI)
supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/mL), and 100 μg/mL streptomycin
at 37 ◦C in a humidified atmosphere of 5% CO2 and 95% air. Cells were dissociated twice a week using
0.05% trypsin/EDTA.
4.6.2. Cell Viability
The 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to
analyzed cell viability as previously described [24]. Briefly, the microglia BV-2 cell line was grown
in a 96-well plate at a density of 4 × 104 cells per well. Cells were exposed to different compounds
concentration (0.001, 0.01, 0.1, 1 and 10 μM) for 24 h. Then, cells were rinsed and incubated with
131
Mar. Drugs 2018, 16, 242
MTT (500 μg/mL) diluted in a saline buffer for 1 h at 37 ◦C. The resulting formazan crystals were
dissolved with 5% sodium dodecyl sulfate, (SDS) and the absorbance values were obtained using
a spectrophotometer plate reader (595 nm). Saponin was used for cellular death control and its
absorbance was substrate from the other data.
4.6.3. Measurement of Intracellular ROS Production
The intracellular ROS levels in microglia activation were performed using 7′,2′-dichlorofluorescein
diacetate (DCFH-DA), as previously described [25]. Cells were pre-treated with different compounds
concentration (0.001, 0.01, 0.1, 1, and 10 μM) 1 h prior to the stimulation with LPS (500 ng/mL)
for 24 h. Afterwards, cells were rinsed twice with saline solution and incubated 1 h at 37 ◦C
with 20 μM DCFH-DA. Then, cells were washed and kept in saline solution for 30 min at 37 ◦C.
Intracellular production of ROS was measured by fluorescence detection of dichlorofluorescein (DCF)
as the oxidized product of DCFH-DA on a spectrophotometer plate reader (495 nm excitation and
527 nm emission).
4.6.4. NO Determination
The NO concentration in the culture media was established by measuring nitrite formed by the
oxidation of NO, using the Griess reagent kit, according to manufacturer instructions. The detection
limit of this method is 1 μM. Briefly, microglia cells were seeded in a 12-well plate at a density of
1 × 106 cells per well and pre-incubated with compounds (0.1 and 1 μM) for 1 h and then stimulated
with LPS (500 ng/mL) for 24 h. Thereafter, the following were mixed in a microplate: 150 μL of
cells supernatant, 130 μL of deionized water, and 20 μL of Griess Reagent, which was incubated for
30 min at room temperature. The absorbance was measured on a spectrophotometer plate reader at a
wavelength of 548 nm.
4.6.5. Statistical Analysis
Results were expressed as mean ± SEM of a minimum of three experiments, repeated twice or
three times. Comparisons were performed using Student’s t-test or one-way ANOVA with Dunnett’s
post hoc analysis. p values < 0.05 were considered statistically significant.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/16/7/242/
s1/: HRMS and NMR data for compounds 1 and 2.
Author Contributions: Methodology and Formal Analysis, P.O.G., S.G., K.B.J., K.C.; Validation, E.A., A.A., K.C.;
Writing—Original Draft Preparation, P.O.G.; Writing—Review & Editing, A.A., O.P.T.; Supervision, E.A., O.P.T.;
Project Administration, J.R., O.P.T.; Funding Acquisition, J.R., L.M.B., O.P.T.
Funding: The project is originally funded by the Secretaria de Educación Superior, Ciencia, Tecnología e
Innovación (SENESCYT) in the framework of the PIC-14-CENAIM-001 Project Caracterización de la Biodiversidad
Microbiológica y de Invertebrados de la Reserva Marina “El Pelado” a Escala Taxonómica, Metabolómica y
Metagenómica para su Uso en Salud Humana y Animal. Part of this project (Grant-Aid Agreement No.
PBA/MB/16/01) is carried out with the support of the Marine Institute and is funded under the Marine
Research Programme by the Irish Government. P.O.G. and K.B.J. acknowledge NUI Galway for supporting
part of their Ph.D. scholarship. The research leading to the results of the biological assays has received funding
from the following FEDER cofunded-grants: Consellería de Cultura, Educación e Ordenación Universitaria,
Xunta de Galicia, 2017 GRC GI-1682 (ED431C 2017/01); CDTI and Technological Funds, supported by
Ministerio de Economía, Industria y Competitividad, AGL2014-58210-R, AGL2016-78728-R (AEI/FEDER, UE),
ISCIII/PI16/01830 and RTC-2016-5507-2, ITC-20161072; European Union POCTEP 0161-Nanoeaters-1-E-1,
Interreg AlertoxNet EAPA-317-2016, and H2020 778069-EMERTOX.
Acknowledgments: We acknowledge the support of Cristobal Dominguez (CENAIM-ESPOL, Ecuador) in the
collection of the sample and Frederic Sinniger (University of the Ryukyus, Japan) for his help with the taxonomic
identification of this species through the training of K.B.J.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to
publish the results.
132
Mar. Drugs 2018, 16, 242
References
1. Rao, C.B.; Anjaneyula, A.S.R.; Sarma, S.S.; Venkatateswarlu, Y.; Chen, M.; Clardy, J.; Rosser, R.; Faulkner, J.
Zoanthamine: A novel alkaloid from a marine zoanthid. J. Am. Chem. Soc. 1984, 106, 7984–7985. [CrossRef]
2. Rao, C.B.; Anjaneyulu, A.S.R.; Sarma, N.S.; Venkateswarlu, Y.; Rosser, R.M.; Faulkner, J. Alkaloids from a
marine zoanthid. J. Org. Chem. 1985, 50, 3757–3760. [CrossRef]
3. Fukuzawa, S.; Hayashi, Y.; Uemura, D.; Nagatsu, A.; Yamada, K.; Ijuin, Y. The isolation and structures of five
new alkaloids, norzoanthamine, oxyzoanthamine, norzoanthamine, cyclozoanthamine and epinorzoanthamine.
Heterocycl. Commun. 1995, 1, 207–214. [CrossRef]
4. Atta-ur-Rahman; Alvi, K.A.; Abbas, S.A.; Choudhary, M.I.; Clardy, J. Zoanthaminone, a new alkaloid from a
marine zoanthid. Tetrahedron Lett. 1989, 30, 6825–6828. [CrossRef]
5. Cen-Pacheco, F.; Norte, M.; Fernández, J.J.; Daranas, A.H. Zoaramine, a zoanthamine-like alkaloid with a
new skeleton. Org. Lett. 2014, 16, 2880–2883. [CrossRef] [PubMed]
6. Cheng, Y.-B.; Lo, I.-W.; Shyur, L.-F.; Yang, C.-C.; Hsu, Y.-M.; Su, J.-H.; Lu, M.-C.; Chiou, S.-F.; Lan, C.-C.;
Wu, Y.-C.; et al. New alkaloids from Formosan zoanthid Zoanthus kuroshio. Tetrahedron 2015, 71, 8001–8006.
[CrossRef]
7. Daranas, A.H.; Fernández, J.J.; Gavin, J.A.; Norte, M. Epioxyzoanthamine, a new zoanthamine-type alkaloid
and the unusual deuterium exchange in this series. Tetrahedron 1998, 54, 7891–7896. [CrossRef]
8. Daranas, A.H.; Fernandez, J.J.; Gavin, J.A.; Norte, M. New alkaloids from a marine zoanthid. Tetrahedron
1999, 55, 5539–5546. [CrossRef]
9. Behenna, D.C.; Stockdill, J.L.; Stoltz, B.M. The biology and chemistry of the zoanthamine alkaloids. Angew. Chem.
Int. Ed. 2008, 47, 2365–2386. [CrossRef] [PubMed]
10. Hsu, Y.-M.; Chang, F.-R.; Lo, I.W.; Lai, K.-H.; El-Shazly, M.; Wu, T.-Y.; Du, Y.-C.; Hwang, T.-L.; Cheng, Y.-B.;
Wu, Y.-C. Zoanthamine-type alkaloids from the zoanthid Zoanthus kuroshio collected in Taiwan and their
effects on inflammation. J. Nat. Prod. 2016, 79, 2674–2680. [CrossRef] [PubMed]
11. Miyashita, M.; Sasaki, M.; Hattori, I.; Sakai, M.; Tanino, K. Total synthesis of norzoanthamine. Science 2004, 305,
495–499. [CrossRef] [PubMed]
12. Takahashi, Y.; Yoshimura, F.; Tanino, K.; Miyashita, M. Total synthesis of zoanthenol. Angew. Chem. Int. Ed.
2009, 48, 8905–8908. [CrossRef] [PubMed]
13. Yoshimura, F.; Sasaki, M.; Hattori, I.; Komatsu, K.; Sakai, M.; Tanino, K.; Miyashita, M. Synthetic studies of
the zoanthamine alkaloids: The total syntheses of norzoanthamine and zoanthamine. Chem. Eur. J. 2009, 15,
6626–6644. [CrossRef] [PubMed]
14. Yoshimura, F.; Tanino, K.; Miyashita, M. Total synthesis of zoanthamine alkaloids. Acc. Chem. Res. 2012, 45,
746–755. [CrossRef] [PubMed]
15. Fischer, D.; Nguyen, T.X.; Trzoss, L.; Dakanali, M.; Theodorakis, E.A. Intramolecular cyclization strategies
toward the synthesis of zoanthamine alkaloids. Tetrahedron Lett. 2011, 52, 4920–4923. [CrossRef] [PubMed]
16. Nakajima, T.; Yamashita, D.; Suzuki, K.; Nakazaki, A.; Suzuki, T.; Kobayashi, S. Different modes of cyclization
in zoanthamine alkaloid system, bisaminal versus spiroketal formation. Org. Lett. 2011, 13, 2980–2983.
[CrossRef] [PubMed]
17. Villar, R.M.; Gil-Longo, J.; Daranas, A.H.; Souto, M.L.; Fernández, J.J.; Peixinho, S.; Barral, M.A.; Santafé, G.;
Rodríguez, J.; Jiménez, C. Evaluation of the effect of several zoanthamine-type alkaloids on the aggregation
of human platelets. Bioorg. Med. Chem. 2003, 11, 2301–2306. [CrossRef]
18. Genji, T.; Fukuzawa, S.; Tachibana, K. Distribution and possible function of the marine alkaloid, norzoanthamine,
in the zoanthid Zoanthus sp. using MALDI imaging mass spectrometry. Mar. Biotechnol. 2010, 81–87. [CrossRef]
[PubMed]
19. Guillen, P.O.; Calabro, K.; Jaramillo, K.B.; Dominguez, C.; Genta-Jouve, G.; Rodriguez, J.; Thomas, O.P.
Ecdysonelactones, ecdysteroids from the Tropical Eastern Pacific zoantharian Antipathozoanthus hickmani.
Mar. Drugs 2018, 16, 58. [CrossRef] [PubMed]
20. Guillen, P.O.; Jaramillo, K.B.; Genta-Jouve, G.; Sinniger, F.; Rodriguez, J.; Thomas, O.P. Terrazoanthines,
2-aminoimidazole alkaloids from the Tropical Eastern Pacific zoantharian Terrazoanthus onoi. Org. Lett. 2017, 19,
1558–1561. [CrossRef] [PubMed]
133
Mar. Drugs 2018, 16, 242
21. Jaramillo, K.B.; Reverter, M.; Guillen, P.O.; McCormack, G.; Rodriguez, J.; Sinniger, F.; Thomas, O.P. Assessing
the zoantharian diversity of the Tropical Eastern Pacific through an integrative approach. Sci. Rep. 2018, 8,
7138. [CrossRef] [PubMed]
22. Kuramoto, M.; Hayashi, K.; Fujitani, Y.; Yamaguchi, K.; Tsuji, T.; Yamada, K.; Ijuin, Y.; Uemura, D. Absolute
configuration of norzoanthamine, a promising candidate for an osteoporotic drug. Tetrahedron Lett. 1997, 38,
5683–5686. [CrossRef]
23. Dumont, M.; Beal, M.F. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic. Biol. Med.
2011, 51, 1014–1026. [CrossRef] [PubMed]
24. Sanchez, J.A.; Alfonso, A.; Leiros, M.; Alonso, E.; Rateb, M.E.; Jaspars, M.; Houssen, W.E.; Ebel, R.; Tabudravu, J.;
Botana, L.M. Identification of Spongionella compounds as cyclosporine A mimics. Pharmacol. Res. 2016, 107,
407–414. [CrossRef] [PubMed]
25. Leiros, M.; Alonso, E.; Rateb, M.E.; Houssen, W.E.; Ebel, R.; Jaspars, M.; Alfonso, A.; Botana, L.M. Gracilins:
Spongionella-derived promising compounds for Alzheimer disease. Neuropharmacology 2015, 93, 285–293.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Anti-Inflammatory Effects of a Mytilus coruscus
α-D-Glucan (MP-A) in Activated Macrophage Cells
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Abstract: The hard-shelled mussel (Mytilus coruscus) has been used as Chinese traditional medicine
for thousands of years; however, to date the ingredients responsible for the various beneficial health
outcomes attributed to Mytilus coruscus are still unclear. An α-D-Glucan, called MP-A, was isolated
from Mytilus coruscus, and observed to exert anti-inflammatory activity in THP-1 human macrophage
cells. Specifically, we showed that MP-A treatment inhibited the production of inflammatory
markers, including TNF-α, NO, and PGE2, inducible NOS (iNOS), and cyclooxygenase-2 (COX-2), in
LPS-activated THP-1 cells. It was also shown to enhance phagocytosis in the analyzed cells, but to
severely inhibit the phosphorylation of mitogen-activated protein kinases (MAPKs) and the nuclear
translocation of NF-κB P65. Finally, MP-A was found to exhibit a high binding affinity for the cell
surface receptor TLR4, but a low affinity for TLR2 and dectin-1, via surface plasmon resonance (SPR)
analysis. The study indicates that MP-A suppresses LPS-induced TNF-α, NO and PEG2 production
via TLR4/NF-κB/MAPK pathway inhibition, and suggests that MP-A may be a promising therapeutic
candidate for diseases associated with TNF-α, NO, and/or PEG2 overproduction.
Keywords: THP-1 macrophages; anti-inflammatory; TLR4; NF-κB; MAPK; SPR analysis
1. Introduction
The hard-shelled mussel (Mytilus coruscus) is one of the main species of marine shellfish inhabiting
broad regions of East Asian coastal areas, and has been used as both a food and medicine for thousands
of years [1]. Many health benefits have been attributed to its use as a Chinese traditional medicine,
including the nourishment of the liver and kidneys, the strengthening of the immune system, and
the treatment of various diseases, such as goiter tumors, male impotence, and female menoxenia.
In recent years, some biologically active polysaccharides [1], peptides [2,3], and lipid extracts [4]
have been isolated from Mytilus coruscus, and evaluated to determine their pharmacological efficacy;
nevertheless, to date, the ingredients responsible for the various beneficial health outcomes attributed
to Mytilus coruscus are still unclear.
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Polysaccharides isolated from natural sources can affect a variety of biological activities, such as
immunity, suggesting their potential use as immunomodulatory agents with broad applications [5,6].
For example, a glycogen polysaccharide extracted from Perna canaliculus has been shown to exert
anti-inflammatory activities [7], and similarly, a heparin-like substance isolated from the marine clams
Anomalocardia brasiliana, has been shown to bind anti-thrombin III (ATIII) and to thereby exert a strong
anticoagulant effect [8].
Various polysaccharides isolated from the hard-shelled mussel have received increasing attention
in recent years. For example, the MP-1 polysaccharide from Mytilus coruscus has been demonstrated to
exert a protective effect against acute liver injury [1], and the MEP polysaccharide from Mytihus edulis
Linnaeus has been shown to both significantly ameliorate delayed-type hypersensitivity and
phagocytosis, and to improve immune function in mice [9]. In our previous studies, we isolated
the MA polysaccharide from Mytilus coruscus, and identified it to have anti-hyperlipidemic effects on
experimental atherosclerosis in rabbits [10]. In the present study, we isolated a high-molecular-weight
α-D-Glucan, named MP-A, from the hard-shelled mussel (Mytilus coruscus). We identified MP-A to
contain repeating units of D-glucose, and to be structured such that the main chain was connected by
α1-4 glucosidic bonds, and that a D-glucose was connected to this chain every twelve monosaccharides
by α1-2 glucosidic bonds to form a branch. The molecular weight of MP-A was established to be
approximately 1.2 × 103 kDa, and the structure was shown in Figure 1A.
Figure 1. MP-A structure and effects of MP-A on cell viability and nitric oxide (NO) production of
THP-1 cells with and without lipopolysaccharide (LPS) treatment. (A) MP-A structure; (B) Effects of 24,
48, and 72 h of MP-A and/or LPS treatment on THP-1 cell cytotoxicity. * p < 0.05 as compared to the
control group (n = 3); (C) Effect of MP-A treatment on NO production in THP-1 cells with or without
LPS. NO production was inferred from the level of nitrite formed in the supernatant, as detected using
the Griess reagent. The absorbance of treated cells at 540 nm was measured against distilled water
using the Griess reagent as a blank, and sodium nitrite as a standard sample. ** p < 0.01, *** p < 0.001,
and **** p < 0.0001 compared with 1 μg/mL LPS treatment group (n = 3).
Glucans have been previously reported to exhibit significant bioactivity, and in particular,
β-Glucans were extensively investigated between 1990 and 2000. These previous studies showed
β-Glucans to exert anti-infective and anti-tumorigenic activity via the activation of leukocytes [11–13],
and the production of reactive oxygen intermediates, inflammatory mediators such as NO, and
TNF-α [11,14,15]. More recently, the α-glucans have begun to attract the attention of various research
groups. For example, the α-glucan YCP, which is composed of α-D-(1–4)-linked glucose residues,
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has been recently revealed to inhibit tumor growth by modulating the innate and adaptive host
immune responses to enhance macrophage activity, promote lymphocyte proliferation, and to induce
cytokine secretion [16]. Similarly, six homogeneous, low-molecular-weight α-glucans (LMWYCP-1
to LMWYCP-6) have been shown to modulate the activity of toll-like receptors (TLRs), and thus,
B lymphocytes [17].
Macrophages play a unique role in the immune system, in that they do not only elicit an innate
immune response, but also are effector cells that counteract inflammation and infection. Furthermore,
they are also critical to the maintenance of a functional interface between no-adaptive and adaptive
immunity, and mediate various other functions, such as antigen processing and presentation to T cells.
THP-1 is a human leukemia monocytic cell line that has been widely used to study
monocyte/macrophage function, signaling pathway mechanisms, and drug transport, and is
commonly used to investigate the regulation of macrophage activity [18]. Lipopolysaccharide (LPS) is
a major component of the outer membrane of gram-negative enteric bacteria [19]. During inflammatory
processes, LPS induces the production of pro-inflammatory cytokines and small mediators, such as
nitric oxide (NO), and PGE2 [20]. LPS-stimulated THP-1 macrophages have been shown to express the
MD2, CD14, and MyD88 genes that are required for LPS signaling in vivo [18]. When macrophages
are activated by LPS, the TLR4 signaling pathway is initiated, leading to the phosphorylation of
mitogen-activated protein kinase (MAPK), and the activation of the transcription factor nuclear
factor-kappa B (NF-κB) [21], and the induction of pro-inflammatory factors including NO, inducible
nitric oxide synthase (iNOS), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor (TNF)-α,
and cyclooxygenase-2 (COX-2), etc. The MAPK family of proteins, including extracellular signal
regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, regulate inflammatory and immune
responses, and their respective signaling essential for LPS-induced iNOS and COX-2 expression in
macrophages [22,23].
In the present study, LPS-induced THP-1 cells were used as an inflammatory model to investigate
the effects of MP-A immunomodulation of THP-1 macrophages. To identify possible cell membrane
receptors for MP-A, and putative molecular mechanisms underlying MP-A immunomodulation
of THP-1 macrophages, the binding affinity of MP-A for TLR4 and/or TLR2 was assessed using
surface plasmon resonance (SPR). To our knowledge, limited publications currently report on the
immunomodulatory effects of combined treatment with LPS with MP-A. Thus, in the present study,
we investigated the effects of MP-A on LPS-induced pro-inflammatory cytokine secretion by THP-1
cells, and on LPS-induced signal transduction.
2. Materials and Methods
2.1. Reagents and Antibodies
MP-A (purity 97.9% w/w) was produced and purified by Shandong Academy of Pharmaceutical
Science (Jinan, China), and verified to have an average molecular weight (Mw) of 1200 kDa via a
size exclusion chromatography multi-angle laser scattering (SEC-MALLS) system (Wyatt Technology
Corp, Santa Barbara, CA, USA), the preparation and structural characterization of MP-A has been
introduced in other paper. LPS from Escherichia coli O55:B5, phorbol-12-myristate-13-acetate (PMA),
and FITC-dextran (FD40S) were purchased from Sigma–Aldrich Chemical Co. (St. Louis, MO, USA)
and the average MW of Dextran was 40,000 Da. Recombinant human Dectin-1, TLR4, and TLR2
were purchased from R&D Systems (Minneapolis, MN, USA). Fetal bovine serum (FBS), and other
cell culture reagents were purchased from Gibco BRL Co. (Grand Island, NY, USA). The Cell
Counting Kit-8 (CCK-8) Assay Kit was obtained from Beyotime (Wuhan, China). Penicillin and
streptomycin were purchased from HyClone (Logan, UT, USA). ELISA kits for PGE2, and TNF-α were
purchased from Biolegend (San Diego, CA, USA). The p-p38, p38, p-JNK1/2, JNK1/2, p-ERK1/2,
ERK1/2, p-P65, P65, COX-2, and iNOS antibodies were obtained from Abcam (Cambridge, UK).
The β-actin monoclonal antibodies were obtained from Cell Signaling Technology (Beverly, MA,
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USA). NF-κB Activation-Nuclear Translocation Assay kits were purchased from Beyotime Institute of
Biotechnology (Haimen, China). All of the other chemicals were of analytical grade. The horseradish
peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary antibody was purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA).
2.2. THP-1 Cell Culture
THP-1, a human leukemia monocytic cell line extensively used to study the modulation of
monocytes and macrophages, was purchased from the Shanghai Cell Bank, the Institute of Cell Biology,
China Academy of Sciences (Shanghai, China). THP-1 cells in the monocyte state can be differentiated
into a macrophage-like phenotype via stimulation with phorbol-12-myristate-13-acetate (PMA)
(50 ng/mL, 24 h). The cells were cultivated in RPMI 1640 medium (containing 10% heat-inactivated
FBS, and 1% penicillin/streptomycin), at 37 ◦C in a humidified atmosphere (5% CO2, 95% air).
2.3. Cell Viability Assay
The viability of THP-1 cells was determined using the Cell Counting Kit-8 (CCK-8) Assay Kit
(Beyotime, Wuhan, China). The cells were primed for differentiation with 50 ng/mL PMA for 24 h [24],
and then seeded on 96-well plates at a density of 5 × 104 cells/mL, in 100 μL medium, and left
to incubate overnight. They were then treated with MP-A (10, 50, 100, or 200 μg/mL dissolved in
serum-free medium), and/or LPS (1 μg/mL dissolved in serum-free medium) for 24, 48, or 72 h (37 ◦C,
5% CO2). CCK-8 (10 μL) was added to each well 4 h prior to culture termination, and the optical
density of each well was measured (450 nm) using a microplate reader (Infinite M200 PRO, TECAN,
Männedorf, Switzerland).
2.4. Determination of Phagocytic Uptake of FITC-Labeled Dextran
The cells were primed for differentiation with 50 ng/mL PMA for 24 h [24], and then seeded
on 24-well plates at a density of 5 × 104 cells/mL in 1 mL medium and left to incubate overnight.
They were then treated with MP-A (10, 100 or 200 μg/mL dissolved in serum-free medium), and/or LPS
(1 μg/mL dissolved in serum-free medium) for 24 h. Then THP-1 cells were collected, resuspended, and
incubated in 100 μL FITC-labeled dextran (1 mg/mL, 37 ◦C, 30 min). Cells incubated with FITC-labeled
dextran only (4 ◦C, 30 min) were used as a control and cells incubated without FITC-labeled dextran
were used as a blank control. After incubation, ice-cold PBS (2 mL, containing 2% FBS) was added to
the cells to inhibit phagocytosis, and they were then washed three times (ice-cold PBS). Cellular uptake
of FITC-labeled dextran was analyzed by flow cytometry (BD FACSAria ™ III).
2.5. ELISA for Cytokine Estimation
TNF-α and PGE2 were measured by using a commercial ELISA kit according to the
manufacturers’ instructions. THP-1 cells were primed with PMA and seeded in a 96-well plate (density
1 × 106 cells/mL), and cultured overnight. They were then treated first with MP-A (10, 50, 100, or
200 μg/mL, 1 h), and secondly with LPS (1 μg/mL, 6 or 24 h to enable the measurement of TNF-α or
PGE2, respectively. Cell-free supernatants were finally collected and analyzed to measure the levels of
both cytokines.
2.6. Nitric Oxide (NO) Production
The total nitrite content in the cell culture supernatant was measured using the Griess reagent.
An equal volume of Griess reagent was added to the respective samples, and they were then incubated
(30 min, 37 ◦C). The nitrite concentration was estimated by measuring the absorbance of samples at
545 and 630 nm (wavelength correction) against a sodium nitrite standard using an ELISA plate reader
(Infinite M200 PRO, TECAN, Männedorf, Switzerland).
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2.7. Western Blot Analyses
THP-1 cells were primed with PMA, seeded in a 100-mm culture dish (density 1 × 106 cells/mL),
cultured overnight, and then treated with MP-A (10, 50, 100, or 200 μg/mL) and LPS (1 μg/mL),
and the cells were then incubated (37 ◦C) for 24 h. Cytosolic proteins were isolated using the
Cytosol Fractionation Kit, according to the manufacturer's instructions. Total protein was measured
by the bicinchoninic acid assay (BCA assay), and proteins were separated by SDS-PAGE and
electro-transferred onto a polyvinylidene difluoride (PVDF) membrane. The PVDF membrane blots
were blocked (1 h) using 8% non-fat powdered milk in TBST buffer, and then incubated overnight at
4 ◦C with appropriate primary antibodies against p-p38, p38, p-JNK1/2, JNK1/2, p-ERK1/2, ERK1/2,
iNOS, COX-2, P65, and/or p-P65. After three washes (TBST buffer, 5 min), the PVDF membranes were
incubated (2 h) with a goat anti-rabbit IgG, or goat anti-mouse IgG second antibody. After a final three
washes (TBST buffer, 5 min), specific proteins were detected using an enhanced chemiluminescence kit
(ECL, Millipore, Billerica, MA, USA) according to the manufacturer’s instructions. β-actin was used as
a loading control.
2.8. Detection of NF-κB Activation and Nuclear Translocation
The detection of NF-κB nuclear translocation was carried out following the instruction of the
kit (Beyotime Institute of Biotechnology, Haimen, China) [25,26].THP-1 cells were primed with PMA
and seeded on glass coverslips in a 24-well plate (density 1 × 106 cells/mL), cultured overnight,
and then treated with 200 μg/mL MP-A with or without 1 μg/mL LPS treatments for 2 h. Then,
cells grown on coverslips were fixed and blocked, and incubated overnight with the primary
antibody against the p65 subunit of NF-κB at 4 ◦C, then washed in PBS, and incubated with
Cy3-labeled secondary antibody for 2 h at room temperature. Finally, the cells were stained with
2 μM 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI) solution for 5 min. Each step
above was followed by washing with ice-cold PBS three times for 5 min each. Then, the activation and
nuclear translocation of NF-κB were observed using a laser scanning confocal microscope (LSM 780,
Zeiss, Oberkochen, Germany).
2.9. Affinity Assay for MP-A with TLR4, TLR2 and Dectin-1
The affinity of MP-A for recombinant human TLR4, TLR2, and Dectin-1 was examined via
SPR, and performed using a BIAcore 3000 (GE Healthcare, Uppsala, Sweden) according to the
manufacturer’s instructions. Prior to analysis, recombinant human TLR4, TLR2, and Dectin-1 proteins
(R&D Systems) were each immobilized on a CM5 sensor chip using an amine coupling kit. The surface
of the chip was activated by EDC/NHS, and then TLR4, TLR2, and/or Dectin-1 (25 μg/mL) suspended
in 10 mmol/L sodium acetate solution (pH 4.5) was flowed over it. When the ligand density reached the
target resonance unit (RU) level, remaining active esters were quenched with a 1 mol/L ethanolamine
solution (pH 8.5). (Control flow cells received identical treatment, but no TLR4, TLR2, and/or Dectin-1
protein was added to the 10 mmol/L sodium acetate solution). The resultant sensor chip was stored
in 10 mM phosphate-buffered saline as a running buffer, and maintained at 25 ◦C for all of the
experiments. MP-A (dissolved in running buffer at a series of concentrations) was injected into the
channels, and resulting signals were detected using the BIAcore program (GE). The sensor chip was
regenerated in a 10 mM NaOH solution after each analysis. Affinity constants were calculated using
BIA evaluation 4.1 software, by globally fitting the association and dissociation phases of overlay plots
to a 1:1 Langmuir binding model.
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2.10. Statistical Analyses
Multiple comparisons were statistically assessed using a one-way ANOVA, followed by a Tukey’s
multiple comparison test. Results were expressed as the mean ± SEM, and a p-value of <0.05 was
considered to indicate statistical significance.
3. Results
3.1. Effects of MP-A on THP-1 Cell Viability
Treatment of THP-1 cells with up to 200 μg/mL of MP-A over 48 h did not result in any significant
cytotoxic effect; however, 72 h of MP-A treatment induced a slight decrease in cell viability (Figure 1B).
LPS treatment (1 μg/mL), alone over a 24-h period, was insufficient to cause a significant increase in
cell viability, as compared with the negative control (p > 0.05). We therefore studied the effects of MP-A
on phagocytosis, and on NO and cytokine production, using a 24-h culture model that was unaffected
by changes in cell quantity.
3.2. Effect of MP-A on NO Release by THP-1 Cells
LPS stimulation resulted in a significant increase in NO production (nitrite 31.34 ± 1.84 μM)
relative to that in of unstimulated controls (nitrite 7.46 ± 1.38 μM) (Figure 1C). MP-A treatment
dose-dependently inhibited NO production in LPS-stimulated THP-1 cells, such that approximately
33% inhibition was observed at an MP-A concentration of 200 μg/mL (Figure 1C). In contrast, NO
production was not significantly affected by MP-A treatment alone when compared to the negative
control group (p > 0.05).
3.3. Effect of MP-A on Phagocytic Uptake of FITC-Labeled Dextran by THP-1 Cells
The Phagocytic Uptake of FITC-labeled Dextran by THP-1 cells was analyzed using flow cytometry.
The results of this analysis showed that MP-A significantly increased the capacity of cell phagocytic
uptake of FITC labeled dextran in a dose-dependent manner at concentrations as low as 10 μg/mL,
as compared to controls (e.g., phagocytic uptake of FITC labeled dextran was 1.13 ± 0.06% and
0.73 ± 0.15% in MP-A-treated and control cells, respectively, p < 0.05, n = 3; Figure 2A–D). LPS treatment
also markedly stimulated THP-1 cell phagocytosis (e.g., phagocytic uptake of FITC labeled dextran
was 16.73 ± 1.01% and 0.73 ± 0.15% in LPS-treated and control cells, respectively, p < 0.0001,
n = 3; Figure 2A,E), and combined LPS and MP-A treatment further stimulated phagocytosis in
a dose-dependent manner (Figure 2F–H).
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Figure 2. Effect of MP-A on THP-1 cell phagocytosis. (A–H) Representative fluorescence activated
cell sorter (FACS) plots (three independent experiments), showing phagocytosis of THP-1 cells treated
with (A) vehicle only (control); (B) 10 μg/mL MP-A; (C) 100 μg/mL MP-A; (D) 200 μg/mL MP-A;
(E) 1 μg/mL LPS; (F) 1 μg/mL LPS + 10 μg/mL MP-A; (G) 1 μg/mL LPS + 100 μg/mL MP-A; and
(H) 1 μg/mL LPS + 200 μg/mL MP-A; (I) blank control (J) Statistical analysis of results shown in (A–H).
* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 compared to control (MP-A) group; # p < 0.05,
and ## p < 0.01, when compared to LPS group (n = 3).
3.4. MP-A Inhibition of TNF-α and PGE2 Release by LPS-Stimulated THP-1 Cells
When compared with control cells, LPS treatment significantly increased TNF-α and PGE2
production in THP-1 cells. In contrast, MP-A treatment suppressed TNF-α production such that 60%
inhibition was achieved by treating cells with 200 μg/mL MP-A for 6 h. Similarly, 24 h of MP-A
treatment (200 μg/mL) resulted in a 35%-inhibition of PGE2 production (Figure 3A,B).
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Figure 3. Effect of MP-A on TNF-α and PGE2 production and iNOS and COX-2 protein expression in
LPS-stimulated THP-1 cells. (A,B) MP-A inhibition of TNF-α and PGE2 production in LPS-stimulated
THP-1 cells. TNF-α (6-h stimulation) and PGE2 (24-h stimulation) were measured via an ELISA.
The data represent three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001
compared to the LPS group. (C,D) MP-A inhibition of iNOS and COX-2 protein expression, as assessed
by western blotting analysis in LPS-stimulated THP-1 cells. * p < 0.05, ** p < 0.01, and *** p < 0.001,
when compared to controls; # p < 0.05, ## p < 0.05, and ### p < 0.001 compared to the LPS group (n = 3).
3.5. MP-A Inhibits iNOS and COX-2 Expression in LPS-Stimulated THP-1 Cells
A western blot analysis was conducted to investigate the effect of MP-A treatment on iNOS and
COX-2 expression in LPS-stimulated THP-1 macrophages. As depicted in Figure 3C,D, COX-2 and
iNOS protein expression were both dramatically increased by treatment with LPS alone compared to
control group, whereas pre-treatment with MP-A decreased protein levels of COX-2 and iNOS in a
dose-dependent manner. The reduction of iNOS and COX-2 protein expression was consistent with
the above descried observed inhibition of NO and PGE2 (Figures 1C and 3B).
3.6. MP-A Treatment Inhibits LPS-Induced Phosphorylation of MAPKs and NF-κB in THP-1 Cells
LPS from Gram-negative bacteria is known to stimulate inflammatory responses via
TLR4-initiation of several distinct signaling pathways, including the MAPK and NF-κB pathways.
To determine whether either of these pathways was affected by MP-A treatment, cytoplasmic cell
lysates were analyzed by western blotting with specific phosphor-antibodies against P65 (NF-κB),
ERK1/2, JNK1/2, and p38 (MAPK). The results of this analysis showed MP-A to dose-dependently
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inhibit the LPS-induced phosphorylation of P65, ERK1/2, JNK1/2, and p38 in the THP-1 cells
(Figure 4).
Figure 4. MP-A significantly attenuated LPS-induced activation of the mitogen-activated protein
kinases (MAPK) and NF-κB signaling pathways in THP-1 cells. The ratios of p-p38/p38, p-JNK/JNK,
p-ERK1/2/ERK1/2, and p-P65 /P65 were analyzed by western blot analysis. * p < 0.05, ** p < 0.01,
*** p < 0.001, and **** p < 0.0001, when compared to controls; # p < 0.05, ## p < 0.05, ### p < 0.001, and
#### p < 0.0001 compared to the LPS group (n = 3).
3.7. MP-A Prevented LPS-Induced Activation and the Nuclear Translocation of NF-κB in THP-1 Cells
NF-κB regulates many molecules of the various stages of the inflammatory response.
In unstimulated control cells, NF-κB retains its original state as an inactive cytoplasmic complex
by its inhibitor IκB. Upon LPS stimulation, the phosphorylation and degradation of IκB release NF-κB
for nuclear translocation. We studied the NF-κB translocation using a primary antibody against
the p65 subunit of NF-κB and the nuclei dye DAPI (Figure 5). When comparing with the control
(Figure 5A(a–c)), NF-κB p65 traveled from the cytosol to the nucleus in macrophages by 1 μg/mL LPS
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treatment (Figure 5B(d–f)), however, 200 μg/mL MP-A obviously prevented LPS-induced activation
and the nuclear translocation of p65 (Figure 5C(g–i)).
Figure 5. MP-A prevented LPS-induced activation and the nuclear translocation of NF-κB p65.
THP-1 cells labeled with NF-κB subunit p65 (red) and DAPI (blue) were imaged simultaneously
and merged (pink). (A) Control cells were treated with neither MP-A nor LPS solution. (B) Cells were
treated with 1 μg/mL LPS for 24 h (C) Cells were treated with 200 μg/mL MP-A and 1 μg/mL LPS
for 2 h. (a–i) Magnification imaging corresponding to the white boxes in Figure 5A–C. The images
were obtained by confocal laser microscopy and overlay; the pink fluorescence (as white arrows show
above) indicates location of p65 protein in nuclei.
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3.8. Affinity of MP-A for Recombinant Human TLR4, TLR2, and Dectin-1
SPR technology (with a BIAcore 3000 biosensor system) was applied to analyze the affinity
of MP-A for recombinant human TLR4, TLR2, and Dectin-1 proteins. Each of the proteins was
immobilized on a CM5 chip (Figure 6A,C,E). The RU for TLR4, TLR2, and Dectin-1 bound to the CM5
chip surface was, respectively, 5022.4, 8333.8, and 1131.7. The sensorgrams of MP-A for TLR4, TLR2,
and Dectin-1 demonstrated that MP-A exhibited a high binding affinity for TLR4 (KD = 5.07 × 10−5 M),
but hardly any affinity for TLR2 and Dectin-1 even up to a concentration of 2500 μg/mL (Figure 6B,D,F).
Figure 6. Binding affinity of MP-A for TLR4, TLR2, and Dectin-1, as evaluated by surface plasmon
resonance (SPR) analysis. Cumulative MP-A concentrations were injected at 30 μL/min over 60-second
association periods, with the concentrations shown next to the arrows. (A,C,E) TLR4, TLR2, and
Dectin-1 immobilization on CM5 sensor chips, respectively. (B,D,F) Kinetic-binding responses of MP-A
to TLR4, TLR2, and Dectin-1, respectively.
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4. Discussion
The preset study used THP-1 macrophages as an in vitro cell model to investigate the effect
of MP-A on immune modulation. Given that LPS has been previously shown to activate multiple
signaling pathways in macrophages, and to thereby induce the production of pro-inflammatory
mediators and cytokines such as NO, TNF-α, and interleukins, we chose LPS-stimulation as the
method for inducing experimental inflammation of the THP-1 cells. The results of the present study
demonstrate MP-A to exert an anti-inflammatory effect in LPS-stimulated THP-1 cells, via the inhibition
of the TLR4/NFκB and MAPK pathways.
An increase in phagocytic activity is one of the most characteristic features of macrophage
activation, and the phagocytosis and subsequent destruction of microorganisms is the most important
function of monocytes and macrophages in maintaining the immune response against infection.
LPS has been previously reported to suppress the phagocytosis of immunoglobulin G-opsonized
sheep red blood cells (SRBCs) by peritoneal macrophages. LPS suppresses phagocytosis of SRBCs by
altering the distribution of microfilaments and microtubules, and this suppression is independent of
cytokine (IL-1, IL-6, TNF- or IFN α/β) production [27,28]. LPS has been reported to increase obviously
the phagocytic activity in RAW264.7 macrophages [29,30]. The data generated in the present study
suggest that LPS treatment markedly increased phagocytic activity in THP-1 macrophage cells, and
furthermore, these effects were synergistically increased by combined treatment with LPS and MP-A.
While the molecular mechanism underlying the increased phagocytosis induced by MP-A is unknown,
we hypothesize that it is likely to be independent of cytokine production in a similar manner to
LPS, since cytokine production was observed to be reduced by MP-A treatment in LPS-simulated
THP-1 cells.
NO is a key molecule in immune function, and has been shown to exert beneficial biological effects
in a variety of cell types involved in immunomodulatory, inflammatory, and/or other physiological
processes [31,32]. NO is synthesized by a family of enzymes known as NOS, comprising three
main isoforms, constitutive NOS (nNOS), endothelial constitutive NOS (eNOS), and inducible NOS
(iNOS). Of these, iNOS is the pro-inflammatory enzyme that is most critical for upregulating the
levels of NO production in response to pro-inflammatory stimuli. For example, LPS macrophage
stimulation induces NO production via iNOS [33,34]. In the present study, MP-A treatment was shown
to effectively inhibit NO production in LPS-activated THP-1 macrophages via the inhibition of iNOS
protein expression, without affecting cell viability. In contrast, MP-A treatment alone was found to be
insufficient to affect NO production.
Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) can regulate the production of
prostaglandins [35]. COX-2 mediates the conversion of arachidonic acid to prostaglandin H2, a
precursor of PGE2, in activated macrophages. Overexpression of iNOS and COX-2 has been previously
found to lead to the overproduction of NO and PGE2, and this results in the development of
inflammatory diseases. The results of the present study suggest that MP-A significantly suppresses
COX-2 expression in LPS-stimulated THP-1 macrophages. Since one of the current strategies to
mitigate inflammatory disorders is the modulation of iNOS and COX-2 expression, MP-A may be a
promising potential therapeutic candidate for controlling inflammatory mediator overproduction.
TNF-α has been reported to trigger the downstream activation of inflammatory gene expression,
and to cause rheumatoid arthritis, inflammatory bowel disease, psoriasis, and refractory asthma [36–39].
The present study demonstrated MP-A treatment of THP-1 cells to significantly attenuate TNF-α
production in a dose-dependent manner. We previously observed a similar phenomenon to occur
while treating RAW264.7 cells with curdlan sulfate (CS3) [29]. In the previous study, treatment
with CS3 or curdlan alone was found to stimulate TNF-α production, whereas treatment of
LPS-stimulated RAW264.7 cells with CS3 or curdlan instead attenuated TNF-α production to some
extent. Another β-Glucan, LNT-S, that was isolated from Lentinus edodes, has also been determined to
suppress NO and TNF-α production in LPS-stimulated RAW264.7 cells [15]. Interestingly, CS3, curdlan,
and LNT-S have a β-glucan structure, while MP-A instead exhibits an α-glucan structure. Nevertheless,
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the results of the present study indicate that MP-A is similar to those β-glucans, and is a promising
potential therapeutic agent for use in controlling diseases associated with pro-inflammatory mediator
overproduction. β-glucans such as CS3 and LNT-S have been identified to bind the key macrophage
surface receptor, Dectin-1 [15,28,29]. This receptor has been documented to be required for β-glucan
recognition, and can collaborate with TLR2 to mediate the biological effects of β-glucans [40,41].
To determine whether MP-A binds to TLR2, TLR4, and/or Dectin-1 receptors, we evaluated potential
interactions between MP-A and each of the three receptors using an SPR analysis. The results of this
analysis show that MP-A can strongly bind TLR4, but not TLR2 nor Dectin-1, thus, TLR4, but not TLR2
or Dectin-1, can recognize the water-soluble α-glucan, MP-A.
TLR4 alone is not sufficient for LPS signaling, and indeed a secretory protein, MD-2, has also been
shown to be an essential to this process [42]. TLR4 recognizes LPS in conjunction with MD-2 and CD14,
such that they have been shown to form a physical complex on LPS-responsive cell surfaces [43,44].
We recently demonstrated LPS to exhibit a poor binding affinity for recombinant TLR4 using SPR
technology, and provided more evidence for LPS signaling via TLR4 as a receptor is required for an
additional molecule [30].
Various inflammatory diseases upregulate pro-inflammatory cytokines (such as TNF-α and IL-1β)
and inflammatory mediators (such as NO and PGE2) via the NF-κB and MAPKs signaling pathways
in macrophages [45,46]. The present study aimed to elucidate the way in which MP-A interacts in
these processes. The results show that MP-A can prevent LPS-induced activation via regulating the
phosphorylation of MAP kinase and/or NF-κB p65 signaling pathway components (Figures 4 and 5).
Specifically, MP-A inhibited LPS-induced iNOS and COX-2 expression, and subsequent NO and
PGE2 production, via the selective suppression of the phosphorylation of ERK1/2, JNK, and p38 in
the MAPK signaling pathway, and the nuclear translocation of P65 in the NF-κB signaling pathway.
The mechanism by which MP-A exerts this anti-inflammatory activity in LPS-stimulated THP-1 cells
is likely due to competitive binding to TLR4 at the cell membrane, leading to the inhibition of the
LPS-TLR4 signaling pathway, and thus inhibiting the downstream phosphorylation of MAPK and
the nuclear translocation of NF-κB pathway components. Other molecules involved in the inhibition
mechanism will be further studied in detail in our future work.
5. Conclusions
In summary, the high-molecular-weight α-D-Glucan MP-A, isolated from the hard-shelled mussel
(Mytilus coruscus), has been observed to exert an anti-inflammatory effect, and thus represents a
promising therapeutic candidate for the control of disease-associated pro-inflammatory mediator
overproduction. The current study provides a preliminary pharmacological basis, and underlying
molecular mechanism, for the use of MP-A in the control of inflammatory disorders.
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Abstract: Ecklonia cava (E. cava) can alleviate vascular dysfunction in diseases associated
with poor circulation. E. cava contains various polyphenols with different functions, but few
studies have compared the effects of these polyphenols. Here, we comparatively investigated
four major compounds present in an ethanoic extract of E. cava. These four major compounds
were isolated and their effects were examined on monocyte-associated vascular inflammation
and dysfunctions. Pyrogallol-phloroglucinol-6,6-bieckol (PPB) significantly inhibited monocyte
migration in vitro by reducing levels of inflammatory macrophage differentiation and of its related
molecular factors. In addition, PPB protected against monocyte-associated endothelial cell death
by increasing the phosphorylations of PI3K-AKT and AMPK, decreasing caspase levels, and reducing
monocyte-associated vascular smooth muscle cell proliferation and migration by decreasing the
phosphorylations of ERK and AKT. The results of this study show that four compounds were effective
for reduction of monocyte-associated vascular inflammation and dysfunctions, but PPB might be more
useful for the treatment of vascular dysfunction in diseases associated with poor circulation.
Keywords: poor blood circulation; Ecklonia cava; phlorotannins; pyrogallol-phloroglucinol-6,6-
bieckol; functional ingredients; endothelial cell death; vascular smooth muscle cell proliferation
and migration; inflammation
1. Introduction
Weight gain has been intimately associated with diseases associated with poor circulation, such as
stroke, atherosclerosis and high blood pressure [1,2]. Most obese individuals have elevated blood
levels of glucose, low-density lipoprotein (LDL) or free fatty acids (FFA), and these changes can alter
blood functions and blood vessel construction.
In blood vessel walls, endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) influence
vessel tone. ECs form vessel barriers, regulating blood flow and inflammatory response, whereas
VSMCs have proliferative, contractile and biosynthetic roles in vessel walls. Alterations in the
differentiated states of these cells play critical roles in the pathogeneses disease associated with poor
circulation. Saturated free fatty acids (FFA), elevated glucose or LDL lead to EC and VSMC dysfunction.
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Furthermore, these abnormal changes induce bioavailable nitric oxide (NO) deficiency, reduce vascular
relaxation, induce the overproductions of growth factors, increase adhesion and inflammatory molecule
expressions, induce the generation of reactive oxygen species (ROS) in ECs [3–5], adversely influence
glucose metabolism, and promote the abnormal proliferation and migration of VSMCs [6,7].
High glucose, LDL and FFA can also indirectly affect ECs and VSMCs via the inflammation
induction of monocytes. Obesity affects the activations of circulating monocytes. In particular,
high glucose levels increase monocyte adhesion and trans-endothelial migration by activating the
AKT-GSK axis [8], which leads to the inductions of inflammatory factors, such as tumor necrosis
factor-alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1), interleukin-beta (IL-1β) and
Toll-like receptors (TLRs) via oxidant stress [9–11].
Edible marine plants have emerged as a potential source of bioactive compounds for the
developments of cosmeceutical ingredients [12]. Ecklonia cava (E. cava) is an edible marine brown
alga, and it is one of nature’s richest sources of phlorotannins, and phlorotannin derivatives which
do not exist in land-originating plants. The phlorotannins are a sub-classification of polyphenolic
compounds that are confirmed by dibenzo-1,4-dioxin backbone which is this backbone linkage can
make the structure tight and strongly interact with various biological molecules [13,14]. E. cava extracts
have been shown to suppress the production of inflammatory cytokines and the activation of NF-κB in
lipopolysaccharide (LPS) challenged human ECs and to reduce vascular inflammation by preventing
oxidation [13,15].
Some studies have shown these compounds have different beneficial effects of various
E. cava phlorotannins, but the efficacies of these compounds have not been previously compared.
In a previous study [16], we successfully isolated four phlorotannins from an ethanoic extract
of E. cava, that is, dieckol, 2,7-phloroglucinol-6,6-bieckol (PHB), phlorofucofuroeckol-A (PFFA),
and pyrogallol-phloroglucinol-6,6-bieckol (PPB), by centrifugal partition chromatography. In the
present study, we sought to determine which compound most effectively inhibits monocyte migration
and differentiation to inflammatory macrophages and monocyte-associated vascular cell dysfunction
in vitro.
2. Results and Discussion
2.1. Structures of the Four Compounds Isolated from E. cava
The four compounds were isolated and purified using centrifugal partition chromatography
in one step [16]. The peaks a-d on the high-performance liquid chromatography (HPLC) shown in
Figure S1 were assigned to DK, PHB, PFFA and PPB, respectively by mass spectrometry analysis
(Figure S2). They show a single peak in the HPLC chromatogram and had a purity of 90% or
more. Our previous study shown the 4 compounds identified using 1H NMR and 13C NMR and
HPLC–DAD–ESI/MS (negative ion mode) analyses [16] and each chemical structure shown in
Figure 1. Previous studies on various biological properties of phlorotannins including anti-oxidant [17],
anti-inflammation [18], anti-neurodegeneration [19], anti-cancer [20,21], and anti-cardiovascular
diseases [22] of E. cava extract have shown. Among numerous properties, anti-oxidant activities
of E. cava phlorotannins extract on reactive oxygen species (ROS) have shown it exhibits radical
scavenging activity against oxidized low-density lipoprotein (ox-LDL), 1,1-diphenyl-2-picrylhydrazyl
(DPPH) radicals, and peroxynitrite [14,16,17] and these anti-oxidant activities closely related with
other beneficial effects of E. cava.
Interestingly, the difference in anti-oxidant effect between various E. cava phlorotannins is related
to the number of hydroxyl groups present. According to a study by Li and colleagues, dieckol and
6,6′-bieckol (more than 10 OH groups) had higher anti-oxidant efficacy than phloroglucinol and eckol
(less than 10 OH groups) [14]. The PPB used in this study is also expected to have anti-inflammatory
effects, including monocyte migration and macrophage polarization, because of the presence of 15
OH groups.
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Figure 1. The chemical structures of the four major compounds isolated from E. cava. (A–D) Chemical
structures of dieckol (DK), 2,7-phloroglucinol-6,6-bieckol (PHB), phlorofucofuroeckol-A (PFFA),
and pyrogallol-phloroglucinol-6,6-bieckol (PPB).
2.2. Analysis of the Effects of 4 Compounds on Monocyte Migration and Macrophage Polarization
In diseases associated with inadequacy of blood flow in organs [23], monocyte migration
is important and closely related to vascular inflammation. Figure 2A provides a schematic
of the inhibitory effects of these four compounds on palmitic acid conjugated bovine serum
albumin (PA-BSA) induced monocyte trans-migration and macrophage polarization (Figure 2A).
Experiments were performed on two monocyte cell lines (P388D1 and Raw 264.7). Numbers of
trans-migrating monocytes were greatest for PA-BSA-treated monocytes, and all four compounds
significantly reduced numbers of migrating cells (Figure 2B) and the results were similar in Raw
264.7 (Figure S3A). Trans-migrating monocytes differentiated to macrophages of the pro-inflammatory
(M1 type macrophages) or anti-inflammatory (M2 type macrophages) types (Figure 2C–F). Furthermore,
PA-BSA-treated monocytes contained elevated levels of inflammatory factors, including inducible
nitric oxide synthase (iNOS), CD80, TNF-α and interleukin-1β (IL-1β) (Figure 2C,D) and low levels
of anti-inflammatory like arginase-1 (Arg-1), CD206, transforming growth factor beta 1 (TGF-β)
and interleukin-10 (IL-10) (Figure 2E,F) and the results were similar in Raw 264.7 (Figure S3B–E).
Interestingly, when monocytes were treated with four compounds with PA-BSA and these inductions
were reduced, PPB had the greatest effect. As well as its anti-oxidant effects, E. cava extract has
anti-inflammatory effects. For example, an ethanoic extract of E. cava was found to contain large
amounts of phlorotannins and to inhibit the productions of prostaglandin-E2 (PGE2) and nitric oxide
(NO) and suppress cyclooxygenase-2 (COX-2) and iNOS expressions in LPS-stimulated Raw 264.7
cells [24]. In inflammatory lung diseases, E. cava extract was found to significantly reduce inflammatory
reactions, such as eosinophil migration to lungs, inflammatory cell and cytokine increases, and to
reduce airway epithelial hyperplasia, lung fibrosis and smooth muscle cell thickness [14,15,17,25].
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Figure 2. Inhibitory effects of PPB on monocyte polarization and related cytokines and EC dysfunction.
(A) Illustration showing the palmitic acid conjugated bovine serum albumin (PA-BSA)-treated
monocyte trans-migration model. (B) Migrating monocytes levels in 4 compounds with PA-BSA
as determined by the trans-well migration assay. (C,D) mRNA expression levels of M1 type
macrophages (inducible nitric oxide synthase (iNOS) and Cd80) and M2 type macrophages (arginase-1
(Arg-1) and Cd206) as determined by quantitative real-time polymerase chain reaction (qRT-PCR).
(E,F) mRNA expression levels of M1 related cytokines (tumor necrosis factor-alpha (TNF-α) and
interleukin-beta (IL-1β)) and M2 related cytokines (transforming growth factor beta 1 (TGF-β)
and interleukin-10 (IL-10)) by qRT-PCR. Kruskal–Wallis tests were used to determine differences
between groups and post-hoc comparisons were made with the Mann–Whitney U test **, p < 0.01,
***, p < 0.001, vs. PBS; $, p < 0.05, $$, p < 0.01, vs. PA-BSA; #, p < 0.05, ##, p < 0.01, vs. PA-BSA
with PPB, DK; dieckol, PHB; 2,7-phloroglucinol-6,6-bieckol, PFFA; phlorofucofuroeckol-A, PPB;
pyrogallol-phloroglucinol-6,6-bieckol.
2.3. Effects of Four Compounds on Monocyte-Induced Endothelial Cell Death
The inhibiting effects of four compounds on PA-BSA treated ECs and VSMCs dysfunctions
induced by monocytes are summarized in Figure 3 and Figure 4. Monocytes were treated four
compounds with PA-BSA respectively, and then each conditioned medium (CM) from the four
compounds treated monocytes was incubated with ECs or VSMCs for 24 h (Figure 3A and Figure 4B).
Adhesion molecule expressions (E-selectin, intercellular adhesion molecule 1; ICAM-1, vascular cell
adhesion molecule 1; VCAM-1 and von Willebrand factor; vWF) in ECs were significantly higher
when they were treated with PA-BSA CM than BSA CM, but the expression was significantly lowest
when ECs were treated with PPB CM (Figure 3B). The various adhesion molecules are related to
vascular inflammation, and these molecules are regulated by mast cells, macrophages, and neutrophils,
which also secrete pro-inflammatory cytokines, such as TNF-α, interferon gamma (IFN-γ), and IL-6.
These pro-inflammatory cytokines induce the expressions of adhesion molecules in ECs and recruit
leukocytes, which are important components of the pathogenesis of vascular inflammation [26,27].
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Adhesion molecules are also related to EC survival [21]. In addition to the abovementioned adhesion
molecule changes, all four compounds improved the survival ratios of PA-BSA CM treated ECs,
and PPB CM treated cells had the lowest levels of caspases 3 and 8 and it was related with
the phosphorylated PI3K-AKT-eNOS and AMPK signaling pathways (Figure 3C,E and Figure S4).
In addition, although the AKT inhibitor A6730 was treated, the expression of pAKT was increased in the
single compounds treated group (Figure 3D). In ECs, the PI3K-AKT pathway is essential for mediating
cell survival, migration, proliferation, and angiogenesis [28,29]. In particular, high glucose-induced
EC apoptosis depends on Akt de-phosphorylation and activation of the PI3K/AKT/eNOS signaling
pathway protects ECs from apoptosis [30].
Figure 3. Prevention of monocyte-induced endothelial cell death by DK, PHB, PFFA or PPB. (A)
Endothelial cells (ECs) were treated with conditioned medium (CM) collected from PA-BSA induced
transmigrating monocytes. (B) mRNA expression levels of adhesion molecules (E-selectin, ICAM-1,
VCAM-1 and vWF) in CM treated ECs were measured by qRT-PCR. (C) Protein levels of cell-death
related molecules, that is, AMPK, pAMPK, AKT, pAKT, PI3K eNOS, peNOS, Caspase 3, and Caspase 8
in CM treated endothelial cells were determined by western blotting. (D) The AKT inhibitor (A6370)
was treated to monocyte and collected CM was treated EC. The ECs determined by western blotting.
(E) Survival levels of CM treated ECs were measured using a cell survival assay. Kruskal–Wallis tests
were used to determine differences between groups and post-hoc comparisons were made with the
Mann–Whitney U test. **, p < 0.01, ***, p < 0.001, vs. PBS; $, p < 0.05, $$, p < 0.01, $$$, p < 0.001, vs.
PA-BSA; #, p < 0.05, ##, p < 0.01 vs. PA-BSA with PPB, DK; dieckol, PHB; 2,7-phloroglucinol-6,6-bieckol,
PFFA; phlorofucofuroeckol-A, PPB; pyrogallol-phloroglucinol-6,6-bieckol.
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Figure 4. DK, PHB, PFFA or PPB inhibited monocytes migration and prevented monocyte-associated
vascular smooth muscle cell proliferation and migration. (A) Illustration of the CM-induced vascular
smooth muscle cells (VSMCs) proliferation and trans-migration model. (B) VSMC proliferation after
CM treatments were measured using a proliferation assay. (C) Trans-migrating VSMC numbers were
measured using a trans-migration assay. (D) Protein levels of proliferation and migration related
molecules, that is, ERk, pERK, AKT, pAKT, α-SMA in CM treated VSMCs were determined by western
blotting. Kruskal–Wallis tests were used to determine differences between groups and post-hoc
comparisons were made with the Mann–Whitney U test. **, p < 0.01, vs. PBS; $, p < 0.05, $$, p < 0.01, vs.
PA-BSA; #, p < 0.05, ##, p < 0.01, vs. PA-BSA with PPB, DK; Dieckol, PHB; 2,7-phloroglucinol-6,6-bieckol,
PFFA; phlorofucofuroeckol-A, PPB; pyrogallol-phloroglucinol-6,6-bieckol.
2.4. Effects of All Four Compounds on Monocyte-Induced VSMC Proliferation and Migration
DK, PHB, PFFA and PPB CM treated VSMCs proliferated and migrated significantly less than
PA-BSA CM treated VSMCs, and PPB CM was related with phosphorylations of the AKT and ERK
pathways (Figure 4B–D), and the results were similar in Raw 264.7 (Figure S5). In addition, PA-BSA
CM treated VSMCs had the highest α-SMA levels, and PPB CM had greatest effect, suggesting VSMCs
would be closer to the contractile phenotype (Figure 4D and Figure S5C). Phenotype switching of
VSMCs is important for the maintenance of vascular tone and alpha-smooth muscle actin (α-SMA)
promotes the synthetic phenotype. In previous studies, higher expression of α-SMA in PA-BSA than
in BSA treated VSMCs was found to reduce the contractile phenotype and increase proliferation and
migration rates via the AKT and ERK pathways [31–33]. VSMCs can perform both contractile and
synthetic functions, which are associated with the maintenance of vascular tone. The synthetic VSMCs
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phenotype has characteristics that include increased proliferation and migration rates, extensive ECM
degradation/synthesis abilities, and an increased cell size, which is closely related with neo-intima
hyperplasia formation [31–34].
3. Materials and Methods
3.1. Materials
3.1.1. E. cava Extraction
E. cava powder (2.5 g) was soaked in 50% ethanol (100 mL) and stirred at 130 rpm for 1 h at room
temperature. The mixture was then centrifuged at ~3667× g for 10 min, and the supernatant was
filtered through 3M paper and concentrated under vacuum. The crude extract was stored at −20 ◦C
until required.
3.1.2. Isolation of Compounds from E. cava Extract
Compounds were isolated, as previously described [16]. Briefly, centrifugal partition chromatography
(CPC) was performed using a two-phase solvent system comprised of n-hexane/ethyl
acetate/methanol/water (2:7:3:7, v/v/v/v). The CPC column was first filled with the organic stationary
phase and the mobile phase was pumped into the column in descending mode at the same flow rate
used for separation (2 mL/min).
3.1.3. Experimental Cell Models
To prepare PA-BSA, 2.267 g of fatty acid-free BSA (Sigma-Aldrich; St. Louis, MO, USA) was
thawed in pre-warmed 100 mL of 150 mM NaCl. The mixture was stirred at 37 ◦C (no higher than
40 ◦C) in a water bath until completely dissolved. The BSA solution was from a filtered new bottle and
it was stirred at 37 ◦C. While the BSA was being stirred in the water bath, 30.6 mg of Sodium palmitate
was thawed in 150 mM NaCl 50 mL in a water bath at 70 ◦C.
The PA-BSA was divided into 5 mL portions and transferred to the BSA solution, stirred at 37 ◦C
for 1 h, and adjusted to a final volume of 100 mL with 150 mM NaCl and pH 7.4 with 1N NaOH.
The solution was stored −20 ◦C until required and thawed in a 37 ◦C water bath for 10 min prior
to use.
3.2. Cell Culture and Treatment
3.2.1. Monocytes
Monocytes (P388D1 cells) were purchased from ATCC (Washington, DC, USA). RPMI 1640 (Gibco;
Grand island, NY, USA), 10% fetal bovine serum (FBS), 25 mM hydroxyethyl-piperazineethane-sulfonic
acid buffer (HEPES) buffer and 1% penicillin-streptomycin were used as growth medium.
To investigate the inhibitory effects of DK, PHB, PFFA and PPB in 0.25 mM PA-BSA treated monocytes,
we used the same concentration (2.5 μg/mL) for a treatment time of 48 h. To collect conditioned
medium (CM), monocytes were treated with PA-BSA with or without DK, PHB, PFFA or PPB for 48 h.
3.2.2. Vascular Endothelial Cells (ECs)
ECs (SVEC 4–10 cells) were also purchased from ATCC. Dulbecco’s Modified Eagle’s medium
(DMEM; Gibco) and 1% penicillin-streptomycin (Gibco) were used as growth medium.
3.2.3. Vascular Aortic Smooth Muscle Cells (VSMCs)
VSMCs (MOVAS cells) were also obtained from ATCC. DMEM, 10% FBS and antibiotics G-418
were used as growth medium.
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3.3. Extraction and Isolation
3.3.1. RNA Extraction and cDNA Synthesis
The cells were homogenized in ice using a disposable pestle in 1 mL of RNisol (TAKARA; Kusatsu,
Japan), and homogenates were added to 0.2 mL of chloroform, mixed, and centrifuged at 12,000× g
for 15 min at 4 ◦C. Aqueous phases were collected, placed in cleaned tubes, mixed with 0.5 mL of
isopropanol, and centrifuged using the same conditions. Isolated RNA was then washed with 70%
ethanol and dissolved in 50 μL of diethyl pyrocarbonate (DEPC) treated water. To perform quantitative
real-time polymerase chain reaction (qRT-PCR), cDNA was synthesized from 1 μg of total RNA using
a Prime Script 1st strand cDNA Synthesis Kit (TAKARA, Japan).
3.3.2. Protein Isolation
Cell proteins were extracted using the EzRIPA lysis kit (ATTO; Tokyo, Japan). Initially, tissues were
homogenized with lysis buffer containing proteinase and phosphatase inhibitors and briefly sonicated
for 10 s in a cold bath sonicator. After centrifuging at 14,000× g for 20 min at 4 ◦C, supernatants were
collected and protein concentrations were determined using a Bicinchoninic acid assay kit (BCA kit;
Thermo Fisher Scientific, Inc.; Waltham, MA, USA).
3.4. Monocyte Trans-Well Migration Assay
Monocytes were seeded at a density of 106 per well onto 8-μm Transwell inserts (Thermo Fisher
Scientific). The lower chamber was filled with 500 μL low serum medium containing DK, PHB, PFFA
or PPB and 0.25 mM PA-BSA and incubated for 48 h at 5% CO2 incubator. Migration activities were
evaluated using water-soluble tetrazolium salts (WST; Daeil Lab Service Co.; Seoul, Korea) and optical
densities were measured.
3.5. Monocyte-Associated EC Viability Assay
To analyze monocyte-associated EC viability, 5000 ECs were seeded in the wells of a 96-well
culture plate (Thermo Fisher Scientific) and incubated for 24 h in a 5% CO2 humidified incubator
at 37 ◦C. The WST was mixed with serum free DMEM (1:9, v/v, 200 μL/well) and the mixture was
incubated for 4 h in ECs. Optical densities were measured using a plate reader at 450 nm (Spectra max
plus, Molecular devices).
3.6. Monocyte-Associated VSMC Proliferation Assay
To analyze monocyte-associated VSMC proliferation, VSMCs were seeded in a 96-well culture
plate (Thermo Fisher Scientific Inc.; Waltham, MA, USA) at 5000 per well and incubated for 24 h in 5%
CO2 humidified incubator at 37 ◦C. VSMC proliferations were determined using the WST assay as
described above.
3.7. Monocyte-Associated VSMC Trans-Well Migration Assay
VSMCs were seeded at 5 × 104 per well onto 8-μm Transwell inserts (Corning Inc.; Corning, NY,
USA). Lower chambers were filled with 500 μL of containing each CM and incubated for 48 h in a 5%
CO2 atmosphere. Migration activities were evaluated using the WST assay as described above.
3.8. Western Blotting
Inhibitory effects of DK, PHB, PFFA and PPB on monocyte-associated EC survival and VSMC
proliferation and migration were investigated by western blotting. Cell lysates were prepared as
described above. Equal amounts of proteins were separated by 8–12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene fluoride (PVDF)
membranes, which were incubated with appropriate diluted primary antibodies at 4 ◦C overnight.
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Membranes were then washed with tris buffered saline containing 1% Tween 20 (TTBS) three times
and incubated with secondary antibodies for 1 h at room temperature. Primary and secondary
antibodies are listed in Table S1. Membranes were developed by enhanced chemiluminescence (ECL)
on LAS-4000s (GE Healthcare; Chicago, IL, USA).
AKT Inhibition Study
EC were seeded at a density of 105 per well in 100 mm culture dish (SPL Life Science; Pocheon,
Korea) and incubated for 24 h in 5% CO2 humidified incubator at 37 ◦C. Then ECs were treated with
A6730 (Sigma) 40 μM for 1 h. 1 h later, the supernatant of monocyte was treated for 48 h. Then EC
were isolated EzRIPA lysis kit (ATTO).
3.9. Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
qRT-PCR was performed using the CFX384 TouchTM Real-Time PCR detection system and
reaction efficiencies and threshold cycle numbers were determined using CFX ManagerTM Software.
Primers are detailed in Table S2.
3.10. Statistical Analysis
Non-parametric analysis was used given the small samples available. Comparisons were made
using the Mann-Whitney U test. Significant differences are indicated as follows; by an asterisk (*)
versus PBS, $ versus PA-BSA, and # versus PA-BSA with PPB. Results are presented as means ± SDs
and experiments were performed in triplicate. The analysis was conducted using SPSS version 22
(IBM Co.; Armonk, NY, USA).
4. Conclusions
Four major phlorotannins, that is, DK, PHB, PFFA and PPB, were isolated for the ethanoic
extraction of E. cava. Monocyte trans-migration and inflammatory macrophage differentiation by
monocytes were effectively reduced by PPB, which also modulated vascular tone by protecting
monocyte-associated EC death, by increasing phosphorylations of PI3K-AKT and AMPK and reducing
monocyte-induced VSMC proliferation and migration via the phosphorylations of ERK and AKT in
PPB treated the cells. The study suggests PPB be considered as a component in healthy functional
foods to ameliorate vascular dysfunction in diseases associated with poor circulation.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/16/11/441/
s1, Materials and methods: High-performance liquid chromatography (HPLC) chromatogram, Raw 264.7 cell
cultivation and quantification of Western blotting; Figure S1: HPLC chromatograms and purity of four compounds
from E. cava extract; Figure S2: Mass spectrometry analysis of four compounds from E. cava extract; Figure S3:
Inhibitory effects of PPB in monocyte polarization and related cytokines; Figure S4: Inhibitory effects of PPB
in Raw 264.7 cell-associated endothelial cell death; Figure S5: Inhibitory effects of PPB in Raw 264.7-associated
VSMC proliferation and migration. Table S1: List of antibodies for western blotting; Table S2: List of primer
for qRT-PCR.
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Abstract: An UPLC-qTOF-MS-based dereplication study led to the targeted isolation of seven
bromoindole alkaloids from the sub-Arctic sponge Geodia barretti. This includes three new metabolites,
namely geobarrettin A–C (1–3) and four known compounds, barettin (4), 8,9-dihydrobarettin (5),
6-bromoconicamin (6), and L-6-bromohypaphorine (7). The chemical structures of compounds 1–7
were elucidated by extensive analysis of the NMR and HRESIMS data. The absolute stereochemistry
of geobarrettin A (1) was assigned by ECD analysis and Marfey’s method employing the new
reagent L-Nα-(1-fluoro-2,4-dinitrophenyl)tryptophanamide (L-FDTA). The isolated compounds were
screened for anti-inflammatory activity using human dendritic cells (DCs). Both 2 and 3 reduced DC
secretion of IL-12p40, but 3 concomitantly increased IL-10 production. Maturing DCs treated with 2
or 3 before co-culturing with allogeneic CD4+ T cells decreased T cell secretion of IFN-γ, indicating a
reduction in Th1 differentiation. Although barettin (4) reduced DC secretion of IL-12p40 and IL-10
(IC50 values 11.8 and 21.0 μM for IL-10 and IL-12p40, respectively), maturing DCs in the presence of
4 did not affect the ability of T cells to secrete IFN-γ or IL-17, but reduced their secretion of IL-10.
These results indicate that 2 and 3 may be useful for the treatment of inflammation, mainly of the
Th1 type.
Keywords: 6-bromoindole; Geodia barretti; anti-inflammatory activity; dendritic cells; T cell differentiation
1. Introduction
Many chronic illnesses, including cancer, neurological diseases, diabetes, and autoimmune
diseases, exhibit dysregulation of pathways that have been linked to inflammation [1,2]. A vast
number of unique marine natural products possessing in vitro and in vivo anti-inflammatory activity
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have been isolated [3,4], however, no marine-derived anti-inflammatory agent is currently on the
market. Therefore, the search and development of new natural products to treat chronic inflammatory
diseases is of great importance [5,6]. Marine sponges, due to their phenomenal biological and chemical
diversity, are considered as a notable source of natural products with potential anti-inflammatory
activity [5,7,8].
Geodia barretti Bowerbank (family Geodiidae, class Demospongiae, order Astrophorida) is an
abundant cold-water sponge with a wide geographic distribution, including the Icelandic waters.
G. barretti has been reported to contain 6-bromoindole alkaloids [9–13], including barettin (4) [10],
8,9-dihydrobarettin (5) [11], bromobenzisoxazolone barettin [12], 6-bromoconicamin (6) [14], and
2-(6-bromo-1H-indol-3-yl)-2-hydroxy-N,N,N-trimethylethanaminium [13], as well as nucleosides [15],
peptides [16], sterols and fatty acids [17].
The chemical structure of barettins isolated from G. barretti feature a diketopiperazine (DKP)-type
cyclic dipeptide, a condensation product of arginine (Arg) and 6-bromo-8-en-tryptophan residues
in a “head-to-tail” fashion [11,18]. The DKP core, present in many bioactive compounds, is a
relevant scaffold for drug discovery and development [19]. Barettins display interesting biological
activities, such as anti-inflammatory, antioxidant, antifouling, acetylcholinesterase (AChE) inhibitory,
and selective serotonin (5-HT) receptor ligand effects [11–13,20,21]. In particular, barettin (4), the
major compound in G. barretti has shown potent antifouling, antioxidant, and anti-inflammatory
activities [11,12,20], making it a potential lead compound in prevention of chronic inflammatory
diseases. Therefore, the search for new barettins is of great interest for investigation of their
anti-inflammatory effects and structure–activity relationships.
The present study was undertaken to isolate 6-bromoindole derivatives from the Icelandic sponge
G. barretti and to evaluate their anti-inflammatory activity on human monocyte-derived dendritic
cells (DCs) and their ability to activate T cell responses. DCs play an important role in initiation of
adaptive immune responses by activating naïve T cells and inducing their differentiation by cytokine
secretion [22]. The naïve CD4+ T cells differentiate into different T helper (Th) effector cells, such
as Th1, Th2, Th9, or Th17 phenotypes, which participate in various inflammatory diseases [23–25]
or, if the DCs secrete anti-inflammatory cytokines, such as IL-10, into T regulatory cells (Tregs) [26].
In this study, we describe (i) the isolation and structure elucidation of three new 6-bromoindole
derivatives, geobarrettin A–C (1–3) and four known 6-bromoindole alkaloids (4–7), (ii) the absolute
stereoassignment of geobarrettin A (1) using the Marfey’s method employing the new reagent
L-Nα-(1-fluoro-2,4-dinitrophenyl)tryptophanamide (L-FDTA) followed by HPLC comparison with
standards, and (iii) the re-evaluation of the stereochemical configuration of barettin (4).
2. Results
The sponge G. barretti was collected at the west of Iceland (−388 m) and kept frozen until
work-up. The CH2Cl2:CH3OH (v/v, 1:1) soluble extract of the sponge was partitioned into
five subextracts (hexane, chloroform, dichloromethane, n-butanol, and water) using a modified
Kupchan solvent partitioning method [27,28]. The crude extracts and subextracts were chemically
profiled by UPLC-qTOF-MS for selective and sensitive detection of bromoindoles and other trace
components [29,30]. The bromoindole containing chloroform and dichloromethane subextracts were
combined and purified by a combination of RP-VLC and HPLC to afford three new 6-bromoindole
derivatives geobarrettin A–C (1–3) and four known alkaloids 4–7 (Figure 1).
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Figure 1. Chemical structures of compounds 1–7 and 5a.
2.1. Structural Elucidation
Compound 1 was obtained as a yellow solid. Its UV spectrum was characteristic for an oxindole
skeleton with absorption λmax at 217 and 263 nm [31,32], while the IR spectrum showed the presence
of OH (νmax 3352 cm−1), NH2 (νmax 3285, 3214, and 1614 cm−1), and lactam (νmax 1679 cm−1)
functionalities. The characteristic isotope pseudo-molecular ion peaks at m/z 451.0728:453.0732
([M + H]+) in a 1:1 ratio in the HRESIMS spectrum of 1 suggested the presence of a bromine atom in
the molecule. The HRESIMS data indicated the molecular formula of C17H2079BrN6O4, corresponding
to eleven degrees of unsaturation. This formula was supported by the 1H, 13C NMR, and HSQC
data, indicating the presence of three methylenes (δC 42.0, 32.6 and 24.8), three aromatic methines
(δC 127.1, 126.9 and 115.0), one aliphatic methine (δC 56.0), an isolated olefinic methine (δC 112.8),
four quaternary aromatic carbons (δC 143.9, 132.4, 132.2, and 124.7), one tertiary alcohol (δC 78.3), and
four quaternary heteroatom-bounded sp2 carbons (δC 179.3, 167.2, 160.5 and 158.7). The 1H NMR
spectrum in CD3OD contained three aromatic resonances, including a broad singlet at δH 7.11 (1H)
and an overlapped 2H broad singlet at δH 7.25 (Table 1). When acquired in DMSO-d6, these aromatic
signals were resolved into a well-separated ABX system at δH 7.26 (1H, d, J = 7.9 Hz, H-4), 7.23 (1H,
dd, J = 7.9, 1.5 Hz, H-5), and 7.03 (1H, d, J = 1.5 Hz, H-7), suggesting the presence of a trisubstituted
benzene ring. The chemical shift of the quaternary aromatic carbon C-7a (δC 143.9) indicated that C-7a
was substituted by an NH group. The characteristic resonances of the amide carbonyl C-2 at δC 179.3
and the oxygenated carbon (C-3, δC 78.3), as well as the HMBC correlations observed from H-4 to C-3,
C-6, and C-7a, and from H-7 to C-3a, assisted the construction of a 3-hydroxy-2-oxindole skeleton.
The chemical shifts for carbon atoms were in good agreement with those of previously published
3-hydroxy-2-oxindole scaffolds [33,34]. The position of the bromine atom at C-6 was determined
based on the HMBC correlations H-4/C-3, H-4/C-6, and H-4/C-7a; H-5/C-3a and H-5/C-7; as
well as H-7/C-3a, H-7/C-5, and H-7/C-6. This was supported by the NOE correlations between
H-4/H-8 observed in spectrum run in CD3OD and a weak cross peak between H-7/NH-1 in spectrum
run in DMSO-d6, in combination with characteristic coupling constant values, namely J4,5 (7.9 Hz)
and J5,7 (1.5 Hz). A similar weak cross peak between H-7/NH-1 has previously been observed for
6-bromoindole cyclic guanidine alkaloids [35]. The presence of two amide carbonyl signals C-11
(δC 167.2) and C-14 (δC 160.5) suggested the presence of a DKP moiety attached to the oxindole
skeleton and the chemical shift of C-14 indicated that this carbon was conjugated to a double bond
(Δ8). Cross correlations observed in the HMBC spectrum between H-12/C-11, H-12/C-14, H-8/C-14,
H-8/C-3, and H-8/C-9 supported this assumption. 1H-1H COSY spectrum indicated the presence of
an additional linear spin system starting from H-12 (δH 4.28, 1H, t, J = 6.0 Hz) and including three
aliphatic methylene signals H2-15 (δH 1.89, 1H, m; δH 2.01, 1H, m), H2-16 (δH 1.67, 1H, m; 1.74, 1H,
m), and H2-17 (δH 3.24, 2H, t, J = 6.0 Hz). The molecular fragments described above account for all
atoms except three nitrogen atoms and one quaternary carbon atom (δC 158.7, C-19) and for 10 of
11 degrees of unsaturation. The position of the remaining three nitrogen atoms and the carbon atom
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was assigned to a guanidine group connected to the linear spin system at C-17 based on the HMBC
correlation between H2-17/C-19 (Figure 2). This suggested that the aliphatic side chain linked to the
DKP moiety was an Arg residue. Further examination of the NMR data revealed that spectroscopic
data of compound 1 were very similar to those of compound 4 [10], with the main differences being the
upfield shift of the H-7 resonance (δH 7.03 (1H d, J = 1.5 Hz) in compound 1; δH 7.67 (1H d, J = 1.6 Hz)
in compound 4) and the replacement of the indole Δ2 double bond by a hydroxyl group at C-3 and
a carbonyl group at C-2. The latter was confirmed by the HMBC correlation observed between H-8
and C-2 (Figure 2). The structure proposed for compound 1 is consistent with its molecular formula
(m/z 451.0728 [M + H]+, C17H2079BrN6O4) in comparison to that of compound 4 (m/z 419.0830
[M + H]+, C17H2079BrN6O2). The geometry of the exocyclic double bond Δ8 was defined as Z based
on NOESY correlations observed in H-8/H-4 and NH-10/NH-1.
Figure 2. Key HMBC (H→C), 1H-1H COSY (−) and NOESY (H↔H, in dashed blue) correlations of
compounds 1–3.
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The configurations of two chiral centers at C-3 and C-12 in compound 1 were determined using
a combination of techniques. The absolute configuration of C-3 was determined by comparison
of the ECD spectra (Figure 3) of the hydrogenolysis product of compound 1 with the compound
(R)-3-propyldioxindole (8), which share the dioxindole core structure. (R)-8 was obtained by
hydrogenolysis of R-dioxindole (8a, a gift from Dr. Annaliese K. Franz (University of California,
Davis)) (Scheme 1) [37]. The CD spectra of (R)-8 (EtOH, 23 ◦C) revealed Cotton effects (λ 208 nm
(Δε +13.1), 232 (−10.7), 259 (+3.5)) similar to dioxindoles recently investigated [38]. Hydrogenolysis of
geobarretin A (1) (Scheme 1) gave debromodihydrogeobarrettin A (1a) with a CD spectrum identical
to that of (R)-8 (Figure 3). Given the identical CD spectra of 1a and (R)-8, whose absolute configuration
was established by X-ray crystallography, and the similarity of their Cotton effects with those of
(R)-5-methyldioxindole [39] and the natural product (+)-trikentramide I [38], the C-3 configuration of
compound 1 was assigned as R, unambiguously.
Figure 3. Comparison of CD of model compound (R)-3-propyldioxindole (8) and












Scheme 1. Hydrogenolysis of (R)-(8a) to (R)-(8) and hydrogenation, hydrolysis, and L-FDTA-derivatization
of geobarrettin A (1) to 9.
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Determination of amino acid configuration using Marfey’s method and chiral derivatizing
agents (CDAs) such as L-fluoro-2-4-dinitrophenyl-5-L-alanine amide (FDAA, Marfey’s reagent) or
the homolog, L-fluoro-2,4-dinitrophenyl-5-L-leucineamide (FDLA), are popular and effective [40].
Compound 1a was hydrolyzed (6 M HCl, 110 ◦C) and the product was derivatized with the new
CDA, L-FDTA [41], to produce 9. Comparison with standards D- and L-Arg-DTA derivatives was
then achieved using HPLC (Figure S32) and UPLC-MS analyses. D- and L-Arg-DTA derivatives were
observed with integral values of 19:81 suggesting either natural 1 is partially racemic at C-12, or that
Arg underwent partial racemization under the conditions of hydrolysis. The latter possibility is ruled
out by precedence; Arg essentially is stable to the conditions of hydrolysis. In a careful systematic study
Kaiser and Benner (2005) demonstrated that the amount of D-Arg produced during acid hydrolysis of
L-Arg (110 ◦C, 6 M HCl, 20 h) is not more than 1.0 ± 0% of the total for free amino acid, or 2.8 ± 0.4%
when bonded in lysozyme [42]. We conclude that compound 1 is a cryptic mixture of diastereomers
with stereofidelity at C-3, but partial epimerization at C-12. Therefore, the configuration of geobarrettin
A (1) is 3R, 8Z, 12S.
Geobarrettin B (2) was isolated as a yellow solid. The UV spectrum showed the characteristic
indole chromophore with absorptions at λmax 230, 270, and 289 nm [43]. Its molecular formula
C17H1879BrN6O2 was deduced by HRESIMS (m/z 417.0675/419.0685 1:1, [M + H]+), indicating the
presence of a bromine atom and 12 degrees of unsaturation. Detailed analysis of the 1H, 13C NMR
(Table 1) and HSQC data suggested the planar structure of compound 2 to be very similar to that
of the known compound barettin (4). Comparison of the 1D NMR spectra of compounds 2 and 4
suggested that the only difference was the presence of a double bond in the Arg side chain of 2, namely
between C-12 (δC 130.5) and C-15 (δC 114.9). The HMBC correlations from H-15 (δH 5.98, t, J = 7.8 Hz)
to C-11 and C-17, and from H-16 (δH 2.57, q, J = 7.8 Hz) to C-12, as well as COSY correlations between
H-15/H2-16 and H2-16/H2-17 supported the position of the unsaturation at Δ12. Finally the two mass
units difference between the molecular formulae of 2 and 4, as determined by HRESIMS data, clearly
supported 2 being the Δ12 unsaturated analog of 4. The geometry of Δ12 in α,β-dehydroamino-acids
was determined by analyzing the reported trends in chemical shift differences of vinyl protons in
E- and Z-isomers. Comparison of the chemical shift of H-15 (δH 5.98) in compound 2 with that of
alkylidene-2,5-piperazinedione derivatives reported in the literature [44,45] therefore supports an
E-Δ12 configuration. Hence compound 2 is the Δ12 dehydro-derivative of barettin (4), which we named
as geobarrettin B.
Geobarrettin C (3) was obtained as a yellow oil. The molecular formula C13H16BrN2O+
was assigned to compound 3 by its HRESIMS data. Analysis of the 1H and 13C NMR
spectra pointed out the presence of a substituted 6-bromoindole scaffold. The substituent
was identified as N,N,N-trimethyl-2-oxoethanaminium salt, based on the 1D NMR spectra
that possessed resonances of a methylene group at δC 67.8 and δH 4.92 (2H, s, H-9), a
conjugated keto group at δC 186.0 (C-8), and three methyl signals at δC 54.9; δH 3.42 (9H,
s, -N(CH3)3). The HMBC correlations observed between CH3-N/C-9, H2-9/C-8, and H-2/C-8
indicated the N,N,N-trimethyl-2-oxoethanaminium moiety to be attached to 6-bromoindole at C-3
position (δC 116.1). A literature search showed that 3 is an oxidation product of a previously
isolated secondary alcohol 2-(6-bromo-1H-indol-3-yl)-2-hydroxy-N,N,N-trimethylethanaminium
(C13H18BrN2O+) [13]. Thus, compound 3 was identified as the quaternary ammonium salt
2-(6-bromo-1H-indol-3-yl)-N,N,N-trimethyl-2-oxoethanaminium and named as geobarrettin C (3).
The gross structures of the remaining known compounds, barettin (4) [10], 8,9-dihydrobarettin
(5) [11], 6-bromoconicamin (6) [14], and L-6-bromohypaphorine (7) [46] were identified by comparison
of their NMR, HRMS, and specific rotation data with those reported in the literature.
The sole chiral amino acid residue in barettin (4), first reported in 1986 from a deep-water
specimen of G. barretti collected in Sweden, presumably from Koster fjord [12], was assigned as
Pro, but the configuration was not determined at that time. A second report of 4 in 2004 from a
Norwegian deep-water sample of G. barretti [11] corrected the structure to an Arg-containing DKP,
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but also omitted the specific rotation. Finally, the configuration of 4 was established as L-Arg by
comparison of optical rotations of natural and synthetic 4 [42]. Although they had similar signs, the
specific rotations of synthetic and natural 4 were different ([α]26D −32.5 (c 2, MeOH) [18]; natural 4 [α]D
−25 (c 3, MeOH)) [9]. In the present study, the rotation of 4 was found to be even higher ([α]25D −84
(c 0.5, MeOH)). In order to resolve this paradox, the L-FDTA method was applied to the hydrolysate
as described above for 1. HPLC analysis detected the presence of D-Arg-DTA and L-Arg-DTA in a
ratio of 19:81 suggesting L-Arg was predominant, but—as with 3—our sample of 4 was also partially
racemic. Assuming no racemization occurred during the synthesis of 4 [42], our finding would be
consistent with partially racemic natural 4 in the Swedish sample. The hydrolysis was repeated
on debromo-8,9-dihydrobarettin (5a) (Figure 1), obtained by hydrogenolysis of 4, and the product
was again converted to L-DTA derivatives and analyzed by HPLC as before to give D-Arg-DTA and
L-Arg-DTA (19:81).
The structure of compound 7 was assigned as 6-bromohypaphorine by comparing the recorded
and published NMR data [46]. The sign of optical rotation of compound 7 ([α]23D +36, c 0.2, EtOH)
was similar to that of L-6-bromohypaphorine ([α]D +58, c 0.25, EtOH) [46] and opposite to that of
the D-6-bromohypaphorine ([α]17D −27, c 0.80, MeOH-CF3COOH, 8:1) [47]. Hence, compound 7 was
assigned as L-6-bromohypaphorine.
2.2. Anti-Inflammatory Activity
To evaluate the potential anti-inflammatory activity of compounds 1–7, their effects on DC
secretion of the pro-inflammatory cytokine IL-12p40 and the anti-inflammatory cytokine IL-10 was
determined. The tested compounds did not show cytotoxic effects on the DCs, with the cell viability
being more than 90% in the presence of the compounds at 10 μg/mL (data not shown). Compound
4 inhibited by more than 50% secretion of both IL-12p40 and IL-10. Compounds 2 and 6 decreased
DC secretion of IL-12p40 by 29 and 32%, respectively, without affecting secretion of IL-10, which
suggests an overall anti-inflammatory activity of these compounds. Compound 3 slightly decreased
DC secretion of IL-12p40 (13%) but increased secretion of the anti-inflammatory cytokine IL-10 by 40%,
which also suggests an anti-inflammatory activity. Compounds 1, 5, and 7 did not affect DC secretion
of IL-12p40 or IL-10 (Figure 4).
Figure 4. The effects of compounds 1–7 on dendritic cell (DC) secretion of IL-12p40 and IL-10. DCs were
matured and activated by TNF-α, IL-1β and LPS in the absence (solvent control (CT)) or presence
of compounds 1–7 at 10 μg/mL for 24 h. The supernatants were collected and the concentrations of
IL-12p40 and IL-10 were determined by ELISA. The data are presented as SI, i.e., the concentration of
each cytokine in the supernatant of cells matured and activated in the presence of compounds divided
by the concentration of the cytokine in the supernatant of cells matured and activated in the presence
of solvent control. The results are shown as mean + standard error of the mean (SEM), n = 7–11, except
for compound 7, n = 3. Different from CT: * p < 0.05, *** p < 0.001.
We next examined whether compounds 2, 3, and 4 affected cytokine secretion by the DCs in
a dose-dependent manner. The effects of compounds 2 and 3 on IL-12p40 and IL-10 secretion by
DCs were not dose-dependent although for compound 2 there was a tendency towards an increasing
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effect on IL-12p40 secretion at higher concentrations. Compound 4 inhibited secretion of IL-12p40
and IL-10 in a dose-dependent manner with IC50 being 21.04 μM for IL-12p40 and 11.80 μM for
IL-10 (Figure 5), with IL-12p40 and IL-10 secretion decreasing at the lowest concentrations tested, i.e.,
5.96 μM (2.5 μg/mL) and 11.93 μM (5 μg/mL), respectively.
Figure 5. Dose-dependent inhibition of cytokines IL-12p40 and IL-10 by compounds 2–4. DCs were
matured and activated by TNF-α, IL-1β, and LPS in the absence (solvent control (CT)) or presence of
indicated concentration of compound 2 (5.99, 11.98, 17.97, and 23.97 μM), compound 3 (8.44, 16.88,
25.32, and 33.76 μM), and compound 4 (5.96, 11.93, 17.89, and 23.85 μM). The levels of IL-12p40 and
IL-10 in the supernatants were determined by ELISA. The data are presented as SI. The results are
shown as mean + SEM, n = 5–11. Different from CT: * p < 0.05, ** p < 0.01, *** p < 0.001.
To further elucidate the anti-inflammatory activity of compounds 2–4, DCs matured in their
presence were co-cultured with allogeneic CD4+ T cells and the differentiation of the T cells investigated
by determining secretion of the cytokines IL-10, IL-17, and IFN-γ. T cells co-cultured with DCs matured
in the presence of compounds 2 or 3 secreted less IL-10 and IFN-γ than T cells co-cultured with DCs
matured in the absence of the compounds, but maturing DCs in the presence of compounds 2 or 3 did
not affect T cell secretion of IL-17 (Figure 6). Co-culturing T cells with DCs matured in the presence of
compound 4 resulted in a substantial decrease in secretion of IL-10 with no effect on secretion of either
IL-17 or IFN-γ.
Figure 6. The effects of compounds 2–4 on the ability of DCs to induce cytokine secretion by allogeneic
CD4+ T cells. DCs matured and activated in the absence (solvent control (CT)) or presence of
compounds 2–4 at a concentration of 10 μg/mL for 24 h were co-cultured with isolated allogeneic
CD4+ T cells for six days and the concentrations of IFN-γ, IL-17, and IL-10 in the supernatants were
determined by ELISA. The data are presented as SI, i.e., the concentration of each cytokine in the
supernatant of co-cultures containing DCs treated with compounds divided by the concentration of
each cytokine in the supernatant of co-cultures containing DCs treated with solvent control. The results
are shown as mean + SEM, n = 9–12. Different from CT: *** p < 0.001.
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3. Discussion
Three new 6-bromoindole derivatives were isolated from G. barretti, including a dioxindole
featuring a DKP-type cyclic dipeptide, geobarrettin A (1); a 6-bromoindole possessing DKP system,
geobarrettin B (2); and a new 6-bromoindole alkaloid, geobarrettin C (3).
Compounds 2 and 3 inhibited IL-12p40 production by DCs and DCs treated with compounds 2
and 3 reduced IFN-γ secretion by co-cultured T cells, hence reduced Th1 responses, which are linked to
inflammatory disorders and many chronic inflammatory diseases [48,49]. As IL-12 is the main inducer
of Th1 polarization of T cells with subsequent IFN-γ secretion [50], the down-regulation of IFN-γ
observed in the co-culture of T cells with DCs is most likely resulting from a reduced ability of the DCs
matured in the presence of compounds 2 and 3 to secrete IL-12p40 (one of the two chains that form the
IL-12 molecule). Compound 2 did not affect IL-10 secretion by DCs but compound 3 increased IL-10
secretion by DCs. Therefore, the decreased concentration of IL-10 in co-cultures of T cells and DCs
matured in the presence of compounds 2 and 3 was unexpected. The reduced IL-10 levels observed
in the co-cultures were most likely the result of reduced secretion by the T cells but not the DCs, but
whether it is so needs to be confirmed, e.g., by intracellular staining for IL-10 on T cells and DCs in
the co-culture experiments. Although the decreased secretion of IL-10 in the co-cultures may hamper
the anti-inflammatory effect of compounds 2 and 3, the downregulation of IFN-γ secretion is strongly
suggestive of inhibition of inflammatory Th1 response and subsequently that compounds 2 and 3 may
have the potential of being a starting point for development of new anti-inflammatory drugs.
The anti-inflammatory effect of compound 4, shown previously in a monocytic cell line [6], was
confirmed in the present study as it downregulated secretion of IL-12p40 by the DCs. However,
compound 4 also downregulated IL-10 production, which could interfere with the anti-inflammatory
effect observed by reduced IL-12p40 secretion. This seemed to be the case as, when DCs treated
with compound 4 were co-cultured with T cells, the effect of compound 4 was not anti-inflammatory
as neither Th1 nor Th17 cytokines were affected. These results were unexpected and suggest that
the effect of compound 4 to decrease IL-10 secretion by the DCs seems to be the determining factor,
overriding the effect of downregulation of IL-12p40 and subsequently leading to a reduction in IL-10
in the co-culture of the two cell types.
Despite structural similarities of compounds 1, 2, 4, and 5, which all possess the structure of
a DKP-type cyclic dipeptide, there were remarkable differences in their anti-inflammatory effects.
Oxidation of the indole ring in compound 1 as compared with compound 4 caused the disappearance
of the anti-inflammatory activity, indicating that the indole skeleton is important in inhibition of
cytokine secretion by the DCs. Both the number and the position of double bonds on the DKP-type
cyclic dipeptide may affect the anti-inflammatory activity (2 vs. 4 vs. 5). The disappearance of the
double bond at C-8 could decrease the anti-inflammatory activity, as compound 5 did not affect
cytokine secretion by the DCs whilst compounds 4 and 2 did, suggesting that the double bond at C-8
is required for the activity. However, the double bond at C-12 may be responsible for the reduction
of anti-inflammatory activity when comparing compound 2 with compound 4. Considering these
observations, the bromotryptophan containing the double bond at C-8 may be important for the
activity. The double bond at the N,N,N-trimethylethanaminium group increased the suppression of
IL-12p40 production and increased the IL-10 secretion (6 vs. 7). Collectively, 6-bromoindole derivatives
may have anti-inflammatory activity that depends on the bromotryptophan nucleus (1, 2, 4, and 5) or
the side chain at C-3 position of the 6-bromoindole (3, 6, and 7), suggesting that there may be more
than one potential target site or mode of action.
The observations described above indicate that G. barretti is a prolific source of 6-bromoindoles
with potential anti-inflammatory activities, which may be a starting point for the development of new
drug s with a potential for being used in the treatment of inflammatory diseases in the future.
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4. Materials and Methods
4.1. General Produres
Optical rotations were measured on a P-2000 polarimeter (Jasco, OK, USA) equipped with a 10
mm pathlength cell. UV spectra were recorded on a NanoVueTM spectrophotometer (GE Healthcare
Life Science, Little Chalfont, UK). ECD spectra were measured on a JASCO J-810 spectropolarimeter in
quartz cells (1 or 5 mm pathlength) at 23 ◦C. IR spectra were measured on a Spectrum TwoTM FTIR
spectrometer (Perkin Elmer, Waltham, MA, USA). NMR spectra were recorded on a Bruker AM-400
spectrometer (proton frequency 400.13 MHz and carbon frequency 100.62 MHz, respectively) for
compounds 4–7 (in CD3OD and/or DMSO-d6) using TMS as an internal standard or a Bruker Avance
600 spectrometer (proton frequency 600.13 MHz and carbon frequency 150.76 MHz, respectively)
for compounds 1 (in CD3OD and DMSO-d6), 2–3 (in CD3OD), and 7 (in DMSO-d6). The 1H NMR
spectrum of compound 8 (in CDCl3) was recorded on a Varian Mercury 400 spectrometer and the
13C NMR spectrum was measured on a Varian Xsens 500 spectrometer equipped with a 13C{1H}
cryoprobe at 125 MHz. High-resolution mass spectra were obtained on a Waters G1 Synapt qTOF
mass spectrometer. An UHPLC system (ACQUITY UPLC Waters) was coupled in line with a qTOF
mass spectrometer (Synapt G1, Waters) operating in the positive mode. HPLC was performed on a
Dionex 3000 HPLC system equipped with a G1310A isopump, a G1322A degasser, a G1314A VWD
detector (210 nm), a 250 × 21.2 mm Phenomenex Luna C18(2) column (5 μm), and a 250 × 4.6 mm
Phenomenex Gemini-NX C18 column (5 μm). Alkaloids were detected by TLC on Merck silica gel F254
plates by immersing the plates in Dragendorff’s reagent. VLC chromatography was performed on C18
adsorbent (LiChroprep RP-18, 40–63 μm, Merck Inc., Darmstadt, Germany). All organic solvents were
purchased from Sigma-Aldrich and were HPLC grade or the highest degree of purity.
4.2. Animal Materials
The sponge material Geodia barretti was collected in the west of Iceland (65◦27.6′ N–30◦46.6′ W)
at 388 m depth in September 2010. The sponge was identified by Dr. Hans Tore Rapp, University
of Bergen (Norway). A voucher specimen was deposited at the Department of Natural Products
Chemistry, Faculty of Pharmaceutical Sciences, University of Iceland. The collected specimens (six in
total) (wet weight, 1.8 kg) were immediately frozen and stored at −20 ◦C.
4.3. Extraction and Isolation
The frozen sponge material was cut into small pieces and lyophilized prior to extraction with
CH2Cl2:CH3OH (v/v, 1:1) mixture (3 × 20 L, each for 24 h) at room temperature. The combined extracts
were concentrated under vacuum to yield a dark gum and stored at −20 ◦C. The crude extract (1.8 g)
was submitted to a modified Kupchan partition to yield five subextracts, namely hexane (fraction A),
chloroform (fraction B), dichloromethane (fraction C), n-butanol (fraction D), and water (fraction E).
Each fraction was analyzed by UPLC-qTOF-MS before preparative-scale isolation work commenced
and the data were processed and analyzed by MassLynx programme and compared to available
references in ChemSpider database [51] and SciFinder Scholar (Chemical Abstracts Service, Columbus,
OH, USA). The fractions B and C showed similar patterns on TLC and the analysis of qTOF-MS data
revealed similar chemical compositions. Thus, they were combined and fractionated by VLC on a C18
reversed-phase column using gradient elution of MeOH-H2O (10:90→ 100:0) mixtures to obtain nine
fractions (F2.1−F2.9). F2.2 (750 mg) was purified by preparative HPLC (28:72:0.1 CH3CN-H2O-TFA,
8.0 mL/min) to afford compounds 3 (3.5 mg), 4 (7.3 mg), and 6 (1.5 mg) and two impure fractions
(F2.2.1 and F2.2.2). F2.2.1 (78.9 mg) was purified by semi-preparative HPLC using CH3CN-H2O-TFA
(27:73:0.1) to yield compounds 1 (1.8 mg) and 5 (1.2 mg). F2.2.2 (10.1 mg) was also re-chromatographed
by semi-preparative HPLC (ACN-H2O-TFA, 31:69:1) to give compound 7 (5.3 mg). F2.4 (12.1 mg) was
purified by semi-preparative HPLC (30:70:0.1 MeOH-H2O-TFA, 2.2 mL/min) to yield compound 2
(3.0 mg).
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Geobarrettin A (1): yellow solid (1.8 mg); [α]27D +7 (c 0.2, MeOH); UV (MeOH) λmax (log ε) nm: 217 (3.17),
263 (2.64); IR νmax cm−1: 3352, 3214, 1679, 1441, 1205, 1138, 1057, 841, 802, 724; 1H and 13C NMR data,
see Table 1; HRESIMS m/z 451.0728 [M + H]+ (calcd for C17H2079BrN6O4, 451.0729).
Geobarrettin B (2): yellow solid (3.0 mg); UV (MeOH) λmax (log ε) nm: 231 (3.62), 270 (3.39), 289 (3.41),
372 (3.51); IR νmax cm−1: 3297, 1677, 1438, 1206, 1139, 843, 803, 725; 1H and 13C NMR data, see Table 1;
HRESIMS m/z 417.0675 [M + H]+ (calcd for C17H1879BrN6O2, 417.0675).
Geobarrettin C (3): yellow solid (3.5 mg); UV (MeOH) λmax (log ε) nm: 211 (3.42), 247 (3.17), 269 (3.12),
283 (2.95); IR νmax cm−1: 3207, 1676, 1523, 1445, 1203, 1134, 892, 802, 722; 1H and 13C NMR data, see
Table 1; HRESIMS m/z 295.0440 [M]+ (calcd for C13H1679BrN2O+, 295.0446).
Barettin (4): dark yellow solid (7.3 mg); [α]25D −84 (c 0.5, MeOH), lit. [α]26D −32.5 (c 2, MeOH) [18], lit.
[α] −25 (c 3, MeOH); HRESIMS m/z 419.0830 [M + H]+ (calcd for C17H2079BrN6O2, 419.0831); all
remaining spectroscopic data are in good agreement with those previously published [9].
8,9-Dihydrobarettin (5): yellowish solid (1.2 mg); [α]25D −12.5 (c 0.096, MeOH), lit. [α]21D −24 (c 0.096,
MeOH); HRESIMS m/z 421.0987 [M + H]+ (calcd for C17H2279BrN6O2, 421.0988); all remaining
spectroscopic data are in good agreement with those previously published [11].
6-Bromoconicamin (6): colorless amorphous solid (1.5 mg); HRESIMS m/z 279.0495 [M]+
(C13H1679BrN2+, 279.0497); all remaining spectroscopic data are in good agreement with those
previously published [14].
L-6-Bromohypaphorine (7): yellow solid (5.3 mg); [[α]23D +36 (c 0.2, EtOH); HRESIMS m/z 325.0550
[M + H]+ (calcd for C14H1879BrN2O2, 325.0546); all remaining spectroscopic data are in good agreement
with those previously published [46].
4.4. Hydrogenolysis of R-Dioxindole (8a) to (R)-3-Propyldioxindole (8)
To a solution of (R)-dioxindole (8a) (16.7 mg, 59 μmol) (92% ee, [α]D −30 (c 0.72, MeOH); lit.
(88% ee) −24.3 (c 0.8, MeOH) [37]) in MeOH (5.0 mL) containing Et3N (3 drops) was added 10% Pd-C
(10 mg). The mixture was evacuated-purged with H2 and allowed to hydrogenate (1 atm, H2) for 7 h.
Filtration of the mixture (Celite), followed by concentration of the eluate and passage through a short
plug of silica (1:1 EtOAc-hexanes) to remove Et3N•HBr gave (R)-3-propyldioxindole (8) as a colorless
solid. UV (CF3CH2OH) λmax (log ε) nm: 208 (3.10), 257 (3.32), 268 (sh), 286 (2.74). CD (CF3CH2OH)
λmax (Δε) nm: 208 (+13.1), 219 (0), 232 (−10.7), 249 (0), 259 (+3.5). [α]D + 96 (c 0.19, MeOH); + 50 (c 0.21,
CF3CH2OH). IR (ZnSe) νmax 3404, 2962, 1703, 1609, 1495, 1470, 1377, 1119, 1082, 754 cm–1; 1H NMR
(CDCl3, 400 MHz) δ 7.37 (1H, d, J = 7.2 Hz, H-4), 7.33 (1H, t, J = 7.6 Hz, H-6), 7.10 (1H, t, J = 7.6 Hz,
H-5), 6.83 (1H, d, J = 7.6 Hz, H-7), 3.19 (3H, s, N-Me), 1.93 (2H, m, CH2-1′), 1.12 (2H, m, CH2-2′); 0.84
(3H, t, J = 7.2 Hz, C-CH3-3′); 13C NMR (CDCl3, 125 MHz) δ 178.4 (C, C-2), 143.6 (C, C-7a), 130.1 (C,
C-3a), 129.7 (CH, C-6), 124.0 (CH, C-5), 123.2 (CH, C-4), 108.5 (CH, C-7), 76.8 (C, C-3), 40.9 (CH2, C-1′),
26.3 (CH3, N-Me), 16.8 (CH2, C-2′), 14.2 (CH3, C-3′); HRESIMS m/z 228.0992 [M + Na]+ (calcd for
C12H15NO2Na+, 228.0995) (Figures S26–S30).
4.5. Hydrogenolysis of Geobarrettin A (1) to Debromodihydrogeobarrettin A (1a)
A sample of compound 1 was hydrogenated (1 atm H2, MeOH, 20 equiv. Et3N) for 15 h.
The mixture was filtered and concentrated to give a colorless solid (~0.4 mg) consisting of an
equimolar mixture of debromodihydrogeobarrettin A (1a) and Et3N•HBr that was used, directly,
for CD measurements and subsequent hydrolysis-DTA derivatization. UV-vis (CF3CH2OH) λmax
(log ε) nm: 207 (4.15), 269 (3.65), 281 (sh) (Figure S31); CD (CF3CH2OH) λmax (Δε) nm: 208 (+13.1), 232
(−10.7), 259 (+3.5). Identical with that of (R)-(8) (Figure 3).
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4.6. Acid Hydrolysis of Debromodihydrogeobarrettin B (1a)
Approximately 0.31 mg of compound 1a was separately hydrolyzed with 6 M HCl (0.8 mL) for
15 h at 110 ◦C, dried under a stream of N2 followed by high vacuum to remove volatiles, and the
resulting material subjected to further derivatization (see below).
4.7. Absolute Configuration of the Amino Acid of Geobarrettin A (1)
The determination of absolute configuration of the amino acids was performed as previously
described [41]. After hydrolysis of 1a, the residue was dissolved in acetone (50 μL) and treated
with L-FDTA (25 mM in acetone, 50 μL) and 1 M NaHCO3 (50 μL) and heated to 80 ◦C for 20 min.
After cooling to 23 ◦C, the sample was quenched with 1 M HCl (50 μL), centrifuged, and the
supernatant analyzed by RP HPLC (10 μL injection, Phenomenex Luna C18, 4.6 × 250 mm, gradient
elution profile (15/85–65/35 CH3CN-H2O-0.1 M NH4OAc-0.1% TFA, over 40 min, 0.7 mL/min).
The L-FDTA derivatives were detected by UV-vis (λmax 335 nm). Two peaks were eluted with
retention times (ratio 19:81), coinciding with authentic L-DTA derivatives of D-Arg (25.33 min), L-Arg
(26.78 min), respectively.
4.8. Absolute Configuration of the Amino Acid of Barettin (4)
A sample of barettin (4, 1.7 mg) was hydrogenated (1 atm H2, 10% Pd-C, MeOH) for 19 h.
The mixture was filtered and concentrated to give debromo-8,9-dihydrobarettin (5a) as a colorless solid
(1.4 mg) consisting of an equimolar mixture of C-3 epimers. HRESIMS m/z 343.1874 [M + H]+ (calcd for
C17H23N6O2, 343.1877). The residue was hydrolyzed under standard conditions (6 M HCl, 15 h, see
above) and the hydrolysate converted to the L-DTA derivatives and analyzed by RP HPLC as before.
Two peaks, A and B, were eluted with retention times of tR = 25.33 and 26.78 min (ratio A:B = 19:81),
respectively, coinciding with authentic L-DTA derivatives of D- and L-Arg (25.33 and 26.78 min,
respectively). When the same procedures were conducted on 4 without prior hydrogenation, D- and
L-Arg-L-DTA derivatives were obtained in a ratio of 19:81 indicating partially racemic 4 (62% ee).
4.9. Maturation and Activation of DCs
DCs were developed and matured from human monocytes as previously described [52,53].
CD14+ monocytes were isolated from peripheral blood mononuclear cells obtained from
healthy human donors using CD14 Microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany).
Immature DCs were obtained by culturing CD14+ monocytes at 5 × 105 cells/mL for 7 days in the
presence of IL-4 at 12.5 ng/mL and GM-CSF at 25 ng/mL (both from R&D Systems, Abingdon,
England), with fresh medium and cytokines added at day 3. The immature DCs were matured and
activated by culturing them at 2.5 × 105 cells/mL for 24 h with IL-1β at 10 ng/mL, TNF-α at 50 ng/mL
(both from R&D Systems), and lipopolysaccharide (LPS) at 500 ng/mL (Sigma-Aldrich, Munich,
Germany). Pure compounds were dissolved in DMSO at the concentration of 10 μg/mL and added to
the DCs at the same time as the cytokines and LPS. The final concentration of DMSO in the medium of
DCs cultured with the pure compounds was 0.002% and the same concentration of DMSO was used as
solvent control. In order to determine whether the effects of compounds 2–4 were dose-dependent,
the concentrations of 2.5, 5, 7.5, 10 μg/mL were used. After 24 h the mature and activated DCs were
harvested and the effects of the pure compounds on DC maturation and activation determined by
measuring cytokine concentration in the culture medium by ELISA. Cell viability was determined by
counting cells following staining with trypan blue and calculating the percentage of live cells.
4.10. Co-Culture of DCs and Allogeneic CD4+ T Cells
DCs matured in the presence/absence of a pure compound at 10 μg/mL or solvent control
only were co-cultured with allogeneic CD4+ T cells at DC:T cell ratio of 1:10 (2 × 105 DCs/mL:
2 × 106 T cells/mL) for 6 days. CD4+ T cells were obtained from PBMCs using CD4 Microbeads
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(Miltenyi Biotec). The effects of the pure compounds on the ability of the DCs to differentiate the
CD4+ T cells were determined by measuring cytokine concentrations in the co-culture supernatants
by ELISA.
4.11. Determination of Cytokine Concentration by ELISA
The concentrations of IL-12p40 and IL-10 in culture supernatants from DCs and of IFN-γ, IL-17 and
IL-10 in supernatants from co-cultures of DCs and allogeneic CD4+ T cells were measured by sandwich
ELISA using DuoSets from R&D Systems according to the manufacturer’s protocol. The results were
expressed as secretion index (SI), which was calculated by dividing the cytokine concentration in
supernatants from DCs cultured with pure compound or co-cultures of these DCs with allogeneic CD4+
T cells by the cytokine concentration in supernatants of DCs cultured with solvent only or co-cultures
of these DCs with allogeneic CD4+ T cells.
4.12. Statistical Analysis
Data are presented as the mean values ± standard error of the mean (SEM). As the data were not
normally distributed, Mann-Whitney U test or Kruskal Wallis one-way ANOVA with Tukey’s post-hoc
test were used to determine statistical differences between treatments (SigmaStat 3.1, Systat Software,
San Jose, CA, USA) and p < 0.05 was considered as statistically significant.
5. Conclusions
In conclusion, three new 6-bromoindole derivatives, geobarrettin A–C (1–3), and four known ones
(4–7) were obtained from the marine sponge G. barretti collected from west of Iceland. Compounds
2, 3 and 4 showed anti-inflammatory properties by inhibiting DC secretion of IL-12p40 with varying
effects on IL-10, and the anti-inflammatory effect of compounds 2 and 3 was confirmed by inhibition
of IFN-γ secretion in co-cultures of T cells and DCs matured in the presence of the compounds. It is
increasingly being recognized that low-grade, subclinical inflammation is a significant pathogenic
factor in many chronic diseases that have not, until now, been considered inflammatory in nature.
Importantly, this includes most diseases that today are the main cause of morbidity and mortality in
Western countries, such as atherosclerotic diseases, cancers, chronic pain disorders, and Alzheimer’s
disease [54]. Therefore, the discovery of the two new 6-bromoindole derivatives with anti-inflammatory
effects is important as they could be used in the development of treatments for diseases with
inflammatory components.
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Abstract: Prostaglandins (PGs) are lipid mediators belonging to the eicosanoid family. PGs were
first discovered in mammals where they are key players in a great variety of physiological and
pathological processes, for instance muscle and blood vessel tone regulation, inflammation, signaling,
hemostasis, reproduction, and sleep-wake regulation. These molecules have successively been
discovered in lower organisms, including marine invertebrates in which they play similar roles to
those in mammals, being involved in the control of oogenesis and spermatogenesis, ion transport,
and defense. Prostaglandins have also been found in some marine macroalgae of the genera Gracilaria
and Laminaria and very recently the PGs pathway has been identified for the first time in some species
of marine microalgae. In this review we report on the occurrence of prostaglandins in the marine
environment and discuss the anti-inflammatory role of these molecules.
Keywords: prostaglandins; clavulones; punaglandins; thromboxane; inflammation; marine
vertebrates; marine invertebrates; diatoms; macroalgae
1. Introduction
Marine organisms have a great potential to produce a vast variety of bioactive molecules with
high antibiotic, anti-proliferative, and anti-inflammatory activity [1]. The biodiversity hosted by the
oceans is greater than in terrestrial environments [2] but nonetheless, marine bioresources are still
underexplored, and many species await to be discovered.
The high probability to find new interesting bioactive molecules from marine organisms has
fostered the effort of the scientific community to adopt new technologies and approaches to increase the
success of biodiscovery from marine resources, with a main focus on products with antibiotic, antitumor
and anti-inflammatory activities. Of particular interest is the search for new anti-inflammatory
compounds since inflammation processes are often related to the onset of chronic pathologies
and tumors.
Indeed, inflammation processes represent a fundamental way to restore the original equilibrium
of a cell or tissue whose physiology has been impaired by damaging stimuli [3]. At the same time,
if inflammation is not blocked it can stimulate a cascade of events that eventually lead to serious
diseases such as cancer and autoimmune disorders [4]. The inflammation-resolution process can
have different features depending on the type of tissue and injurious stimulus [5], therefore, specific
types of pro-resolution stimuli or drugs may be necessary [6]. Both the onset and the resolution of
the inflammation are active processes that involve a complex interplay of different molecules [7] like
chemokines, cell adhesion molecules, proteolytic enzymes, eicosanoids [8], reactive oxygen species
(ROS), and reactive nitrogen species (RNS) [9,10]. Among these, eicosanoids deriving from oxidation of
polyunsaturated fatty acids (PUFA) through cyclooxygenase (COX) and lipoxygenase (LOX) pathways
play a pivotal role both in the onset and in the resolution of inflammation [9]. The main products of
COX enzymes are prostaglandins (PGs), fatty acid derivatives with a molecular structure based on 20
carbon atoms that share a prostanoic acid skeleton.
Mar. Drugs 2019, 17, 428; doi:10.3390/md17070428 www.mdpi.com/journal/marinedrugs179
Mar. Drugs 2019, 17, 428
Prostaglandin E2 was the first PGs to be identified in the early 1930s in human seminal plasma by
Von Euler [11] and, independently, by Goldblatt [12] although the chemical structures were determined
only 30 years later by Bergström, Samuelsson, and co-workers [13].
PGs are very well studied and described in mammals where they are active in a great variety of
physiological and pathological processes such as smooth muscle and vaso-tone regulation, signaling,
hemostasis sleep-wake regulation, reproduction, and especially inflammation. In these organisms,
they are synthetized and released in response to external stimuli [14] and rapidly inactivated by
metabolizing enzymes after they have accomplished their function [15].
PGs represent very important and interesting lipid mediators in all vertebrates and in both
terrestrial and marine invertebrates [16,17]. Plants utilize chemically related molecules (jasmonic acid)
that have a defensive role, similarly to PGs [16,18,19]. Nevertheless, in some plant species like onions
and poplar, a few PGs have also been identified [20].
In the marine environment, prostaglandins have been reported both in vertebrates such as carps,
sheatfish and leopard sharks, and invertebrates such as sea squirts, mussels, scallops, crawfish, blue
crabs, and sea-anemones and in some macroalgae as the red alga Gracilaria asiatica C. F. Zhang & B. M.
Xia, 1985 and the brown alga Laminaria digitata (Hudson) J. V. Lamouroux, 1813.
The earliest report about the presence of prostaglandins in marine invertebrates was by Weinheimer
and Spraggins (1969) that discovered 15-epi-prostaglandin A2 and its acetate methyl ester in the
gorgonian-type coral Plexaura homomalla Esper, 1794 [21]. The discovery of high PGs levels in
gorgonians contributed to the rapid growth of the study and application of PGs in the pharmaceutical
and biomedical sector [22].
Very recently, Di Dato et al. (2017) described the presence of all the three series of PGs molecules
also in diatoms, an ecologically successful group of marine microalgae [23].
In this review, we present a short background on prostaglandin structure and function and give
an updated overview of the presence of PGs in marine organisms, discussing the anti-inflammatory
role of PGs from the marine environment.
2. Structure, Biosynthesis, and Activity of Prostaglandins in Mammals
Prostaglandins consist of a cyclopentanone nucleus with two side chains. Primary prostaglandins,
which include prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α),
and prostaglandin I2 (PGI2), contain a 15-hydroxyl group with a 13,14-trans double bond (Figure 1).
Currently, three classes of prostaglandins are categorized, based on the number of double bonds
present within the molecule and on the fatty acid precursor. Prostaglandins belonging to the series 1
have one double bond and derive from 8,11,14-eicosatrienoic acid (di-homolinolenic acid, ETrA), those
of the series 2 have two double bonds and derive from 5,8,11,14-eicosatetraenoic acid (arachidonic acid,
ARA), and those of the series 3 have three double bonds and derive from 5,8,11,14,17-eicosapentaenoic
acid (EPA).
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Figure 1. Prostaglandin biosynthetic pathway. Enzymes involved in the pathway are reported next to
the arrows. For the abbreviation, refer to the text. Modified from [24].
Their nomenclature comprises 10 specific molecular groups, identified by the letters A through J,
that differ by variation in the functional groups attached to positions 9 and 11 of the cyclopentane ring.
For PGF, the additional subscript “α” or “β” denotes the spatial configuration of the carbon 9 hydroxyl
group. For additional details on the nomenclature of prostaglandins see Lands, 1979 [25].
PGs action is mediated by the interaction with specific receptors present on the plasma membrane.
These are transmembrane G-protein coupled receptors (GPCR), named as prostaglandin EP receptor
(EP), prostaglandin F2α receptor (FP), prostaglandin DP receptor (DP), and prostacyclin I2 receptor
(IP) receptors, that are highly selective for PGE2 PGF2α, PGD2, and PGI2, respectively [26]. The EP
family comprises four isoforms (EP1-4) that play a relevant role in inflammation processes [27]. The
downstream signaling of this receptor family is responsible for the pleiotropic ability of PGE2 to activate
different processes, including cell proliferation, apoptosis, angiogenesis, inflammation, and immune
surveillance in different cell types [24].
Most prostaglandins display a marked structure-activity specificity mainly determined by
substitutions in the cyclopentanone ring and the degree of unsaturation of the side chains. They
exert their function once secreted into the extracellular medium, where they are rapidly metabolized
by 15-hydroxyprostaglandin dehydrogenase (15-OH-PGDH). This enzyme selectively oxidizes the
hydroxyl group at carbon 15 into a 15-keto derivative [28] accompanied by a substantial loss of
biological activity.
Prostaglandins derive from the sequential actions of highly specific enzymes (Figure 1). Their
synthesis is initiated by phospholipases A2 (PLA2), a family of enzymes that hydrolyze membrane
phospholipids at the sn-2 position, liberating free fatty acid precursors, mainly ARA [15]. These
enzymes represent a key step in the PG biosynthetic pathway, being regulated by Ca2+ binding
and phosphorylation by mitogen-activated protein kinase (MAPK) in response to different stimuli.
Membrane-released ARA is then rapidly converted through the cyclization and inclusion of molecular
oxygen in the precursor by the action of cyclooxygenase (COXs) enzymes into the unstable metabolite
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PGG2, which is subsequently reduced to PGH2 by the same enzyme [14]. Cyclooxygenases exist in
a substrate-limiting environment; thus, liberation of fatty acids from esterified stores results in the
prompt formation of the products. There are two major COX isoforms; COX-1 is constitutively active
and present in most cells in the body; expression of the COX-2 isoform is inducible in many tissues
by pro-inflammatory and mitogenic stimuli, such as cytokines [29]. The specific transformation of
the first product PGH2 to other PGs and thromboxanes (TXs) by downstream enzymes is complexly
orchestrated and is cell specific, since each cell tends to form mainly one of these compounds as
the major product. For example, in brain and mast cells, PGH2 is converted to PGD2, whereas it is
converted in PGF2α in the uterus; from the same precursor, vascular endothelial cells produce PGI2
(prostacyclin) and platelets release thromboxane A2 (TXA2).
The conversion to PGE2, the most widespread PG, is due to PGE synthase-1, also present in
different isoforms in mammals: microsomal PGE synthase-1 (mPTGES-1), mPTGES-2, and cytosolic
PGE synthase (cPTGES), the latter of particular interest since frequently associated to the tumorigenic
activity of PGE2 [30].
Prostaglandin E2 synthesis is a key event for the development of the three principal signs of
inflammation: swelling, redness, pain and fever. Moreover, PGE2 also contributes to the amplification
of the inflammatory response by enhancing and prolonging signals produced by pro-inflammatory
agents, such as interleukin 1α bradykinin, histamine, neurokinins, and complement [31,32]. These
signals, in turn, can increase COX-2 expression thus further increasing PGE2 synthesis. This PG,
however, can have a double, inverse role, being also able to act as an immunosuppressant, repressing
the differentiation of T helper 1 cells and limiting cytokine release and further prostaglandin synthesis
by activating a negative feedback on mPGES-1 (Figure 2a).
PGD2-synthesizing enzymes exist as two distinct genes coding for hematopoietic- and
lipocalin-type PGD synthases (H-PTGDS and L-PTGDS, respectively). H-PTGDS is generally localized
in the cytosol of immune and inflammatory cells, whereas L-PTGDS has a tissue-based expression [33].
The activity of PGD2 has been mainly associated with inflammatory conditions, being involved in
immunologically relevant functions. Its action seems to be mediated by the non-enzymatic production
of the PGJ2 family, which occurs through a spontaneous dehydration in aqueous solutions. One of the
most studied PGJ2 metabolites, 15-deoxy-Δ12-PGJ2 (15dPGJ2), showed anti-inflammatory properties
based on interaction with the intracellular targets Nuclear Factor kappa-light-chain-enhancer of
activated B cells (NF-κB), Activator Protein 1 (AP-1), and Peroxisome Proliferator-Activated Receptor
gamma (PPAR-γ) [31]. 15dPGJ2 also induces the reduction of neutrophil migration and inhibits the
release of Interleukin 6 (IL-6), Interleukin 1β (IL-1β), Interleukin 12 (IL-12), and Tumor Necrosis
Factor-α (TNF-α) from macrophages (Figure 2b).
PGD2 can be further metabolized to PGF2α, although the latter can also be synthesized from
PGH2 via PGF synthase. PGF2α acts via FP receptors, resulting in the elevation of intracellular
free calcium concentrations that regulates numerous important physiological functions related to
reproduction linking multiple molecular mechanisms that are fine-tuned coordinated events in
mammalian physiology [34] (Figure 2c). The emerging role of PGF2α in acute and chronic inflammation
has opened new opportunities for the design of novel anti-inflammatory drugs.
A non-enzymatic dehydration reaction is also responsible for the formation of the PGA series
from the corresponding PGE. The PG series A and J contain an α,β-unsaturated carbonyl group within
the cyclopentenone ring, which seem to contribute to the anti-inflammatory activity of these PGs [35].
The enzyme prostaglandin I synthase (PGIS), a member of the cytochrome P450 superfamily,
specifically converts PGH2 to PGI2 [33]. This PG has anti-mitogenic activity and inhibits DNA synthesis
through specific IP receptors. It mediates pro-inflammatory stimuli in non-allergic acute inflammation,
while acting as an anti-inflammatory mediator in Th2-mediated allergic inflammatory responses. Soon
after having exerted its action, PGI2 is rapidly converted by non-enzymatic processes to the inactive
product 6-keto-PGF1α (Figure 2d).
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Figure 2. Prostaglandins and inflammation. (a) Prostaglandin E2 (PGE2) stimulation of inflammatory
response. Numbers indicate the sequence of events from PGE2 synthesis to stimulation of inflammation
trough positive feedback on cyclooxygenase (COX)-2 and negative feedback on microsomal PGE
synthase-1 (mPTGES-1); (b) The anti-inflammatory role of prostaglandin J2 (PGJ2); (c) prostaglandin
F2α (PGF2α) signaling; (d) prostaglandin I2 (PGI2) signaling. For details, refer to the text.
3. Prostaglandins and Derivative Molecules in Marine Organisms
Similar to terrestrial vertebrates, in marine vertebrates prostaglandins are involved in reproduction,
osmoregulation, regulation of oxygenation, and cardiovascular system [36]. Marine invertebrates,
including sponges, corals, and molluscs, also contain a wide range of prostaglandins, many of which
are of the conventional type (PGA2, PGE2, PGD2, PGF2α), with similar functions as in mammals
(reproduction, ion transport) and are also probably used as defense compounds [17]. Interestingly,
in some invertebrates, PGs are able to perform different actions based on the tissue or compartment
localization [37].
Complex marine photosynthesizing organisms, like some genera in the brown, green, and red
algal groups (respectively, Laminaria, Euglena, and Gracilaria species) express the cyclooxygenase gene
synthesizing PGE2, PGF2α, and other PGs whose functions are not yet known, but seem to be associated
to a defensive role [17].
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3.1. Corals
Among marine invertebrates, corals represent a very interesting group producing specific PGs
that are not present in mammals. The Caribbean gorgonian Plexaura homomalla was indeed the species
in which PGs were firstly identified in a marine organism, representing also a major source of these
compounds in nature [38] (Figure 3a).
Figure 3. Corals prostaglandins. (a) Plexaura homomalla; (b) Euplexaura erecta; (c) Lobophytum
depressum; (d) Gersemia fruticosa.
Weinheimer A. and Spraggins R. were the first to perform PGs extraction in P. homomalla, identifying
in its dry cortex 15-epi-PGA2 and its methyl ester acetate (respectively 0.2% and 1.3%) [15] in an
R-configuration on their C-15 asymmetric center, a configuration not present in mammals. In addition
to (15R)-epi-PGA2, also (15R)-PGE2, its methyl ester and a complex mixture of other prostaglandins
were subsequently found by Light R. and Samuelsson B. [39]. However, these molecules were found
also in S configurations [40] and the occurrence of one of the two seems to be related to the geographical
distribution of P. homomalla [38].
The high PGs concentration in these invertebrates stimulated the attempt to use them as precursors
for the chemical synthesis of the biologically active prostaglandins A2, E2, and F2α, since their chemical
synthesis in large-scale for medical and pharmaceutical purposes was complicated by the necessity of
16 different chemical reactions [41].
The observation that P. homomalla present in coral reefs is not commonly eaten by fishes,
led Gerhart [42] to hypothesize that the high amount of PGs they contain could be used as chemical
defense against potential predators, since it is known that in mammals they can cause vomiting and
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nausea when administered orally. Indeed, oral doses of both (15R)-PGA2 and (15S)-PGA2 caused
vomiting in a test with fishes, while the PGA2 present in the surrounding water did not cause any
effect [42]. However, the hypothesized defensive role seems not to be realistic since PGA2 is stored in
coral tissues only as acetoxy methyl esters, whose conversion to (15R)-PGA2 (the compound tested
by Gerhart) needs about 24 hours [40]. Moreover, while (15R)-PGA2 inhibits fishes from feeding,
the acetoxy methyl ester form, orally delivered, does not show any repellent effect. For this reason,
as the process of production of the active (15R)-PGA2 seems too slow to provide the coral with an
effective defense mechanism, the function of these molecules in corals is still an open question.
The R-prostaglandins extracted from P. homomalla collected on the Island of San
Andreas, in the Caribbean Ocean, were also tested in vivo on mouse ear edema induced by
12-O-tetradecanoylphorbol-13-acetate (TPA) and in vitro, in anti-inflammatory screenings as leucocyte
degranulation, myeloperoxidase (MPO), and elastase enzymatic activity inhibition. The results showed
that (15R)-PGE2 and, to a lesser extent, (15R)-O-AcPGA2 had an anti-inflammatory activity in vivo and
in vitro (Table 1). In particular, in the leucocyte degranulation assay, (15R)-PGE2 greatly inhibited the
release of both MPO and elastase, while the other prostaglandins tested were moderately active in the
inhibition of elastase release but not of MPO [43].




Activity Target Cells Reference
(15R)-PGE2
(15R)-O-AcPGA2
Plexaura homomalla Anti-inflammatory Leucocyte/TPA-inducedmouse-ear edema Reina et al., 2013 [43]
Clavulones I-III Clavularia viridis Anti-inflammatory fertilized chicken eggs Kikuchi et al., 1983 [44]
Clavulones I-III Clavularia viridis Anti-cancer HL-60 Honda et al., 1985 [45];Huang et al., 2005 [46]
Clavulone II Clavularia viridis Anti-viral VSV infected L929 Bader et al., 1991 [47]
Chlorovulone I Clavularia viridis Anti-proliferativeand cytotoxic HL-60 Iguchi et al., 1985 [48]
PGs
Epoxy-prostanoid Clavularia viridis Anti-proliferative HL-60 Iguchi et al., 1987 [49]
Bromovulone I and
Iodovulone I Clavularia viridis
Anti-proliferative
and cytotoxic HL-60 Iguchi et al., 1986 [50]
Bromovulone III Clavularia viridis Cytotoxic PC-3/HT-29 Shen et al., 2004 [51]
Chlorovulones II
and III Clavularia viridis Cytotoxic PC-3/HT-29 Shen et al., 2004 [51]
Claviridenone F Clavularia viridis Cytotoxic A549/HT-29/P-388 Duh et al., 2002 [52]
Claviridenone G Clavularia viridis Cytotoxic A549 Duh et al., 2002 [52]
Clavirins I-II Clavularia viridis Growth-inhibition HeLa S3 Iwashima et al., 1999 [53]
Clavubicyclone Clavularia viridis Growth-inhibition MCF-7/OVCAR-3 Iwashima et al., 2002 [54]
Punaglandins I–IV Telesto riisei Cytotoxic L1210 Baker et al., 1985 [55]
Euplexaura erecta Kükenthal, 1908 [56] (Figure 3b), Lobophytum depressum Tixier-Durivault, 1966 [57]
(Figure 3c), and Gersemia fruticosa Sars, 1860 [58] (Figure 3d) also produce PGs. Interestingly, PGF2α and
its derivatives were principally found in these species: PGF2α in E. erecta [56]; (15S)-PGF2α-11-acetate
methyl ester, its 18-acetoxy derivative compound and their corresponding free carboxylic acids in
L. depressum [57]; PGF2α and 15-keto-PGF2α together with PGD2, PGE2 in G. fruticosa [58].
In addition to the identification of PGs molecules in corals, also the enzyme responsible for their
synthesis, the cyclooxygenase, was isolated and characterized for the first time from P. homomalla and
G. fruticosa [59].
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3.2. Other Marine Invertebrates
One of the first studies on marine invertebrates, excluding corals, was a comparative analysis
done by Christ E. and Van Dorp D., on representative species in the Mollusca (Mytilus), Crustacea
(Homarus), and Cnidaria (Cyanea) phyla versus terrestrial animals [60]. The authors were able to find
PGs, particularly PGF1α but only at very low levels. In some cases, the arachidonic acid precursor
was also not detectable making it difficult to assert the existence of PGs and their functional role [60].
These results were confirmed in extended studies including more species in the Chordata, Mollusca,
Cnidaria, and Crustacea phyla [16,61,62].
With the improvement of instrument sensitivity, it was possible, more than 10 years later, to conduct
functional studies on PGs in molluscs (Figure 4a) and crustaceans (Figure 4b).
Figure 4. Marine invertebrate prostaglandins. (a) Molluscs; (b) Crustaceans; (c) Echinoderms. Except
for Tethys fimbria and Aplysia californica, pictures show organisms that are only representatives of each
phylum. For details, refer to the text.
Results obtained highlighted different roles for PGs in marine invertebrates, like reproduction,
regulation of ion flux, and thermoregulation and fever, mediated respectively by PGF2α, PGE2,
and PGE1 (Table 2) [63].
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Table 2. Update of prostaglandins and its derivatives, and functional roles in marine organisms.
Compound Producer Organism Biological Activities Reference
PGF2α
Marsupenaeus japonicus Ovarian maturation Tahara et al., 2004 [64]
Thunnus thynnus
Contraction of smooth muscles
during ejaculation and
metabolism of testis
Nomura et al., 1973 [65]
PGE1
Marine Invertebrates Thermoregulation and fever Stanley-Samuelson, 1987 [63]
Laminaria digitata
Protection against stress
conditions induced by copper
excess
Ritter et al., 2008 [19]
Salmo sp.
Contraction of smooth muscles
during ejaculation and
metabolism of testis
Chirst and Van Dorp, 1972 [60]
PGE2
Marsupenaeus japonicus Ovarian maturation Tahara et al., 2004 [64]
Paralichthys olivaceus and
Thunnus thynnus
Contraction of smooth muscles
during ejaculation and
metabolism of testis
Nomura et al., 1973 [65]
Gracilaria vermiculophylla Wounding-activated chemicaldefense molecules Nylund et al., 2011 [66]
Laminaria digitata
Protection against stress
conditions induced by copper
excess





Tethys fimbria Reproduction and multiple rolesdepending on body localization
Cimino et al., 1991 [67];
Di Marzo et al., 1991 [37]
PGF1α Oncorhynchus keta
Contraction of smooth muscles
during ejaculation and
metabolism of testis
Nomura et al., 1973 [65]
15-keto-PGE2
Gracilaria vermiculophylla Wounding-activated chemicaldefense molecules Nylund et al., 2011 [66]
Laminaria digitata
Protection against stress
conditions induced by copper
excess
Ritter et al., 2008 [19]
PGE2-1,15-lactone Tethys fimbria Reproduction and multiple rolesdepending on body localization
Cimino et al., 1991 [67];
Di Marzo et al., 1991 [37]
PGE3-1,15-lactone-11-acetateTethys fimbria Reproduction and multiple rolesdepending on body localization
Cimino et al., 1991 [67];
Di Marzo et al., 1991 [37]
PGE3-1,15-lactone Tethys fimbria Reproduction and multiple rolesdepending on body localization
Cimino et al., 1991 [67];
Di Marzo et al., 1991 [37]
PGD1 Laminaria digitata
Protection against stress
conditions induced by copper
excess
Ritter et al., 2008 [19]
PGA2
Gracilaria vermiculophylla Wounding-activated chemicaldefense molecules Nylund et al., 2011 [66]
Laminaria digitata Protection against copper stressand trigger of oxidative responses Zambounis et al., 2012 [68]
PGB2 Laminaria digitata
Protection against stress
conditions induced by copper
excess
Ritter et al., 2008 [19]
PGJ2 Laminaria digitata
Protection against stress
conditions induced by copper
excess
Ritter et al., 2008 [19]
Clavulones Clavularia viridis
Suggested to be hypothetical
repellents against other marine
organisms
Honda et al., 1985 [45]
iTXB2 Dayatis sabina Blood clotting Cabrera et al., 2003 [69]
TXB2 Oncorhynchus mykiss Vasodilator agent Thomson et al., 1998 [70]
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In the mollusc Modiolus demissus Dillwyn, 1817 the uptake and binding of prostaglandins by
gills was investigated, considering that bivalves can both synthetize and accumulate PGs from the
surrounding medium [71]. The study revealed the presence of tissue specific, time and pH dependent,
PGs binding sites with higher affinity to PGA2 with respect to PGE2 or PGF2α [71].
Moreover, three prostaglandin-lactones (PGE2-1,15-lactone, PGE3-1,15-lactone, and PGE3-1,15
-lactone-11-acetate) of the E and F series were identified in the mantle and body, respectively, of the
nudibranch mollusc Tethys fimbria Linnaeus, 1767 (Figure 4a). High quantities of a complex mixture of
PGF2α and PGF3α 1,15-lactones fatty acid esters (PLFE) were found in its eggs, particularly in mature
ovotestis but not in immature ones suggesting a role for PLFE in mollusc reproduction [67]. Altogether,
these results led to hypothesize a multiple biological role of prostaglandin-lactones, precursors of PGEs,
as defense allormones, and involved in the control of smooth muscle contraction, and egg production
and fertilization, depending on their body localization (Table 2) [37].
Crustaceans (Figure 4b) also use PGs for physiological functions. Indeed, PGE2 and PGF2α were
identified in the ovary of the prawn Marsupenaeus japonicus Spence Bate, 1888 where they participate in
ovarian maturation (Table 2) [64] whereas in the crab Carcinus maenas Linnaeus, 1758 they are produced
in blood cells following a stimulus induced with a calcium ionophore, in the presence of exogenous
fatty acids (FA) [72].
Echinoderms (Figure 4c) also represent a source of PGs. Among all the echinoderms analyzed,
the starfish Patinia pectinifera Muller and Troschel, 1842 had the highest amount of prostaglandins [73].
PGE2 and PGF2α have been identified from the sea cucumber Stichopus japonicus Selenka, 1867 using
TLC [73]. A study conducted with PGs-3H evidenced that the sea urchin Arbacia punctulata Lamarck,
1816 could accumulate PGs from the surrounding water into its gut or stomach [74], and to accumulate
PGA1 both in fertilized and unfertilized eggs, with fertilized eggs accumulating more PGs than
unfertilized eggs [74].
Strongylocentrotus nudus A. Agassiz, 1864 and S. intermedius A. Agassiz, 1864 were also reported to
have a PGs-like activity in their inner organs [74].
3.3. Marine Vertebrates
As already mentioned, in fish PGs are involved in several processes, such as ovulation, spawning,
osmoregulation, regulation of branchial ion fluxes and of the cardiovascular system [36]. Christ and
Van Dorp in their comparative studies on PGs considered not only invertebrates, but also fish [60]. They
identified moderate yields of PGE1 in freshwater fish and lower yields in homogenates of gills of Salmo
sp. [60]. Successively, PGE2 was identified for the first time in the testis of the flounder Paralichthys
olivaceus Temminck & Schlegel, 1846, PGF1α in the semen of the salmon Oncorhynchus keta Walbaum,
1792 and PGE2 and PGF2α in the testis of the tuna Thunnus thynnus Linnaeus, 1758 [65] (Figure 5a).
In order to explain the reason why prostaglandins are present in these marine animals, although
they are oviparous, it was suggested that the identified prostaglandins might be used for the contraction
of smooth muscle during ejaculation and for the metabolism of testis in lower animals as in mammals
(Table 2) [65]. After this study, PGE2 was isolated and subsequently identified in the gastrointestinal
tract and in the skin of the shark Triakis scyllia Müller & Henle, 1839 [16,75] (Figure 5b).
In the brook trout Salvelinus fontinalis PGE2 and PGF2α (Figure 5a) are synthetized in the follicle
wall of mature oocytes, but the highest quantity of prostaglandins was found in the extra-follicular
tissue [76]. PGE2 was also found in the skin of Pleuronectes platessa Linnaeus, 1758 (Figure 5a) in
response to the fungal extract of Epydermophyton floccosum (Harz) Langeron & Miloch, 1930 known be
an inducer of erythema [77].
Leucocytes of the dogfish Scyliorhinus canicula Linnaeus, 1758 secerned high levels of PGE2, PGD2
and PGF2α (Figure 5b) when exposed to the Ca2+ ionophore A23187 [78]. PGE2 and PGF2α were found
in the red blood cells of the toadfish Opsanus tau Linnaeus, 1766 [79] (Figure 5a).
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Figure 5. Marine vertebrate prostaglandins. (a) Teleosts (Salmo sp., Paralichthys olivaceus,
Oncorhynchus keta, Thunnus thynnus, Salvelinus fontinalis, Pleuronectes platessa, Opsanus tau);
(b) Elasmobranchs (Triakis scyllia, Scyliorhinus canicula). Pictures show organisms that are only
representatives of each class. For details, refer to the text.
3.4. Macroalgae
3.4.1. Red Macroalgae
Marine red algae are rich in C20 polyunsaturated fatty acids that, in animals, are precursors
of prostaglandins, thromboxane, and other eicosanoids. Although the presence of the
prostaglandin-endoperoxide pathway has been demonstrated in non-mammal marine vertebrates and
invertebrates, for a long time less was known about these enzymes in non-animal organisms. The first
report about the presence of prostaglandins in macroalgae (Figure 6) described the identification of
PGE2 and PGF2α in Gracilaria lichenoides Greville, 1830 [80].
Figure 6. Red algae prostaglandins. The picture shows an organism representative of the genus.
For details, refer to the text.
The genus Gracilaria, that comprises algae used in the food and cosmetic industry, is very rich
in ARA, varying from 45.9% and 62.0% of the total FA depending on the season. Among these,
G. vermiculophylla (Ohmi) Papenfuss, 1967 is one of the algae with the highest content of ARA [81].
This, with other Gracilaria species such as G. asiatica and G. chorda Holmes, 1896, seem to be responsible
for a gastrointestinal disorder known as “onogori” poisoning in Japan when it is eaten raw [18]. The
possible reason for this poisoning seems to be the fact that the COX contained in raw seaweeds use
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the highly unsaturated fatty acids to produce great amounts of PGE2 in the stomach of victims in
a short lapse of time [81]. G. vermiculophylla is a source of different types of prostaglandins besides
PGE2, such as PGA2, PGF2, 15-keto-derivatives of prostaglandins, as well as other eicosanoids [82],
whereas the congeneric species G. asiatica produces only 15-keto-PGE2 [83]. G. vermiculophylla use
PGA2, PGE2, 15-keto-PGE2 and other eicosanoids as wounding-activated chemical defense molecules
(Table 2) [66], and recently a COX gene producing PGF2α was cloned from this alga and heterologously
expressed [84].
Other evidence of prostaglandins as defense molecules in red algae is the fact that gametophytes
of the alga Chondrus crispus Stackhouse, 1797, when challenged with pathogens, metabolize C20 and
C18 PUFAs not only into the corresponding hydroperoxides and derivatives, but also into molecules
with mass fragmentation patterns very similar to prostaglandin B1 and B2 [85]. Furthermore, when the
crude extract of this alga was treated with 50–100 μM methyl jasmonate for 6 h, PGA2 and 15-keto-PGE2
were identified [86].
3.4.2. Brown Macroalgae
Much less is known about the presence of prostaglandins in brown algae, and most studies have
mainly focused on the brown algal kelp Laminaria digitata. Ritter et al. [19] showed that this brown
alga uses the generation of oxylipins as a protective mechanism against stress conditions induced by
an excess in copper (Table 2). Indeed, high concentrations of copper led to oxygen reactive species
(ROS) accumulation in L. digitata cells, and consequently to a cascade of cellular responses. One of
these responses was a significant release of PUFAs after 24 h of treatment, followed by the generation
of oxylipins. Among complex oxylipins, also PGE1 and PGD1, deriving from ETrA and PGJ2, PGA2,
15-keto-PGE2 and PGB2, deriving from ARA were identified for the first time in brown algae [19].
Successively, the same authors showed that PGA2 does not simply modulate but also triggers an
oxidative response in L. digitata that, differently from the response induced by other molecules like
methyljasmonate and lipopolysaccharides, occurs in seconds after treatment and in a dose-response-like
manner. The authors hypothesized that PGA2 can activate the generation of two different sources
of ROS that can be used by the brown alga as defense molecules as in other marine organisms [68]
(Figure 7).
Figure 7. Brown algae prostaglandins: only Laminaria digitata has been studied for prostaglandins
content. For details, refer to the text.
3.5. Microalgae
PGs were discovered for the first time in diatoms, phytoplanktonic marine microalgae, only
in 2017 [23]. Diatoms are a rich source of polyunsaturated fatty acids (PUFA), that, in some
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species, are precursors of polyunsaturated aldehydes (PUAs), i.e., oxylipins with pro-apoptotic
and anti-proliferative activity, with a defensive role against predator (copepods) grazing [87].
Di Dato et al. [23] explored the presence of PGs in some diatom species, i.e. Skeletonema marinoi
Sarno & Zingone, 2005 (Figure 8a) (two different strains, FE7 and FE60) and Thalassiosira rotula Meunier,
1910 (Figure 8b) (Valeria Di Dato, Roberta Barbarinaldi, Alberto Amato, Federica Di Costanzo, Carolina
Fontanarosa, Anna Perna, Angela Amoresano, Francesco Esposito, Adele Cutignano, Adrianna Ianora,
Giovanna Romano. Variation in prostaglandin metabolism during growth of the diatom Thalassiosira
rotula. Sci Rep, under review), identifying in their transcriptome genes involved in PGs biosynthesis,
with some differences between the two species.
Figure 8. Microalgae prostaglandins. (a) Skeletonema marinoi (A. Ianora laboratory clones name FE7 and
FE60); (b) Thalassiosira rotula; (c) Euglena gracilis; (d) Microcystis aeruginosa. For details, refer to the text.
More specifically, whereas cyclooxygenase-1 (COX-1) and microsomal prostaglandin E synthase
1 (mPTGES) were found in both species; prostaglandin H2 D-isomerase (PTGDS) was found only
in S. marinoi, while prostaglandin F synthase (PTGFS) was only detectable in T. rotula. The authors
demonstrated the functioning of the pathway by measuring enzyme expression and molecule
production by quantitative real time PCR (qPCR) and liquid chromatography/mass spectrometry
(LC/MS) analysis, respectively. Interestingly, a wide set of PGs was revealed with representative
molecules of each of the three series. In addition, a differential expression and concentration of
molecules was reported among different species and strains of the same species, during different
phases of growth and nutrient conditions [23]. However, the absence of PTGDS in T. rotula and of
PTGFS in S. marinoi could be considered as a “potential absence.” Indeed, the lack of a transcript in a
transcriptome annotation can be due to a technical shortcoming and a limitation of the sequencing
technology used, as in the case of very low expression levels of a target gene, that may fall under the
detection limit.
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It is interesting to note that, although the PGs pathway has been experimentally confirmed only
in two diatom species, in silico analysis of transcriptomes from different species in different growth
conditions, suggests the presence of PGs in many other diatom species [23].
Prostaglandins were identified also in the unicellular green alga Euglena gracilis G. A. Klebs, 1883
(Figure 8c), in which PGE2 and PGF2α were found at levels three times higher in cells grown in the
dark than those grown in the light [88].
The presence of PGA, PGE, and PGF series and their esters have also been documented in
the cyanobacteria of the taxa Oscillatoria and Microcystidaceae [89]. Indeed, PGF2α was identified in
Microcystis aeruginosa (Kützing) Kützing, 1846 [90] (Figure 8d).
Currently, to the best of our knowledge, no other marine microalga has been explored for the
presence of PGs, and their role in diatoms is still under investigation. Di Dato and co-authors
hypothesized that they can be used by diatoms for intercellular signaling and communication [23],
in agreement with the role of these molecules in other organisms.
Microorganisms, and in particular microalgae such as diatoms, could represent a potential
source of bioactive PGs, as alternative to their chemical synthesis to produce adequate amounts for
pharmacological purposes as anti-inflammatory compounds. The biotechnological production of PGs
from microalgae may also be convenient due to the natural presence of the full PGs pathway and the
possibility to easily grow microalgae on a large scale in bioreactors under controlled culture conditions.
4. Marine Cyclopentenone Prostaglandins
Cyclopentenone prostaglandins are a sub-group of PGs characterized by the presence of a
cyclopentenone moiety (CP) with a α,β-unsaturated ketone group in their cyclopentane ring. Their
chemical reactivity is responsible for their anti-inflammatory, anti-tumoral and anti-viral activities [91],
and the presence of the CP fragment in molecules with anticancer activity, can add more potency to
these molecules. For instance, methyl-jasmonate increases its strength of action as an anti-tumor agent
when a CP group is inserted in the molecule [92].
The group of cyclopentenone prostaglandins (CPPGs) includes canonical PGs of the A and J series,
clavulones, and punaglandins.
Differently from the conventional PGs, that require receptor interaction to trigger their signal,
cyclopentenone prostaglandins are actively transported inside the cells [91], where the CP group can
interact with a wide variety of target molecules [92] including nuclear factors such as the heat shock
protein 70 (HSP70) transcription factor, cyclin-dependent protein kinase (CDK), and NF-kB [35] and
still not well defined mitochondrial factors [92].
4.1. Clavulones and Related Molecules
Clavulones (Figure 9) are acetoxy derivatives of PGA [91] characterized by a cyclopentenone
fragment, a 12-S acetoxy function and two chains of different length: the α- and the ω-chain with
respectively seven and eight carbon atoms [93]. These are anti-tumor marine prostanoids isolated from
the soft coral Clavularia viridis Quoy & Gaimard, 1833, a single Clavularia genus that inhabits Okinawa
bay in Japan [44,94,95].
Clavulones exists in three isoforms, I, II, and III and two stereoisomers at the C-4 and C-12
positions. These molecules possess a significant anti-inflammatory effect at a concentration of 30
μg/mL in a fertilized chicken egg assay (Table 1) [44,95]. The effects of clavulones on the growth of
human cancer cells were first studied using clavulone I, the form that is more abundant in C. viridis.
At concentration of 4.0 μM there was an impairment of DNA synthesis in human HL-60 leukemic cells
after 1 h incubation, causing irreversible cytotoxic changes after 3 h of exposition [45]. In a more recent
study, the anti-cancer activity of clavulone II on HL-60 cells has been deeply studied [46] revealing that
low concentrations of clavulone II induce anti-proliferative effects by inducing the down-regulation
of cyclin D1 with consequent arrest of the cell cycle in G1. On the contrary, higher concentrations of
clavulone II induces apoptosis through the disruption of mitochondrial membrane potential and the
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activation of caspase-9, -8, and -3 and of B-cell lymphoma 2 (Bcl2)-family proteins (Table 1) [46]. It was
suggested that corals might use clavulones as repellent and toxic substances against other marine
organisms (Table 2) [45].
Figure 9. Clavulones and related molecules in Clavularia viridis (Cnidaria, soft corals). For details, refer
to the text.
Clavulones, similarly to PGAs, also possess antiviral activity. In particular, clavulone II inhibits
replication of the vesicular stomatitis virus (VSV) in infected mouse L929 fibroblasts, by blocking the
transcription of viral RNA, and consequently the viral protein (Table 1) [47].
Interestingly, both the anti-proliferative and antiviral activities of clavulones are stronger than
those of PGAs [47].
Other than clavulone I, II, and III, from the same stolonifer coral, 20-acetoxi-claviridenone b
and 20-acetoxi-claviridenone c were discovered [96]. In addition to these, also four halogenated
analogues, called chlorovulones I-IV were identified and, among these, chlorovulone I was shown to
have anti-proliferative and cytotoxic activities (Table 1) [48]. The structure of an epoxy prostanoid with
anti-proliferative activity was also identified in the same soft coral [49] together with bromovulone I
and iodovulone I. Both had anti-proliferative and cytotoxic activities even though slightly lower than
those of chlorovulone I [50]. All these molecules showed a stronger anti-tumor activity against HL-60
cells in vitro with respect to clavulone I (Table 1) [48–50].
More recently, seven new prostanoids were identified from the same soft coral:
4-deacetoxyl-12-O-deacetylclavulone I, 4-deacetoxyl-12-O-deacetylclavulone II, bromovulone II,
iodovulone II, 4-deacetoxyl-12-O-deacetylclavulone III, bromovulone III, and iodovulone III. These
molecules showed in vitro cytotoxic activity against human prostate carcinoma (PC-3) and colon
adenocarcinoma (HT-29) cells and, among these, bromovulone III showed the highest anti-tumor
activity, together with chlorovulone II and III, used as standard, that exhibited a slightly lower activity
(Table 1) [51].
Through an assay-guided fractionation of a dichloromethane (CH2Cl2) extract of C. viridis,
three new cytotoxic molecules were isolated: claviridenone E, claviridenone F, and claviridenone G.
In particular, claviridenone F showed a significant cytotoxicity against human lung adenocarcinoma
(A549), HT-29, and mouse lymphocytic leukemia cells (P-388), while claviridenone G exhibited a
high cytotoxic activity only against A549 (Table 1) [52]. In addition to these molecules, there are
clavulone-related oxylipins from C. viridis, named clavirins I and II, for which it was proposed a
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derivation from clavulone III and I, respectively, having growth-inhibitory activity against human
cervix carcinoma cell line (HeLa S3) (Table 1) [53].
Other clavulone-related molecules that have been discovered are tricycloclavulone and
clavubicyclone that may be derived from cycloaddition and electrocyclization of clavulone III,
respectively. The latter molecule showed a moderate growth-inhibition activity against breast
carcinoma (MCF-7) and ovarian carcinoma cells (OVCAR-3) in vitro (Table 1) [54]. Preclavulone
lactone I and II and two minor chemical congeners, 17,18-dehydroclavulone I and clavulolactone I,
were also isolated and characterized from C. viridis. Among these, 17,18-dehydroclavulone I has a
(14Z,17Z)-double bond in the ω side chain, and this suggests that, differently from the other clavulones,
it can derive from EPA instead of ARA [97].
Although there are structural similarities between prostaglandins and clavulones, the latter are
not generated by a variant of the endoperoxide pathway, but from the lipoxygenase pathway by which
arachidonic acid is converted into 8-(R)HPETE and then to preclavulone A [98]. Preclavulone A was
identified also in an unrelated Caribbean coral, Pseudoplexaura porosa Houttuyn, 1772, suggesting
that this molecule is widespread in corals [99]. In another study, the same authors isolated and
defined the structures of 15 new halogenated iodo-, bromo-, and chlorovulones in C. viridis as minor
constituents [100], but overall about 50 congeners of clavulones were identified in this soft coral [101].
4.2. Punaglandins
These molecules (Figure 10), structurally related to clavulones, were isolated in the Hawaiian
octocoral Telesto riisei Duchassaing & Michelotti, 1860 [102].
Figure 10. Punaglandins in Telesto riisei (Cnidaria, octocoral). For details, refer to the text.
The lack of symbiotic algae suggests that T. riisei is the source of these prostaglandins [103].
A total of 19 punaglandins were obtained from this octocoral, which also included acetate and epoxide
versions of the four canonical punaglandins [104]. Punaglandins 3 and 4 formally results from
elimination of acetic acid from punaglandins 1 and 2 respectively, and possess a cross-conjugated
dienone structure [105]. They are halogenated derivatives of PGA [91] characterized by various
oxygenations at C -5, -6, -7, and -12 and a 10-chloro-9-cyclopentenone function with a 5S, 6S, 12R
stereochemistry [102].
At the moment of their discovery, there was great interest in the study of punaglandins, because
of their anti-inflammatory and potent antitumor activities [104]. Indeed, these molecules, and in
particular punaglandin 3, was shown to inhibit L1210 leukemia cell proliferation (IC50 = 0.04 μM)
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(Table 1) [102] with an activity 15-fold higher compared to the corresponding clavulone [55]. This
cytotoxic activity is approximately equal to the one of vincristine and doxorubicin that are among the
most effective anticancer molecules used today [103].
5. Marine Thromboxane
Thromboxanes (TXs) are closely relate to PGs that bind specific receptors, called thromboxane
receptors (TP) and act as strong promoters of platelet aggregation and vaso- and broncho-constriction
in mammals [106]. They are labile and biologically active molecules deriving from arachidonic acid in
the cyclooxygenase pathway in human platelets. Thromboxane A2 (TXA2) has a short half-life (30 s in
human blood) being rapidly converted to a stable B form (TXB2), which is used as a marker for the
presence of TXA2 [69].
Other than in mammals, the presence of TXs is documented also in marine organisms.
TXB2, along with prostaglandins, has been reported in aqueous homogenates of the mollusc
A. californica J. G. Cooper, 1863 (Figure 4a) [74] using radioimmunoassay. In the marine bivalve M. edulis
Linnaeus, 1758 (Figure 4a), arachidonic acid metabolism, in addition to PGs, leads to the production of
TXs in the gills, mantle, and adductor tissues [107]. In the polychaetae Arenicola marina Linnaeus, 1758
small amounts of TXB2 are detectable in the digestive and reproductive tracts [107].
Different species of fish also produce TXs [69]. In the plasma of the elasmobranch Dasyatis sabina
Lesueur, 1824 (Figure 5b), the presence of an immunoreactive TXB2 (iTXB2) has been detected at
concentrations of 0.57 ± 0.03 ng/mL. The level of iTXB2 increased to 3.0 ± 0.27 ng/mL when the plasma
clots, but decreased to 1.5 ± 0.17 ng/mL in the presence of indomethacin, a cyclooxygenase inhibitor.
These findings suggest that TXA2, the active thromboxane form, may be involved in blood clotting
and may be generated by a cyclooxygenase-like enzyme as in mammals (Table 2) [69]. The binding
of agonist (radiolabeled [125I]-BOP) and antagonist (L-657925 and L-657926) ligands of mammalian
TP receptors to those of D. sabina, also demonstrates the similarity between this elasmobranch and
mammalian TP receptors [69]. Three different species of shark (Figure 5b) (Chiloscyllium griseum Müller
& Henle, 1838, Carcharhinus plumbeus Nardo, 1827 and Carcharhinus melanopterus Quoy & Gaimard,
1824) were also shown to produce TXB2 as a major product of arachidonic acid metabolism suggesting
that TXB2 may be a biologically active prostanoid in these species [70].
Rowley et al. [78] tested the ability of leucocytes extracted from the blood of the dogfish Scyliorhinus
canicula (Figure 5b) to produce and release PGs and TXs during their degranulation induced by the
calcium ionophore A23187. While PGF2α, PGE2, and PGD2 levels were always high after the stimulus,
the levels of TXB2 were low and detectable in the supernatant only 5 min after the start of the stimulus,
with levels increasing after 10 and 15 min [78].
Another direct evidence of the generation of TXB2 in fish was demonstrated by the ability of
washed whole blood cells from a variety of fishes of the Arabian Gulf to produce prostanoids from
exogenous 14C-arachidonic acid in vitro [70]. In addition, rainbow trout thrombocytes, clotting cells
similar to mammalian platelets, were shown to convert arachidonic acid mainly to TXB2 [108,109].
These findings again suggest a role also for TXB2, in rainbow trout as a vasodilator (Table 2), while in
mammals TXB2 has no significant biological activity [70]. However, not all fish thrombocytes have
the ability to produce thromboxane, possibly suggesting that these molecules are not essential for
thrombocyte aggregation in certain species [110].
6. Conclusions
Prostaglandins and their derivatives, although first identified in terrestrial organisms, are also
widespread in the marine environment testifying the great importance of these molecules. Nevertheless,
the eco-physiological role of marine PGs remains mostly unclear because of contrasting and often
old data available in the literature, although it has been suggested that they have a possible role as
defensive molecules against predators.
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Interestingly, many marine organisms have been shown to produce classical PGs along with new
derivatives that are not found in terrestrial animals, e.g., corals that are able to produce punaglandins
and clavulones, which are specific of the marine environment and have shown potent pharmacological
activity against inflammation, tumors, and viruses. These findings, together with the discovery of
PGs in unicellular eukaryotic microalgae, provides new stimuli to pursue the search for new marine
PG-derived molecules with anti-inflammatory activity.
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Abstract: Lipids used in intravenous nutrition support (i.e., parenteral nutrition) provide energy,
building blocks, and essential fatty acids. These lipids are included as emulsions since they need
to be soluble in an aqueous environment. Fish oil is a source of bioactive omega-3 fatty acids
(eicosapentaenoic acid and docosahexaenoic acid). Lipid emulsions, including fish oil, have been
used for parenteral nutrition for adult patients post-surgery (mainly gastrointestinal). This has been
associated with alterations in biomarkers of inflammation and immune defense, and in some studies,
a reduction in length of intensive care unit and hospital stay. These benefits, along with a reduction in
infections, are emphasized through recent meta-analyses. Perioperative administration of fish oil may
be superior to postoperative administration, but this requires further exploration. Parenteral fish oil
has been used in critically ill adult patients. Here, the influence on inflammatory processes, immune
function, and clinical endpoints is less clear. However, some studies found reduced inflammation,
improved gas exchange, and shorter length of hospital stay in critically ill patients if they received
fish oil. Meta-analyses do not present a consistent picture but are limited by the small number and
size of studies. More and better trials are needed in patient groups in which parenteral nutrition is
used and where fish oil, as a source of bioactive omega-3 fatty acids, may offer benefits.
Keywords: fish oil; omega-3; eicosapentaenoic acid; docosahexaenoic acid; inflammation; eicosanoid;
cytokine; surgery; critical illness; parenteral nutrition
1. Introduction
Eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) are biologically
active long-chain omega-3 (n-3) polyunsaturated fatty acids [1,2]. EPA and DHA are produced from
simpler n-3 fatty acids in a metabolic pathway involving sequential desaturation and elongation of
the precursor fatty acids (Figure 1). For a variety of reasons, endogenous synthesis of EPA and DHA
through this pathway is considered to be relatively poor in humans [3], placing a focus on intake of
preformed EPA and DHA. Naturally rich sources of EPA and DHA include many marine organisms
particularly fatty fish like salmon, trout, mackerel, herring, and sardines [4]. The body oils of fatty
fish (and the liver oils of nonfatty (lean) fish like cod) can be isolated; these oils are rich in EPA and
DHA although the content and relative amounts of EPA and DHA present are dependent upon the fish
source [4]. These oils are generically termed “fish oils” and “fish liver oils” and are commonly used as
dietary supplements. Other sources of EPA and DHA include krill oil and algal oils. For most people
on a Western style diet, intake of EPA and DHA is low, but this can be increased markedly by eating
fatty fish regularly or by using supplements which contain EPA and DHA [4]. When intake of EPA and
DHA is increased, the amounts of those fatty acids in blood, blood cells, and tissues is increased [5–7].
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Figure 1. Pathway of biosynthesis of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
from precursor omega-3 (n-3) fatty acids.
EPA and DHA are readily incorporated into the phospholipids of cell membranes and this is
central to their biological activity (Figure 2), including their effects on inflammation and immune
responses [8,9]. For example, they have been shown to modulate the physical characteristics of
the membrane (termed membrane order or membrane fluidity) and the formation of signalling
platforms called lipid rafts in many cell types, including in cells involved in inflammatory and
immune responses [8,9]. These alterations in membrane structure and function have been shown to
modify the signals generated at the membrane level that go on to influence cytosolic and nuclear
events. For example, the ability of DHA to suppress phosphorylation of the inhibitory subunit of the
proinflammatory transcription factor nuclear factor kappa B (NFκB) and to inhibit proinflammatory
protein production in cultured macrophages in response to bacterial lipopolysaccharide (LPS) [10] was
identified to be due to disruption of the formation of lipid rafts that occurs when the cells are exposed
to LPS [11]. This observation creates a direct link between the incorporation of n-3 fatty acids into
membranes, altered membrane responses to external stimuli, initiation of signalling cascades, gene
expression, and protein production in inflammatory cells.
EPA and DHA released from cell membrane phospholipids can be converted to bioactive lipid
mediators through the action of cyclooxygenase, lipoxygenase, and cytochrome P450 enzymes (Figure 3).
In this way, EPA and DHA are rather like the long-chain omega-6 (n-6) polyunsaturated fatty acid
arachidonic acid (ARA, 20:4n-6), although the mediators produced from these three fatty acid substrates
often have different biological activities or potencies [12,13].
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Figure 2. Generalized scheme of the mechanisms of action of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA).
Figure 3. Overview of the pathways of conversion of eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) to bioactive lipid mediators. EPA is metabolized via cyclooxygenase-2 (COX-2) to yield
3-series prostaglandins (PGs) and via 5-lipoxygenase (5-LOX) to yield 5-hydroperoxyeicosapenataenoic
acid (HpEPE) which is converted to 5-hydroxyeicosapentaenoic acid (5-HEPE), the precursor of 5-series
leukotrienes (LTs). EPA can also be metabolized to 18-HpETE by cytochrome P450 (CytP450) or by
COX-2. In turn 18-HpEPE is converted to 18-HEPE which is metabolized by 5-LOX to resolvins E1 and
E2 or by 15-lipoxygenase (15-LOX) to resolvin E3. DHA is metabolized via 12-lipoxygenase (12-LOX) to
14-hydroperoxydocosahexaenoic acid (14-HpDHA) which is converted to maresins. DHA can also be
metabolized to 17-HpDHA by 15-LOX or by COX-2. 17-HpDHA is the precursor of protectin D1 and of
17-hydroxydocosahexaenoicacid (17-HDHA). 17-HDH is metabolized by 5-LOX to D-series resolvins.
Different enantiomers of resolvins and protectins are produced in the absence or presence of aspirin.
EPA and DHA are incorporated into cell membranes at the expense of ARA, resulting in a shift
in the pattern of the lipid mediators being produced. EPA, DHA, and their lipid mediator products
also influence various transcription factors resulting in an altered expression of genes involved in
many biological processes which include metabolism, immune function, and inflammation [9,12].
Consequently, through these actions from the membrane to the nucleus, EPA and DHA modify cell and
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tissue behavior and responses, and in general, these modifications are associated with more optimal
function, an improved risk factor profile, a reduction in disease risk, and in some cases, therapeutic
possibilities (Figure 2). EPA and DHA have long been recognized to have anti-inflammatory properties,
including decreasing production of proinflammatory lipid mediators from ARA, decreasing production
of key proinflammatory cytokines like tumor necrosis factor (TNF), interleukin (IL)-1β and IL-6, and
reducing leukocyte-endothelium adhesion interactions [12,14]. More recently, EPA and DHA have been
shown to be the precursors for potent inflammation resolving mediators termed resolvins, protectins,
and maresins [15,16], which are produced through the pathways outlined in Figure 3. These molecules,
collectively termed specialized pro-resolving mediators, have a range of potent actions including
upregulating phagocytosis promoting clearance of damaged tissue and cellular debris and reducing
production of classic inflammatory cytokines like TNF and IL-1β [15,16]. The combined actions of EPA
and DHA suggest that they could be important in preventing, reducing the severity, and even treating
chronic inflammatory conditions like rheumatoid arthritis [17–19]. Accumulation of EPA and DHA in
cells and tissues from the diet or from oral supplements occurs over a time frame of days to weeks
to months, depending upon the tissue involved [5–7]. In acute settings, more rapid delivery of EPA
and DHA may be required. Lipid emulsions (LEs) that include fish oil as a source of EPA and DHA
are commercially available for intravenous infusion as part of nutrition support for patients [20,21].
Intravenous administration of these LEs can quickly provide relatively high amounts of EPA and DHA
if it is desired. This article will describe the rationale for the development of fish oil containing LEs
and their application in surgical and critically ill patients.
2. Fish Oil Containing LEs for Intravenous Use
2.1. The Role of LEs in Intravenous Nutrition Support
It is not possible for some patients to consume food either transiently or in the longer term. If food
intake beyond a few days is not possible, patients require what is termed “nutrition support” in order
to maintain or restore optimal nutritional status and health. Nutrition support for patients should
use the gastrointestinal tract whenever it is possible. However, there are instances where use of the
gastrointestinal tract is not possible. These include patients with:
• a non-functional gastrointestinal tract due to:
 surgical removal because of disease
 intestinal blockage or leakage
 impaired absorptive capacity
• severe gastrointestinal disease
• severe malnutrition
• trauma or critical illness
In such patients, the intravenous route should be used to provide nutrition support. This is
referred to as parenteral nutrition. Parenteral nutrition should include a mix of macronutrients, as
energy sources and substrates for biosynthesis, and micronutrients. It is important to include lipids as
a component of parenteral nutrition. This is because the fatty acids within lipids are good sources
of energy and reduce the need to provide large amounts of carbohydrates and they are building
blocks for cell membranes required for tissue repair and host defenses. In addition, the provision of
essential fatty acids is necessary to avoid a deficiency, which has been described in infants receiving
long-term parenteral nutrition that was lipid free [22]. Finally, the fatty acids and the complex lipids
that carry them may have bioactivities that affect the outcome for the patient [1,20,21]. In parenteral
nutrition, lipids are provided as aqueous emulsions of oils that are mainly triglycerides, with a
phospholipid monolayer which is usually phosphatidylcholine (lecithin) of soybean origin. A range of
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LEs are commercially available comprising various mixtures of soybean oil, oil rich in medium chain
triglycerides (MCTs), olive oil, and fish oil. The composition of these LEs is summarized in Table 1.




















Soybean 100 50 64 - 20 40 30
MCT - 50 36 - - 50 30
Olive - - - - 80 - 25
Fish - - - 100 - 10 15
Fatty acids (%)
Saturated 15 58 46 21 14 49 37
Monounsaturated * 24 11 14 23 64 14 33
Polyunsaturated 61 31 40 56 22 37 30
Omega-3 8 4 5 48 3 10 7
ALA 8 4 5 1 3 4 2
EPA - - - 20 - 3.5 3
DHA - - - 19 - 2.5 2
Omega-6 ** 53 27 35 5 19 27 23
ALA, α-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid. * mainly oleic acid (18:1n-9).
** Mainly linoleic acid (18:2n-6). Note that the fatty acid composition of fish oil is more variable than that of vegetable
oils so that the precise contribution of different fatty acids may differ in different batches.
2.2. Rationale for Fish Oil Containing LEs
As outlined above, EPA and DHA have a number of bioactivities [1,2,9,12,20,21]. Through these
bioactivities EPA and DHA can affect metabolism, inflammation, immune responses, oxidative stress,
blood coagulation, organ function (e.g., liver, lung, muscle, brain), and wound healing amongst
others [1]. These effects are likely to be of relevance to patients receiving parenteral nutrition
support [20,21]. In this regard there has been significant attention on the ability of EPA and DHA to
modulate inflammation and the immune response. This is because of the increasing recognition that
uncontrolled inflammation and a period of immune paralysis can occur in certain groups or subgroups
of patients, sometimes concurrently, and that these are linked with poor patient outcomes such as
increased risk of infections, longer stay in hospital, and in more seriously ill patients increased mortality.
For example, patients undergoing gastrointestinal surgery showed elevated plasma concentrations
of the inflammatory cytokine interleukin (IL)-6 in the hours to days following surgery, with higher
concentrations observed in the more severely stressed patients [23]. At the same time, there was a
decline in T lymphocyte function in those patients [23]. Patients in the early stages of sepsis showed
higher concentrations of TNF, IL-1β, and IL-6 than healthy controls and they had an elevated activation
of the proinflammatory transcription factor NFκB in blood leukocytes [24]. Both the inflammatory
cytokines and the activation of NFkB were higher in the patients who did not survive than in
survivors [24], suggesting an association between hyperinflammation and mortality. Bozza et al. [25]
identified that the concentrations of some plasma cytokines measured at entry to the intensive care unit
(ICU) predicted 48-hour and 28-day mortality in patients with sepsis. Andaluz-Ojeda et al. [26] studied
29 mainly elderly male patients with infections of whom 17 survived and 12 did not. They found that
the blood concentrations of IL-6, IL-8, IL-10, and monocyte chemoattractant protein-1 were higher
on the first day of admission to the ICU in non-survivors than in survivors, and that these cytokines
were associated with mortality at days three and 28 after adjusting for disease severity at ICU entry.
These authors reported that 28-day survival was over 90% in those patients with IL-6, IL-8, and IL-10
concentrations all < 75th percentile on day one, while survival was around 30% in those patients with
IL-6, IL-8, and IL-10 concentrations all > 75th percentile on day one [26]. These observations suggest
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an important association between a strong inflammatory response and a poor outcome, perhaps
mediated through organ damage and failure (Figure 4). Likewise, immune paralysis could lead to a
poor outcome related to an increased susceptibility to infections (Figure 4).
Figure 4. Schematic depiction of the response to insult with activation of inflammation and impairment
of acquired immunity. It is considered that overwhelming inflammation and immune paralysis directly
lead to adverse patient outcomes as depicted in the red area on the right. Examples of the “insult”
include major surgery, wound or tissue injury, and the presence of infection. Modified from [27] with
permission from Karger Publishers, Basel, Switzerland. Original figure Copyright© 2014, 2015 Karger
Publishers, Basel, Switzerland.
Using cell culture and animal models, the effects of EPA and DHA have been demonstrated
on the following: eicosanoids like prostaglandin E2 and leukotriene B4; chemokines like monocyte
chemoattractant protein 1; cytokines like TNF, IL-1β, IL-6, and IL-10; reactive oxygen species production;
and NFκB activation as reviewed elsewhere [12,14]. Although less well explored, effects of EPA and
DHA on the function of antigen presenting cells [28] and T cells [29] are also described in the literature.
These effects provide a rationale for inclusion of fish oil in LEs used for nutrition support in patients
undergoing major surgery or with critical illness (Figure 5). Preclinical models strongly support this
approach. For example, fish oil decreases vasoconstriction, hypertension, and vascular permeability
and leakage in an animal model of lung injury [30]; decreases the metabolic and inflammatory response
to endotoxin, improving heart and lung function and survival [30–32]; and enhances survival in some
models of infection [29]. The pro-resolving effects of EPA- and DHA-derived lipid mediators may also
be relevant in this regard. For example, Spite et al. [33] reported that DHA-derived resolvin D2 reduced
bacterial load in blood and peritoneum and improved survival in a caecal ligation and a puncture
model of sepsis in mice. This was associated with much reduced plasma levels of several inflammatory
cytokines (TNF, IL-1β, IL-6, IL-10, IL-17) and chemokines, reduced leukocyte infiltration into the
peritoneum, and reduced peritoneal concentrations of prostaglandin E2 and leukotriene B4. In a murine
model of sepsis induced by caecal ligation and puncture, DHA-derived resolvin D1 decreased the
bacterial load in the blood and peritoneum, decreased lung injury, decreased plasma concentrations
of TNF, IL-6, IL-10, and interferon-γ, and improved survival [34]. In parallel with these effects on
inflammation, resolvin D1 decreased the proportion of T lymphocytes undergoing apoptosis [34].
207
Mar. Drugs 2019, 17, 274
Figure 5. Rationale for inclusion of omega-3 fatty acids (eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA)) in intravenous nutrition support in patients at risk of or already
displaying overwhelming inflammation and immune paralysis. Modified from [27] with permission
from Karger Publishers, Basel, Switzerland. Original figure Copyright© 2014, 2015 Karger Publishers,
Basel, Switzerland.
2.3. Anti-Inflammatory and Immune Enhancing Effects of Fish Oil Containing LEs in Patients
LEs that include fish oil are an effective way of delivering EPA and DHA directly into the
circulation [35–37]. Infusion of a blend of soybean oil, MCTs, and fish oil (50:40:10 vol/vol/vol) daily for
five days in septic patients in the ICU who were intolerant of enteral feeding resulted in an elevation
in the content of EPA, though not DHA, in plasma phosphatidylcholine at the end of the infusion
period [35]. Patients with hepatic colorectal metastases requiring resection received continuous infusion
of a blend of soybean oil, MCTs, and fish oil (50:40:10 vol/vol/vol) for 72 h prior to surgery [36]. EPA in
plasma phosphatidylcholine was higher than at study entry, and higher than in the control group at 20,
44, 68 and 72 h (Figure 6) [36]. Barros et al. [37] infused a pure fish oil LE into ICU patients receiving
enteral nutrition for 6 h on each of 3 consecutive days; blood samples were collected prior to the first
infusion, and 24 and 72 h after the third infusion. There was a significant increased appearance of
EPA and DHA in plasma phosphatidylcholine at the latter two time points as compared with both the
study entry and the control group [37].
It has been estimated that a daily oral dose of 2–2.5 g of EPA plus DHA is required to elicit
an anti-inflammatory effect in humans [38]. LEs are typically infused at a rate of up to 1 g lipid/kg
body weight per day, and therefore a 70 kg patient could receive 70 g of LE if the emulsion was
infused continuously over an entire day. Depending upon the exact LE used (Table 1) this would
provide 70, 7 or 10.5 g fish oil daily for pure fish oil, fish oil blend 1, and fish oil blend 2, respectively.
This amount of fish oil would supply about 27, 4 or 3.5 g EPA plus DHA daily from these three LEs.
Clearly these amounts would differ according to a patient’s body weight, the LE infusion rate, and
the infusion duration. Nevertheless, these figures indicate that anti-inflammatory doses of EPA and
DHA can be delivered with LEs that are currently available. This is supported by the observations
that using these fish oil containing LEs can decrease the blood concentrations or ex vivo production of
proinflammatory eicosanoids [39,40] and cytokines [35,37,41] in surgical [39–41] and critically ill [35,37]
patients. Randomized controlled trials (RCTs) of the effect of fish oil containing LEs on markers
of inflammation and immune function in patients who had undergone surgery for gastrointestinal
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cancers were subject to a very recent meta-analysis [42]. Depending upon the biomarker, the analysis
included between four and 13 RCTs and between 209 and 756 patients. It was determined that fish oil
LEs resulted in significant decreases in the inflammatory markers TNF, IL-6, and C-reactive protein
(all P < 0.00001) and significant increases in markers of acquired immunity including the numbers
of lymphocytes (P < 0.0001), CD3 and CD4 cells and the CD4 to CD8 ratio (all P < 0.00001), and the
concentrations of immunoglobulins A, M, and G (all P < 0.00001) [42]. These observations support
the proposal shown in Figure 5 that fish oil containing LEs can be used to control inflammation and
support immune function in patients receiving parenteral nutrition.
. 
Figure 6. Plasma phosphatidylcholine eicosapentaenoic acid (EPA) in patients with hepatic colorectal
metastases and receiving intravenous infusion of a blend of soybean oil, MCTs, and fish oil (closed
squares) or soybean oil and MCTs (closed circles) daily for 72 h. * Indicates significantly different from
study entry within the same group. † Indicates significant difference between groups at a given time
point. Figure taken from Al Taan et al. [36].
3. Clinical Studies in Patients Undergoing Surgery
According to Figure 5, better control of inflammation and better support of immune defenses
would be linked with improved patient outcomes. Section 2.3 describes that the use of fish oil
containing LEs significantly decreases markers of inflammation and significantly increases markers of
acquired immune defenses, especially in surgical patients. Therefore, it would be expected that fish oil
LEs would improve patient outcomes in surgical patients. Whether this is the case has been mainly
explored in patients undergoing gastrointestinal surgery usually for the removal of malignant tissue.
LEs have mainly been used in the days immediately following surgery (usually days 1 to 5) although
there are a small number of trials of longer duration or using perioperative administration. The clinical
outcomes most often reported are infections and length of hospital stay, while length of ICU stay
where patients went to the ICU post-surgery is also reported. Individual trials are discussed in detail
elsewhere [20,21]. There have been a number of meta-analyses of the studies conducted with fish oil
LEs in surgical patients [42–47]. These meta-analyses are summarized in Table 2. The findings of these
meta-analyses are consistent and it is evident that compared with other LEs, usually based on pure
soybean oil or a 50:50 (vol/vol) blend of soybean oil and MCT oil, fish oil containing LEs can decrease
infections, the length of ICU stay, and the length of hospital stay in surgical patients. As indicated
above, most of the studies have used LEs postoperatively but it would also seem advantageous to use
fish oil containing LEs preoperatively for several days in cases of elective surgery in order to get the
bioactive omega-3 fatty acids into the body in advance of the surgical insult.
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Table 2. Summary of meta-analyses of randomized controlled trials of fish oil containing lipid emulsions
(LEs) in surgical patients.
Effect of Fish Oil LE On
Meta-Analysis and Year Infections Length of ICU Stay Length of Hospital Stay
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4. Clinical Studies in Patients Requiring Critical Care
There are fewer studies that compare different intravenous LEs in critically ill patients to in surgical
patients, yet critically ill patients are more likely to suffer the adverse effects of hyperinflammation and
immune paralysis, are more likely to have poor outcomes like organ failure and death, are more likely
to have a prolonged hospital stay, and are more likely to require nutrition support including parenteral
support. The trials that have been performed most often report infections, respiratory function and
need for ventilator support, length of ICU and hospital stay, and death. Individual trials of fish oil
containing LEs in critically ill patients are reviewed in detail elsewhere [20,21,27,48,49]. There have
been several meta-analyses of the studies conducted with fish oil LEs in critically ill patients [45,50–52].
These meta-analyses are summarized in Table 3. The outcomes of these meta-analyses reflect the mixed
picture that emerges from the different trials, that is to say, different meta-analyses produce different
findings for some outcomes. This may reflect the relatively small number of studies performed, the use
of different fish oil containing LEs, and the heterogeneity of this patient population. Thus, at this stage
it is difficult to make a conclusive statement about the role of fish oil containing LEs in critically ill
patients, although the rationale, as depicted in Figure 5, remains highly relevant.
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Table 3. Summary of meta-analyses of randomized controlled trials of fish oil containing lipid emulsions
(LEs) in critically ill patients.
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Moving away from RCTs and closer to the real patient setting, Edmunds et al. [53] published an
interesting secondary analysis of data from a prospective multicenter international study. The study
included adults admitted to the ICU for more than 72 h and who were ventilated within 48 h. To be
included in the secondary analysis, patients had to have received parenteral nutrition exclusively for
more than 5 days and to have received a single type of LE during that time. Of the available 12,585
patients only 451 (3.5%) met these criteria, most (84.2%) having received enteral nutrition. Among the
451patients included, 223 (49.4%) received pure soybean oil LE while only 19 (4.2%) received a LE that
included fish oil. The findings of the study are summarized in Table 4. As compared with using pure
soybean oil LE or a 50:50 blend of soybean oil and MCTs, use of fish oil was associated with fewer
patient deaths by day 60, shorter lengths of ICU stay, and shorter lengths of hospital stay. Figure 7
shows that the use of fish oil containing LEs increased the likelihood of a patient being discharged alive
from the ICU. These findings from a prospective study rather than from an RCT are indicative of a
significant clinical benefit from fish oil LEs in critically ill patients. However, it needs to be recognized
that the number of patients receiving intravenous fish oil was very small (4.2% of those receiving
exclusive parenteral nutrition with one LE and only 0.15% of the entire patient cohort). Thus, the
findings must be considered cautiously. Furthermore, it is possible that those centers that use fish oil
LEs may use other innovative approaches that benefit their patients. Nevertheless, these findings are
encouraging and support the design of improved trials for the future.
Table 4. Summary of findings of Edmunds et al. [53].
Outcome Soybean Oil Soybean Oil MCT Oil Blend Fish Oil Blend
Patient died within 60 days (%) 28.3 30.8 10.5
Duration of mechanical ventilation
(median days) 4.9 5.3 5.0
Length of ICU stay (median days) 10.9 9.6 7.05
Length of hospital stay (median days) 28.1 31.9 14.1
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Figure 7. Cumulative likelihood of critically ill patients being discharged from the ICU alive according
to the LE received. Modified with permission from C.E. Edmunds, R.A. Brody, J.S. Parrott, S.M.
Stankorb, D.K. Heyland (2014) The effects of different IV fat emulsions on clinical outcomes in critically
ill patients. Critical Care Medicine 42, 1168–1177 [53].
5. Summary and Conclusions
Lipids used in intravenous nutrition support (i.e., parenteral nutrition) provide energy, building
blocks, and essential fatty acids. These lipids are included as emulsions since they need to be soluble
in an aqueous environment. Fish oil is a source of bioactive omega-3 fatty acids (EPA and DHA)
in contrast to the more traditional soybean oil which is rich in the omega-6 fatty acid linoleic acid.
Preclinical research suggests that including fish oil in parenteral nutrition support may control adverse
inflammatory responses and may support acquired immunity, thereby offering advantages to patients
that would be seen through improved clinical outcomes. LEs, including fish oil, have been used for
parenteral nutrition for adult patients post-surgery (mainly gastrointestinal). This has been associated
with alterations in patterns of inflammatory mediators and in immune function, and in some studies,
a reduction in length of ICU and hospital stay. These benefits, as well as a reduction in infections,
are brought out by recent meta-analyses. Perioperative administration of fish oil may be superior to
postoperative, but this requires greater exploration. Parenteral fish oil has been used in critically ill
adults. Here, the influence on inflammatory processes, immune function, and clinical endpoints is
not clear, because there are too few studies and those that are available report inconsistent findings.
However, some studies found reduced inflammation, improved gas exchange, and shorter length of
hospital stay in critically ill patients if they received fish oil. Meta-analyses do not provide a clear
picture of the impact of fish oil containing LEs in critically ill patients, but these are limited by the small
number and size of studies performed so far. A prospective study suggests a benefit from fish oil LEs
in critically ill patients but in that study very few patients received fish oil. More and better trials are
needed in patient groups in which parenteral nutrition is used and where fish oil may offer benefits.
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Abstract: Microalgae have been widely recognized as a valuable source of natural, bioactive molecules
that can benefit human health. Some molecules of commercial value synthesized by the microalgal
metabolism have been proven to display anti-inflammatory activity, including the carotenoids lutein
and astaxanthin, the fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid),
and sulphated polysaccharides. These molecules can accumulate to a certain extent in a diversity of
microalgae species. A production process could become commercially feasible if the productivity is
high and the overall production process costs are minimized. The productivity of anti-inflammatory
molecules depends on each algal species and the cultivation conditions, the latter being mostly related
to nutrient starvation and/or extremes of temperature and/or light intensity. Furthermore, novel
bioprocess tools have been reported which might improve the biosynthesis yields and productivity
of those target molecules and reduce production costs simultaneously. Such novel tools include the
use of chemical triggers or enhancers to improve algal growth and/or accumulation of bioactive
molecules, the algal growth in foam and the surfactant-mediated extraction of valuable compounds.
Taken together, the recent findings suggest that the combined use of novel bioprocess strategies
could improve the technical efficiency and commercial feasibility of valuable microalgal bioproducts
production, particularly anti-inflammatory compounds, in large scale processes.
Keywords: anti-inflammatory; bioactive molecules; microalgae; polysaccharides; carotenoids;
polyunsaturated fatty acids
1. Microalgae as Source of Anti-Inflammatory Compounds
In recent years, the pharmacy of the sea has become a new paradigm for the discovery and
development of novel drugs and bioactive compounds. The increasing need for getting drugs with
no or minimal toxic side effects is one of the main reasons that motivates the search for bioactive
compounds from natural sources, including anti-inflammatory active molecules from microalgae.
Much has been written about the outstanding metabolic properties of microalgae that make them
particularly attractive as a natural source for bioactive molecules production [1–3]. Regarding the
topic of this review, a variety of microalgal metabolites which display anti-inflammatory activity
can accumulate in the cells to a certain extent. The diversity in chemical nature, structures and
biosynthesis pathways of the most abundant anti-inflammatory molecules synthesized by microalgae
are well known and have been many times reported in several noticeable reviews [4–6]. Among them,
some carotenoids, PUFA (polyunsaturated fatty acids) and carbohydrates displaying anti-inflammatory
Mar. Drugs 2018, 16, 478; doi:10.3390/md16120478 www.mdpi.com/journal/marinedrugs216
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activity have been reported [7] which also comply with two requisites a target valuable product to
be produced by microalgae or cyanobacteria should meet: (i) Being accumulated at relatively high
concentrations in microalgal cells grown under standard cultivation conditions, and (ii) being over
produced as an algal response to suboptimal cultivation conditions or when they are subjected to
chemical and/or physical stress. These suboptimal or stress conditions can be related to changes
in nutrient concentration, changes in physicochemical parameters, including pH, temperature, light
quality and irradiance, or addition of chemicals triggering the overproduction of target molecules [3,8].
Table 1 summarizes some of the most marketed microalgae species used for accumulation
of carotenoids, PUFA and carbohydrates, biochemical molecules groups that include the main
anti-inflammatory microalgal compounds.
Table 1. Biochemical molecules groups of microalgae known to display anti-inflammatory activity.














It is apparent that the proven anti-inflammatory activity of the biomolecules listed in Table 1
increases the value of the algal biomass as a source of functional components for the production of
food supplements and novel foods or the production of natural ingredient-based health products.
Before proven active against inflammation, some of the most valuable microalgal molecules,
listed in Table 1, were reported to be commercially valuable due to their antioxidant properties
which confer on the microalgal biomass high potential as a nutritional supplement. For instance,
this is the case for the carotenoids astaxanthin (3,3′-dihydroxy-β,β-carotene-4,4′-dione), lutein
(3R,3′R,6′R-βε-carotene-3,3′-diol) and β-carotene (β,β-carotene), which are considered added-value
molecules produced by microalgae traditionally demanded by the nutrition market for the production
of food supplements [15,16]. The role of the aforementioned microalgal molecules in inflammation
and chronic inflammation has been extensively described in a specific review [7], and other related
papers [15,17]. Besides the anti-inflammatory activity, the antioxidant capacity displayed by many
of these natural molecules increases their value as natural products with potential benefits to
human health [18–20]. In addition to those molecules listed in Table 1, phycobiliproteins, phenolic
compounds and several carotenoid-isomers are also among those microalgal compounds displaying
anti-inflammatory activities and being potentially valuable for commercial applications related to
human health care [7,21].
One of the main advantages of microalgae when used for the production of valuable compounds
in large scale production systems is the high areal biomass productivities. The systematic production
of microalgae biomass at large scale in addition to the high productivity of microalgal cultures under
well established and controlled cultivation conditions [22] make them valuable as a natural source for
the production of a range of bioactive compounds, including molecules displaying anti-inflammatory
activity [3]. The low generation times of microalgal growth and the intensive control of cultivation
parameters in photobioreactors make the production of bioactive compounds-enriched microalgal
biomass technically and economically feasible at large scale throughout the year at suitable latitudes.
Moreover, the algal metabolic plasticity and rapid response to changes in physicochemical conditions
ease to address the accumulation of specific metabolic products in large-scale production processes.
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In this review, the specific microalgae species and cultivation strategies that could be more suitable to
enhance accumulation of anti-inflammatory microalgal molecules are discussed.
Only a few microalgae species are currently being produced with a commercial purpose in
spite of the huge diversity existing in nature which according to literature accounts for about
300,000 species, out of which only 10% (30,000) have been documented [23]. Thus, most of the
existing microalgae species are still to be discovered and tested for biotechnological exploitation.
The worldwide microalgal market for food, feed or high-value ingredients production is mostly
composed of a limited number of algal species belonging to the following genera: Chlorella, Spirulina
(Arthrospira), Dunaliella, Haematococcus, Nannochloropsis, Scenedesmus, Isochrysis, Porphyridium and
Phaeodactylum [16]. Until 2014, only a few high-value molecules produced with microalgae had
reached the food and feed market: (i) Several pigments, such as the carotenoids β-carotene and
astaxanthin, and the protein complex phycocyanin; and (ii) polyunsaturated fatty acids, such as EPA
(eicosapentaenoic acid) and DHA (docosahexaenoic acid). All these compounds have been found to
display anti-inflammatory activity, though most of them reached the market thanks to properties other
than anti-inflammation. In addition, a peptide from Phaeodactylum tricornutum reached the market
based on its anti-inflammatory properties only [16]. Thus, there is still a big room for discovering
microalgae species with the capacity to accumulate anti-inflammatory compounds that could reach
the market.
With no doubt genetic engineering techniques currently offer a large number of procedures
to obtain modified strains which are designed to display specific functionalities. However, several
factors still make the use of genetically modified microalgae difficult at commercial production
scale; for instance, a still little positive consumer perception towards genetically modified organisms
and the restrictive regulations on genetically modified organisms in many countries slow down
development of industrial production of microalgae enriched in high-value compounds. However,
the huge diversity of wild microalgae species that remain unexplored and unexploited should still for
a long time allow addressing research on their natural potential for the production of target molecules
by means of triggering key biosynthetic pathways through the use of specific chemicals and cultivation
conditions [8,23]. This is one of the key messages of this review article, and the information and
discussion below directly focus on this approach.
The biotechnological potential of most marketed microalgae species is actually very well known,
and the expectations to unveil novel, abundant bioactive compounds from non-extremophilic
microalgae are decreasing. In coming years, the production of novel microalgal compounds
should expectedly be carried out from novel microalgal species isolated from locations where they
could eventually be further produced at large scale. In this respect, extremophilic microalgae are
microorganisms with unique metabolic capabilities yet unexploited, with a competitive advantage (as
compared to non-extremophiles) to grow in open systems under restrictive cultivation conditions (for
example, highly acid pH or very low temperature) which limit microbial contamination. For instance,
Dunaliella salina is an outstanding example of extremophilic microalga commercially used for the
production of a high value compound which displays anti-inflammatory activity, β-carotene [24].
2. Chemically-Induced Oxidative Stress to Improve Production of Anti-Inflammatory Compounds
2.1. Chemicals Triggering Accumulation of Anti-Inflammatory Compounds
Marketing of anti-inflammatory compounds obtained from microalgae is possible only if
commercial feasibility of the product production process is achieved. A production process could
become commercially feasible if the biosynthesis yields and productivity of target molecules are
high and the overall production process costs are minimized. The productivity of anti-inflammatory
molecules depends on each microalgal species and the specific cultivation conditions that boost the
biosynthesis pathways involved. These conditions must be optimized for each microalgal species.
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A number of anti-inflammatory molecules obtained from microalgae have also been shown
to display high antioxidant capacity, thus they could in theory be produced under oxidative stress
conditions. A list of the most abundant microalgal molecules with both anti-inflammatory and
antioxidant activities should include the pigments β-carotene [25], astaxanthin [26], lutein [27],
zeaxanthin [28] and phycobiliproteins [29]. The carotenoids exhibit high antioxidant activity which
has been reported to positively impact human health, based on the chemical ability of carotenoids to
scavenge reactive oxygen species (ROS) produced in the cell by the oxidative metabolism [7,15,30].
In addition to the aforementioned antioxidant pigments, LC-PUFAs (long chain polyunsaturated
fatty acids, including EPA and DHA) have also been proven to exert antioxidant activity,
which for instance was exemplified by studies in human vascular endothelial cells demonstrating
reduced excretion of lipid peroxidation products after omega 3-intake and superoxide scavenging
by LC-PUFAs [31]. The third group of anti-inflammatory molecules produced by microalgae,
the polysaccharides, has also been proven to exert antioxidant activity, and their applications and
benefits to human health can be found in several outstanding reviews published in recent years [7,32].
Polysaccharides isolated from Porphyridium [33] and Rhodella [34] are noticeable examples of antioxidant
microalgae polysaccharides.
In addition to the above mentioned compounds, a number of other microalgal molecules have
recently been reported which also have high antioxidant capacity besides anti-inflammatory activity:
Phenolic compounds (flavonoids) [21], peptides [35], and the carotene isomers trans-β-carotene and
9-cis-β-carotene.
According to the aforementioned antioxidant capacity of a large number of microalgal molecules
which also display anti-inflammatory activity, some of the main chemical strategies to enhance their
biosynthesis and intracellular accumulation could be based on inducing oxidative stress in the cells
which might result in increased production rates of antioxidant molecules. In this sense, ROS can act as
chemical signals to specifically induce the biochemical production of antioxidant molecules, including
the enzymes of the antioxidant cellular response to stress [36]. Therefore, the use of oxidative stress
applied to microalgal cultures can be one of the strategies to achieve increased productivities of those
specific target molecules.
In microalgal cultures, oxidative stress can be induced by a range of strategies which involve the
use of chemicals. The knowledge of the chemical properties and reactivity of the main added-value
molecules obtained from microalgae, as well as the principal metabolic steps of their biosynthesis have
allowed to carry out novel research aimed at searching for chemical triggers that enhance accumulation
of those molecules. The chemical triggers are different in nature and action mechanisms. According
to the latter, these chemicals can be classified into several groups [8]: Oxidative stress inducers,
metabolic regulators and metabolic precursors. Besides, chemicals can also be used to induce changes
in the physicochemical conditions around the cell environment with the result of the intracellular
accumulation of valuable molecules. For instance, surfactant addition to growing microalgal cultures
results in foam production containing growing microalgal cells with shifted availability of carbon,
oxygen and light [37]. This shifted environment induces physiological responses, including the shifted
biochemical profile of valuable microalgal major biomolecules, as further discussed.
In a recent study, Franz et al. [38] described a screening of 42 chemicals for their roles on lipid
metabolism in microalgae, and identified 12 chemicals that are capable of enhancing intracellular
lipid levels by >100%. Three of these chemicals (epigallocatechin gallate, CDK2 inhibitor 2 and
cycloheximide) enhanced intracellular lipids –PUFA included- by 200–400% based on Nile Red
fluorescence intensity measurements. In addition, the researchers took a further step to verify
these chemicals effectiveness in large-scale cultures and concluded that propyl gallate and butylated
hydroxyanisole could be used in large-scale applications considering the low cost of the chemicals and
the lipid content increases [38], demonstrating that the application of chemical enhancers could be a
valuable, practical approach in addressing the enhanced productivity of microalgae-based products.
The main algal molecules with both anti-inflammatory and antioxidant activity, the main chemicals
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triggering their accumulation and the induction mechanisms in the algal metabolism are summarized
in Table 2.








H2O2, SeO32, Fe (II) Oxidative stress Haematococcus pluvialis [39,40]
MV Oxidative stress Chlorococcum sp. [41]
Fe (II) Oxidative stress Cromochloris zofingiensis [42]
Jasm., salic. acid Oxidative stress Haematococcus pluvialis [43]
N starvation, NaCl Oxidative stress Haematococcus pluvialis [44–46]
Lutein
H2O2, NaClO Oxidative stress Chlorella zoofingiensis [47,48]
Fe (II), Cu (II) Oxidative stress Coccomyxa onubensis [3,24,49]
N starvation Oxidative stress Coccomyxa onubensis [50]
NaCl Oxidative stress Botryococcus braunii [51]
EPA
Low oxygen PUFA stimulation Pavlova lutheri [52]
N, P repletion PUFA stimulation Nannochloropsis oceanica [53]
DHA
Low oxygen PUFA stimulation Schizochytrium sp. [54]
N, P repletion PUFA stimulation Pavlova lutheri [55]
Sulphated
polysaccharides
N starvation Oxidative stress Rhodella violacea [56]
P starvation Oxidative stress Phaeodactylum tricornutum [57]
NaCl Oxidative stress Dunaliella salina [58]
Phenolic
compounds
Cu (II), Fe (II) Oxidative stress Dunaliella tertiolecta [59]
N repletion + Phe Phenylpr. synth. Spirulina platensis [60]
Phe: Phenylalanine; Phenylpr. synth.: Phenylpropanoid synthesis stimulation; Jasm., salic. acid: Jasmonate,
salicylic acid.
2.2. Induced-Oxidative Stress: A Key Strategy to Trigger Accumulation of Anti-Inflammatory Compounds
An increasing interest exists about how microalgae can cope with oxidative stress. Such interest is
related to the microalgal potential for the large scale production of valuable molecules accumulated
under oxidative stress, the so-called antioxidants. The primary microalgal antioxidant response
to oxidative stress conditions imposed to their cultures consists of producing a range of enzymes,
such as superoxide dismutase, ascorbate peroxidase, catalase, glutathione reductase and peroxidase,
as well as other molecules, such as phytochelatins, pigments, polysaccharides, and polyphenols [61].
In addition, PUFA can also accumulate in response to oxidative stress as described below in
this manuscript. As explained, polysaccharides, polyphenols, several pigments—particularly the
oxygenated carotenoids called xantophylls—and some PUFA have been demonstrated to display
anti-inflammatory activity. Thus, the production of such anti-inflammatory bioactive compounds could
in theory be enhanced through chemically-induced oxidative stress of the microalgal cultures (Table 2).
As well described by Cirulis et al. [61], chemically-induced production of antioxidant compounds from
microalgae requires to research: (i) What chemicals induce oxidative stress in microalgae, (ii) which are
the main microalgal metabolism responses to the imposed oxidative stress and what target molecules
are produced most abundantly to dissipate the oxidative state, (iii) how to modulate the use of oxidative
stress chemical triggers in order to simultaneously boost the accumulation of target molecules whilst
obtaining high volumetric productivities, and (iv) how to integrate the acquired knowledge into
production processes of target molecules both at laboratory and at large scale.
The simple fact that life occurs in an oxygenated atmosphere results in the continuous presence of
oxygen in living cells. As a reactive molecule, oxygen takes part in many chemical and biochemical
reactions by means of which ROS permanently arise. ROS are chemically reactive species containing
oxygen. ROS include species with unpaired electrons and non-radical species, e.g., hydrogen peroxide,
and form during oxygen metabolism through several well identified enzymatic pathways. DNA,
proteins and membrane lipids, among other biomolecules, are direct targets of ROS which can alter
the normal biological functions of those principal biomolecules: This is the so-called oxidative stress.
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In photosynthetic cells like those of unicellular microalgae and cyanobacteria, ROS are produced in
plastids, mitochondria and cytosol, among other organelles [62]. It is apparent that the light-dependent
oxygen production largely contributes to an increase in ROS production in photosynthetic membranes:
The greater the photosynthetic activity, the greater the oxygen production in the chloroplasts and,
consequently, the potential oxidative damage produced by the ROS generated. Therefore, the reaction
centers of photosystem II (PSII) and photosystem I (PSI) play a key role in the production of ROS
(Figure 1). In the 1950s Mehler [63] unveiled and described the light-dependent reduction of oxygen
to hydrogen peroxide in PSI, therefore superoxide anion being identified as primary reactive oxygen
species generated in the chloroplasts [64]. Figure 1 shows details of the chloroplastic ROS-generating
reactions (upper frame, a). As indicated, part of the electron flow derived from the water splitting
reactions in PSII is derived to the chloroplastic photoreduction of oxygen.
 
Figure 1. Reactive oxygen species (ROS) production and scavenging mechanisms in photosynthetic
organisms. (a) Reactive oxygen species production mechanisms, and detoxification of hydrogen
peroxide catalyzed by ascorbate peroxidase (2); (b) AsA recovery reactions: Enzyme-catalyzed
(NAD(P)H-dependent) (3) and spontaneous (red-Fd dependent) biochemical mechanisms of
monodehydroascorbate (MDA) reduction, spontaneous disproportion of MDA to Dha and AsA,
and enzyme-catalyzed (4) biochemical mechanism of NADPH-GSSG dependent AsA recovery. PSII-RC,
photosystem II reaction center; PSI-RC, photosystem I reaction center; AsA, reduced ascorbate;
MDA, monodehydroascorbate; red-Fd, reduced ferredoxin; Dha, dehydroascorbate; GSSG, oxidized
glutathione; GSH, reduced glutathione; (1) Superoxide dismutase; (2) Ascorbate peroxidase; (3) MDA
reductase; (4) Dha reductase; (5) Glutathione reductase.
In order to minimize the ROS damage to key cellular processes and functionalities, the cells express
diverse antioxidant biochemical mechanisms to neutralize, or at least minimize, the harmful effects of
ROS (reviewed by Deawal et al. [18]). The primary antioxidant mechanisms in most organisms include
molecules with antioxidant capacity, such as α-tocopherol (vitamin E), glutathione and ascorbic acid,
and enzymes with antioxidant activity, such as superoxide dismutase, catalase, ascorbate peroxidase
and glutathione peroxidase (Figure 1). In photosynthetic cells other molecules, such as carotenoids,
PUFA and polysaccharides also contribute to cope with a harmful excess ROS. When ROS production
exceeds the antioxidant capacity of the cells, harmful effects arise. The above referred antioxidant
mechanisms contribute to keeping the intracellular physiological contents of ROS at low levels.
In this sense, the enzyme superoxide dismutase catalyzes the subsequent disproportion of superoxide
anion to oxygen and hydrogen peroxide [64], thus eliminating the oxidative risk associated with the
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superoxide anion but still generating a highly reactive, toxic compound, hydrogen peroxide. The main
detoxification reaction for hydrogen peroxide is its enzyme-mediated reduction to water catalyzed
by ascorbate peroxidase (APX). The subsequent group of reactions shown in Figure 1b expresses the
reduced ascorbate (AsA) recovery reactions dependent of NAD(P)H or reduced ferredoxin (red-Fd).
The AsA-dependent enzyme-catalyzed reduction of hydrogen peroxide to water is a crucial step to
produce an efficient detoxification of ROS. As shown in Figure 1 (frame a), the highly reactive hydrogen
peroxide generated in the reduction of superoxide anion by the enzyme superoxide dismutase, can react
with chemical species able to reduce it resulting in the production of additional, extremely active oxygen
species. This is the case for Fe (II) which reduces hydrogen peroxide resulting in Fe (III), hydroxyl group
and hydroxyl free radical production. This is the so-called Fenton reaction. Therefore, in presence
of Fe (II), part of the hydrogen peroxide produced in photosynthetic cells can be diverted to ROS
generation instead of being detoxified by the action of APX. Accordingly, Fe (II) can trigger oxidative
stress in photosynthetic cells when added to a culture medium at optimized concentrations [36,39,44].
Some reports have been published which provide evidence of direct involvement of ROS in the
enhanced biosynthesis of microalgal molecules with both antioxidant and anti-inflammatory properties,
namely carotenoids and PUFAs. In 1994, Asada [36] described mechanisms of production and action
of reactive oxygen species in photosynthetic cells, suggesting that such ROS might be acting as signal
molecules to trigger the biosynthesis of a number of antioxidant molecules, carotenoids among them.
Further studies have contributed to support the ROS function as signaling molecules and their action
as signal transduction processes activators in response to stress. However, the knowledge on the
chemical reactions involved in ROS production, their relative rates and the molecular mechanisms
by which photosynthetic cells sense ROS is yet scarce. Particularly, for the activation of signaling cell
events to happen, ROS with signaling functions (H2O2, OH·, O2) must interact with specific molecular
targets. The mechanisms of such interactions and whether each ROS is specifically recognized by a
given mechanism or receptors remain unknown [62].
The role of antioxidants in inflammation has been recently reviewed by Arulselvan et al. [65].
In this respect, carotenoids, PUFA, polysaccharides and other natural molecules have been reported
to exert antioxidant properties which may play a key role in the anti-inflammatory response [7,65].
Such antioxidant activity consists of scavenging ROS, and/or dissipating photons excess which
cannot be photochemically quenched. The basic principle by which the anti-inflammatory microalgal
unsaturated fatty acids and terpenoids (carotenoids, xantophylls) act as ROS scavengers is shown in
Figure 2. Whether, and how, the biosynthesis of these antioxidant molecules is triggered by the action
of ROS acting as signal transduction process activators remains unclear yet; however, many evidence
have been published which prove enhanced biosynthesis and accumulation of those anti-inflammatory
antioxidant molecules upon induced oxidative stress in microalgae. Consequently, the addition of
certain chemicals which act as oxidative stress inducers should be expected to result in enhanced
accumulation of carotenoids, PUFAs and/or polysaccharides and is indeed one of the strategies
preferred in recent years [8].
The nature of chemicals that can induce oxidative stress in photosynthetic cells is diverse and
the number of those can be enormous. Those being most commonly used in laboratory experiments
currently are listed in Table 2 and include hydrogen peroxide, sodium hypochlorite, Fe (II and III),
Cu (II), sodium chloride, selenite or selenate, herbicides, such as methyl viologen (MV), salicylic
acid (SA), methyl jasmonate (MJ) and giberellic acid (GA), among other compounds. Some of them,
for instance SA, MJ and GA, play roles in regulating expression of genes involved in the biosynthesis
of anti-inflammatory xantophylls [8,66] and, more interestingly, they can play roles as oxidative stress
inducers when used in concentrations that are relatively high in relation to the antioxidant capacity of
the microalgal cells. Therefore, some of these compounds which are phytohormones and analogous
molecules can trigger the accumulation of anti-inflammatory molecules by either playing regulatory
roles in their biosynthetic pathways or directly acting as oxidative stress inducers when added in excess
to the microalgal cultures [8]. Moreover, the cell response is mostly proportional to the concentration
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of the chemical trigger used which allows design production processes based on the modulate action
of such a trigger compound on the algal metabolism. A productive process should be that one in
which the target molecule accumulation is enhanced whilst growth rates remain sufficiently high as
to keep overall productivity also high. From the practical point of view, the selection of an oxidative
stress chemical inducer could be made according to at least the following criteria: (a) The chemical
should induce modulate responses in algal growth and target molecules biosynthesis rates that are
proportional to the inducer concentration, so that the productivity of target antioxidants can also
be maximized accordingly; (b) the chemical should not be toxic to photosynthetic growth at low
concentrations; (c) the chemical should be compatible with further biomass processing and with
specific applications of the target molecules.
Figure 2. Joint action of ROS scavenging activity exerted by the microalgal anti-inflammatory molecules
PUFA and carotenoids. PUFA (unsaturated lipids) and carotenoids are involved in scavenging reactive
oxygen species (green frame, left; yellow frame, right); the resulting oxidized peroxidation products
are chemically damaging for lipids and DNA, among other molecules (orange frame, right). CAR:
Carotenoids; L: Lipid; LOO : Peroxidized lipid; Vit C: Vitamin C; Vit E: Vitamin E.
In addition to the latter, other chemical strategies producing oxidative stress and addressing
the accumulation of microalgal molecules with anti-inflammatory activity are commonly based on
nutrient limitation or starvation. It should be noticed that nutrient starvation, particularly inorganic
nitrogen, is an effective chemical tool to induce accumulation of lipids—including carotenes and
xantophylls—and polysaccharides in microalgae. This subject has been widely reviewed [3,67]. In the
following subsections, the most relevant strategies to address the chemically-induced accumulation of
anti-inflammatory microalgal compounds are discussed.
2.3. Production of Pigments with Anti-Inflammatory Activity
Carotenoids have been found to positively impact the anti-inflammatory cellular response
mechanisms and the immunoresponse modulation [7,68,69]. In addition, their antioxidant nature
confers carotenoid-enriched diets properties to diminish the risk of suffering from degenerative
diseases [70] and protect the eye macula from adverse photochemical reactions [71]. In people over
the age of 65, visual sensitivity and vision loss directly has been found to be associated with lutein
and zeaxanthin concentrations in the retina [15,72,73]. Astaxanthin, a powerful, natural antioxidant
xanthophyll produced by the microalga Haematococcus pluvialis, has been proven effective as an
anti-inflammatory [7,74–77]. In addition, astaxanthin was shown to be effective against benign prostatic
hyperplasia and against prostatic cancer [70,78]. The protective action of astaxanthin involves an
antioxidant mechanism based on the activation of its hydroxyl groups, which results in the formation
of an ortho-dihydroxyconjugate polyene system. This polyene system acts as a chain-breaking
antioxidant [79].
In photosynthetic organisms, carotenoids may act as accessory pigments in light harvesting
functions during the light phase of photosynthesis and may also exert protection of the photosynthetic
machinery from excess light and from other oxidative stress chemical factors (e.g., oxidative species,
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salt, and nutrient deficiency), by scavenging reactive oxygen species (ROS) [3,15,79]. In general, the
level of carotenoids in microalgae increases with oxidative stress. Though chlorophyll is also a valuable
antioxidant which has been described to display anti-inflammatory properties [80], its content in
photosynthetic cells under oxidative stress usually decreases. Thus, the chlorophyll production is
by far more efficient in microalgal cultures growing under non-limiting accumulation conditions,
in highly dense cultures produced in controlled photobioreactors [81].
Only a limited number of microalgae genera are commonly used in research to test pigment
accumulation under oxidative stress, such as Haematococcus for astaxanthin, Chlorella, Scenedesmus
and Botryococcus for lutein, and Dunaliella for β-carotene [23]. A few reports demonstrate that direct
addition of hydrogen peroxide triggered astaxanthin accumulation, for example in Haematococcus
pluvialis [44], Chlorococcum [41] and Chlorella zofingiensis [47], showing maximal increased astaxanthin
contents up to 30% higher than those of standard cultures. Astaxanthin accumulation can also
be boosted indirectly, by intracellular production of hydrogen peroxide through oxidative stress
induced by addition of selenite to the culture medium. Selenite-mediated oxidative stress induction
was unveiled by significantly increased levels of the hydrogen peroxide antioxidant enzyme activity
content of the microalgal cells upon selenite addition, which indirectly resulted in increased astaxanthin
accumulation in H. pluvialis as part of the cellular antioxidant response [40]. Thus, the application
of a suitable type and dosage of a given ROS can be potentially used as an efficient chemical tool for
large-scale production of anti-inflammatory xanthophylls, such as astaxanthin.
The increased intracellular content of ROS that is required to boost astaxanthin accumulation
can also be achieved by the addition of herbicides to microalgal cultures. Herbicides, such as methyl
viologen, are commonly used in laboratory research and have been reported to enhance accumulation
of astaxanthin in Haematococcus [44] and Chlorococcum [41] though it is a detriment to the microalgal
growth and, obviously, to the quality of the microalgal products. Looking at the large-scale production
process feasibility, the use of herbicides implies the associated problem of its toxicity and thus would
not be suitable for industrial production. Interestingly, Ma and Chen [41] demonstrated that the
hydroxyl (OH) radical might be a key ROS in the molecular signaling pathway that activates the
astaxanthin biosynthesis, therefore suggesting a direct effect of a specific ROS on the astaxanthin
production pathway induction. Indeed, an early study of Kobayashi et al. [39] demonstrated that
several oxidant chemical species, including superoxide anion radical (O2−), hydrogen peroxide and
2,2′-azo-bis(2-amidinopropane)-dihydrochloride for peroxy radical (AO2), and Fe (II), were capable of
boosting astaxanthin accumulation in H. pluvialis. These chemical species might be playing a role as
oxidizers in the oxidative enzyme reactions chain leading to astaxanthin biosynthesis [82].
The use of ferrous iron-Fe (II) as astaxanthin biosynthesis inducer is of particular interest. Fe (II)
is an essential metal ion required for microalgal growth, therefore included in the culture medium
composition. As described by Kobayashi et al. [39], Fe (II) catalyzes the so-called Fenton reaction
by which OH radical generates. When added in excess, Fe (II) addresses the boosted generation of
OH radical, thus largely increasing the oxidative state of the cells. As discussed above, OH radical
triggers the molecular signaling pathway that activates astaxanthin biosynthesis. Thus, Fe (II) can be
effectively used to enhance astaxanthin accumulation, as reported for example for H. pluvialis [83] and
Chromochloris zofingiensis [42]. One of the advantages of Fe (II) as astaxanthin biosynthesis inducer is
the dose-response of the microalgal growth II to this ion. This allows for the better control of chemical
conditions (Fe (II) concentrations) that can simultaneously address astaxanthin accumulation and
microalgal growth [84].
Nitrogen limitation or starvation and high salinity levels induce oxidative stress in microalgal
cells and also the subsequent cellular antioxidant responses, including enhanced biosynthesis and
accumulation of anti-inflammatory carotenes and xanthophylls [85]. Indeed, astaxanthin and
other carotenoids displaying anti-inflammatory activity (e.g., lutein, β-carotene) can accumulate
in microalgal cells in response to nitrogen limitation or starvation (astaxanthin, [45,46]; β-carotene, [67];
lutein [50]) and high salinity of the culture medium (astaxanthin, [39]; lutein [51]). Nitrogen
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starvation-based strategies come with the disadvantage of the time-limited cell viability of the
microalgal cultures. Thus, the nitrogen starvation-based pigment production consists of a two-phase
process, with the first phase of microalgal growth in nutrient replete medium followed by a second
phase of incubation in a nitrogen-starved medium.
In spite of lutein being one of the most valuable carotenoids, chemically-induced accumulation
of lutein has not been extensively studied in microalgae. Considering the valuable applications of
lutein and the increasing market demand of natural sources of this pigment [16], this is with no doubt
a challenging research field for algaers. In microalgae, lutein has been shown to accumulate in cultures
subjected to oxidative stress. For instance, the lutein content of Chlorella zoofingiensis was shown to
increase in response to ROS generated by low concentrations of H2O2 or NaClO [48]. The cultures were
grown heterotrophically and the lutein increase accounted just for about 11% with respect to control
cultures, which suggests there is still room for lutein production improvement under optimized process
conditions. But not only the use of oxidants triggers lutein biosynthesis in microalgae; induction
of oxidative stress based on nutrient starvation [50], or increased salinity (NaCl), have been found
to induce increased accumulation of lutein in C. onubensis. Interestingly, lutein accumulates at a
high intracellular concentration in Fe (II) or Cu (II)-added cultures of C. onubensis, an extremophilic
microalgal species isolated from the highly acidic environment of Río Tinto (Southwestern Spain) [49].
The large lutein accumulation is probably one of the physiological microalgal responses to the oxidative
conditions of acidic habitats which contain relatively high levels of solved metal ions, such as Fe (II),
Mn (II), Al (III) and Zn (II) [24].
Almost no studies have been published dealing with ROS-mediated induction of β-carotene
biosynthesis, probably due to the efficient chemical strategies applied for β-carotene mass production
at industrial scale and the high intracellular β-carotene content and productivities achieved by the
only β-carotene producing microalga Dunaliella salina which makes the search for novel chemical
triggers unnecessary.
2.4. Production of Polyunsaturated Fatty Acids (PUFA) with Anti-Inflammatory Activity
The anti-inflammatory properties of PUFA from microalgae have been widely described and
recently reviewed by several authors [7,32]. A large number of scientific papers described the effective
therapeutic role of PUFA in a variety of inflammatory pathologies, such as Alzheimer, arthritis
and lupus [7,86,87], with a demonstrated activity in chemopreventive functions when used as ω-3
PUFA-rich microalgal oil diet [88].
In photosynthetic cells, PUFA carry out a variety of cellular key functions. Besides the principal
roles of PUFA as energy storage molecules, cell membrane components and in the physiology of
photosynthetic cells, their antioxidant capacity is one of the cellular defense mechanisms against the
harmful presence of ROS. In fact, PUFA show affinity towards ROS generated in algal cells subjected
to oxidative stress conditions [89]. Indeed, PUFA have been described to react chemically with ROS
(Figure 2), which results in the formation of lipid hydroperoxides [90,91] resulting in an altered profile
of lipids. This is of course an inevitable consequence of oxygen-dependent life but is often ignored [33].
Particularly, PUFA autoxidation reaction is mediated by ROS, which results in the formation of
lipid hydroperoxides as primary products. The lipid hydroperoxides can be further converted into
more oxidized products, such as ketones and malonaldehyde. Other oxidation products are hydroxy
alkenals which are formed by peroxidation of 4-hydroxy-2-nonenal (HNE), generated by peroxidation
of ω-6 PUFAs.
Thus, together with carotenoids and polysaccharides, PUFA are included among the wide
range of antioxidant compounds that are produced by microalgal cells to diminish the harmful
consequences derived from oxidative stress [92]. However, such antioxidant role obviously causes
the time course-dependent decreased proportion of PUFA with respect to saturated fatty acids,
in microalgal cells. In spite of this fact, the production of microalgal PUFA can be improved under
suitably controlled oxygen levels [33].
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Besides the negative impact of ROS in the growth and high-value compounds accumulation of
microalgae, ROS seem to play a relevant role in triggering lipid accumulation in microalgae [93,94]
though experimental evidence of ROS-mediated lipid accumulation mechanisms is still lacking [33].
The aforementioned apparent contradiction suggests that lipid accumulation could be induced by
suitable intracellular ROS levels which could be achieved by subjecting the microalgal cultures to
controlled stress conditions, specifically through controlled oxygen levels. In this respect, bioprocess
engineering can help to optimize the oxygen supply to the microalgal cultures. Sun et al. [33] suggest
this can be done either by direct oxygen regulation strategies or through new bioreactor designs
to improve oxygen supply. Overall, PUFA production can thus be enhanced by keeping oxygen
concentration in the photobioreactor at relatively low levels, therefore favoring a ROS production
low activity in the cells as a mean to stimulate PUFA accumulation whilst minimizing the excess
ROS-dependent lipid peroxidation. As low oxygen concentrations are detrimental to the microalgal
growth, the production of PUFA-enriched microalgae can be carried out in a two-step process: The first
step of biomass production under normal aeration, followed by the second step of cultivation under
low oxygen concentration for enhancing PUFA accumulation. This strategy was used by Qu et al. [54]
to produce DHA-enriched biomass of Schizochytrium sp. Alternatively, simultaneous growth and
PUFA production can be carried out at a constant, average oxygen concentration optimized in order
to achieve maximal productivities, as described by Huang et al. [95] for growth and simultaneous
accumulation of DHA.
As previously described above, chemical factors other than oxygen and ROS also generate
oxidative stress. For example, nutrient limitation or deprivation (-N, -P) and high salinity
cause increased intracellular ROS level in microalgae [96,97], thus triggering the expression of
antioxidant defenses as carotenoids and lipids in the microalgal cells. If the intracellular ROS
levels exceed the antioxidant cellular capacity, oxidative stress originates. Some of the consequences
were aforementioned and include decreased PUFA proportion due to their reaction against ROS.
For example, a reduced content of PUFA was observed in Phaeodactylum tricornutum cultures under
nitrogen limitation [98], and a trend between increasing EPA yields and decreasing salinity was found
in Pavlova lutheri [52], both results indirectly suggesting the intense oxidative state arose from nutrient
limitation or increased salinity.
In spite of this negative correlation between accumulation of anti-inflammatory PUFA and nutrient
limitation or salinity level, the accumulation of these compounds in microalgae can also be enhanced
under nitrogen limitation or relatively high salinity but only if these conditions are optimized and
applied to the right time of the stress phase, the accumulation being also species-dependent [99,100].
Although the connection between salinity or nutrient starvation and intracellular antioxidant capacity
has been often reported [11,50,101], this does not necessarily imply systematic, continuous intracellular
accumulation of antioxidants as they can also be involved in coping with intracellular ROS under
intense oxidative stress, thus decreasing their concentration in the microalgal cells. Therefore, as the
main conclusion, the oxidative stress-mediated accumulation of antioxidant, anti-inflammatory PUFA
in microalgae should be carefully addressed by controlling the oxidative pressure and selecting the
right experimental time to harvest the PUFA-enriched microalgal biomass.
Conversely, the reduced oxidative damage of microalgal cells growing in a replete culture medium
can explain the highest EPA content displayed under nitrogen repletion conditions by Nannochloropsis
oceanica (above 30% of total fatty acids cell content) [53], the highest DHA content observed in
Pavlova lutheri (approximately 30% of total fatty acids cell content) [55] and the increased PUFA content
in Tetraselmis marina [99]. Both nitrogen and phosphorus repletion conditions promote microalgal
growth which implies the more active biosynthesis of cell membranes, and particularly tylakoid
membranes in light limited high cell density cultures aimed at improving light capture [102].
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2.5. Production of Sulphated Polysaccharides (sPS) with Anti-Inflammatory Activity
The anti-inflammatory properties of sPS from microalgae have been recently reviewed [32].
The anti-inflammatory properties of sPS-enriched microalgae have been proven in vivo and in vitro
for diverse microalgae, such as species of Chlorella and Phaeodactylum [103,104]. According to the
literature, probably the large majority of cyanobacterial polysaccharide structures contains sulfate
groups [105] and thus can be considered to be sPS. However, the lack of knowledge on structural
data of cyanobacterial polysaccharides limits the possibilities to establish relationships between their
chemical structures and biological properties. In addition to it, the cyanobacterial polysaccharide
structures can vary depending on species. Thus, further research on the structure of cyanobacterial
polysaccharides is required before their real bioactive potential and applications to human health can be
evaluated. The current knowledge on the production, extraction and characterization of cyanobacterial
polysaccharides has been recently revised in an outstanding review by Delattre et al. [105].
In cyanobacteria, a large fraction of assimilated carbon can be diverted to the synthesis of
polysaccharides [106]. Polysaccharides have the function of serving as carbon and energy reserves in
microalgae. In addition, a fraction of the produced polysaccharides can be excreted to cover the cells
with a mucilage layer to protect them from harsh environmental conditions and/or predators [105].
Some of these cyanobacterial polysaccharides have also been found to display antioxidant activity in
addition to their reported anti-inflammatory activity. For example, antioxidant activity has been found
in extracellular polysaccharides from Rhodella reticulata [34] and Porphyridium [107].
Cyanobacterial polysaccharides are also included among the antioxidant molecules produced by
microalgae in response to oxidative stress. Cyanobacteria produce exopolysaccharides, which according
to literature are sPS, up to more than 20 g·L−1 [108,109] in response to a range of physic-chemical
conditions. Nutrient limitation and starvation, particularly lack of N, is the classical strategy to induce
cyanobacterial polysaccharides accumulation [105], which most probably derives from the N/C ratio
metabolic imbalance rather than from the antioxidant cellular response. N limitation, rather than N
starvation, might be a more productive strategy. N limitation can be applied to one-phase production
strategy in photobioreactors outdoors, by which N concentration is adjusted to limiting levels only
when the cultivation conditions are suitable to boost sPS accumulation. Microalgal growth declines
under N-limitation, but still a compromise between sPS intracellular accumulation and growth can be
achieved in order to maximize sPS productivity. Limitation or starvation of main nutrients other than
N, for instance P and S, can also result in polysaccharide accumulation [110], though their effectiveness
depends much on the algal species and cultivation conditions, and it has to be specifically determined
and optimized in each case [111,112]. As explained by Delattre et al. [105], almost no studies have
been conducted to analyze what nutrient does really determine polysaccharides production and how
to simplify the culture medium composition.
As explained above, salinity induces oxidative stress in microalgae. Accordingly, and considering
the antioxidant character of microalgal polysaccharides, salinity could act as polysaccharide
accumulation inducer in microalgae which could use the produced polysaccharides for protective
roles. Indeed, the polysaccharide layer around the cells can limit the diffusion of ions through the
cell cover [113]. Such this role might be played by polysaccharides produced by several species of
cyanobacteria, for instance Aphanocapsa, Anabaena or Synechocystis [105,114,115], which should mostly
be sulphated (sPS) and thus expected to display anti-inflammatory activity [32].
2.6. Production of Phenolic Compounds with Anti-Inflammatory Activity
Phenolic compounds are secondary metabolites produced by photosynthetic organisms and
have awaked interest in recent years, particularly due to their antioxidant character. Based on such
properties, the phenolic compounds are known for their benefits to human health. Specifically,
the anti-inflammatory properties of microalgal phenolic compounds have been recently reported [116]
and contribute to augment the industrial interest of microalgae as raw material for the generation of
novel health products. The phenolic compounds found in microalgae and cyanobacteria and cited in
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the literature include phenolic acids and flavonoids, such as gallate, chlorogenate, cinnamate, gentisic
acid, isoflavones, flavanones, flavonols, and dihydrochalcones [59,60].
The action mechanism of anti-inflammatory compounds is performed by a variety of
inhibitory activities of pro-inflammatory mediators and/or gene expression [116]. In inflammation,
pro-inflammatory cytokines induce the formation of nitric oxide (NO) by inducible nitric oxide synthase,
and compounds that inhibit NO production have anti-inflammatory effects. Phenolic compounds, e.g.,
flavonoids, are among the molecules displaying inhibitory activities of pro-inflammatory mediators.
In this regard, a study of Hämäläinen et al. [117] shows that the anti-inflammatory action of
flavonoids is due to the inhibitory activity of lipopolysaccharide-induced NF-κB (nuclear factor
kappa-light-chain-enhancer of activated B cells) activation. Anti-inflammatory effect of flavonoids
consists of inhibiting NF-κB activation only, along with their inhibitory effect on nitric oxide synthase
expression and nitric oxide production in activated macrophages.
Phenolic compounds accumulation in microalgae has been directly related to the antioxidant
response mechanisms of the cells to increased intracellular oxidative states. Indeed, the anti-inflammatory
activity of phenolic compounds is directly related to their antioxidant activity against ROS. Phenolic
compounds have been described as radical scavengers based on their role as donors of hydrogen
atoms or electrons, producing stable radical intermediates. They can also inhibit iron-mediated ROS
formation to prevent the subsequent oxidative stress [92].
However, only a few studies have been reported so far which deal with the accumulation of
phenolic compounds in microalgae as a specific cellular response to ROS generated under oxidative
stress conditions, for instance, exposure to metal stress [61]. In this regard, a number of factors, such
as nutrient level or presence of metal ions can trigger biosynthesis and accumulation of phenolic
compounds in microalgae. As an example, El-Baky et al. [60] reported that intracellular accumulation
of polyphenols in Spirulina was stimulated by nitrogen, both in inorganic (NaNO3) or organic
(L-phenylalanine) forms. Particularly, the authors reported the presence of phenolic acids and
flavonoids predominantly with gallate, chlorogenate, cinnamate and p-OH-benzoates. Moreover,
in relation to the microalgal antioxidant response, accumulation of phenolic compounds has been
described in Dunaliella tertiolecta in response to stress produced by addition of Cu (II) or Fe (II).
Cu-exposed (790 nmol·L−1) D. tertiolecta cultures contained 1.4-fold higher intracellular levels of
phenolic compounds than standard cultures [59], thus suggesting that the intracellular accumulation
of phenolic compounds in microalgae can be triggered by a metal-induced enhanced oxidative state of
the microalgal cells.
3. Surfactant-Facilitated Accumulation of Anti-Inflammatory Molecules
Microalgae cultivation in foam is a novel concept that consists of growing microalgal cells in
surfactant-based foam [118]. A surfactant is a chemical compound that lowers the surface tension
between two liquids, or a liquid and a solid, or a gas and a liquid. The chemical structure of a
surfactant is composed of zones of different polarity, typically both a polar and a non-polar part.
When mixed in culture medium at a given concentration (at least the so-called CMC, critical micelle
concentration) and bubbled with air, foam arises. If the culture medium contains growing microalgal
cells, microalgae-enriched foam with actively growing cells is produced. In doing so, microalgae can
be continuously grown in foam for which specific foam-bed reactors should be designed [118].
The foam-bed photobioreactor is a novel bioengineering concept originally emerged at
Wageningen University [119]. In a foam-bed photobioreactor the microalgal cells grow in liquid
foams [118], and it has several advantages when compared to liquid cultures: Mass transfer
increase, reduction in aeration and biomass harvesting costs, and minimization of water consumption.
The successful performance of a foam-bead photobioreactor depends on several factors that have been
recently studied [37,120]. Poloxamers, non-ionic surfactants, were demonstrated to be effective for
microalgal growth in foam [37].
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In the foam formed, the microalgal cells grow in the liquid layer that surrounds foam bubbles
(Figure 3). The foam is formed by the air volume contained in micelles of surfactant molecules.
The non-polar zone of a surfactant molecule is oriented towards the air inside the surfactant micelles
whilst the polar zone points to the water layer around the bubble. The cell cover of microalgal cells
usually presents electrical charge density which may change towards neutral values during growth.
Accordingly, electrostatic interactions between either polar or non-polar zones of the microalgal cell
cover and polar or non-polar zones of the surfactant molecules, respectively, may produce molecular
disorders in the cell wall and thus influence their functions, including nutrient uptake. This can impact
primary metabolism and growth of microalgal cells in foam [1,121], and can result in a modified
biochemical composition of the cell. Consequently, cultivation in foam could be investigated as a
tool to modify the major biochemical composition of the microalgal cells, i.e., total content of lipids
and/or carbohydrates, which include molecules with anti-inflammatory activity as described above in
this review.
 
Figure 3. Scheme of physicochemical features that might contribute to enhanced growth and/or shifted
biochemical composition of microalgae growing in liquid foams. Symbols: Black sphere with tail,
surfactant molecules.
In a foam-bed photobioreactor, once foam reaches the top part of the cultivation vessel it has to
be continuously broken to release the gas contained in the foam bubbles which can produce growth
inhibition by oxygen, or lowered growth by carbon limitation. Foam can be broken at the top of the
reactor by means of different procedures [118]. Thus, the gas is rapidly released to the atmosphere
when foam breaks. This allows for a better control of the oxygen level in the reactor, which can
be used to create conditions that stimulate accumulation of high-value compounds, for instance,
anti-inflammatory PUFA. Indeed, oxygen concentration has been found to greatly influence the
accumulation of value compounds in microalgae [122]. The accumulation of anti-inflammatory
compounds in microalgae, such as specific PUFA and carotenoids, can be induced under low oxygen
supply. Accordingly, bioprocess engineering strategies are required which lead to an oxygen supply
adjusted to the specific demand, and efficient in the oxygen transfer from the gas phase to the culture
broth particularly in heterotrophic production [123]. In this regard, novel cultivation strategies and
reactor designs that improve mass transfer to the growing cells could help increase productivity
of biomass and of the aforementioned target compounds. As described by Janoska et al. [118],
the foam-bed photobioreactor has the advantage of high gas holdup which results in both increased
mass transfer and lower pressure drop. The increased mass transfer results in higher both carbon and
oxygen transfer rates from the gas bubbles to the microalgae cells that grow in the liquid layers between
gas bubbles (Figure 3). The improved transfer rates in foam result in increased biomass productivity
in well oxygenated microalgal cultures. The opposite, under low oxygen supply, the microalgal
metabolism rapidly adapts to enhance PUFA biosynthesis, which can be due to the higher activity
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of the polyketide synthase (PKS) pathway as it does not require oxygen [124]. PKSs related to PUFA
synthase are involved in the biosynthesis of long-chain polyhydroxy alcohols and contribute to the
formation of the glycolipid envelope in cyanobacterial heterocysts [125].
The chemical interaction between the polar groups of surfactant molecules and the microalgal cell
wall obviously results in a reduced charge density of the microalgal cell cover. In the case of positively
charged groups in the surfactant structure, it has been speculated that their neutralization at the cell
surface by negatively charged groups should be a reason for better surfactant adsorption to the algal
cells [126]. Accordingly, the hydrophobic nature of the oxygen molecule should facilitate its diffusion
to the theoretically less polar microalgal cell. Consequently, it could be suggested that the impact of
either high or low oxygen concentrations in microalgal cells growing in foam should most probably
be faster and more intense than in liquid cultures. This reasoning can partly explain results recently
obtained which show that microalgae growing in foam are apparently more sensitive to stress than
those growing in liquid cultures. This could be useful as a tool to address the faster accumulation
of carbohydrate and lipids, the two major groups of biomolecules with anti-inflammatory activity,
in microalgae growing in foam through suitable control of the oxygen and CO2 levels in the gas
supplied to the cultures, among other factors.
4. Conclusions
Besides being used as feed and food, microalgae are currently recognized as natural producers
of highly valuable bioactive compounds. Several biomolecules produced by microalgae, namely
carotenoids, polyunsaturated fatty acids, sulphated polysaccharides and phenolic compounds,
have been found to display anti-inflammatory activity. This finding expands the range of applications
of microalgal biomass from healthy diet ingredient in food to nutraceuticals that contribute to diminish
the intensity of specific symptoms and/or to prevent specific pathologies related to inflammation
processes. Many of those anti-inflammatory biomolecules have also high antioxidant capacity that
has been reported to impact human health positively, in particular at advanced ages. Consequently,
microalgae are considered to play a relevant role in the future map of novel strategies for the prevention
and treatment of inflammatory diseases that includes the use of natural products obtained through
well controlled biotechnological processes. The number of microalgae species still to be isolated from
nature that could be promising for the accumulation of anti-inflammatory compounds is enormous.
To achieve high productivities of target compounds, the isolation of fast-growth species and the
enhancement of metabolic fluxes leading to increased biosynthesis of those target products are key
aspects. In this sense, chemical tools such as specific triggers of target products and cell growth in
foam, are being developed which will be very promising in the short term in order to exploit the
production of microalgae enriched in molecules displaying anti-inflammatory activity.
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